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Abstract 
Obstructive sleep apnoea (OSA) and insomnia are the two most prevalent sleep 
disorders. Their respective treatments Continuous Positive Airway Pressure 
(CPAP) and Cognitive Behaviour Therapy for insomnia (CBT-I), are effective, but 
at the same time challenging.  It is this challenge that may translate to poor 
adherence, which ultimately leads to a reduction in treatment effectiveness. 
The evaluation of these treatments should not fall short of understanding 
effectiveness by only considering efficacy; the effort to establish what 
influences adherence makes up a large part of that goal. The aim of this thesis is 
to contribute to the literature by adopting a biopsychosocial approach (BPS). 
That is, the consideration of biomedical, psychological and social factors and 
how they interact to influence behaviour. The implications for both CPAP and 
CBT-I adherence literature were tested in the context of four experimental 
studies.  
Semi-structured interviews were conducted with 11 CPAP users, with 5 
individuals completing the three required interviews prior to, at 1 week and 3 
months after treatment initiation. The core themes emerging from a thematic 
analysis were ‘internal conflict around acceptance and adherence’, ‘integration 
of CPAP into life’ and ‘motivators and resources for CPAP use’. The interviews 
with 11 individuals having completed a CBT-I program revealed three important 
issues: ‘Making sense of CBT-I’, ‘Ongoing evaluation of components’ and 
‘Obstacles to implementation’.  Both studies reveal potential psychological and 
social factors contributing to adherence to CPAP and CBT-I, which need to be 
considered in a BPS framework.  
A patient-level meta-analysis of three randomised placebo-control studies 
showed that the relationship between CPAP adherence and improvements in 
daytime sleepiness was caused by both physiological (high use of real CPAP 
reduced sleepiness more than high use of placebo and more than low use of real 
CPAP) and psychological effects (high use of placebo was superior to low use of 
placebo), possibly as a result of an expectation of benefit. The results support 
the importance of considering both biomedical and psychosocial factors and 
their interactive effects on adherence.  
The translation of the BPS approach to clinical practice will be facilitated 
by the development of brief, reliable and valid measures to assess psychological 
iii 
and social variables in addition to the existing biomedical tools. The Stage of 
Change Scale for Insomnia (SOCSI) assessing components of the transtheoretical 
model (stage of change, self-efficacy, decisional balance and processes of 
change), was constructed and cognitively pre-tested in 13 individuals completing 
CBT-I. The reliability and validity of this comprehensible scale was subsequently 
examined in the context of a sleep restriction trial. Insomnia-related symptoms 
at post-treatment and follow-up, which were significantly different from 
baseline in the 27 individuals with insomnia, were associated with actigraph-
determined adherence to the agreed bed window. The SOCSI was deemed a valid 
tool with participants in the self-identified action/maintenance stage revealing 
significantly better adherence, higher motivation and self-efficacy than those in 
the contemplation and preparation stage. Test-retest reliability of the SOCSI was 
excellent and the content analysis of open-box responses revealed information 
for further validation of decisional balance and processes of change scales.  
This thesis provides novel information about the variables that influence 
adherence to CPAP and CBT-I. It distinguishes itself from previous efforts by 
acknowledging the need for the adoption of a BPS framework. This approach is 
necessary to successfully advancing not only the CPAP and CBT-I adherence 
literature individually, but potentially the adherence field in general. 
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Overview 
Thesis Overview 
This section aims to provide a brief chapter-by-chapter overview of the thesis. 
This Ph.D. was completed as a Cotutelle Agreement between the Universities of 
Glasgow (United Kingdom) and Sydney (Australia). The sleep research facilities 
at the respective universities have expertise in both obstructive sleep apnoea 
and insomnia. Consequently, this thesis has considered these two clinical 
populations and presented them in this thesis as separate disorders.  
 
Chapter 1- Introduction 
This chapter provides a brief overview of the diagnosis, pathophysiology and 
treatments of both sleep disorders, which is relatively brief. With the main focus 
of this thesis directed towards adherence to treatments, the large part of this 
chapter presents the measurement and predictors of and interventions to 
improve adherence.  
 
Chapter 2-Literature Review 
Chapter 2 is a narrative review of the CPAP adherence literature and provides 
the basis for the thesis aims: a biopsychosocial (BPS) approach to adherence. 
The CPAP literature was chosen as the focus, merely because of the extensive 
literature available in this area and it provides a good example of where 
biomedical and psychosocial models of adherence diverge. However the research 
and clinical implications can be transferred to the CBT-I adherence literature as 
discussed where appropriate. At the time of thesis submission, this review was 
under peer-review in the journal Sleep Medicine Reviews. The finished article 
(with slight adaptations for the thesis) is presented in chapter 2 and thus some 
information might slightly overlap with the introduction in chapter 1. The thesis 
aims are presented at the end of this chapter. 
 
Chapter 3-6 (Experimental Chapters) 
The experimental chapters have the purpose of reaching the broad aims of the 
thesis, which stem from the overarching aim to adopt a BPS approach to 
adherence described in chapter 2. The qualitative studies outlined in chapter 3 
Overview   xx 
and 4 offer information particularly about psychological and social factors that 
influence both CPAP and CBT-I in addition to biomedical factors. The patient-
level meta-analysis in chapter 5 provides initial support for integrating 
biomedical, psychological and social aspects into a holistic model. Finally, 
chapter 6 describes the development and validation of a scale to assess the 
psychological construct of readiness to change, contributing to building a 
database of brief scales that will facilitate the identification of bio-, psycho-, 
social variables that predict adherence to treatment for the disorders of 
interest. At the time of submission, Chapter 5 was published in the journal 
Thorax. This paper has been included in this thesis as complete work and thus 
any references to this chapter are to the publication (Crawford et al. 2012).(1) 
Slight adaptations have been made for the inclusion in the thesis (e.g., 
supplementary material are included in the appendix). The methodology and 
result of each chapter are critically evaluated in each individual chapter 
discussions; further directions for research and implications for clinical practice 
are also provided here. As the work in this thesis is pragmatic in its nature the 
discussion for each experimental chapter will not include separate sections for 
research and clinical practice, but these are interwoven in each discussion. The 
experimental chapters are then assessed in context with the thesis aims in the 
overarching discussion.  
 
Chapter 7 Overarching Discussion 
This section aims to merge the information provided in each experimental 
chapter within the context of the thesis aims. Results particularly relevant to 
consider within the biopsychosocial framework are discussed in this section, with 
further information on future directions and strengths and limitations of the 
thesis as an overall body of work.      
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Chapter 1- Introduction to Disorders of Sleep and 
Wakefulness 
1.1 Obstructive Sleep Apnoea 
The International Classifications of Sleep Disorders-2 diagnostic nosology (ICSD-
2)(2) classifies sleep related breathing disorders (SRBD) into four distinct 
categories: Central Sleep Apnea Syndromes, Obstructive Sleep Apnea Syndromes, 
Sleep Related Hypoventilation/Hypoxemic Syndromes, and Other Sleep Related 
Breathing Disorders. The underlying characteristic is an abnormality in breathing 
that solely occurs in or is even exacerbated by the sleep state. The most 
common condition- obstructive sleep apnoea in adults (from hereon referred to 
as OSA)- is given exclusive attention in this thesis, thus the introduction will be 
reduced to the diagnostic and pathophysiological descriptions and treatments of 
this disorder only.  
1.1.1 Diagnostic Classification 
OSA is characterised by the obstruction of the upper airway during sleep that 
leads to complete cessation (apnoea) or reduction (hypopnoea) of airflow. This 
occurs irrespective of continued ventilatory effort. Before termination, most 
often through arousals, these events lead to a decrease in blood oxygen 
saturation and associated increase in carbon dioxide levels during longer events. 
These effects (disrupted sleep and hypoxemia) are identified as the possible 
causal factor for the daytime sleepiness and resulting impairment witnessed in 
these individuals.(3)  
According to the ICSD-2 the diagnosis of obstructive sleep disordered 
breathing is reliant on the clinical (e.g. daytime sleepiness, breathing 
interruptions or snoring and witnessed gasping for air) and, or just 
polysomnographic (respiratory events) characteristics.(2) Table 1 highlights the 
diagnostic criteria outlined by the ICSD-2.  
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Table 1: Diagnostic criteria for OSA according to the ICSD-2 
ICSD-2 criteria for obstructive sleep apnoea (verbatim from 2):  
A,B and D or C and D satisfy the criteria: 
A. At least one of the following applies: 
i) The patient complains of unintentional sleep episodes during 
wakefulness, daytime sleepiness, unrefreshing sleep, fatigue or insomnia. 
ii) The patient wakes with breath holding, gasping, or choking. 
iii) The bed partner reports loud snoring, breathing interruptions, or 
both during the patient’s sleep  
B. Polysomnographic recording shows the following: 
i) Five or more scoreable respiratory events (i.e. apneas, hypopneas, 
or RERAs) per hour of sleep  
ii) Evidence of respiratory effort during all or a portion of each 
respiratory event (In the case of a RERA, this is best seen with the use of 
esophageal manometry) 
OR:  
C. Polysomnographic recording shows the following 
 
i) Fifteen or more scoreable respiratory events (i.e. apneas, 
hypopneas or RERAs) per hour of sleep 
ii) Evidence of respiratory effort during all or a portion of each 
respiratory event (In the case of a RERAs, this is best seen with the use of 
esophageal manometry). 
D. The disorder is not better explained by another current sleep disorder, 
medical or neurological disorder medication use, or substance use disorder. 
 
 
The AASM has defined an apnoea, objectively determined by 
polysomnography (PSG), as a complete pause in airflow (more than 90% 
reduction from baseline) for at least 10 seconds. An airflow reduction of at least 
30% (alternative 50%) with an associated minimum 4% decrease in oxygen 
saturation (alternative 3% or associated arousal), lasting for at least 10 seconds 
is classified as a hypopnoea. Lastly, the respiratory effort-related arousal event 
(RERAs) are episodes that last at least 10 seconds. Increased respiratory effort 
follows these events eventually leading to an arousal from sleep. The RERAs do 
not meet criteria for apnoea or hypopnoea and are therefore included in the 
respiratory disturbance index (RDI), but not to Apnoea/Hypopnoea Index (AHI) 
(4). Apart from the AHI and RDI, the oxygen desaturation index (ODI) may be 
used as a marker of severity. The ODI measures the amount of times per hour 
the oxygen saturation levels fall >3 or 4% below the baseline value.(4) 
The AHI, the number of apnoeas and hypopnoeas per hour of recorded 
sleep, is most commonly used, and cut-offs for severity are as followed(3):  
mild OSA= AHI between 5 and 15  
moderate OSA= AHI between 15 and 30    
severe OSA= AHI greater than 30  
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Obstructive sleep apnoea can be differentially diagnosed from Central 
Sleep Apnoea, the latter condition being associated with an absence of 
respiratory effort. However events in the OSA patient may also be central or 
even mixed in nature, which is defined by central followed by obstructive 
characteristics.(3) 
1.1.2 Diagnosis of OSA 
As alluded to above, the main clinical features of OSA are snoring, witnessed 
apnoeic events and daytime sleepiness (non-specific symptom of OSA and often 
measured with the Epworth Sleepiness Scale, ESS(5)). Clinical risk factors that 
OSA patients might present with in clinical practice are obesity,(6) or more 
likely visceral fat(7), increased neck circumference,(8) older age(9) and male 
gender.(10) Certain craniofacial features (e.g. size and position of the mandible 
and maxilla(11, 12)) and upper airway abnormalities (e.g. narrow posterior 
pharynx, airway length(13, 14)) are often related to the prevalence of OSA, or at 
least a more collapse prone airway. Consequences of OSA, as outlined below, 
such as impaired cognition and performance(15) low mood/depression(16) and 
sexual/erectile dysfunction(17) may also be signals for the practitioner at the 
first point of contact. 
Prediction models based on these clinical features are however not 
sufficient for diagnosis, and the “gold standard” clinical pathway for the 
diagnosis of OSA is through an in-lab attended polysomnogram (PSG).(18) A full 
PSG includes a variety of measures that obtain information about electrical 
activity of the brain, muscle and eye movement, respiration, oxygen saturation 
in the blood, respiratory effort and cardiac rhythm, usually measured in 30-
second epochs. Electrical brain activity, as measured by the 
electroencephalogram (EEG) is a marker of objective sleep and provides partial 
information about sleep stages. It is not within the boundaries of this thesis to 
give an extensive description of sleep architecture, but it is sufficient to say that 
sleep occurs in stages, cycling in roughly 90 minute episodes between lighter 
(higher wave frequency) stages 1 and 2, to deeper (lower wave frequency) 
stages 3, 4 and Rapid Eye Movement Sleep (REM). Stages 1-4, also termed Non-
REM sleep, are most prevalent during the first part of the night and dissipate, 
whilst REM sleep increases in length and frequency towards morning.(19) The 
two other channels that help to define stages of sleep are electromyography 
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(EMG), which measures muscle activity and electrooculography (EOG) which 
records eye rotation; output from these channels can measure the loss of muscle 
tone and the rolling eye movement, respectively, both of which are 
characteristic of REM sleep.  
However what is essential to the diagnosis of OSA are the recordings of 
respiratory events (airflow), and blood oxygen levels, respectively measured by 
a nasal cannula pressure transducer (superior to a thermistor(20)) and pulse 
oximetry. The former measurement is needed to record a reduction in airflow, 
which detects both apnoeas and hypopnoeas, the latter is required for the 
identification of hypopnoeic events. To distinguish between obstructive and 
central events thoracic and abdomen movement are recorded as a marker of 
respiratory effort. Recordings not essential for the diagnosis of OSA, but also 
included in routine PSG recordings are body position, snoring intensity, cardiac 
rhythm (electrocardiogram (ECG)) and EMG of the anterior tibialis muscle in 
order to rule out periodic limb movement disorder (PLMD).  
Modifications to the full night in-lab diagnosis may include the split night, 
unattended portable monitoring (PM) and limited study (excluding EEG, EOG and 
EMG). PM and limited study can be provided in the patients home. Pulse 
oximetry as a single channel is not recommended for the diagnosis of OSA, but 
may be useful for screening purposes.(3) The second half of a split night study is 
allocated for titration of the pressure delivered during Continuous Positive 
Airway Pressure (CPAP) treatment, described below. This type of diagnosis, 
along with PM and attended limited studies, is appropriate in selected patients, 
where certainty of moderate to severe OSA is high.(18, 21)  
1.1.3 Pathophysiology  
A simplistic view of the complex pathophysiology of OSA(22) is that physiological 
and situational changes during sleep lead to an imbalance of forces that 
normally ensure the patency of the airway during wakefulness. Figure 1 is a 
schematic representation of the forces during wakefulness. During normal 
respiration whilst awake, the air flows unobstructed through the upper 
respiratory tract (nasal cavity, pharynx, larynx), through to the lower respiratory 
tract (trachea, primary bronchi and finally the lungs). To allow for the functions 
of the upper airway, i.e., speech ventilation and deglutition- this area must rely 
on both muscle activity and collapsibility.  
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During inspiration a negative pressure develops, as a result of basic 
physical principles. Alongside external pressures to the airway (e.g. fat 
deposition and a small mandible), these negative pressure forces promote the 
collapse of the airway during inspiration. Counteracting forces (activation of 
pharyngeal dilator muscles and increase in lung volume) ensure airway patency.  
The interaction of these forces enables continuous un-obstructive airflow during 
wakefulness; however changes associated with the sleep state disrupt the 
balance between these factors, leading to an increased risk of airway collapse. 
For example a change associated with muscle atonia during REM sleep leads to 
the reduced activation of the pharyngeal dilator muscle. Supine body position 
during sleep can also contribute to airway collapse as a result of gravitational 
forces. Why this partial or full obstruction only occurs in certain individuals is 
still debated, however it is likely a combination of abnormal anatomy and 
neuromuscular functioning.(23, 24) 
 
Figure 1: The upper airway during wakefulness  
Source: Malhotra & White, Lancet 2002(22) 
1.1.4 Prevalence 
Obstructive Sleep Apnoea is the second most common sleep disorder following 
insomnia (see 1.2). Rates can vary extensively depending on the diagnostic 
criteria used.(3) In 1993 Young derived the prevalence of OSA from the 
Wisconsin Sleep Study Cohort in the US.(10) Using an AHI cut-off of 5 events per 
hour, they reported rates of 9 and 24% for women and men respectively. 
However, when daytime sleepiness was also considered, rates dropped to 2% for 
women and 4% for men and similar rates have been reported in Australia(25).  
Reported prevalence rates in the UK are lower, between 1-2%,(26-28) which may 
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relate to an under-diagnosis of OSA in the UK.(26) Prevalence rates and severity 
of OSA tend to be higher in non-white minority groups, however not after 
controlling for differences in body habitus.(29-31) 
1.1.5 Treatment of OSA 
Treatment of obstructive sleep apnoea can largely be divided into non-
implantable mechanical devices (NIMDs), surgery, pharmacological and 
conservative treatments. One of these NIMDs, Continuous Positive Airway 
Pressure (CPAP)(32) has been the treatment of choice until recently for the 
amelioration of apnoeaic, hypopnoeic and RERAs during sleep in all severity 
ranges.(33)  
1.1.5.1 Continuous Positive Airway Pressure 
CPAP delivers a fixed pressure of compressed air, creating a pneumatic splint to 
keep open the airway, thus allowing normal breathing and uninterrupted 
sleep.(32) Pressure is generated through a machine and delivered through a hose 
attached to an interface that is sealed closely to the patients face. Interfaces 
can vary from full head, face or nasal masks or nasal prongs, fitting just over the 
nostrils. The delivered pressure is individually and manually titrated for each 
patient. A modification of the in-lab titration with the CPAP machine has 
evolved through the introduction of the AutoCPAP machine, which automatically 
detects the occurrence of an event breath-by-breath and increases the pressure 
to a pre-set maximum from a pre-set minimum. Thus variations of the titration 
include AutoCPAP unattended at home/ward or attended in the lab, as well as 
split-night studies as outlined above. Practice parameters indicate the use of 
AutoCPAP for in-lab titration in moderate or severe cases, and at home only in 
patients without co-morbidities.(34) AutoCPAP is also used as long-term 
treatment when preferred over CPAP, or the latter is intolerable.(34) A further 
modification of pressure delivery is BiPAP, which provides a higher predefined 
inspiratory than expiratory pressure. Lastly, expiratory pressure relief is a 
modification to CPAP (also called CFlex), which delivers a slightly lower 
expiratory level to lessen the feeling of breathing against pressure. 
The efficacy of CPAP was apparent in Sullivan’s initial presentation of 
CPAP, where the re-occurrence of obstructive events was witnessed by simply 
switching off the pressure in all 5 patients.(32) There is now considerable 
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evidence documenting the efficacy of CPAP to reduce OSA severity(35, 36) and 
establishing its cost-effectiveness above placebo/conservative treatment.(37) 
CPAP can reduce the consequences of OSA, such as daytime sleepiness and 
improve cardiovascular health and driving performance, which is outlined in 
detail below.   
CPAP does not present a cure, but rather a crutch: one night without 
CPAP can witness the return of nightly and daily symptoms.(38) Adherence to 
CPAP is generally poor (see below) and some have argued this reduces the 
potential benefit (‘effective AHI’)(39, 40) leaving less optimal, but less intrusive, 
treatments comparable to CPAP. The AASM describes that alternative treatment 
options may be suitable depending on factors such as treatment preference or 
anatomical features.(33) Alternatives to CPAP include conservative treatments 
(weight loss, positional therapy), oral appliances, and surgery and will briefly be 
reviewed.  
1.1.5.2 Other Non-Implantable Medical Devices 
Oral appliances (OAs) provide another form of non-implantable mechanical 
device. These appliances increase the size of the airway using two broad 
functions; jaw repositioning and tongue retention. Recently updated practice 
parameters recommend the use of OAs in mild to moderate individuals unable or 
unwilling to tolerate CPAP, however the use of these devices for severe cases is 
not indicated at present.(41) In a comprehensive meta-analysis, the use of OAs 
successfully treated (AHI<5/hr) 35% of patients across randomised placebo 
controlled cross-over studies. Comparing these types of devices with CPAP 
(75%), OAs (42%) were more similar to surgery (30%) in percentage of reduction 
of AHI. Perhaps unsurprisingly, OAs were preferred by patients in the majority of 
studies, which might have resulted in relatively good adherence rates; 56–68% of 
patients were still using CPAP after 33 months.(42) Objective use with these 
devices is still to be established. 
There is little evidence for the efficacy of nasal dilators, but this 
technique might be appropriate for snoring relief.(43, 44) A novel technique 
making use of a two-wave valve at the nostrils providing positive back-pressure 
from the individual’s own expiratory pressure, was introduced after a pilot study 
in 2008.(45) Testing this device in 229 OSA patients in a randomised control trial 
(RCT) revealed significant effects, however the treatment did not reduce the 
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AHI below 5/hr.(39). Subjective adherence however seems to be excellent, with 
patients reporting all night use of the device on most nights(46, 47)), which, like 
OAs, might render it comparable to the poorly adhered to CPAP device.  
1.1.5.3 Surgical Management of OSA 
Surgery to alleviate symptoms of OSA can occur at the nasal passage (e.g. nasal 
reconstruction) or the upper airway (e.g. Uvulopalotopharyngoplasty, 
tracheotomy), or aims to achieve skeletal/geniglossus advancement. A Cochrane 
review evaluating these surgical options concluded there were too few studies to 
establish the efficacy of these treatments(48) Removing the obstruction through 
surgery (e.g. through tonsillectomy, septoplasty) has been hypothesised to 
improve acceptance and adherence; some studies have shown lowered pressure 
requirements(49, 50) and increased adherence(51) post surgery. 
1.1.5.4 Conservative Treatments 
Conservative treatments include lifestyle changes targeting areas that are known 
risk factors, which exacerbating the frequency of events. These may include 
excess weight, alcohol, smoking and sleep deprivation. Because of the known 
association between obesity and OSA, weight loss is most often suggested in 
conjunction with more effective treatments such as CPAP.(52) The difficulty 
with this option is the reduced motivation to loose weight in these sleepy 
individuals, as well as the lack of applicability to the non-obese OSA population,. 
Likewise, as body position exacerbates the frequency of events, positional 
therapy (PT, avoidance of the supine position) is often considered as a 
conservative option. An early study questioned the effectiveness of PT in 
patients with non position-dependent OSA.(53) 
1.1.6 Consequences of OSA and subsequent improvement with 
CPAP 
Figure 2 is a schematic representation of how the obstructive events lead to the 
known neurocognitive and cardiovascular consequences of the disorder. The 
termination of the apnoea is often preceded by an arousal, which leads to sleep 
fragmentation and activation of the sympathetic nervous system. The former 
explains the pathway to the neurocognitive sequelea, whilst the latter leads to a 
strain on the cardiovascular system. Fortunately, there is evidence to show that 
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CPAP is effective in preventing some of these outcomes. Thus, the subsequent 
sections are devoted to exploring the main consequences of OSA and how 
effective CPAP use is protective against this sequelae. 
  
Figure 2: The neurocognitive and cardiovascular consequences of OSA  
Source: Malhotra & White, Lancet 2002(22) 
1.1.6.1 Daytime Sleepiness  
Daytime sleepiness is one of the core symptoms of OSA as a result of the 
continued arousals from sleep and is often a presenting symptom. In Young’s 
epidemiological evaluation, 23% of women and 16% of men with OSA also 
reported sleepiness on 2 or more days per week. The authors note these 
subjective reports are likely underestimating the true hypersomnolence 
rates,(10) particularly in individuals with mild OSA who are asymptomatic.(54) 
Recent meta-analyses have reported the effectiveness of CPAP improving both 
subjective sleepiness and objective sleepiness as measured with the Multiple 
Sleep Latency Test (measures the propensity to fall asleep) and Maintenance 
Wakefulness Test (measures the ability to stay awake).(55, 56) A number of 
studies have indicated this relationship manifests itself in a dose-dependent 
manor, where increased use of CPAP is associated with increased improvements 
in sleepiness.(1, 57-59) However both Weaver et al. and Antic et al. report a 
moderate proportion (10-50%) does not achieve normal values for sleepiness 
related measures despite adequate use. Further research is necessary to 
understand this paradox.  
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1.1.6.2 Cardiovascular Health 
A variety of cardiovascular outcomes have been linked to OSA, which includes 
hypertension, and cardiovascular disease such as stroke. After an initial debate, 
OSA is now considered an established independent risk factor for 
hypertension,(60) in sleep clinic patients(61, 62) and in both cross-sectional 
epidemiological(63-65) and longitudinal studies.(66) A recent longitudinal study, 
however revealed no relationship in 1,180 patients with OSA after controlling for 
age, gender, BMI, neck circumference and lifestyle factors such as fitness levels, 
alcohol and coffee consumption. The authors call for further longitudinal studies 
to confirm the causal relationship between hypertension and OSA.(67) Support 
for the link between OSA and hypertension may come from studies showing 
improvements in blood pressure with CPAP treatment. Two recent meta-
analysis, however present contradicting results on the effects of CPAP on this 
measure.(68, 69) The meta-analysis reporting no significant difference with 
CPAP use, however do not exclude the effectiveness in selected patient e.g. 
those with substantial hypertension.(68) 
Similarly OSA has been linked to stroke, heart failure and an overall 
measure of cardiovascular disease/death, with CPAP acting as a protective 
against the incidence of these events.(70-75) 
1.1.6.3 Cognitive Functioning and Performance  
As outlined in Figure 2, sleep fragmentation caused by repeated arousals can 
lead to a wide range of deficits in neurocognitive functioning. This may include 
attention, memory and executive functioning and performance related quality of 
life. Whether these deficits are attributable to the sleep disruption caused by 
the arousals or the intermittent hypoxemia remains unanswered.(15) 
Furthermore, the effect of CPAP treatment on these domains is still unclear. For 
example, irrespective of a sound study design, large sample size (1105 OSA 
patients) and assessing major neurocognitive domains, the delivery of CPAP only 
produced marked improvements in executive functioning over sham CPAP (p = 
0.0074) at 2- months, but not attention and psychomotor function, or learning 
and memory. The authors note that these results along with other negative 
findings in the literature are suggestive of a complex interaction between OSA 
and neurocognitive sequelae, with a mediating effect of individual differences in 
resilience towards sleep deprivation.(76) 
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One particular concern is road traffic safety. The increased risk of 
automobile accidents may be two-fold, resulting from lapses in attention 
through increased sleepiness and cognitive/perceptual difficulties.(77) Two 
meta-analyses have recently shown a decrease in automobile accidence both on 
the road and in a driving simulator(77, 78) and a further indicated that when 
motor vehicle accidents were taken into account, CPAP represents a cost-
effective option for the treatment of OSA.(79)  
1.1.6.4 Erectile and sexual functioning 
Erectile and sexual (E/S) dysfunction as a potential consequence of OSA are 
largely under researched and overlooked in clinical practice. A study on 401 
male OSA patients found a strong relationship between E/S dysfunction and OSA 
(AHI>5/hr), irrespective of known associates of E/S dysfunction, such as age or 
obesity. The authors concluded that hypoxemia likely explains the high 
prevalence of erectile and sexual dysfunction in this population.(17) When 
treating OSA with CPAP, marked improvements can be witnessed in this area, as 
highlighted by a paper presented at the 2012 Associated Professional Sleep 
Societies Conference in Boston.(80) Interestingly after 1, 3 and 6 months of CPAP 
use, improvements were documented in both those that did and did not report 
E/S dysfunction at baseline. In the former group there was a relationship 
between CPAP use and improvement, however the authors concluded E/S 
dysfunction did not completely resolve, with only 41% of adequate users 
reaching normal values on the erectile functioning scale.  
1.1.6.5 Mortality 
Perhaps unsurprisingly, with the cardiovascular sequelae outlined above, 
moderate to severe OSA has been linked to a four to six-fold increased risk of 
mortality, irrespective of factors such as age, diabetes or high cholesterol.(81, 
82) Fortunately, CPAP has been shown to increase rates of survival in selected 
patients, such as stroke patients(83) females(84), and the elderly(85). To date, 
longitudinal community-based samples have not been completed.  
1.1.7 Summary 
Despite being the treatment of choice for OSA - a condition associated with a 
number of health and quality of life related consequences -CPAP is intrusive to 
the patient’s life, and perhaps unsurprisingly, associated with poor adherence. 
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In order to prevent the negative sequelae outlined above, it is important to 
understand what influences adherence and which interventions are most 
effective in the task of improving CPAP use; this will be discussed in chapter 1.3. 
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1.2  Insomnia 
Most individuals experience a sleepless night at some point in their lives. 
However, where there is continued re-occurrence and subsequent difficulties in 
daytime functioning the problem is labelled as chronic. The chapter is concerned 
with the diagnostic classifications, prevalence, consequences and treatments of 
chronic insomnia.  
1.2.1 Diagnostic Classifications 
Two distinct nosologies are currently utilised for the diagnosis of insomnia: 
Diagnostic and Statistical Manual of Mental Disorders, DSM-IV-TR(86) and 
International Classification of Sleep Disorders, ICSD-2(2) respectively). Despite 
subtle differences in the classification of the condition, these two nosologies 
describe ‘primary insomnia’(86) or ‘general insomnia disorder’(2) as a condition 
characterised by difficulty initiating and/or maintaining sleep, waking too early 
and/or non-restorative sleep. Importantly, the complaint is associated with 
significant distress or daytime dysfunction voiced by the individual. The 
nosologies diverge at the point where the ICSD-2 further defines this 
dysfunction, specifying nine possible areas (see Table 2). It further indicates the 
sleep disturbance must occur despite adequate opportunity for sleep.  
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Table 2: Description of DSM-IV-TR and ICSD-2 Classifications of Insomnia 
DSM-IV : Primary Insomnia (verbatim from 86) ICSD: General Insomnia Disorder (2) 
(A)$The$predominant$compliant$is$difficulty$initiating$or$
maintaining$sleep,$or$nonrestorative$sleep,$for$at$least$one$
month&
(A)$A$complaint$of$difficulty$initiating$sleep,$difficulty$
maintaining$sleep,$or$waking$up$too$early,$or$sleep$
that$is$chronically$nonrestorative$or$poor$in$quality 
(B)$The$sleep$disturbance$(or$associated$daytime$fatigue)$
causes$clinically$significant$distress$or$impairment$in$social,$
occupational,$or$other$important$areas$of$functioning$
(B)$At$least$one$of$the$following$forms$of$daytime$
impairment$related$to$the$nighttime$sleep$difficulty$is$
reported$by$the$patient:$
a.$Fatigue$or$malaise$
b.$Attention,$concentration$or$memory$impairment$
c.$Social$or$vocational$dysfunction$or$poor$school$
performance$
d.$Mood$disturbance$or$irritability$
e.$Daytime$sleepiness$
f.$Motivation,$energy,$or$initiative$reduction$
g.$Proneness$for$errors$or$accidents$at$work$or$while$
driving$
h.$Tension,$headaches,$or$gastrointestinal$symptoms$
in$reponse$to$sleep$loss$
i.$Concerns$or$worries$about$sleep$
(C)$The$sleep$disturbance$does$not$occur$exclusively$during$the$
course$of$Narcolepsy,$BreathingIRelated$Sleep$Disorder,$
Circadian$Rhythm$Sleep$Disorder,$or$a$Parasomnia&
(C)$The$above$sleep$difficulty$occurs$despite$adequate$
opportunity$and$circumstances$for$sleep$
(D)$The$disturbance$does$not$occur$exclusively$during$the$
course$of$another$mental$disorder$(e.g.,$Major$Depressive$
Disorder,$Generalized$Anxiety$Disorder,$a$delirium)&
(E)$The$disturbance$is$not$due$to$the$direct$physiological$
effects$of$a$substance$(e.g.$a$drug$of$abuse,$a$medication)$or$a$
general$medical$condition.&
 
Contrarily, the DSM-IV makes reference to the duration and the 
occurrence of the insomnia: for at least 1 month and not exclusively in the 
context of other sleep disorders, mental and physical conditions or substance 
abuse. These two additional criteria do however feature in the ICSD-2’s 
description of Psychophysiological Insomnia (PPI), and Paradoxical Insomnia (PI), 
two of the insomnia subtypes. In addition to meeting criteria for insomnia 
disorder, PPI is a sleep disturbance resulting from learned sleep-preventing 
associations and/or heightened arousal. Consequently, the individual will 
present with one or more of the following: increased sleep anxiety; difficulty 
initiating sleep at desired times (i.e. no problems when not intending to sleep); 
improved sleep when away from home and cognitive or somatic arousal in 
bed.(2) 
 Although it is one of the most frequently occurring subtypes of general 
insomnia,(87) the diagnostic category of PPI is not considered particularly 
reliable or valid, along with the paradoxical subtype(88). Paradoxical insomnia is 
characterised by a chronic subjective report of little or no sleep that is 
considerably below age appropriate standards/ does not reveal any homeostatic 
patterns (rebound nights) and/or in misalignment with objective reports 
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obtained by polysomnography or actigraphy. The individuals will also describe 
feeling awake all night with reference to external events and/or excessive 
thoughts or rumination throughout most of the night. Furthermore the daytime 
impairment is in discord with the level of sleep deprivation reported.(2)  
 Idiopathic insomnia on the other hand is considered a more reliable and 
valid diagnostic entity.(88) Meeting criteria for insomnia and not better 
explained by another sleep, medical or psychological condition or medication 
use, the disorder’s onset is during infancy or childhood, has no identifiable 
cause/precipitant and occurs without periods of remission.(2)  
Table 3 outlines additional subtypes detailed in the diagnostic nosologies, 
a comprehensive description of these will not be undertaken in this thesis.  
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Table 3: Insomnia Subtypes according to DSM-IV-TR and ICSD-2 
DSM-IV-TR : Insomnia Subtypes (verbatim 
from 86) 
ICSD-2: Insomnia Disorder Subtypes (verbatim from 2) 
Primary Insomnia Adjustment Insomnia 
Secondary Insomnia due/related to a 
…Breathing-related sleep disorder 
Psychophysiological Insomnia 
…Circadian rhythm sleep disorder Paradoxical Insomnia 
…Dyssomnia Not otherwise specified Idiopathic Insomnia 
… a mental disorder Insomnia Due to Mental Disorder 
…;a medical condition Inadequate Sleep Hygiene 
…Alcohol-related sleep disorder  Behavioral Insomnia of Childhood 
… a substance  Insomnia due to Drug or Substance 
…Other sleep disorder Insomnia due to Medical Condition 
Insomnia Not Due to Substance or Known Physiological 
Condition, Unspecified (Non-organic Insomnia, NOS) 
Physiological (Organic) Insomnia, Unspecified 
 
Because of the limited evidence for some diagnostic criteria, only 
moderate overlap between nosology classifications,(88, 89) and the majority of 
cases presenting in concord with another medical or psychiatric disorder(87), 
there has been a recent development towards eliminating the distinction 
between ‘Primary’ and ‘Secondary’ insomnia. This is replaced with the term 
‘Insomnia Disorder’, whilst simply denoting any comorbid conditions.(90) This 
change in the fifth edition of the DSM, which is to be published in 2013, is 
particularly pertinent considering it is often difficult to infer causal relationships 
in the clinical setting, and brings hope for an eventual convergence of diagnostic 
nosologies with the eventual publication of the ICSD-3.(91) In 2004 a workforce 
from the AASM devised research diagnostic criteria aimed to standardise these 
criteria for insomnia with the hope that these will find their way into the 
diagnostic manuals.(92) These are outlined in Appendix 1.  
This transition also moves away from the implicit assumption in the non-
sleep field that insomnia is secondary to other conditions, rather than a disorder 
in its own right. There is ample evidence to indicate that insomnia can be a 
predictor of psychiatric conditions, particularly depression(93) following the first 
longitudinal report in 1989.(94) Furthermore, the treatment of insomnia 
concomitant to the treatment of depression is associated with larger 
improvements in depressive symptoms,(95) insomnia may persist long after 
completion of treatment of only the primary disorder,(96) and individuals with 
sleep difficulties have poorer outcome trajectories for their depression post 
treatment, compared to those without,(97) and higher rates of remission.(98) 
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The largest evidence comes from studies of mood disorders, however there is 
emerging evidence for similar patterns in other psychiatric conditions.(99)  
These concerns of course merit the refinement of diagnostic tools for both 
the classification of insomnia and differential diagnosis of other sleep disorders. 
Currently there are a variety of well-validated techniques; these will only be 
briefly mentioned here, and discussed in more detail (where relevant) in the 
subsequent chapters. The diagnosis of insomnia is mostly reliant on the clinical 
interview, for which there are a variety of structured validated tools (e.g. the 
Structured Interview for Sleep Disorders(100); Duke Structured Interview for 
Sleep Disorders(101) as well as an insomnia-specific interview schedule.(102) 
PSG as the gold standard for the assessment of sleep is useful in the differential 
diagnosis of sleep related breathing or periodic limb movement disorders, but is 
not considered essential for the classification of insomnia. Less cost and time 
intensive methods such as actigraphy and sleep diaries are most often used in 
this population and highlight certain sleep habits or provide information about 
sleep/wake patterns over longer time periods, particularly useful for the 
diagnosis of disorders of the circadian rhythm.(103) Both techniques have been 
validated in insomnia populations against PSG, however actigraphy records tends 
to underestimate sleep onset latency, and individuals generally misperceive 
sleep for wakefulness in sleep logs, thus overestimating sleep onset latency and 
underestimating total sleep time, compared to more objective measures.(104) 
Self-reported questionnaires, of which the Insomnia Severity Index (ISI,(102)) 
and Pittsburgh Sleep Quality Index (PSQI(105))are most frequently used, help 
establish the severity of the insomnia disorder or are used as screening tools.(91)  
1.2.2 Prevalence and Consequences 
Without consensus surrounding the diagnostic criteria it is perhaps not surprising 
that there are large variations in the cited prevalence rates of these types of 
sleep difficulties, ranging from around 6-30%.(87, 106, 107) When only 
considering a chronic sleep difficulty, with a concurrent complaint of sleep 
dissatisfaction and daytime impairment and not occurring exclusively in the 
context of another medical or psychiatric condition or other sleep disorder, the 
rates tend to be lower. In a recent study, Ohayon and colleagues collected data 
in seven different countries (France, the United Kingdom, Germany, Italy, 
Portugal, Spain and Finland) using a validated interview system via the 
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telephone and concluded that 35% of the sample reported symptoms (difficulty 
initiating or maintaining sleep, early morning awakenings or un-refreshing sleep 
≥3 days a week) 10% reported that these were associated with daytime 
impairment and 7% met for DSM-IV criteria for insomnia disorder. Primary 
insomnia (DSM-IV) and psychophysiological insomnia (ICSD-2) were present in 3 
and 1.4% of the sample respectively.(87) 
A recent epidemiological study in Australia (apart from the UK, the other 
population this thesis draws samples from) reported similar rates.(108) 
The prevalence rates of insomnia tend to increase in older adults to 
around 20%, again rates depending on the criteria used.(109, 110) Using more 
stringent criteria this upward trend tends to dissipate, and studies in later older 
life report lower prevalence rates.(111) Insomnia is generally more common in 
females than males; a meta-analysis reported a risk ratio of 1.6 for females 
compared to males and the increased risk was present irrespective of 
differences in the criteria used.(112)  
The consequences of insomnia are numerous, most frequently cited 
problems are the reduction in quality of life and productivity, and increased risk 
of accidents and absenteeism.(106, 113) Insomnia may also be a risk factor for 
various psychiatric conditions as outlined above. Recent studies have also 
indicated risks of various health problems. Although only cross-sectional, one 
study showed that individuals with insomnia and objective short sleep ≤ 5 hrs 
were 500% more likely to have hypertension compared to good sleepers, even 
after controlling for age, gender, sleep disordered breathing and other potential 
mediating factors(114). The same working group showed similar results for type-
2 diabetes(115) and even mortality in men after controlling for hypertension and 
diabetes.(116) 
1.2.3 Pathophysiology 
It is beyond the remit of this thesis to provide a detailed account of the 
aetiological models of insomnia- this can be found elsewhere.(117) Instead, 
where relevant to the respective treatments, these models will be briefly 
introduced in the next section.  
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1.2.4 Treatment 
In becomes evident that insomnia is a debilitating disorder that warrants 
treatment. To date, the approaches range from complementary/‘over the 
counter’ medications to pharmacological, psychological and ‘third-wave’ 
therapies and will be outlined in the subsequent parts of this chapter  
1.2.4.1 ‘Over the counter’ and prescription medication 
‘Over the counter’ (e.g. antihistamines), alternative treatments (e.g., valerian) 
and prescription medications (e.g. benzodiazepines, melatonin [in the UK]) are 
options many individuals with insomnia pursue(107), and these feature most 
frequently in primary care.(118, 119) However, patients usually indicate a 
preference for non-pharmacological options(120) and the reason for this paradox 
is this is largely thought to occur because non-pharmacological options are not 
readily available.(121)  
Prescription medication can be largely divided into those that are 
specifically indicated for insomnia (benzodiazepine receptor agonists, BZRAs, 
melatonin [for older adults>55yrs]) by the Food and Drug Administration (FDA) 
and those approved for other disorders, but used as ‘off label’ medication for 
insomnia (e.g. sedating antidepressants).(122) A recent comprehensive review of 
the literature on short and long-term effects and safety of BZRAs revealed these 
hypnotics might be beneficial and safe in the short term, however might confer 
greater risks than benefits in the elderly.(123) They also concluded at the time 
that limited evidence to determine the long-term safety and efficacy was 
available.  These results echoed the statements issued by both the National 
Institute for Clinical Excellence (NICE) in 2004(124) and the National Institute of 
Health (NIH) in 2005,(125) the latter concluding there is little evidence for the 
use of ‘off label’ medication and complementary/alternative treatments in this 
population. Since then the use of BZRAs has increased with off-label medication 
decreasing.(122)  
Pharmacological treatment is largely based on the physiological model of 
insomnia, which describes elevated autonomic (heart rate, body temperature, 
heart rate variability, whole body metabolism, skin conductance response) and 
cortical arousal (increase in higher electroencephalographic [EEG] frequencies; 
increase in cortical responsiveness/sensitivity to auditory stimuli [event-related 
potentials]; and poorer ‘sleep quality’ as determined by cyclic alternating 
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patterns) as well as increased neuroendocrine (cortisol) output and changes in 
the neuroimmune response, both during sleep and the day in individuals with 
insomnia compared to controls.(126)  
In conclusion, there is sufficient evidence for pharmacological options in 
the short, but not long-term. Considering the NICE guidelines indicated the use 
of hypnotics should occur in the short term only ‘after due consideration of the 
use of nonpharmacological measures’,(124, p.4) it is necessary to further 
consider these options.  
 
1.2.4.2 Psychological/behavioural 
1.2.4.2.1 Sleep Hygiene 
This behavioural strategy is based on the assumption that individuals engage in 
activities during the day or before bedtime that are sleep incompatible, for 
example consuming caffeine, nicotine, heavy meals or alcohol and/or exercising 
too close to the desired bedtime and napping during the day. Unstable 
sleep/wake patterns are also considered poor sleep hygiene along with a sleep-
inhibiting bedroom environment (noise, light, temperature). There is currently 
no evidence to suggest that the removal of these factors (sleep hygiene 
treatment) produces meaningful effects and is not recommended as a 
standalone therapy by the AASM.(103)   
1.2.4.2.2 Relaxation Therapy 
A number of different relaxation strategies have been developed to deal with 
the somatic hyperarousal characteristic of insomnia described above. These 
include progressive muscle relaxation,(127-129) passive relaxation 
(diaphragmatic breathing, body focusing, autogenic phrases),(130)  and 
biofeedback.(131, 132) Progressive muscle relaxation is probably the most 
frequently referenced technique; it includes the progressive tensing and relaxing 
of each major muscle group. Passive relaxation is similar to the above, with 
focus on full body relaxation, but excluding the element of tension.(133) 
Biofeedback encourages relaxation through amplifying physiological arousal 
through visual or auditory stimuli; in the earlier studies individuals were trained 
to reduce the tone of the auditory feedback linked to their level of relaxation. 
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Imagery is often considered a type of relaxation, however this, contrary to 
biofeedback and progressive muscle and passive relaxation strategies, are not 
provided guideline or standard level of approval, respectively, by the AASM 
practice parameters.(103) 
Some of these techniques are not confined to the reduction of somatic 
arousal, but may also target cognitive arousal featured in other models of 
insomnia outlined below.(102, 134-136) 
 
1.2.4.2.3 Sleep Restriction Therapy 
In 1987 Spielman described a technique designed to deal with one of the 
perpetuating behaviours individuals with insomnia engage in: extending time in 
bed.(137) In an effort to compensate for prior wake-filled nights, individuals 
tend to go to bed earlier, stay in bed later and possibly nap during the day. 
These maladaptive behaviours, can perpetuate the initial sleep complaint, 
pushing someone over the threshold from acute to chronic insomnia, according 
to Spielman’s three-factor model.(138) These perpetuating factors (behavioural 
component) contribute to the development of a chronic problem in addition to 
the predisposing (genetics, personality) and precipitating (stressful live events) 
variables (stress-diathesis component). Sleep restriction, as described by 
Spielman, is designed to break the perpetuating cycle by reducing the time 
individuals spend in bed. The prescribed time is modelled on the individual’s 
average sleep time obtained from the sleep diary. The sleep restriction window 
is reduced by setting a morning time in concordance with the patients circadian 
and social/occupational preferences and subtracting the given average total 
sleep time, to establish the threshold time, after which the individual may retire 
when feeling sleepy. This sleep window is maintained for at least 1 week and 
encourages re-establishing the homeostasis of the sleep wake-process. The 
reduction of time in bed produces minor sleep deprivation and thereby ‘jump 
starts’ the homeostatic drive for sleep. A constant routine also helps regulate 
the circadian sleep-wake cycle. At subsequent sessions the window is titrated on 
the basis of improved and consolidated sleep. The window is extended in steps 
of 15-30 minutes once sleep efficiency (the percentage of time in bed spent 
asleep) reaches 90% or more. As most individuals will present with a low average 
total sleep time (approx. 5-6 ½ hours), many will struggle to follow this 
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routine.(139) Nevertheless, when this treatment is implemented in isolation, it 
can produce meaningful improvements that are comparable to other behavioural 
techniques.(140) However, at the point of publication of the AASM practice 
parameters, there was only sufficient evidence to endorse this treatment 
component as guideline, but not as a standard treatment.(103) 
A variant of sleep restriction has been explored by Lichstein and 
colleagues, termed sleep compression.(130) Rather than immediate restriction, 
this technique invovles the gradual reduction of time in bed over the course of 
the program, ultimately reaching the baseline total sleep time. Weekly 
reductions are calculated based on the difference between baseline sleep time 
and time in bed, divided by the number of treatment weeks. Titration based on 
sleep efficiency is made akin to sleep restriction therapy. Sleep compression is 
compatible with Lichstein’s biodevelopmental model, describing insomnia as a 
discord between developmental changes and sleep expectation,(130) thus there 
is uncertainty whether this would be effective for individuals with paradoxical 
insomnia or where the reduced sleep time is not a result of developmental 
changes.   
1.2.4.2.4 Stimulus control 
This therapy, along with relaxation strategies and cognitive behaviour therapy is 
the only treatment to have been evaluated as standard for the treatment of 
chronic insomnia by practice parameters.(103) Although classic conditioning 
principles may contribute to the development of chronic insomnia,(117) this 
treatment is based on the notion that the sleep problem emerges because of 
poor stimulus control (operant conditioning). Adapted from principles of 
behaviourism, Bootzin describes the sleep environment of the insomnia patient 
as characteristic of stimulus dyscontrol.(Bootzin, 1972 as cited in 117) During 
good stimulus control, the desired response (sleep onset) is evoked by the 
exclusive pairing of the bedroom environment (bed, bedroom, bedtime) as a 
discriminative stimulus and sleep (reinforcer). In contrast, during stimulus 
dyscontrol, the bedroom environment is no longer discriminative for the 
occurrence of the reinforcement. This may be because of a lack of strong 
discriminative stimuli, or the presence of sleep prohibiting stimuli (watching TV, 
reading, working). The goal of this therapy is to eliminate sleep incompatible 
stimuli from the bedroom environment (e.g. no TV/reading/working in bed) and 
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re-establish strong discriminative stimuli for sleep (e.g. do not sleep/nap outside 
of bed) i.e. establishing good stimulus control. The addition of the quarter-of-
an-hour rule, instructing individuals to get up out of bed when awake for more 
than about 15 minutes, removes the wakeful/worry/rumination aspect from the 
sleep environment in addition to the other wakefulness promoting behaviour.  
The efficacy of stimulus control was recognised in the earliest meta-
analysis, with effect sizes for sleep onset latency (SOL), wake after sleep onset 
(WASO), and number of awakenings at night (NWAK) of d=0.8; 0.7 and 0.59 
respectively.(140) Stimulus control appears as a component of most cognitive 
behaviour therapy packages and also features, alongside sleep restriction, in the 
brief versions.(118, 141)   
1.2.4.2.5 Cognitive Therapy 
This approach in general aims to target and replace misconceptions, 
maladaptive attitudes towards and beliefs about sleep as outlined in the models 
of insomnia explicitly describing cognitive factors contributing to the aetiology 
and maintenance of the disorder.(102, 135, 136) Initial conceptualisation of the 
cognitive model of insomnia was provided by Morin in 1993(102) and extended by 
Harvey in 2002.(135) According to Morin dysfunctional cognitions are an integral 
part of the intricate, self-perpetuating relationship between arousal (cognitive, 
physiological and emotional) maladaptive behaviour (e.g., napping), 
consequences (e.g., low mood, fatigue) and the disorder.  Thus, targeting these 
beliefs and attitudes is an essential addition to the behavioural strategies; 
cognitive therapy includes the following steps:  
-Outlining the link between thoughts and emotions 
-Identifying and challenging maladaptive attitudes and beliefs 
-Working with the patient in replacing these with more adaptive thoughts.   
 
Strategies and techniques used to accomplish these are borrowed from 
cognitive therapy as outlined by Aaron Beck and include for example Socratic 
questioning or guided discovery.(142) Harvey describes how these maladaptive 
cognitions in combination selective attention, safety behaviour and 
misperception of sleep loss and daytime effects can lead to a real deficit during 
night and during the day and thereby maintain the disorder. This model thus 
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gives equal weighting to night and daytime effects, in line with the view that 
insomnia is a 24hr disorder.(135)   
Additional steps to cognitive therapy thus also include targeting sleep 
misperception, eliminating safety behaviour like napping, and reducing attention 
bias, focusing explicitly on the daytime affects in addition to nighttime.(143) It 
might also include techniques, such as thought management (e.g. imagery(144) 
or simple strategies like saying the word “the” to occupy mental capacity). 
In comparison to the behavioural techniques outlined above, the 
literature on the efficacy of cognitive therapy for insomnia is less extensive. 
There is currently no randomised trial comparing the efficacy of cognitive 
therapy versus behavioural techniques. However a clinical trial is currently 
ongoing comparing cognitive therapy (cognitive restructuring) with behaviour 
therapy (SRT and SC) and CBT-I,(145), its efficacy has been documented in an 
open trial,(143) and there is evidence that maladaptive beliefs are sensitive to 
change with CBT-I.(146-148) 
1.2.4.2.6 Paradoxical Intention  
Initially adapted for sleep-onset insomnia(149, 150) from the original work by 
Frankl(151) this technique was aimed at targeting the patients increased effort 
to sleep and related anxiety when unable to “perform”.(152) Patients are 
instructed to lie in bed, keep their eyes open for as long as possible and give up 
the active effort for sleep. Espie adds a cognitive component to paradoxical 
intention instructing the individual to accept wakefulness, seeing it as an 
opportunity rather than tragedy.(152) This treatment is in concord with Espie’s 
psychobiological inhibition(153) and Attention-Intention-Effort(136) models, 
which consider sleep normalcy as automatic and involuntary and insomnia as a 
disruption to that process. In the A-I-E model, Espie further refines the 
components that contribute to the inhibition of this normal process: a) the 
selective attention towards b) explicit intention to and c) increased effort to 
initiate sleep.(136) In addition to paradoxical intention, both models sit well 
with other therapies described above (e.g. cognitive therapy and stimulus 
control). 
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1.2.4.3 Cognitive-Behavioural Therapy for insomnia (CBT-I) 
Cognitive behavioural therapy for insomnia (CBT-I) is a multi-component therapy 
that combines single or multiple behavioural and cognitive strategies outlined 
above. A total number of 8 meta-analyses have summarised the effects of CBT-I 
for improving sleep related outcomes.(140, 154-159) These meta-analysis 
indicated medium to large effect sizes (Cohen’s d(160)) at the end of treatment 
for SOL [0.4-1.0], WASO [0.6-1.0], sleep efficiency (SE) [0.5-0.8], NWAK[0.25-
0.8], and medium for total sleep time (TST) [0.2-0.5] and large effect sizes for 
sleep quality (SQ)[0.7-1.5]. The magnitude of change tends to increase at 
follow-up, especially total sleep time when studies include a sleep restriction 
component.  
The only model that explicitly combines the psychological and biological 
perspectives is Perlis’ neurocognitive model(134) and is worth mentioning at this 
point. In an attempt to explain phenomena such as sleep misperception, Perlis 
describes the development of insomnia as a result of conditioned cortical 
arousal. The initial precipitating event might induce cognitive, somatic and 
cortical arousal as a result of the stressor. In line with the behavioural 
perspective, chronic insomnia develops and is maintained through maladaptive 
behaviours like extending the time in bed; as a result, the bedroom becomes 
associated with arousal through classic conditioning principles, absent from the 
original stressor. The increased cortical arousal at sleep onset explains changes 
in sensory and information processing as well as long-term memory formation 
and contributes to the individual’s (mis)perception of increased wakefulness and 
decreased sleep. This phenomenon is characteristic of individuals with insomnia 
and to an exaggerated extent in paradoxical insomnia.(161) Thus targeting 
cognitive, behavioural and physiological aspects of the development of insomnia 
with CBT-I fits well with this model.  
1.2.4.4 ‘Third-wave’ techniques 
Interesting ‘third-wave’ techniques have been developed in addition to the CBT-I 
techniques and pharmacological options mentioned above. Mindfulness-based 
stress reduction is an approach that encourages the individual to adopt an 
accepting and non-striving approach to sleep and the negative thoughts they 
might endorse, subsequently reducing the somatic and cognitive arousal and its 
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efficacy has recently been tested in combination with cognitive-behavioural 
techniques.(162) 
Another exciting development is intensive sleep retraining (ISR) developed 
by a group in Adelaide, Australia.(163, 164) It is based on classic conditioning 
and involves retraining the already sleep deprived (5hrs on pre-treatment night 
at home) individual by repeated waking after 3 consecutive minutes sleep. This 
is continued throughout all 50 sleep opportunities over a 25 hr period. A recent 
randomised control trial comparing ISR with or without stimulus control to 
stimulus control alone or control (sleep hygiene) reported despite all active arms 
producing significant improvements, the arms including ISR had speedier 
improvements in SOL and TST by week one, compared to the arms without.(164) 
Lastly, a technique presented at the Associated Professional Sleep Societies 
(APSS) conference in 2011 involved cooling of the frontal cortical areas, which 
have been associated with increased activity in the individual with 
insomnia.(165) This was only a small study of 12 participants with primary 
insomnia, matched with 12 healthy controls, thus larger studies are warranted.  
One novel development worth mentioning is the combination of 
pharmaco- and psychological therapies, which might complement each other, 
and utilise their respective strengths (fast acting vs. sustained effects 
respectively).(166) A recent study tested the delivery of CBT-I alone or in 
combination for 6 weeks, which was further extended by continued CBT-I alone, 
no treatment or no change to treatment (i.e. continued zolpidem+CBT-I). The 
best treatment response was for the combined arm followed by CBT-I 
alone.(167) Further research in these areas is clearly warranted. 
1.2.5 Summary  
It is evident that chronic insomnia is a prevalent and debilitating disorder that 
warrants treatment, either with pharmacological (short-term or in combination 
with CBT-I), cognitive and/or behavioural treatments. The efficacy has been 
established, but to determine true effectiveness, it is now important to turn the 
attention towards adherence.   
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1.3 Adherence 
 
 
“Keep%a%watch%also%on%the%faults%of%the%patients,%which%often%make%them%lie%about%the%taking%
of%things%prescribed”%Hippocrates%(460–377%BC)%
1.3.1 Definition of Adherence:  
As described so potently by Hippocrates himself, adherence is a natural human 
process that yields considerable attention. Especially because adherence to 
medical recommendations is one of the strongest predictors of treatment 
outcome health practitioners need to consider managing and promoting 
adherence as part of treatment itself. The World Health Organisation (WHO) 
recently emphasised that increasing adherence to existing treatments can have a 
far greater impact on health than improvements in specific treatments for 
disorders.(168) 
As reported in a recent meta-analysis, the average non-adherence rate of 
approx. 25% for complex treatment interventions translates to 188.3 million 
medical visits in the US resulting in patients failing to implement 
recommendations and equating to a monetary waste of potentially US$ 300 
billion a year.(169) Apart from this economic cost, non-adherence inhibits the 
evaluation of treatment efficacy at the research level, and can hinder treatment 
effectiveness at the clinical level.  
Reflective of this impact, there has been an increase in research on 
adherence to medical regimes and recommendations in the last decades. In this 
journey to understand complex issue of adherence, a large variance in reported 
adherence rates has been cited. These differences may be accounted for by 
illness and treatment type and the assessment method of adherence.(169) A 
further reason, only briefly touched upon by the author of the meta-analysis, 
may be differences in conceptualisation of the term adherence. Although the 
terms adherence and compliance have often been used interchangeably in 
research, there are distinct differences that have been recognised.  Compliance 
refers to “the extent to which a person’s behaviour (in terms of taking medications, 
following diets or executing lifestyle changes) coincides with medical or health 
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advice”,(170, pp. 2-3) whereas the use of the term adherence implies that the 
individual’s behavior “corresponds with agreed recommendations from a health 
care provider”(168, p.18) 
Thus the transition away from the term compliance emphasises the 
importance of a non-authoritarian approach and a balanced doctor-patient 
relationship.(171) In order to accomplish this in a clinical setting, the 
practitioner is required to gain insight into the patient’s beliefs and attitudes 
towards changing their behaviour, and to understand which factors play a role in 
motivation to adhere. At the research level, psychosocial variables are 
considered over and above the static biomedical factors, see Table 4. 
 
Table 4: Conceptualisation of adherence vs. compliance 
Level Compliance Adherence 
Conceptual 
Person’s behaviour coincides with medical 
or health advice given 
Person’s  behaviour is in correspondence with 
the agreed recommendations 
Research Biomedical (Biological/treatment 
specific/demographic) variables 
Psychosocial variables (beliefs, attitudes, 
motivation, social support) and biomedical factors 
Clinical 
Biomedical model Patient-centred/ Holistic/ Integrative model (BPS) 
 
Some have argued the term adherence still implies a sense of 
authority,(171) and there has been push towards the term ‘concordance’, which 
is more focused on the success of involving the patient in the decision making 
process.(172) The term adherence will be used in the remainder of this thesis 
because it is frequently cited in the literature, and sufficiently differentiates 
itself from the medical approach to the patient’s behaviour. The exception to 
this is in chapter 5, which has been included as a published paper, where the 
term compliance is used to describe the numeric value rather than the 
behaviour). This introductory chapter will review the literature on adherence to 
CPAP and CBT-I. Three areas will be covered for each treatment: 1) 
measurement and 2) predictors of and 3) interventions to improve adherence, 
with a brief introduction to medication adherence at each section, because this 
is undoubtedly the most frequently researched topic.(169) 
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1.3.2 Measurements of Adherence  
Measurement of adherence to medication can largely be separated into two 
categories: indirect (self or family/physician report, markers such as pill counts 
or filled prescriptions and electronic monitors) and direct (urine/blood 
tests).(173). Electronic monitors and urine/blood tests are often considered gold 
standard,(174) however these are costly and time-consuming; reported 
estimation of adherence is often above objective measurements when reported 
by the practitioner(175) and patient.(176) Due to the large variety in types of 
measurements, average rates of non-adherence are difficult to obtain, however 
a recent meta-analysis reported an adherence rate of 79.4%.(169) 
1.3.2.1 Measurement of Adherence to CPAP  
1.3.2.1.1 Subjective Adherence  
The most common metric for CPAP adherence reported in the literature 
has been ‘average hours of CPAP use per night’. There are however some 
variations, which include ‘percentage of days CPAP was used’, ‘percentage of 
study participants considered adherent using the cut-off of at least 4hrs CPAP 
use/night for at least 70% of nights/week’; ‘percentage of nights used more than 
4hrs’ or ‘average CPAP use per night only considering nights used’. (177) 
Throughout this thesis, where not otherwise specified, adherence to CPAP refers 
to the common metric of ‘average CPAP use in hours/night’.  
The earliest empirical studies assessing CPAP adherence rates relied exclusively 
on subjective self-reported use. The initial consensus was that subjective 
adherence was relatively high and CPAP was a well tolerated therapy for the 
treatment of OSA,(178-180) however subsequent reports found these subjective 
rates to only weakly correlate with objective adherence and reported that 
individuals overestimate actual average nightly CPAP use by as much as 1 
hour.(181-183) In Kribbs seminal prospective study in 1993, thirty-five 
individuals with OSA were provided with a CPAP machine and followed up an 
average of 3 months later.(181) A microprocessor that established mask-on-face 
time, indicated that individuals used the machine on average 4.88 +/- 1.97 
hrs/night. However, when asked to report their use subjectively, this rate was 
increased by 69 +/- 110 min. These differences were replicated in Engleman et 
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al. 1996(182) and Rauscher et al. 1993,(183) who reported differences between 
0.9 hrs and 1.2 hrs/night respectively.  
1.3.2.1.2 Objective Adherence 
Since the initial reports on these covert electronic surveillance in 1993 and 
94(181, 184), recent studies have almost exclusively relied on in-built time 
counters assessing ‘objective’ or microprocessors measuring ‘effective’ use, 
indicating that CPAP adherence is not as high as initially thought. Earliest studies 
evaluating CPAP use other than through self-report, used inbuilt time counters 
that recorded the time the machine was turned on for.(185, 186) However, this 
technique was not considered optimal, with the fear that individuals might be 
aware of being monitored(181) Additionally, it allowed no measure of the time 
the mask was effectively worn, and it was not until the simultaneous publication 
of the use of a technique to measure pressure at the mask from two separate 
working groups,(181, 184) that this was accomplished. A pressure transducer 
located on the air outflow of the machine records the rise in pressure when the 
mask on the face thereby recording effective CPAP use.(181) Although these two 
measurements (objective use and effective use) are strongly correlated(187) 
with only a 10 % difference in these recordings(181), the majority of studies 
today report effective use obtained from a smart card located within the CPAP 
device.  
With these methods of assessment, it is generally accepted that 
adherence to CPAP is less than adequate. Starting with initial acceptance, 
studies have indicated that approximately 1/4 of patients do not take up CPAP 
or discontinue in the first 2 weeks after their titration study.(188-192)  Rauscher 
et al. reported that of 95 individuals with OSA, who had been offered CPAP, 32 % 
rejected CPAP immediately and of those who did 27% refused home treatment 
shortly after the titration night. Similar post titration acceptance rates between 
20-30 % were reported in a subsequent review(190) and again replicated in more 
recent studies.(188, 189, 192)  
The majority of individuals who use CPAP at 1 month will continue doing 
so long term and early use is a strong predictor of long-term adherence (see 
below). However objective studies of those continuing treatment (>1month), 
‘adequate’ adherence rates (often defined as ≥ 4hrs on 70% of the nights(181)) 
can vary between 46-89% depending on definitions of adherence and length of 
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follow-up.(181, 184, 188, 193-202)  The average hours of use per night in these 
studies varies between 4 and 6 hrs. Most of the above studies have used the 
arbitrarily set cut-off of 4 hrs per night on 70 % of the nights for ‘adequate’ 
adherence based on Kribb et al’s work in 1993,(181) and thus adherence is often 
conceptualised as a dichotomous variable (adherent vs. non-adherent). This 
process was initially validated with two distinct patterns emerging from analysis 
of CPAP users,(203, 204) however recent evidence challenges this approach. 
Aloia et al. examined CPAP use in 71 OSA participants across 365 days and 
reported a total of seven categories of adherence, including the 
compliance/non-compliant group, but adding slow improvers/decliners, variable 
users, occasional attempters and early drop-outs.(205) 
In addition, recent work by Weaver et al. in 2007 questions the arbitrary 
cut-off of 4hrs/night. The authors highlighted different values for optimisation 
depending on outcome variable. The majority of individuals returned to normal 
values for daytime sleepiness after an average 4hrs/night of CPAP use, whereas 
for objective sleepiness and daytime functioning, the values were 6 and 7.6 
hrs/night respectively. There was a dose-response relationship between CPAP 
use and improvements in sleepiness, indicating more use leads to a better 
outcome of increased alertness.(57) 
 
1.3.2.2 Measurement of Adherence to CBT-I:  
The information on measurement of adherence to CBT-I is much less abundant. 
This may to a large extent be due to its multicomponent nature(206) and the 
majority of studies have focused on examining adherence to the behavioural 
components of CBT-I, whether these are presented in isolation or within the 
cognitive-behavioural package (see Table 5). Furthermore, CBT-I may inherently 
incorporate efforts to monitor and improve adherence.(see 207)      
Measurements are largely restricted to very crude measures such as 
attendance rates or self/spouse or therapist questionnaires, some of which are 
poorly defined or designed.(e.g. 208, 209-211) One study(208) adapted the five-
item Medical Outcomes Study Specific Adherence Scale(212) to assess adherence 
to sleep restriction and stimulus control. Three of the five items assessed 
individuals’ adherence to the treatment plan (e.g. I was unable to do what was 
necessary...”) however two of the items assessed ‘ease’ and ‘difficulty’ in 
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adhering to the doctors recommendations, aspects that are not exclusively 
associated with adherence. This might explain the moderate Chronbach’s alpha 
of .78 reported by the original authors. 
A more reliable measure perhaps has been the use of sleep diaries to 
obtain an estimation of deviation from their prescribed threshold and rising time 
and time in bed. In 2001 Riedel and Lichstein published a detailed description of 
5 strategies to calculate adherence to a sleep compression program.(213) No 
changes were made to the bed window at the final treatment session, so 
adherence was could also be calculated from the 2-weeks posttreatment sleep 
diary. The following 5 adherence measures were computed: (1) difference from 
prescribed time in bed (TIB) at final treatment to reported TIB at 
posttreatment. (2) reported TIB reduction as a percentage of prescribed TIB 
reduction (3) mean TIB change (4) consistency of TIB (5) consistency of get up 
time. This study found a relationship only between the latter two measures and 
treatment outcome (fewer and shorter awakenings and sleep quality 
improvements), indicating consistency rather than absolute minute adherence 
was related to outcome. Other studies have described a positive relationship 
between various outcome measures and therapist rated(214) or self-
reported/diary obtained adherence,(137, 206, 208, 215-217) however others 
have found no relationship(218) or only non-significant trends.(219) 
Apart from one study examining the optimal “dose” of CBT-I 
sessions,(220) there has been no dose-response study to determine how much of 
any or each component is needed to produce significant improvements. 
There are a few unique issues to consider with CBT-I that are worth 
mentioning. The first is relative adherence, that is, how adherent was the 
individual at times when implementation was required. Importantly, with some 
components (e.g. thought blocking; quarter-of-an-hour rule), increased 
improvement is associated with a decrease in required implementation. Some 
studies outlined in Table 5 have not factored this in to their adherence measure, 
(210, 211, 221-223) in others it remains unclear;(206, 209, 219, 224) overlooking 
this consideration may result in an overestimation of non-adherence.  
Secondly, and this concerns the measures outlined in Riedel and 
Lichstein(213) and used by others,(162, 208, 214) when assessing adherence to 
sleep restriction, there is a need to score bed and get up times within the set 
window as adherent e.g., if an individual is told to go to bed at 1am and retires 
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at 1.30 am when feeling sleepy, this should not be considered non-adherence. 
Perlis et al. 2004(218) for example replaces all time points after the threshold 
time to zero, indicating adherence to the sleep restriction instructions (“go to 
bed on or after threshold time”). This has not been incorporated in Riedel and 
Lichstein’s calculations, failure to do so for both threshold and rising time (at 
least when sleep restriction therapy is administered without stimulus control, 
where the individual is instructed to keep a consistent rising time), could 
overinflate rates of non-adherence.  
Table 5 outlines studies that have examined either single or multiple 
behavioural components and CBT-I. Definite conclusions cannot be drawn 
because of the differences in study designs, recruited samples and adherence 
measures. In summary, a wide range of techniques has been presented to 
measure adherence to components of CBT-I. Thus, it is difficult to draw any 
conclusions about optimal adherence from this data. Nevertheless, it does seem 
that adherence in this population is skewed towards higher rates, and where 
adherence to sleep scheduling is conceptualised in minute deviation, individuals 
are mostly within 30 minutes of their prescribed times, see Table 5. Where 
individual components are compared, adherence rates for sleep hygiene and in 
some studies relaxation seem to be highest. Undoubtedly, our understanding of 
adherence to the cognitive and behavioural treatments for insomnia is relatively 
sparse, especially in terms of 1) optimal measures of adherence 2) possible 
normative values or clinically meaningful cut-offs for ‘adequate adherence’ 3) 
any dose-response relationship with outcome. This information could have 
significant implications for the evaluation of CBT-I effectiveness, this being a 
function of treatment efficacy and patient adherence.(168, 225, 226)  
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Table 5: Overview of studies measuring adherence to CBT-I 
 Author (Date) Sample Description+ Adherence Measure Predictors of Adherence 
(Association with 
adherence) 
Adherence Rates 
Single/Multiple 
Behavioural 
Components 
Spielman et al. 
1987(137) 
35 CI completing sleep 
restriction therapy 
Sleep Diary [less time time in 
bed reduction at follow-up 
compared to posttreatment] 
- Follow-up reduction in TIB was 
less (39 minutes) than at 
posttreatment (74 minutes) 
Schoicket et al. 
1988(209) 
74 SMI randomised to 
sleep hygiene (SH), 
meditation (M) or 
stimulus control (SC) 
Self-report [number of days 
components were adhered to] 
- SH= 5.5 days per week 
M= 5.6 
SC= 4.7 days 
Riedel et al. 1995(227) RCT with older PI and 
older adults without 
insomnia (WoI); 50 
randomised to education 
video and 50 to 
video+guidance on sleep 
compression (video 
included guidance on 
restricting time in bed) 
Sleep Diaries [significant 
reduction of time in bed at 
posttreatment and followup] 
- Education+video= significant 
reduction of time in bed to 
posttreatment (PI and WoI) and 
follow-up (PI only) 
Video only= no significant 
reduction of time in bed 
Riedel & Lichstein 
2001(213) 
22 older PI completing 
SRT 
Sleep Diary [5 measures, variant 
calculations of minute deviation 
from prescribed time in bed] 
- Individuals spent 28 min more 
in bed than prescribed, 64% 
were in bed within 30 min and 
36% within 15 min of their time 
in bed.  
Pallesen et al. 
2003(219) 
RCT with 55 older CI 
randomised to either 
sleep hygiene+stimulus 
control or sleep 
hygiene+relaxation 
Self-report [rating from 1-3 on 
adherence to all components 
with higher scores indicating 
greater adherence] 
- - 
Waters et al. 2003(211) 53 CI randomised to 
either SH, M, SR/SC or 
progressive muscle 
relaxation + Cognitive 
distraction training 
(PMR/CD). In phase 2 
participants in the 
PMR/CD group were also 
provided with SR/SC 
instructions 
Self report [Adherence Checklist 
asking participants if they 
adhered to the relevant 
component with a yes/no 
response format, adherence was 
conceptualised as the % of 
nights the recommendation was 
followed] 
- Participants adhered to the 
components between 47-99% of 
the nights. The highest 
adherence rates were reported 
for medication and lowest for 
cognitive distraction.  
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Carney et al. 2004(228) 68 good sleepers 
randsomised to being 
made aware or not that 
the actiwatch monitors 
adherence to SRT 
Actigraphy [Bedtime and Get–up 
time were determined from 
algorithms to establish a 
reduction or increase 
respectively in activity 
respectively] 
- Aware group: went to bed 12 
minutes after their threshold 
time; got up 16 minutes after 
Non-aware group: went to bed 
1hr12 min late; got up 30 
minutes late. 
Epstein et al. 2012(229) RCT with older PI; 44 
randomised to SC, 44 to 
SRT, 41 multi-
compoment treatment 
(SC+SRT) 
Attendance rates [attended out 
of 6 sessions] 
Self- & significant other report 
[ratings on scale of 0-4 at 
posttreatment and follow-up 
with higher scores indicating 
better adherence; 
Sleep Diaies [self-report 
questions to obtain % of days 
components were adhered to] 
- Significantly more session were 
attended in the SC and multi-
component arm= 5.86 and 5.83 
respectively, than the SRT arm. 
Average self- and spouse 
reported adherence rates were 
≥3 in all treatment arms 
Sleep diary ratings were 89.3% 
for CBT-I; 87.3% for SRT, and 
90.0% for multi-component. 
 
McChargue et al. 
2012(221) 
113 breast cancer 
patients with co-morbid 
insomnia completing 
behaviour therapy (SC, 
SRT, relaxation and 
sleep hygiene) 
Self-report [individuals indicated 
behavioural treatments used on 
all days assessed] 
Increase in depressive 
symptoms  
Improvements in sleep 
 
Individuals implemented 
behavioural components 51-52% 
of nights measured. Highest 
rates reported for sleep 
hygiene, lowest for sleep 
restriction and stimulus control  
CBT-I Mimeault et al. 
1999(224) 
RCT with 36 PI 
randomised to 
bibliotherapy either with 
or without therapist 
guidance  
Self & Significant Other Report 
[adherence items on treatment 
evaluation questionnaire; 
ratings ranged from 0-100 with 
higher score indicating better 
adherence] 
- - 
Vincent et al. 2001(230) 37 CI completing CBT-I Attrition [Completed or did not 
complete treatment] 
Pre-treatment 
acceptability ratings 
of CBT-I treatment 
Dropouts= 18% 
Harvey et al. 2002(206) 90 PI 12 months after 
completion of CBT-I 
Self-report [% of individuals 
indicating the continued use of 
10 components] 
- On average 39% of individuals 
were using components; highest 
reports for relaxation=74%; 
lowest for imagery=19% 
Bouchard et al. 
2003(231) 
39 PI Sleep Diary [Composite Score of 
adherence to 8 behaviours 
obtained from the sleep diary 
entries, scores ranged from 7-49 
for each week with higher scores 
General, task-related 
and self-regulatory 
self-efficacy  
Average score over all 
weeks=44 
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indicated better adherence] 
Morgan et al. 2003(232) RCT with 108 chronic 
hypnotic users 
randomised to CBT-I 
Attendance Rates [individuals 
were separated into those 
completing all and fewer than 
six sessions] 
Poorer sleep quality 
(PSQI) at baseline  
65% completed all 6 therapy 
sessions 
Vincent et al. 2003(214) 50 PI Sleep Diary [consistency of 
bedtime and wake-up time] 
Therapist and Spouse reported 
[scale 5-25 with higher scores 
indicating greater adherence] 
Attendance Rates [ % Therapy 
Sessions Attended] 
Dysthymia*  Attendance Rates 92% 
Therapist reported 48% were 
very much or extremely 
adherent 
Average spouse-report = 21 
Perlis et al. 2004(218) RCT with 10 PPI to 
Modafinil+CBT-I and 12 
PPI to Placebo+CBT-I 
Sleep Diary [adherence was 
considered if the individual went 
to bed on average 15 minutes 
earlier than prescribed time for 
each week; final adherence 
score=% of individuals adherent 
each week] 
-  CBT-I+modafinil= 80% adherent 
CBT-I+placebo=51% adherent 
Vallieres et al. 
2005(233) 
RCT with 17 PI 
randomised to three 
different combinations 
of CBT-I and medication 
Sleep Diary [see Bouchard et al. 
2003; scores were presented in 
percentages] 
-  Sequence 1: CBT-I + Med after 
medication alone; rates of 
behavioural components ranged 
from 68 .3% to 92.5% across 
weeks 
Sequence 2: Combined med and 
CBT-I rates were 92.3% and 
decreased to 72.5% in 
subsequent CBT-I arm  
Sequence 3: CBT-I alone rates 
varied between from 50.0% to 
85.7%. 
Sivertsen et al. 
2006(210) 
 
RCT with 18 PI 
randomised to CBT-I 
Attendance Rates [number of 
sessions attended] 
Self-report [adherence ratings 
on a scale 0 (never) to 5 (every 
day)] 
- Attendance rates 100% 
Average rating= 4.8 (6-week 
posttreatment); 4.1 (6-mth 
follow-up) 
Ong et al. 2008(162) 30 PPI undergoing CBT-
I+mindfulness 
Sleep Diary [see Riedel and 
Lichstein, calculated adherence 
to time in bed and get up time] 
- 22 minutes more time in bed 
30 minutes in bed later than 
get-up time 
Vincent et al. 2008(208) 40 CI completing CBT-I Attendance Rates [%therapy 
sessions attended] 
Increased age* 
Use of medication* 
91% sessions attended 
Average score of 21.4 on self 
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Self-Report [Global ratings 
ranging from 5 to 30] 
Sleep Diary [consistency of 
wake-up time] 
Perceived certainty in 
adherence* 
Fewer barriers  
Pretreatment 
sleepiness  
report 
Variance in wake-up times post 
treatment= 0.91hrs 
Morin et al. 2009(167) RCT with 38 PI to CBT-I 
(6weeks)+extended CBT-
I  (6months); 37 to CBT-I 
+no treatment; 37 to 
CBT-I 
+zolpidem+extended 
CBT-I alone and 37 to 
CBT-I 
+zolpidem+extended 
CBT-I with zolpidem as 
needed  
Attendance Rates [Therapy 
sessions] 
- 6-weeks CBT-I = 5.6 sessions 
attended 
6-week CBT-I +zolpidem= 5.8 
6 month extended CBT-I =5. 5 
6 month CBT-I with no further 
zolpidem=5.4 
6 month CBT-I with zolpidem as 
needed=5.5 
Trembley et al. 
2009(216) 
RCT with 57 cancer 
patients with co-morbid 
insomnia randomised to 
CBT-I 
Sleep Diary [dichotomous 
evaluation (yes/no) of sleep 
diary entries along 5 criteria; 
adherence depicted the % of 
days individuals adhered to 
these criteria) 
- 88% at both 8-week 
posttreatment and 6 months 
follow-up 
Vincent et al. 2009(222) RCT with 59 PI 
randomised to online 
CBT-I 
Self-report [% of individuals 
implementing components ≥4 
nights per week] 
- Lowest adherence rates 
=hypnotic tapering (22..6%);  
highest adherence rates=sleep 
hygiene(76.8%); 
Of relaxation strategies: Paced 
breathing > progressive muscle 
relaxation, hypnosis or imagery 
Hebert et al. 2011(223) 47 PI completing online 
CBT-I 
Self-report [see Vincent et al. 
2009] 
Perceived behavioural 
control* 
Social support* 
Intention to complete 
CBT-I* 
Readiness to change* 
Week 1 range= 39% (exercise)-
95% (alcohol tapering) 
Week 2= 82.6 % (avoid napping, 
regular sleep schedule, avoid 
reading in bed) 
Week 3 range= 39% (muscle 
relaxation and imagery)-
60%(abdominal breathing) 
Manber et al. 2011(215) 301 CI completing CBT-I 
in a clinical setting 
Self-report [assessing the degree 
(0-3) of adherence to all 
components of CBT-I-higher 
scores indicate better 
Depression scores*  Behavioural Components: mean 
2.2 (Low Depression Group) 
mean= 2.1 (High Depression 
Group) 
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CI= Individuals with Chronic Insomnia; PI= Individuals with Primary Insomnia; PSQI= Pittsburgh Sleep Quality Index; PPI= Psychophysiological Insomnia; RCT= 
randomised Controlled Trial; SMI= sleep maintenance insomnia; * correlational or test of differences only (not regression analysis); + Randomised individuals; 
overall sample size might be larger, where RCT included a non-CBT-I  (e.g. medication) arm or placebo/waitlist control; SC=Stimulus Control; SRT= sleep 
restriction therapy. Studies were identified through a PubMed search with the terms “adherence” or “compliance” and “insomnia” and “CBT” and through 
reference lists of other publications.
adherence]   
Cognitive Components: 
mean=2.3 Low Dep Group); 
mean=2.2 High Dep Group) 
 
Matthews et al. 
2012(217) 
34 breast cancer 
patients with co-morbid 
insomnia undergoing 
CBT-I 
Sleep Diary [Daily yes/no 
evaluation according to 1) 
bedtime 15 within prescribed 
time; 2) get up time within 15 
minutes of the prescribed time 
3) total time in bed within 30 
minutes of prescribed time; 
adherence was defined as days 
adherent/week] 
type of cancer 
treatment received 
(Chemotherapy)* 
motivation to change* 
 
baseline fatigue* 
 
Adherence to 1)bedtime= 5.4-
6.1 days/week across all 
treatment weeks  
2) rise time= 3.0-4.1 
3) time in bed= 4.2-5.1 
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1.3.3 Predictors of Adherence 
Establishing predictors of adherence is important for informing potential 
interventions to increase adherence. A recent comprehensive review of medication 
adherence reported certain factors to be associated with better adherence:  
increased age, positive beliefs about the illness and treatment, social support, 
positive doctor-patient relationship; whereas other factors are generally barriers 
for adherence:  psychological status (e.g. depression, anxiety, stress, low self-
efficacy), some sociodemographic factors (low literacy, no insurance and 
homelessness), adverse events, low English proficiency/health literacy and regime 
complexity.(234)  
1.3.3.1 Predictors of Adherence to CPAP  
1.3.3.1.1 Early CPAP use 
CPAP adherence within the first month is a strong predictor of long-term use (1 
month-12 months) with the majority of studies reporting very strong Pearson’s 
correlations of .7-.8, where reported.(181, 188, 196, 199, 201, 203, 204, 235-239). 
Aloia and colleagues showed CPAP adherence at 3 months in a sample of 140 OSA 
patients could be predicted by machine use on the first day. The Pearson 
correlation between CPAP adherence at day 1 and 6 months was moderate (r=.35), 
61 % of >4hr users on day 1 were also considered adherent at 6 months.(204) 
Other factors can be separated into biomedical, psychological and social 
factors as outlined in Table 6 along with references. 
1.3.3.1.2 Biomedical Factors 
1.3.3.1.2.1 Patient-Specific  
1.3.3.1.2.1.1 Age/Gender/Race 
Most studies indicate weak if at all clinically relevant relationships between age and 
CPAP adherence, especially when other factors are controlled for in multivariate 
analysis (e.g. gender, baseline ESS, baseline AHI), the relationship between age and 
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adherence disappears.(240, 241) A recent review however identified factors that 
might be unique to paediatric and geriatric groups.(242) A similar effect has been 
shown for gender, with some studies indicating higher rates in females, others in 
males and others again indicate no difference. Often these differences are too 
small to be considered clinically relevant; for example, a difference of 7 minutes/ 
night was reported between males and females in one study.(243) Limited 
information is currently available to make reliable conclusions on the effects of 
race or ethnic group. The majority of these studies have compared African 
American with Caucasian race and most have found higher adherence rates for 
Caucasians. However, some of these effects observed may be mediated by socio-
economic status, as found in one study comparing lowered adherence rates in 25 
Maori to the increased use in 101 non-Maori CPAP users.(244) 
1.3.3.1.2.2 Treatment-Specific 
1.3.3.1.2.2.1 Pressure modification  
Although the level of pressure (cm H2O) itself does not seem to have any impact on 
CPAP adherence, a number of studies have investigated the effect of different 
pressure delivery modes (i.e. autoPAP, BiPAP, and flexible pressure delivery (C-
Flex)).  Three recent meta-analyses(177, 245, 246) of technological interventions 
investigated pressure delivery modifications (i.e. autoPAP, BiPAP, and flexible 
pressure delivery (C-Flex)) yet found no evidence for increased adherence in any 
modality except for a small, but significant difference of 11-13 minutes/night in 
favour of auto-adjusting PAP in all(246) or only cross-over studies.(177) The authors 
however note that there is little evidence for the use of autoPAP in unselected 
patients. Additionally, only about 20% of the reviewed papers were clearly 
described as double blind studies.(177) 
However, there is some evidence that pressure modifications might be 
beneficial in certain subgroup e.g. less compliant patients or those with a poor 
titration experience.(247-249) A recent pilot study investigated adherence in 51 
individuals with poor initial experience with the CPAP machine who were then 
provided with either CPAP or an auto-bilevel machine. Although not significantly 
different, a higher percentage of individuals using the machine for more than 4hrs 
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per night were in the bi-level group compared with the fixed pressure group (62% 
vs. 54%). The authors attributed this null finding to a lack of power.(247) 
1.3.3.1.2.2.2 Adverse Effects  
Adverse effects from the CPAP machine may include dry mouth, blocked nose, skin 
irritation, mask leaks or frequent awakenings, to name a few. There is conflicting 
evidence on the relationship between side effects and adherence. The majority of 
studies have indicated no relationship, with reports of side effects also occurring in 
adherent patients(204). Interestingly, some studies indicate that specific or clusters 
of side effects might negatively impact on CPAP use,(182, 203, 204, 236, 250) 
others also argue that side effects might be more often reported in certain 
subgroups (Personality Type D).(251). These studies however often fail to control 
for these symptoms as they occur before treatment.(252, 253) One prospective 
study of 385 OSA patients treated with CPAP reported that some symptoms were 
present before the initiation of CPAP and actually improved with effective CPAP use 
[throat, mouth and nose dryness and nasal stuffiness]; rhinorrhoea was the only side 
effect that distinguished users from non-users (those who had abandoned CPAP) at 
1 year(252)  
Reductions in adherence rates, as a result of claustrophobic reactions to 
wearing a mask, have been reported in the literature.(181, 254) Only one study to 
date has identified the impact of a ‘traitlike’ claustrophobic tendency on CPAP use. 
Chasens and colleagues identified individuals with higher pre-treatment 
claustrophobia were almost twice as likely to use their machines for less than 
2hrs/night than those with a lower claustrophobia score.(254) Interventions to 
reduce claustrophobic reactions to the mask have been successful as outlined 
below.  
 
1.3.3.1.2.2.3 Mask Interface   
Increased attention has been devoted to improvements in the CPAP mask interface 
to make this treatment more acceptable for patients. However only a few studies 
have investigated the effect on adherence in randomised controlled environment, 
which leads to uncertain conclusions as to whether less obtrusive interfaces (e.g. 
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nasal pillows/nasal masks) are associated with higher adherence than their more 
obtrusive counterparts (e.g. oral/face masks).(255) Equally, limited data is 
available for humidifiers. The addition of humidification may reduce the presence 
of nasal side effects such as rhinorrhoea(256), however there is limited evidence to 
suggest that this improves CPAP use, and differences are often minor.(177, 256) 
 
1.3.3.1.2.2.4 CPAP pressure titration  
Variations of the titration method are generally not associated with any differences 
in subsequent CPAP use. Comparisons include lab versus home(257-260), manual vs. 
automatic vs. algorithm based(244, 258, 261-264), attended versus unattended in-
lab(265), split night vs. full night(266-269), one versus two full night titrations(270), 
or variations of more than two methods(270-274). What might be more predictive of 
adherence is the actual quality of the titration night, especially when evaluating 
patients’ sleep quality. A qualitative study described those with a poor titration 
night experience were most likely to report difficulties using a machine.(275) This 
finding has been corroborated with recent quantitative studies. Drake and 
colleagues reported that in 71 OSA patients, who had improved sleep quality during 
the titration study compared to the diagnostic overnight stay, used the machine for 
approximately 2 hrs more per night during the first 1½ months. This result 
remained significant after controlling for OSA severity as a potential 
moderator.(276) A number of studies have attempted to prospectively improve the 
sleep quality of the titration night. Following support for the use of a sedative 
hypnotic in a retrospective study and its effect on titration night sleep quality and 
subsequent adherence,(277) Lettieri and colleagues conducted a prospective 
randomised control trial in 98 individuals with OSA comparing eszopiclone or 
placebo pill during the titration night.(278) Improvements in sleep quality and a 1 
hr increase in CPAP use was reported on days used at 4-6 weeks in the active 
treatment arm compared to the placebo. In contrast, one study tested the effects 
of an auto-PAP machine “pre-treatment” for 2-months prior to the lab titration. 
Significantly increased sleep efficiency was found during the titration night 
compared to the control group (no pre-treatment prior to titration night), however 
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at 9- months follow-up there was no significant difference in adherence between 
the groups (5.1 ± 0.5 and 4.9 ± 0.4 hrs/night).(279) 
 
1.3.3.1.2.3 Disorder-Specific  
1.3.3.1.2.3.1 Disease severity (AHI, ODI) and BMI  
Positive relationships have been reported between OSA severity and CPAP 
adherence, these relations are however weak and a large proportion of studies 
show no relationship. Furthermore, there is no consensus on the appropriate 
measure of disease severity, some studies report a relationship with the AHI(240, 
280, 281), some with the ODI(241) and others with the RDI(29), which is known to 
underestimate severity as it represents the events per hour of recording (thus 
including nightly wake time). Some studies have indicated that greater BMI is 
related to increased CPAP use, but again these relationships are weak.  
1.3.3.1.2.3.2 Symptomatic Severity (Baseline ESS)  
Higher rates of daytime somnolence at baseline have been associated with 
adherence in some studies, yet improvements in sleepiness post treatment might be 
a better predictor. Symptomatic improvement (reduction in sleepiness, daytime 
functioning, and health related quality of life) post treatment is associated with 
increased CPAP use. Higher CPAP use might be a result of reductions in functional 
symptoms; however, the reverse might also be true: resulting from a dose-response 
relationship, whereby increased use leads to increased improvements in 
symptoms.(59) There is tentative evidence to suggest both scenarios are equally 
valid. In the attempt to define determinants of CPAP use in South Florida Hispanic 
veterans, Wallace and colleagues reported that normalisation of the Epworth 
Sleepiness Score at week 1 (<10) remained a significant predictor of CPAP use at 1 
month, even when controlling for week 1 CPAP use.(236) Additionally, Weaver and 
colleagues reported only 30% and 50% achieved normal values on the multiple sleep 
latency test (MSLT) and Functional Outcomes of Sleep Questionnaires (FOSQ) 
respectively despite using the machine more than 7hr per night.(57) Antic et al. 
reported similar effects: one in 5 patients did not obtain normal sleepiness values 
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(Epworth<10) at follow-up despite adequate use,(58) thus not all of the 
improvement can be attributable to adherence. These two dose-response studies 
argue against a clear path from increased use to symptomatic improvement and 
together with Wallace’s study (partly) support the direction that symptomatic 
improvement! increased use.  
Support for the alternative direction is provided by a recently published 
study(1), which describes how part of the does-response relationship is a result of 
an expectation of benefit. Improvements as a result of increased use were 
witnessed in the placebo arm, where no therapeutic pressure was provided, 
supporting the direction increased use! increased improvement. However, these 
effects were also observed in the therapeutic arm (and to a larger extent), 
suggesting a possible interactive feedback loop, whereby increased use leads to 
improvements, which further motivates CPAP use.  
1.3.3.1.2.3.3 Nasal Resistance 
There is emerging evidence to support the association between upper airway 
resistance and CPAP adherence and this link is potentially two-fold.(282). A narrow 
upper airway may increase the perception of increased breathing effort and 
ultimately decrease CPAP use. Additionally, a narrow nasal passage and increased 
resistance might increase the frequency of mouth breathing and ultimately the 
possibility of mask leaks. However, the relationship might largely be related to 
initial acceptance rather than long-term CPAP use.(283-285) Interestingly, studies 
have indicated that nasal resistance/stuffiness measured subjectively does not 
predict CPAP adherence/acceptance(252, 253, 282, 284) even in patients where 
objective resistance does.(282, 284)  
1.3.3.1.3 Psychological  
It is clear from the above overview, that patient and treatment specific biomedical 
factors measured alone are relatively poor predictors of CPAP adherence. Thus, 
turning the attention also towards psychological and social factors might prove 
beneficial in our overall understanding of the factors that influence adherence.  
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1.3.3.1.3.1 Cognitive/Motivational  
1.3.3.1.3.1.1 Knowledge   
It is unclear whether increased knowledge of the disorder and its treatment, when 
measured as an independent variable, procures improvements in adherence. When 
knowledge is considered in combination with other variables of Bandura’s social 
cognitive theory (self-efficacy, outcome expectancy, and social support) the model 
explains between 11-40% of the variance in CPAP use.(286, 287) A recent meta-
analysis indicated that educational interventions do not generally produce 
improvements in CPAP use when contrasted with usual care, as outlined 
below.(288) The failure to measure post-intervention knowledge precludes the 
evaluation of the direct relationship between knowledge and CPAP use in these 
comparison studies.   
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Table 6: Variables influencing CPAP adherence 
Variables Impact on 
Adherence  
References 
Biomedical 
 Demographics/Patient Specific 
 Age (Ref=increased age) Increase  Woehrle 2011(243), Fuchs 2010+(289), Means 2010(290), Amfilochiou 2009(291), Collen 2009(277), 
Simon-Tuval 2009+(292), Budhiraja 2007(199), Li 2005(282), Scharf 2004(29), Sin 2002(195), McArdle 
1999(196)  
Decrease  Janson 2000+(293) 
No Difference Alves 2012(201), Pieh 2012(294), Wallace 2012(236), Bakker 2011(244), Gagnadoux 2011(280), Galetke 
2011(295), Letteri 2011(273), Sawyer 2011,(296) Ye 2011(297), Kohler 2010§+(241), Nguyen 2010(235), 
Baron 2009(298), So 2009+(285), Sopkova 2009(299), Poulet 2009§(300), Olsen 2008(301), Wolkove 
2008+(192), Yetkin 2008+(302), Sugiura 2007+(283), Morris 2006+(284), Aloia 2005(237), Chasens 
2005(254), Lewis 2004(303), Lloberes 2004(281); Wild 2004(304), Holland 2003(305), Ball 2001+(306), 
McFayden 2001(307), Pelletier-Fleury 2001§(240); Sage 2001(308), Noseda 2000(309),  Sanders 
2000(268), Pepin 1999(202) Weaver 1997(203); Edinger 1994+(310), Kribbs 1993(181), Rauscher 
1991+(191), Waldhorn 1990+(311), Nino-Murcia 1989+(312) 
Gender (Ref=male) Increase Woehrle 2011(243), Joo 2007(313), Llobreres 2004(281), Pelletier-Fleury 2001(240) 
Decrease Amfilochiou 2009(291), Sin 2002(195) 
No Difference Alves 2012(201), Campbell 2012(271), Stuck 2012(314) Pieh 2012(294), Wallace 2012(236), Bakker 
2011(244),  Gagnadoux 2011(280), Galetke 2011(295), Letteri 2011(273), Ye 2011(297),  Fuchs 
2010+(289), Kohler 2010+(241), Platt 2009(315), Poulet 2009§(300), So 2009+(285), Sopkova 2009(299), 
Ye 2009(316), Olsen 2008(301), Wolkove 2008+(192), Budhiraja 2007(199), Morris 2006+(284), Aloia 
2005(237), Chasens 2005(254), Li 2005(282), Lewis 2004§(303), Scharf 2004(29), Ball 2001+(306), Sage 
2001(308), Janson 2000+(293), Weaver 1997(203), Meurice 1994(193), Rauscher 1991+(191), Waldhorn 
1990+(311), Nino-Murcia 1989+(312) 
Race/Ethnicity (ref= 
minority) 
Decrease Campbell 2012(271), Pamidi 2012(317), Sawyer 2011(296), Ye 2011(297), Means 2010(290), Budhajara 
2007(199), Joo 2007(313) 
No Difference  Bakker 2011(244), Platt 2009(315), Chasens 2005(254), Scharf 2004+(29) 
 Treatment Specific 
 Pressure Modifications (ref= 
Bi-level, C-flex, APAP) 
Increase Ip 2012(246), Gentina 2011(248), Smith 2009 [auto-CPAP in cross-over studies](177) 
No Difference  Powell 2012(247), Blau 2011(318), Kushida 2011(319), Bakker 2011(245), Khayat 2008(320) 
Adverse Effects 
(ref=presence of side 
Increase Brander 1999(253), Weaver 1997(203) 
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effects) Decrease Wallace 2012(236), Ye 2011(297), Brostroem 2010(321), Kreivi 2010+(252), Baltzan 2009(250), Aloia 
2007(204), Broström 2007(251), Chasens 2005(254), Lewis 2004(303), Kalan 1999+(322), Engleman 
1996+(182), Engleman 1994(187), Kribbs 1993(181), Hoffstein 1992+(179) 
No Difference  Stepnowsky 2006§(287), Drake 2003(276), Russo-Mango 2001(194), Pepin 1999(202), Pepin 1995(323), 
Meurice 1994(193), Rauscher 1993(183), Waldhorn 1990+(311) 
CPAP delivery interface 
(ref=less obtrusive) 
No Difference  Ryan 2011(324), Nguyen 2010(235), Li 2005(282) 
Unclear (meta-
analysis) 
Chai 2006(255), 
Humidifiers No Difference  Ryan 2009(256) 
Unclear (meta-
analysis) 
Smith 2009(177) 
Pressure (ref=higher 
pressure) 
Increase Janson 2000+(293), Nino-Murcia 1989+(312), Kohler 2010+(241) 
Decrease Wild 2004(304), Pelletier-Fleury 2001(240)  
No Difference  Pieh 2012(294), Wallace 2012(236), Bakker 2011(244), Kreivi 2010+(252), Amfilochiou 2009(291), So 
2009+(285), Sopkova 2009(299), Berry 2008(262), Olsen 2008(301), Wolkove 2008+(192), Wells 
2007(325),  Morris 2006+(284), Stepnowsky 2006(287), Aloia 2005(237), Lewis 2004(303), Holland 
2003(305), Stepnowsky 2002§(286), Ball 2001+(306), Russo-Mango 2001(194), Sage 2001(308), Pepin 
1999(202), Meslier 1998(200), Weaver 1997(203) Kribbs 1993(181), Rauscher 1993(183), Waldhorn 
1990+(311), 
(Sleep) quality of titration 
night (ref=better quality) 
Increase Collen 2009(277), Lettieri 2009(278), Drake 2003(276), Lewis 2004(303) 
No Difference  Suzuki 2007(279) 
Titration method 
(ref=traditional in-lab full 
night titration) 
Increase Means 2004(265), 
Decrease Rosen 2012(258), Mulgrew 2007(260) 
No Difference  
 
 
Campbell 2012(271), Pamidi 2012(317), Wallace 2012(236), Kushida 2011(319), Bakker 2011(244), 
Skomro 2010(259), Letteri 2011(273), Collen 2010(266), McArdle 2010(272), Platt 2009(315), Berry 
2008(262), Kaplan 2007+(270), Cross 2006(257), West 2006(264), Hukins 2005(263), Lloberes 2004(274), 
Masa 2004(261), McArdle 2000(269), Sanders 2000(268), Strollo 1996(267) 
 Disorder Specific 
 Disease severity (AHI, RDI 
ODI, ref=increased severity) 
Increase Tarasiuk 2012(326), Gagnadoux 2011(280), Galetke 2011(295), Kohler 2010+(241), Kreivi 2010+(252), 
Means 2010(290), Simon-Tuval 2009+(292), So 2009+(285), Yetkin 2008+(302),  Sugiura 2007+(283), 
Bizieux-Thamin 2005(327), Lloberes 2004(281), Scharf 2004(29), Wild 2004(304), Drake 2003(276), 
McFayden 2001(307), Pelletier-Fleury 2001(240), Janson 2000+(293), McArdle 1999(196), Meurice 
1994(193), Reeves-Hoche 1994(184), Rauscher 1991(191), Nino-Murcia 1989+(312) 
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No Difference  
 
Alves 2012(201), Campbell 2012(271), Pieh 2012(294), Wallace 2012(236),  Bakker 2011(244), Letteri 
2011(273), Sawyer 2011(296), Ye 2011(297), Nguyen 2010(235), Amfilouchi 2009(291), Baron 2009(298), 
Platt 2009(315), Poulet 2009(300), Sopkova 2009(299), Berry 2008(262), Olsen 2008(301), Wolkove 
2008+(192), Budhiraja 2007(199), Kaplan 2007+(270), Morris 2006+(284), Aloia 2005(237), Chasens 
2005(254), Li 2005(282), Lewis 2004(303), Holland 2003(305), Sin 2002(195), Ball 2001(306), Russo-
Mango 2001(194), Sage 2001(308), Noseda 2000(309), Sanders 2000(268), Pepin 1999(202), Weaver 
1997(203), Engleman 1996+(182), Edinger 1994+(310), Engleman 1994(187), Kribbs 1993(181), Rauscher 
1993(183), Hoffstein 1992+(179), Waldhorn 1990+(311) 
Body Mass Index (ref= 
higher BMI) 
Increase Gagnadoux 2011(280), Kreivi 2010+(252), Baron 2009(298), Wild 2004(304), Pelletier-Fleury 2001(240), 
McArdle 1999(196), Nino-Murcia 1989+(312) 
No Difference  Alves 2012(201), Pieh 2012(294), Wallace 2012(236), Galetke 2011(295), Letteri 2011(273), Ye 
2011(297), Nguyen 2010(235), Amfilochiou 2009(291), Platt 2009(315), Poulet 2009(300), Simon-Tuval 
2009+(292), So 2009+(285), Sopkova 2009(299), Yetkin 2008+(302), Berry 2008(262), Olsen 2008(301), 
Sugiura 2007§+(283), Morris 2006+(284), Aloia 2005(237), Chasens 2005(254), Li 2005(282), Lewis 
2004(303),  Scharf 2004(29), Holland 2003(305), Sin 2002(195), Russo-Mango 2001(194), Janson 
2000§+(293), Noseda 2000(309), Pepin 1999(202), Weaver 1997(203), Edinger 1994+(310), Engleman 
1994(187), Reeves-Hoche 1994(184), Kribbs 1993(181), Rauscher 1991+(191) 
Symptomatic Severity 
(ref=increased e.g. daytime 
sleepiness or functioning) 
Increase Wolkove 2008(192), Yetkin 2008+(302), Lloberes 2004(281), , Scharf 2004(29), Wild 2004(304) Holland 
2003(305), Pelletier-Fleury 2001(240), Janson 2000+(293), McArdle 1999(196), Engleman 1996+(182), 
Reeves-Hoche 1994(184), W Rauscher 1991+(191) Waldhorn 1990+(311)  
Decrease Edinger 1994+(310) 
No Difference  Pieh 2012(294), Wallace 2012(236), Bakker 2011(244), Gagnadoux 2011(280) Lettieri 2011(273), Platt 
2011(315), Sawyer 2011(296), Galetke 2011(295), Ye 2011§(297), Kohler 2010+(241), Kreivi 2010+(252),  
Nguyen 2010(235), Amfilouchil 2009(291), Baron 2009(298), Poulet 2009(300), Simon-Tuval 2009+(292),  
So 2009+(285), Sopkova 2009(299), Berry 2008(262), Olsen 2008§(301), Budhiraja 2007(199) Kaplan 
2007+(270), Sugiura 2007+(283),  Morris 2006+(284), Aloia 2005(237), Lewis 2004(303), Stepnowsky 
2002§(286), McFayden 2001(307), Sage 2001(308), Sanders 2000(268) Weaver 1997(203), Engleman 
1994(187), Kribbs 1993(181), Rauscher 1993(183),  
Nasal Resistance/Upper 
Airway Obstruction 
(ref=increased resistance) 
Decrease So 2009+(285), Amfilochiou 2009(291), Sugiura 2007+(283), Morris 2006+(284), Li 2005(282), Nakata 
2005(328) 
No Difference  Kreivi 2010+(252), Chasens 2005(254), Holland 2003(305), Brander 1999(253),  
Symptomatic Improvement 
(ref=increased improvement) 
 
Increase Crawford 2012(1), Weaver 2007(57), Wallace 2012(236), Antic 2011(58), Kreivi 2010+(252), Simon-Tuval 
2009+(292), Wells 2007(325), Lewis 2004(303), Holland 2003(305), Sin 2002(195), Ball 2001+(306) 
McFayden 2001(307), Kingshott 2000(59), Rosenthal 2000(238), Pepin 1999(202), Meslier 1998(200), 
Engleman 1996+(182), Meurice 1994(193), Rauscher 1993(183), Kribbs 1993(181), Hoffstein 1992+(179) 
No Difference  Amfilochiou 2009(291), Kaplan 2007+(270), Lloberes 2004(281), Bakker(244), Engleman 1994(187), 
Psychological 
 Cognitive/Motivational 
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 Knowledge (ref=increased 
knowledge) 
Increase Trupp 2011 [negatively framed information](239), Fuchs 2010+(289), Ball 2001+(306), Likar 1997(329) 
No Difference  Smith 2009 [brief education session](288), Golay 2006(330), Stepnowsky 2006(287), Stepnowsky 
2002(286),  
Beliefs about OSA and 
CPAP (ref=maladaptive 
beliefs) 
Decrease Poulet 2009[total score from belief scale(331) ](300) 
Health Value (ref=higher 
health value)  
Increase Wild 2004(304) 
Locus of Control No Difference  Wild 2004(304) 
Perceived risk of OSA 
(ref=higher perceived risk) 
Increase Baron 2009(298), 
Decrease Olsen 2008(301), 
No Difference Wallace 2012(236), Simon-Tuval 2009+(292), Sage 2001(308) 
Outcome Expectancies 
(ref=expecting increased 
improvements) 
Increase Olsen 2008(301), Sage 2001(308) 
No Difference  Wallace 2012§(236), Baron 2009(298),  Stepnowsky 2006(287), Stepnowsky 2002(286), 
Perceived barriers 
(ref=increased barriers) 
Decrease Sage 2001(308) 
Cues to action No Difference Sage 2001(308) 
Self-efficacy 
(ref=increase) 
Increase  Trupp 2011(239), Sawyer 2011(296), Stepnowsky 2006(287), Aloia 2005(237),  
No Difference Wallace 2012§(236), Bakker 2011(244), Ye 2011§(297), Baron 2009(298), Olsen 2008(301), Wild 
2004(304), Stepnowsky 2002(286) Sage 2001§(308) 
Readiness to change 
(ref=increased) 
No Difference Aloia 2005§(237) 
Decisional Balance (ref=pros 
outweigh cons) 
Increase Stepnowsky 2006(287), Stepnowsky 2002(286) 
No Difference  Aloia 2005§(237) 
Personality 
(=negative trait) 
Decrease Moran 2010 [behavioural inhibition](332), Broström 2007[personality type d](251), Edinger 1994+[MMPI 
depression](310) 
No Difference  Wallace 2012(236), Trupp 2011(239), Drake 2003(276) 
Coping Style 
(=active coping style) 
Increase Stepnowsky 2002,(333) 
No Difference  Moran 2010(332), 
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 Psychological Co-morbidities 
 Insomnia (=ref increased 
insomnia severity) 
Decrease Pieh 2012(294), Wallace 2012(236), Wickwire 2010 [sleep maintenance problems only](334) 
No Difference  Nguyen 2010(235), 
Claustrophobia 
(ref=presense of 
claustrophobic tendency) 
Decrease Chasens 2005(254) 
Depression/Anxiety 
(symptoms or disorder) or 
other mental disorder 
(ref=presense of 
symptoms/disorder) 
Decrease Means 2010(290), Kjelsberg 2005+(335), 
No Difference  Pieh 2012(294), Wallace 2012(236), Gagnadoux 2011(280), Poulet 2009(300), Olsen 2008(301), Wells 
2007(325), Lewis 2004(303), Stepnowsky 2002(333), Russo-Mango 2001(194), 
Social   
 Socio-economic status  
(ref=higher SES) 
Increase Alves 2012(201), Tarasiuk 2012(326), Bakker 2011(244), Simon-Tuval 2009+(292), Platt 2009(315), Kribbs 
1993(181), Nino-Muricia1989(312),  
No Difference  Wallace 2012(236), Gagnadoux 2011(280), Galetke 2011(295),  Ye 2011(297), Campbell 2010§(271), 
Amfilouchi 2009(291), Poulet 2009(300), Scharf 2004(29), Weaver 1997(203), 
 Marital Status 
(ref=living alone) 
Decrease Gagnadoux 2011(280), 
No Difference  Wallace 2012(236), Ye 2011§(297), Platt 2009§(315), Poulet 2009(300), Olsen 2008(301), Kaplan 
2007+(270), Lewis 2004§(303), Wild 2004(304) Russo-Mango 2001(194),Weaver 1997(203), Kribbs 
1993(181),  
 Bed-sharing (ref=sleeping 
alone) 
Increase Simon-Tuval 2009+(292), 
Decrease Cartwright 2008(336) 
 Partner’s  sleep  quality 
(ref=improvement) 
Increase McArdle 2001(337) 
 Relationship Quality 
(ref=greater quality) 
Increase Baron 2009[conflict but not support subscale related to adherence](298), 
No difference McFayden 2001(307), 
 Pressure from Spouse 
(ref=increased pressure 
Decrease Baron 2011(338),  
 Support 
(ref=increased support) 
 General No Difference Stepnowsky 2006(287), Stepnowsky 2002(286) 
 Spouse/Close social 
relationships 
Increase Baron 2011+(338), Simon-Tuval 2009+(292), 
Therapist Increase Russo-Mango 2001(194), Smith 2009(288), 
§ becomes non-significant when controlling for other independent variables. + compared to subjective adherence only, or attendance 
rates/acceptance/termination of CPAP as a primary outcome,  AHI=Apnea Hypopnea Index, BMI=Body Mass Index, CPAP=Continuous Positive Airway Pressure, 
MMPI= Minnesota Multiphasic Personality Inventory, ODI= Oxygen Desaturation Index, RDI= Respiratory Disturbance Index, SES=Socio-economic status 
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1.3.3.1.3.1.2 Beliefs about the disorder and treatment 
A number of beliefs about the sleep disorder and the treatment have been 
established as predictors of CPAP use. An exciting trend in the literature is the 
adoption of social cognitive and stage models to explain CPAP adherence, 
ranging from the health belief model, social cognitive theory, the 
transtheoretical model and Wallston’s health locus of control and explaining 
about 11-58% of the variance in CPAP use.  
Wild and colleagues found that components of the health locus of control 
model along with AHI, CPAP pressure BMI and daytime sleepiness, could explain 
24 % of the variance in CPAP use.(304) Attribution of control to oneself, less belief 
in control of others and greater value of health were included in the final model, 
however only the latter variable was a significant independent predictor of CPAP 
use. Self-efficacy and belief that the condition is influenced only by chance had no 
significant impact on adherence in the 119 OSA patients. This null finding might be 
explained by the measurement of self-efficacy prior to initiation of treatment, as 
reported in other studies(237, 244, 286, 296, 298, 300, 304). When measured post 
CPAP experience this variable becomes a significant predictor of CPAP use,(236, 
237, 287, 296, 333) however not after controlling for prior objective CPAP 
use.(236, 237) Self-efficacy features in a number of social cognitive and stage 
models, most notably Bandura’s social cognitive theory (SCT)(339, 340), which 
has been rigorously tested by one particular working group.(237, 286, 287) 
Stepnowsky and colleagues(286) found that outcome expectancy, self-efficacy, 
social support and knowledge measured at 1 week and 1 month accounted for 
26% and 40% of the variance in CPAP use at 1 month respectively. In similar 
studies they replicated these findings in 98 OSA individual’s long term use of 6-
months(237) as well as 58 experienced CPAP users.(287) 
Apart from the SCT, these studies also investigated the predictive validity of 
the transtheoretical model (TTM). This dynamic stage-based model is further 
outlined below, but briefly it encompasses four components; the stage of change, 
processes of change, the decisional balance (pros vs. cons) and self-
efficacy/temptation. In the short-term follow-up study, TTM variables decisional 
balance, processes of change and stage of change were measured and explained 
17% and 33% when measured at week 1 and 1 month, yet baseline values were 
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not predictive of CPAP use.(286) The only component in the cross-sectional study 
was the decisional balance and together with side effects and CPAP pressure, it 
explained 47% of objective CPAP use.(287) The long-term follow-up study 
measured readiness to change and the decisional balance and together with self-
efficacy explained between 23-58% of the variance at week 1 and months 3 and 6. 
However, this model alone did not significantly succeed beyond the predictability 
of prior objective CPAP use.(237) Unfortunately, these studies failed to include all 
four components of the TTM within the same model and thus it is difficult to 
evaluate the TTM model from these studies.  
Another social cognitive model that has been investigated is the health 
belief model (HBM). Sage et al. 2001(308) and Olsen et al. 2008(301) examined 
HBM variables adherences post and pre CPAP initiation respectively. In a sample 
of 40 naïve CPAP users, Sage and colleagues found a univariate association 
between use and self-efficacy and only barriers to and benefits of adherence were 
independent predictors of CPAP use after one month. In this sample, HBM 
variables were assessed with a thematically organised scale against the 
components of the model. The aim of Olsen’s study was to replicate these findings 
when predictor variables were assessed prior to any experience of CPAP use. In 
their sample of 77 newly diagnosed OSA patients, they found benefits; severity 
and susceptibility and self-efficacy explained 21.8% of the variance in CPAP use 
at 4 months. Interestingly, this study made use of already validated sleep 
questionnaires, such as the Functional Outcomes of Sleep Questionnaire (FOSQ, 
341) and the Self-Efficacy Measure for Sleep Apnea (342) as equivalents to the 
constructs of the HBM. No validated sleep apnoea specific questionnaires for the 
constructs ‘barriers’ ‘cues to action’ ‘health motivation’ or ‘barriers’ existed at the 
time and therefore were not assessed. An additional limitation of this study was 
the use of the FOSQ. This scale measures severity of sleepiness-induced 
impairment in daytime functioning; however this does not equate to a complete 
theoretical overlap with the severity construct as outlined in the HBM. Although 
sleepiness is a motive for treatment seeking behaviour in the majority of 
individuals diagnosed with OSA, (341) not all present with excessive daytime 
sleepiness.(10, 54) Severity of all symptoms, not just sleepiness needs to be 
assessed. 
There are a number of studies that have assessed more trait-like variables 
such as personality and coping style. Limited information is available regarding 
personality measures; the inability to avoid unwanted behaviours (behavioural 
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inhibition system model of personality)(332) and personality type D have been 
associated with poorer CPAP adherence.(251). A study, which to date has 
predicted the largest amount of variance in CPAP adherence, used the Minnesota 
Multiphasic Personality Index.(310)The final logistic regression model included 
Body Mass Index, daytime sleepiness, nocturnal sleep quality, and two of the 
MMPI subscales: depression and hypochondriasis, explaining 63% of the variance, 
however only depression and less pre-treatment sleepiness were univariate 
predictors of better subjective CPAP use. The final model could correctly 
identify 75% of 8 non-compliers and 90% of the 20 compliers after 6 months.   
In summary, these cognitive/motivational variables when measured after 
some exposure, even merely a brief education session(296) are predictive of 
adherence, yet rarely when measured at baseline, which suggests that at least 
one form of exposure to CPAP is needed for the patient to formalise these 
beliefs. Studies that are based on social cognitive frameworks are usually 
superior in predicting CPAP use, and provide a holistic framework for 
interventions  
 
1.3.3.1.3.2 Psychological Co-morbidities   
The co-morbidity between insomnia and OSA is high, with prevalence of 
insomnia in those who present to a sleep clinic for assessment of possible sleep 
related breathing disorders ranging between approx. 40-50%.(343, 344) However 
the possible impact of insomnia on CPAP adherence is relatively under-
researched. One of the first studies to examine the impact of insomnia on CPAP 
adherence found Insomnia Severity (ISI) total score and insomnia symptoms (first 
three items of ISI), were unrelated to attrition rates or CPAP adherence at 6- 
months, using data mining techniques in 148 CPAP users.(235) 
In contrast, a recent study in Hispanic veterans found that in the 65 
completed 1-week follow-up and 59 who attended also the 1-month follow-up, 
lower ISI score was the only independent predictor of increased CPAP use at 1 
week (65 CPAP users), but not at one month (59 CPAP users), where only 
increased 7-day adherence and daytime sleepiness normalization (ESS<10) were 
independent predictors.(236) In addition, one chart review of 232 OSA patients, 
who had been prescribed CPAP, and had provided information on possible 
insomnia symptoms, revealed that sleep maintenance symptoms were predictive 
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of average CPAP use and adherent status (≥4hrs use on 70% of nights) on average 
4 ½ months after titration, even after controlling for age and gender.(334) 
Unfortunately this study only assessed insomnia symptoms to classify individuals 
into one of three groups: ‘sleep onset insomnia’, ‘sleep maintenance insomnia’ 
and ‘early morning awakenings’, and thus not considering important symptoms 
necessary for an insomnia diagnosis: 1) dissatisfaction with amount of sleep 2) 
concomitant daytime dysfunction. The relationship with maintenance problems 
only is potentially explained by the timings of these awakenings coinciding with 
time of impaired rational decision making (i.e., when woken from sleep).  
Other mental health symptoms or disorders such as anxiety and 
depression may impact on adherence to CPAP, however there are conflicting 
results as can be seen in Table 6. The difficulty with these studies is that higher 
rates on these scales might be a result of non-adherence per se, in addition to, 
or rather than, a predictor of poorer adherence. Further prospective studies are 
needed to investigate this further.  
1.3.3.1.4 Social  
Obstructive sleep apnoea and the treatment of choice affect the patient’s social 
surroundings on a variety of levels. Not only do the nocturnal symptoms affect 
the partner’s sleep, but also sleepiness and irritability can put a strain on family 
life. The eventual presentation of CPAP to family life may be associated with 
embarrassment as a result of taking on a sick role and changes to the nightly 
routine, which may also include the re-introduction of bed sharing. Thus 
inevitably, the condition and its treatment affect not only the patient, but also 
the bed partner and family. Social influences on CPAP adherence have only 
recently been focus of increased attention.  
1.3.3.1.4.1 Socio-demographic factors   
There is uncertainty about the effect of socio-economic status (SES) on CPAP 
adherence. The majority of studies outlined in Table 6 differ in the definition of 
SES, which may include all or only one of these three variables: income, 
education and occupation. Some studies have indicated that lower socio-
economic status is associated with a decrease in CPAP acceptance and use, even 
in multivariate analysis controlling for other variables.(244, 292) Another socio-
demographic factor, marital status (living alone versus living with a 
partner/spouse) does generally not relate to adherence, see Table 6, which is 
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perhaps surprising, considering a live-in partner might provided augmented 
support. On the contrary, spousal pressure to adhere might effectively reduce 
adherence rates; certainly, when self-referred adherence tends to be increased 
compared to partner-referred.(345) 
 
1.3.3.1.4.2 Social involvement and relationship quality 
Baron and colleagues have investigated exactly this, by measuring three 
different types of spousal involvement: pressure, support and 
collaboration.(298) In 31 couples the authors determined the intricate, 
directional relationship between support and CPAP adherence using a day-to-day 
study design. Whilst controlling for previous day adherence and wife involvement, 
nightly CPAP use was predicted by previous day wife support, however only in 
high disease severity patients. Interestingly, spousal collaboration was increased 
after nights with poor adherence, and the authors relate this to possible sleep 
disruption caused by the re-emergence of nocturnal symptoms (e.g. snoring) with 
non-CPAP use. Spousal pressure was not related to daily measures, however it 
did predict poorer objective adherence at 3 months. The caveat of this study was 
that daily adherence was measured subjectively.   
Apart from support, other variables that have been investigated are 
relationship quality; the partner’s sleep quality and whether or not the patient is 
sharing a bed with the partner, see Table 6. Cartwright investigated the co-
sleeping habits in 10 male OSA patients during a 2-week period post CPAP 
initiation.(336) A strong correlation of r=.74 was reported between number of co-
sleeps and adherence rates. Co-sleeping was also related to the wife’s arousal 
index on both the pre- and post-treatment polysomnography, which might indicate 
that partners who are not co-sleeping are in fear of being woken by the CPAP 
machine. Whether these partners are less accepting of the CPAP machine 
remains to be established. The 2-week period was not sufficient to determine 
whether changes to sleeping habits long-term predict CPAP use.  
In addition to partner/close relationship support, therapist support may play 
a vital role in CPAP adherence. Certainly qualitative studies have revealed that 
patients’ behaviour is encouraged by the supportive environment at the sleep 
centre and/or CPAP distributor, see chapter 3. There are also a number of 
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intervention studies comparing intensive therapist and/or nurse support to 
treatment as usual care, see below.  
In summary, it is evident that the social aspect of CPAP adherence has 
been largely neglected by the literature. However, the studies that have focused 
on this are revealing interesting angles of the multifaceted relationship between 
CPAP adherence and social interactions.    
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1.3.3.2 Predictors of Adherence to CBT-I  
As evident from Table 5 only eight studies have examined potential predictors of 
behavioural and cognitive components of CBT-I. Of all predictor variables 
presented in this table, four common variables seem to emerge in a number of 
studies: depressive symptoms,(214, 215, 221) pre-treatment symptom 
severity(208, 232), readiness/motivation for change(217, 223) and belief in the 
ability to adhere to the treatment programme.(208, 223, 231) 
Although two studies indicated no relationship with depressive 
symptoms,(217, 232) this symptom has been linked to poorer adherence in 
others. In the largest study of 301 clinical outpatients undergoing CBT-I and who 
had completed the Beck Depression Inventory (BDI) prior to treatment, Manber 
and colleagues reported that those with increased depressive symptoms (BDI 
score≥ 14) had increased difficulty adhering to the behavioural components, 
than those with lower BDI scores (<14)(215). Significant differences were found 
for rising time and restricting time in bed, possibly indicating that those with 
increased levels of depression find it more difficult to get out of bed to start the 
day. Unfortunately employment status was not measured in this sample, a factor 
that might have been a moderator (or even mediator) of this relationship. There 
was a trend for a significant difference between the two groups and adherence 
to cognitive components. Similar relationships have been reported in other 
studies. For example, Vincent and colleagues in 2003(214) reported that 
therapist reported patient adherence was reduced when dysthymia was present. 
A crucial limitation of this study was the assessment of a co-morbid dysthymia 
(using the Structured Clinical Interview for DSM-III-R anxiety and mood disorders 
(SCID)), which was carried out by the same psychologist who ran the groups and 
provided therapist rated patient adherence. Using structural equation 
modelling,(221) McChargue and colleagues identified that a increase in 
depressive symptoms, as assessed with the Hospital Anxiety and Depression Scale 
(HADS), was predictive of a decrease in adherence to a modified sleep 
restriction component in cancer patients. Additionally, these authors found a 
decrease in sleep disturbance was associated with a reduction in adherence to 
relaxation strategies, potentially as a result of the implementation becoming 
redundant with perceived improvements. The authors however do not specify 
whether baseline symptom severity was controlled for: potentially those with 
higher baseline sleep disturbance have more room for improvement and are as a 
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result more adherent initially, becoming less adherent with witnessed 
improvements. 
The relationship between adherence and pre-treatment sleep quality and 
sleepiness severity has been reported in other studies with differential effects. 
Morgan et al. reported those with poorer sleep quality at baseline (measured 
with the PSQI) were more likely to attend all CBT-I sessions.(232) A workgroup 
from Canada on the other hand, described increased sleepiness at baseline 
(measured with the Epworth Sleepiness Scale, ESS) was associated with poorer 
adherence (less consistency in wake-up time).(208) Of note, Vincent et al’s 
measure of wake-up time should not truly be considered as a measure of 
adherence, as this variable is out with the individual’s control. Apart from 
differences in study design, treatment components and adherence measures, 
these differential effects might be explained by the finding that individuals with 
insomnia rarely complain of sleepiness as a marker of increased 
hyperarousal.(346) Pretreatment sleepiness as defined in Vincent et al.’s study 
should thus not be considered a symptom of insomnia that improves throughout 
the course of treatment, but a symptom that potentially increases as a side 
effect of treatment implementation.(see 139) Alternatively, one could make the 
tentative suggestion that increased pre-treatment sleepiness is a marker of less-
severe hyperarousal. In contrast higher levels of fatigue at baseline as a 
symptom of insomnia might be predictive of insomnia, as has been indicated in a 
recent study in breast cancer patients with co-morbid insomnia.(217) 
Readiness/motivation to change has been a large predictor of various 
health behaviours such as smoking, substance misuse and exercise. Two recent 
studies have examined this variable in relation to CBT-I adherence.(217, 223) 
One study measured readiness to engage in an online cognitive behavioural 
programme and stated that individuals who were more contemplative (thinking 
about change) were more likely to engage in sleep hygiene instructions.(223) 
Corroborating the importance of motivation, a study in breast cancer patients 
with co-morbid insomnia and higher baseline motivation scores were more likely 
to adhere to their prescribed rising time and time in bed.(217) A detailed 
description of these two studies is presented in chapter 6, which examines the 
use of the transtheoretical model for predicting adherence.  
The last variable seemingly emerging as a common denominator in various 
studies, is the belief in the ability to engage in treatment components, often 
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termed self-efficacy or perceived behavioural control. Although these constructs 
are often considered separate entities, they both describe the belief in the 
capabilities of carrying out the behaviour of interest.(347) In 2003 as part of a 
larger trial, Bouchard and colleagues examined self-efficacy at a general, task 
specific and self-regulatory (when obstacles arise) level and reported no (.17) to 
strong (.67) correlations between higher levels of self-efficacy (at all levels) 
across treatment. There was a U-shaped curve with the strongest correlations 
reported halfway through the 8-week treatment (weeks 3-5), this decrease in 
correlations after week 5 authors attributed to increases in adherence and the 
inability of the conservative adherence measure to distinguish between good and 
excellent adherers. Generally though, this study provided preliminary evidence 
that individuals, who believe in their abilities to implement the behaviour are 
more likely to do so. One working group in two separate studies has reported a 
similar finding.(208, 223) In 2010, Hebert et al. explored the use of components 
from the Transtheoretical Model (TTM, see description below) and the Theory of 
Planned Behaviour in explaining adherence and attrition rates to an online CBT-I 
program.(223). When measured prior to any exposure to treatment, perceived 
behavioural control was strongly correlated (r=.5) with adherence (defined as 
the percentage of participants using homework for at least 4 nights of the 
week). Unfortunately, the scale assessed the perception of participating in the 
online program, rather than implementation of the components themselves e.g. 
“Do you think it would be easy or difficult to complete the online treatment 
program in the next 5 weeks?” These findings are partly supported by another 
study from this working group,(208) who reported perceived certainty in 
adhering to stimulus control and sleep restriction procedures (an item of their 
perceived behavioural control scale) was moderately correlated (r=.3) with 
consistency in wake-up time. However in the overall regression model, perceived 
behavioural control did not emerge as a significant predictor of adherence.  
Other variables that have been associated with poorer adherence are the 
use of medication and perceiving fewer barriers with treatment,(208) and 
factors related to increased adherence are social support, intention to engage in 
behaviour change(223) and pre-treatment perception of CBT-I(230) Younger 
adults were found to be more adherent in one study,(208) however age was not 
a significant predictor in Morgan et al.’s study.(232) 
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In summary, three factors seem to emerge from the existing literature as 
possible strong predictors of adherence to CBT-I. These are depressive 
symptoms, pre-treatment symptom severity, readiness/motivation to change and 
self-efficacy/perceived behavioural control. Undoubtedly, though there is 
considerable scope to investigate further predictors of adherence, and research 
clearly lags behind that on CPAP adherence literature.  
1.3.4 Interventions to Improve Adherence 
Establishing predictors of adherence can benefit the development of 
interventions, which in turn may improve outcome and subsequently increase 
the effectiveness of a treatment (over and above treatment efficacy).(226) A 
recent Cochrane review of interventions for medication adherence concluded 
that there was some evidence to suggest simple interventions produced 
improvements short-term, however for long-term care (e.g. diabetes, 
hypertension) most improvements were reported in studies that included 
complex interventions with combinations of educational, psychological and/or 
behavioural components.  Surprisingly, even the most effective interventions did 
not lead to a meaningful improvement in both adherence and outcome. 
However, the authors note that these negative conclusions might be partly 
explained by poorly defined adherence measures, some poorly designed 
interventions, underpowered studies and stringent inclusion criteria for studies 
reporting both adherence and outcome.(348)  
1.3.4.1 Interventions to improve CPAP adherence   
1.3.4.1.1 Technological 
Recent advancements in technology have generated several improvements to 
CPAP treatment from the original presentation in 1981. These include changes to 
the mask interface, the addition of humidifiers and pressure modifications 
(Auto, Bi-Level, C-Flex and various combinations of these three modalities). As 
outlined in Table 6 these adaptations generally do not procure improvements in 
CPAP adherence, and this is perhaps unsurprising, because they are mainly 
designed to reduce side effects, which again are not clearly linked to changes in 
CPAP use. As described above, three recent meta-analyses(177, 245, 246) of 
technological interventions revealed no evidence for increased adherence in any 
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modality except for a small, but significant difference of 11-13 minutes in favour of 
auto-adjusting PAP in all(246) or only cross-over studies.(177) There is however 
some evidence for these pressure modifications in unselected patients, e.g., 
those who require higher CPAP pressure, are non-adherent or had poor first 
experience with CPAP might benefit from these modes as described above.(177, 
247, 248)  
One side effect that has consistently been linked to poorer adherence is 
claustrophobic reactions to the mask(181, 254) and interventions to reduce 
these have been successful. Following a case report(349), Edinger’s group 
retrospectively examined the effects of gradual desensitisation therapy in 13 
patients who had reported claustrophobia. Post-intervention, in which patients 
were gradually introduced to the machine based on individualised hierarchy of 
steps to acclimatise to the devise, CPAP was used on average 4.4hrs (SD=0.6) on 
only the days implemented, which was significantly more compared to pre-
intervention rates (mean 1.8 hrs, SD=0.6), indicating a large effect size of 
Cohen’s d=1.2. Similarly large effects were reported for percentage of nights 
CPAP was used and mean hours of CPAP use (all nights).  However only half of 
the patients met criteria for adequate adherence (≥4hs on 70% of nights), and 
these low adherence rates might relate to this being a clinical compared with a 
research sample, and as a result there was an of extremely large variation in 
time between titration and desensitisation therapy (2.6 weeks–6.2 years). The 
effects of gradual exposure therapy in a prospective randomised control trial for 
these patients, or administered preventatively for individuals with 
claustrophobic tendencies(254) is warranted.  
1.3.4.1.2 Educational interventions  
In 2009 Smith and colleagues published an updated Cochrane review examining 
the effect of brief one-off education sessions on subsequent adherence.(288) 
Three studies were selected that had machine usage as the main outcome, 
however the pooled difference of 0.11 hrs/night in favour of the intervention 
was not significant with 95% CI between -0.7 and 0.93. A similar result was 
reported for the four studies measuring withdrawal rates. In addition to these 
randomised control trials, case studies that have provided a one-off education 
and comparing pre to post adherence rates have reported no significant 
difference after an extensive education session for patient and spouse in one 
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study,(330) and only a small difference after group education sessions of  
d=0.3.(329)  
A recent study examined the impact of the actual nature of the 
educational message. Trupp and colleagues found that adherence was 
significantly higher in OSA patients who received negatively framed educational 
messages [focused on the consequences of not using CPAP] as opposed to 
positively framed [focus on the benefits of using CPAP].(239) More than 4 hrs per 
night on at least 70% of nights was obtained by 55% of those receiving the 
negative message, compared to only 23% in the positively framed group. 
It is important to note, however that education is not classically 
considered an independent predictor of behavioural adherence, but rather forms 
adequate circumstances under which behaviour change can occur contingent on 
other beliefs and attitudes (e.g. self-efficacy).(350) Thus, education is often 
considered integral to optimal patient care in OSA patients.(41) 
 
1.3.4.1.3 Complex Interventions  
Complex interventions such augmented support, cognitive behavioural therapy 
or motivational interviewing have been examined as potential interventions to 
improve adherence. The Cochrane review described above analysed results from 
ten studies and reported a significant difference of .59 hours in use in favour of 
augmented educational, psychological or practical support in form of follow-up 
home visits or telephone/internet support from either a nurse or physician.(288) 
With large statistical variation in these studies and despite sensitivity analyses, 
the authors were unable to determine whether this was a consistent effect.  
Perhaps the greatest effect of any interventions tested in a randomised trial 
thus far have been for psychological interventions such as cognitive 
behavioural(351, 352) or motivational enhancement(353-355) therapy, with large 
effect sizes at 1 month (where reported) of d=0.5-1.1. 
Richards and colleagues randomised 100 OSA patients to receive either 
cognitive behavioural therapy (CBT) or treatment as usual. CBT was based on 
Bandura’s social cognitive theory and aimed to target self-efficacy, outcome 
expectations, social support and knowledge with two 1hr education sessions 
separated by 1 week. Sessions were aimed to correct distorted beliefs and 
encourage a positive outlook for both patients and their partner. Individuals 
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were also aided in the initial handling of the mask, provided relaxation 
techniques to deal with any anxious reactions and were shown a 15-minute video 
of role models. Lastly, patients were sent home with a booklet that outlined 
strategies for dealing with maladaptive beliefs about the CPAP machine.  CPAP 
use and percentage of patients with more than nightly 4hr use was significantly 
improved in the CBT group at both 7 days and 1 month, with large effect sizes of 
around 1.1. Self-efficacy, social support, but not outcome expectations were 
significantly increased in the intervention group.(351) 
Following successful support interventions via the tele-health route in 
significantly improving CPAP use(356, 357) Sparrow and colleagues tested the 
effect of motivational enhancement therapy for CPAP(358) in the context of a 
telephone linked communication system.(355) A total of 250 CPAP prescribed 
OSA patients were randomised to either an intervention group or tele-health 
placebo control, which providing information about other health aspects. The 
intervention was designed to assess patient’s motivation, goals, barriers to use 
CPAP and self-efficacy and aimed to increase each of these aspects by using 
three non-judgmental and empathic strategies consistent with motivational 
interviewing: 1) decisional balance (although this is not strictly a MI technique, 
but has often been misrepresented as such(359)), e.g. “On the one hand you 
noticed discomfort as a problem with CPAP, but on the other hand you see the 
benefits to your health.  Please think more about that.” [online supplemental 
material], and 2) self-efficacy and 3) motivation rulers, with which patients rate 
their confidence and motivation to continue using CPAP on a scale of 1 to 10. 
The intervention arm used the CPAP machine 1hr more and even 2hrs more per 
night at 6 and 12 months respectively.  Unfortunately the adherence rates were 
low in both arms (less than 3hrs/night on average), which might be attributed to 
the late introduction of the intervention, i.e. after initiation of CPAP. 
Interestingly, the intervention produced significant effects for self-efficacy and 
the decisional balance and mediation analysis revealed that 60% of the variance 
explained by the treatment effects was actually attributable to these 
psychological variables.   
In summary these cognitive behavioural and motivational enhancement 
type interventions seem to be effective for improving CPAP use, however the 
literature could benefit from further and larger randomised control trials 
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introducing these interventions prior to CPAP titration and potentially even 
targeting those struggling or have low self-efficiency and motivation to change.  
1.3.4.1.4 Treating co-morbidities  
As outlined above and in Table 6, co-morbidities are common in this population, 
especially insomnia. To date no study has directly investigated the effect of 
treating co-morbid insomnia and how this impacts on CPAP adherence. However 
a number of studies provide preliminary support for this approach, by targeting 
aspects that may be particularly problematic in this kind of population. Two 
studies have examined the effect of sedative hypnotics with the aim of 
improving sleep quality during the initial experience of CPAP, with early use 
predictive of subsequent adherence.(360, 361)  Adherence at one month did not 
significantly improve in a study administering zolpidem for 14 days compared to 
either a placebo or no treatment intervention,(360) but this study was likely 
underpowered. In contrast, the use of eszopliclone during the first 14 days was 
associated with higher adherence and less discontinuation rates across the 6 
months study period.(361) However both studies did not actively recruit 
individuals with co-morbid insomnia. 
In addition to these hypnotic approaches, one working group has 
investigated behavioural approaches in a co-morbid sample that voiced 
resistance towards the CPAP titration.(362) A retrospective chart review was 
conducted of 39 OSA patients with co-morbid insomnia, who received a brief 
daytime exposure to CPAP prior to titration (60-120 min) that aimed to target 
issues particularly prominent in the insomnia population (e.g. heightened arousal 
and anxiety, increased wakefulness). The intervention included sleep 
deprivation (increasing homeostatic drive), imagery and desensitisation and 
revealed a greater percentage of regular users (≥4hrs on 70% of the nights) 
compared to controls (59 vs. 20%) Unfortunately, the comparison was made 
against historical controls (patients before the introduction of the intervention 
into routine clinical care) rather than a concurrent placebo control group. Again, 
the intervention was not aimed at improving insomnia, but targeted issues that 
might be problematic in this population. In a recently accepted study(363) 
patients who were using a sedative hypnotic for their posttraumatic stress 
disorder and/or insomnia had higher adherence rates that those who were not. 
Undoubtedly, there are other issues in this posttraumatic stress disorder group, 
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however this study adds to the information above that treating insomnia might 
have beneficial effects on CPAP adherence and yields the importance of a 
behavioural sleep medicine aspect this area.(364, 365) 
1.3.4.2 Interventions to improve CBT-I adherence  
Currently there are no studies that have actively set out to design and test an 
intervention to improve CBT-I adherence. A clearer understanding of what 
constitutes optimal adherence and how to best measure it is most likely 
warranted before such studies can be undertaken. Two studies however do lay 
the path for possible avenues to pursue. One mixed method analysis of 18 
individuals completing a sleep restriction programme revealed how the 
completion of SRT can induce certain side effects, such as sleepiness, fatigue, 
reduced energy/motivation and even migraines/headaches. Qualitative data 
corroborated these findings and exposed how individuals struggled with the 
negative daytime effects induced by their restricted time in bed and how this 
impacted on their ability to adhere to the programme.(139). Counteracting 
these effects during the day might lead to improvements in adherence. In Perlis 
et al. reported increased adherence in the trial arm that received modafinil 
concomitant with CBT-I, arguably because the modafinil counteracted the 
experienced sleepiness during the day and individuals were able to stay up till 
their given threshold time.(218) Adherence was only measured for sleep 
restriction therapy, however the authors note the use of modafinil might equally 
be beneficial for the potential side effects experienced with repeated removal 
from the bedroom with extended periods of wakefulness (stimulus control).  
These side effects might be occurring due to reduced initial total sleep 
time in these individuals in the early stages of treatment. Matthew et al.’s 
study(217) reported that those who were implementing the treatment were also 
those who rated their sleep quality poorly in the first week. Thus, the use of 
pharmacological aids to produce immediate benefits in consolidating sleep might 
contribute to minimising the impact sleep restriction and stimulus control have 
on the individual. Using a multiple baseline design, Valieres and colleagues(233) 
examined the effectiveness of three different treatment combinations of 
behavioural and pharmacological options: 1) Medication- arm first, then 
combined medication and CBT-I; 2)Combined treatment then CBT-I alone and 
lastly 3) CBT-I alone. The presence/absence of ‘adherent behaviour’ obtained 
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from the sleep diary, was assessed against seven criteria (e.g. going to bed 
within 30 minutes of threshold time as described by Bouchard et al. 2003(231)) 
They report that the average weekly adherence percentages to behavioural 
strategies (100%= total of 49 possible points achieved) in the medication! 
combined group varied between 68.3% to 92.5%.  In the CBT-I alone group, 
adherence varied between 50-85.7%.  They describe further that average weekly 
adherence percentages to behavioural components for the combined!CBT-I 
group reduced from 92.3% to 72.5%. Although the authors did not make 
statistical comparisons in adherence rates across treatment modalities, it seems 
that adherence is largest in the arms combining medication and CBT-I. This 
might be because of beneficial short term effects to sleep with medication, 
making adherence to the behavioural components easier. Again this assumption 
is speculative, because test of differences were not made and results are 
presented ambiguously.   
In summary, initial steps need to be completed prior to the development 
and implementation of interventions to improve CBT-I adherence. Initial studies 
do however provide some prospective for intervening when CBT-I is most 
difficult: i.e. when implementation leads to unwanted side effects during the 
day.  
1.4 Summary 
In conclusion, there is a substantial amount of evidence from which to draw 
preliminary conclusions about potential variables that influence CPAP use, 
nevertheless, no single variable has been consistently linked to adherence and 
complex psychosocial interventions are still very much under-researched. In 
comparison, the literature on adherence to CBT-I must benefit from studies that 
can establish dose-response relationships and ‘optimal’ cut-offs, until this is 
provided, adherence research in this area is unstandardised and will not provide 
clarity for optimal patient care. It seems then that both areas are virtually at 
the cusp of an agenda change; CBT-I in terms of standardising the approach to 
measuring adherence (much like the CPAP literature has attempted with Kribbs’s 
cut off of 4hrs per night on 70% of nights), and CPAP in terms of a more 
philosophical changes as clearly the approach currently adopted is two-fold: 
biomedical or psychosocial. This latter point needs to be addressed and could 
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potentially inform the CBT-I field; and will now be discussed in more detail in 
chapter 2.  
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Chapter 2- Integrating Psychology and Medicine In 
CPAP Adherence- New Concepts? 
2.1 Abstract 
To date, Continuous Positive Airway Pressure (CPAP) is the most effective 
intervention in the treatment of obstructive sleep apnoea, but adherence to this 
treatment is often less than optimal. A variety of factors and interventions that 
influence and improve CPAP use have been examined. There is increasing 
recognition of the multifaceted nature of CPAP adherence: the patient’s 
psychological profile and social environment have been recognised, in addition 
to the more extensively researched patient’s treatment and physiological 
profile. Understanding how these multiple factors impact on CPAP use in an 
integrative fashion, might provide us with a useful holistic model of CPAP 
adherence. This concept of integration - a biopsychosocial (BPS) approach to 
health and illness- has previously been described to understand care provision 
for various chronic health disorders. This chapter proposes an adherence 
framework, whereby variables integrally affect CPAP use. The BPS model has 
been on the agenda for nearly 35 years; the presence of poor CPAP adherence 
was acknowledged in the early 90s- it is timely to incorporate this approach into 
our care pathway of CPAP users.  
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2.2 Introduction 
 
‘The%whole%is%more%than%the%sum%of%its%parts’%
44Metaphysica,%Aristotle%(384%BC%–%322%BC)%
 
Aristotle understood that a holistic approach is crucial to a complete 
understanding of all aspects of life. More than 2000 years later medicine has 
seemingly caught up with the value of integration as opposed to reductionism: In 
the quest to deliver optimal patient care, psychiatrist George Engel’s seminal 
paper published in 1977(366) was a call towards a biopsychosocial model (from 
here on referred to as the BPS model), recognising that multiple domains 
(biomedical, psychological and social) integrally and interactively influence 
health and illness. The aetiology and progress of a disease is influenced by 
biological processes, psychological experience and social behaviours, which are 
reciprocally related.(367) To warrant optimal treatment outcome for these 
diseases, there is then a need for interventions to target all three domains. 
Haynes stated that “[e]ffective ways to help people follow medical treatments 
could have far larger effects on health than any treatment itself.”(368, p. 10) 
and this importance of adherence has recently been acknowledged by the World 
Health Organisation (WHO) in 2003.(168) Implicit within these claims, is the 
need to study adherence within an integrative framework.  
Non-adherence is now considered a public health concern: around 30,000 
articles have been published on patient adherence, a figure similar to asthma 
(50,000) and 1/3 of what has been published on diabetes (MEDLINE search with 
MeSH Headings ‘patient compliance’, ‘asthma’ and ‘diabetes’). A recent meta-
analysis reported that the average non-adherence rate of approx. 25% for 
complex treatment interventions translates to 188.3 million medical visits in the 
US resulting in patients failing to implement recommendations and equating to a 
monetary waste of potentially US$ 300 billion a year.(169) Apart from this 
economic cost, non-adherence inhibits the evaluation of treatment efficacy at 
the research level, and can hinder treatment effectiveness at the clinical level.  
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There has been a major growth in the medical literature related to CPAP 
adherence following the initial reports on covert electronic surveillance of CPAP 
use by Kribbs et al.(181) This work is most frequently cited for the commonly 
used (arbitrary) cut-off of ≥4hrs per night on 70% of the nights. Figure 3 depicts, 
based on a MEDLINE search, the 362 articles published since 1984 with the terms 
‘continuous positive airway pressure’ and ‘adherence/compliance’ appearing in 
the title or as MeSH headings (not exploded). A clear surge of articles is evident 
after Engleman’s review in 2003, possibly denoting the recognition that 
psychosocial variables influence CPAP use.  
 
Figure 3: Published articles on CPAP adherence 
 
Our understanding of what mediates CPAP use has increased considerably 
in the last decade. Undoubtedly, the recognition that various biomedical, 
psychological and social variables may impact adherence has advanced the field 
and contributed to the development of more comprehensive interventions to 
improve use. Despite the awareness of its multifaceted nature, an integrative 
model has not been proposed for CPAP adherence. As previously proclaimed by 
Aristotle, a holistic approach requires more than simply taking account of and 
summing the variables. The objective of this chapter then, is to outline new 
concepts for the field in light of the current knowledge of CPAP adherence. It is 
timely to pursue a holistic approach to this problem and consider potential 
interventions to improve adherence in terms of a biopsychosocial framework. 
Publication Year
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
1996
1995
1994
1993
1992
1991
1990
1989
1988
1987
1986
1985
1984
Fr
eq
ue
nc
y
50
40
30
20
10
0
Page 1
Chapter 2 Integrating Models of CPAP Adherence 91 
 
2.3 A brief review of CPAP adherence  
Failure to adhere to CPAP, which is a demanding and invasive treatment, may 
compromise service delivery and treatment effectiveness. There is evidence of 
improved treatment effectiveness when the CPAP mask is worn for a large 
proportion of sleep time.(57) This means that cut-offs of “good adherence” may 
be suboptimal. However, approximately 25% of patients do not take up CPAP or 
discontinue in the first 2 weeks after their titration study.(188-192)  
Furthermore, for those who continue long term (>1month), ‘adequate’ 
adherence (often defined as ≥4hrs on 70% of the nights(181)) can vary between 
46-89% depending on definitions of adherence and length of follow-up.(181, 184, 
188, 193-202)  
Chapter 1 summarised the variables that have been investigated as 
predictors of CPAP use. Historically, early studies concentrated almost 
exclusively on biomedical (biological, demographic, treatment specific) 
variables, such as sleep apnoea severity, age, gender, sleepiness, required 
pressure.(369) It is evident that apart from severity and symptomatic 
improvement, most biomedical variables alone have demonstrated little 
predictive power.  Subsequently, studies diverged exploring the role of either 
psychosocial variables or basic biomechanical factors. To varying degrees, 
psychosocial variables (such as self-efficacy, illness and treatment beliefs or 
social support) have been found to predict CPAP use.(369-371) In contrast, the 
value of biomechanical variables such as mask changes, humidifiers, or machine 
type have resulted in no or marginal improvements in adherence. Three recent 
meta-analyses(177, 245, 246) of technological interventions investigated 
pressure delivery modifications (i.e. autoPAP, BiPAP, and flexible pressure 
delivery (C-Flex)) yet found no evidence for increased adherence in any modality 
except for a small, but significant difference of 11-13 minutes in favour of auto-
adjusting PAP in all(246) or only cross-over studies.(177) The authors however 
note that there is little evidence for the use of autoPAP in unselected patients. 
Additionally, only about 20% of the reviewed papers were clearly described as 
double blind studies.(177) 
Heated humidification can ameliorate adverse upper airway side effects 
in some patients but there are mixed findings regarding the effect on CPAP 
adherence(177) and most benefit is found in the first few weeks.(372) The 
greatest effect of any interventions tested in a randomised trial thus far have 
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been for psychological interventions such as cognitive behavioural(351, 352) or 
motivational enhancement(353-355) therapy, with large effect sizes at 1 month 
(where reported) of d=0.5-1.1, whereas effect sizes for support or educational 
interventions generally fall within the small to medium range [~d=0.4] or are not 
significantly different from the comparison group.(242, 288, 369) Although some 
interventions have been associated with improvements in CPAP adherence, in 
comparison to a control condition;(288) reported average CPAP usage rarely 
exceeds 6hrs per night in most intervention studies. However, it is understood 
from recent dose-response observations that the majority of individuals achieve 
normal values of daytime functioning at 7.5hrs/night of CPAP use.(57) Of course, 
even the best options available may be sub-optimal, because they focus 
primarily on one domain, rather than all domains and their interactions. It seems 
then that the healthcare approach to CPAP use might benefit from a new holistic 
concept of both the patient and his/her adherence behaviour.  
2.4 Conceptualisation of adherence 
The transition from the study and reporting of biomedical variables, to 
psychosocial variables at the research level, parallels a transition in emphasis 
from compliance to adherence on the conceptual level (see Table 4); a shift in 
thinking urged by the World Health Organisation (WHO). ‘Compliance’, defined 
as ‘the extent to which a person’s behaviour (in terms of taking medications, 
following diets or executing lifestyle changes) coincides with medical or health 
advice’(170, pp. 2-3) was replaced with the notion of ‘adherence’, described by 
WHO as “the extent to which a person’s behaviour […] corresponds with agreed 
recommendations from a health care provider”(168, p.18) (see chapter 1 and 
Table 4). The conceptualisation of an individual as compliant/non compliant 
overlaps with a stringent biomedical model,(369) which frames the patient’s 
behaviour as somewhat passive, coinciding/not coinciding with the physician’s 
recommendation and influenced by relatively static factors such as age, gender 
or disease characteristics. The biopsychosocial model, however regards the 
patient’s behaviour as the consequence of an interaction between such static 
traits and more fluid variables such as beliefs, attitudes, motivation or social 
circumstances. WHO advocates a more patient-centred approach to adherence; 
conceptualising the individual’s behaviour as a rational (or sometimes irrational) 
decision, influenced by the interaction between biomedical and psychosocial 
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variables; in turn, this behaviour may or may not correspond with the agreed 
recommendations. WHO specifies that ‘non-adherence is a multi-determined 
problem caused by the interplay of four factors. The factors have reciprocal 
influence on the process of care for chronic conditions’.(225, p. 8) This 
approach is akin to a biopsychosocial model and the four factors, the health care 
team/system, condition/illness related factors, characteristics of therapy and 
patient-related factors, largely map onto the three domains of the BPS model.  
CPAP, then is a complex treatment for a chronic disorder and according to 
WHO, such conditions are best managed with a biopsychosocial model. Thus far 
the CPAP literature has largely considered these elements independently rather 
than as part of an integral whole. The next part of this paper therefore proposes 
a working model for a biopsychosocial model of CPAP adherence.  
2.5 A Biopsychosocial model of CPAP use 
2.5.1 Development of the model 
Before considering potential interactions, it is important to take account of all 
possible variables. Figure 4 therefore provides a visual representation of the 
proposed biopsychosocial model for CPAP adherence.   
 
Figure 4: A BPS model of CPAP adherence 
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As can be seen, the model comprises biomedical, psychological and social 
domains, each subsuming a person- illness- and treatment- specific level. The 
biomedical domain encompasses static clinical/medical variables about the 
patient [e.g. age, gender, BMI, race/ethnicity], the illness [e.g. OSA severity] 
and its treatment [e.g. pressure delivery, side effects]. The psychological 
domain on the other hand is made up of variables that are more dynamic and 
malleable. Coping style, stress and affect, for example are personal level 
variables that may impact adherence, whereas beliefs and attitudes about their 
sleep problem [illness level] and CPAP [treatment level], will also inform their 
adherence behaviour. Such factors may be targeted with psychological 
interventions. Finally, any individual presents with particular socio-demographic 
features [personal level]; individuals with different socio-demographic 
backgrounds might present with different adherence patterns. CPAP does not 
only concern the individual, but also in the social network around the patient. 
Thus, adherence might also be influenced by how the illness and treatment is 
placed into this social framework, how the illness/treatment impacts on their 
social system and what type of acceptance and support is available from their 
surroundings.  
2.5.2 Integration of the model   
It may be helpful to consider case examples to understand the potential 
advantages of the model. Here the focus is on the important clinical issue of side 
effects associated with CPAP use. As highlighted in Box 1 Person A’s 
psychological and social resources make it easier to deal with the side effects he 
experiences, and so biomedical factors alone explain little of the variance within 
his CPAP use [weakly weighted dashed arrow in Box 1]. Conversely, Person B has 
identical biomedical characteristics (side effects, AHI, CPAP settings), but poorer 
psychological and social resources. Consequently, her side effects have a far 
greater impact on CPAP use. This individual appears less equipped to deal with 
the barriers compared to person A. In this case, the side effects (biomedical 
variable) alone explain considerably more of the variance in CPAP use [strongly 
weighted dashed arrow in Box 1].  
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Box 1: Case examples 
!!
BOX!1:!!
Person A is a 45-year-old male, with an AHI of 39 and has recently been provided with a CPAP machine. Throughout the first weeks of use, he experiences residual side effects [not ameliorated 
within the short term follow-up] such as dry throat, blocked nose and increased nocturnal awakenings. Person A could be described as an individual who takes any situation head on; as a result of this 
active coping style he informed himself extensively about the sleep disorder and CPAP in internet forums prior to the titration sleep study. He is also feels encouraged to actively seek help with his 
side effects, whether these are further changes to the mask or any strategies that might help with the nightly awakenings. His wife, who also initiated the first consultation with the GP regarding his 
snoring, accompanies him to all meetings at the respiratory centre. She supports him emotionally, but also practically where she can- remembering follow-up appointments, maintenance of the 
machine/mask and suggesting strategies to deal with the side effects. Overall, as a result of his persevering nature and support from his wife, Person A uses the machine throughout the night despite 
the side effects.  
 
Person B is a 34-year-old female, with an AHI of 40 and has recently been provided with a CPAP machine. Throughout the first weeks of use, she experiences side effects [not ameliorated within the 
short term follow-up] such as dry throat, blocked nose and increased nocturnal awakenings. Person B could be described as an individual who tends to shy away from difficult situations. She has 
found the diagnosis of OSA and prescribed CPAP treatment a change difficult to cope with. She tries not to ask for help, as she feels this may be a sign of weakness. She is currently single and 
concerned with the potential negative impact CPAP might have on a new relationship. Her social support network is confined to her mother, who has limited understanding for her daughter’s situation, 
blaming her for neglecting her health. These concerns also further fuel her nocturnal awakenings initially caused by the CPAP machine. She tries to use the machine for the first few hours, but 
generally gives up when she wakes up at night frustrated and feeling lonely.   
Side!effects!(Biomedical)!
Person!A!Psychological!Resources!!Social!Resources! Person!B!Psychological!Resources!! Social!Resources!
Person!B!Adherence!Person!A!Adherence!
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The examples also highlight the reciprocal interaction between 
biomedical, psychological and social factors: For person B the side effects might 
not only impact on adherence, but might also have a reciprocal effect on her 
motivation/feelings of isolation, leaving her even less equipped to deal with the 
side effects. Additionally, the nightly rumination about these concerns might 
further increase the wakefulness during the night, possibly potentiating the 
impact the side effects have during the night. The result: an interacting cycle of 
effects across domains of the biopsychosocial model of CPAP adherence. 
As far as treatment is concerned, then, one can conclude that it is likely 
to be less than optimal to consider biomedical, psychological or social variables 
in isolation. Support requirements for person A might be limited to technological 
interventions to eliminate side effects as much as possible, whereas support for 
person B might include resources for improving psychological and social 
functioning to mitigate the impact of side effects.  
2.5.3 Implications of the model for research 
There is now need for the investigation of possible interactions amongst 
variables that have previously been examined in isolation (see chapter 1). The 
systematic investigation of these interactions will have implications at the 
research level, and may benefit from more sophisticated statistical methods, for 
example structural equation modelling(373). This technique enables assessment 
of causal relationships and interaction effects between variables; and calculates 
the effects of any latent determinants.(374) Analysis of this kind can handle 
complex interactions and will permit greater determination of proportions of 
variance explained by BPS profiles (phenotypes) that might be common to a 
group of individuals. This task might also be facilitated by the use of cluster 
analysis. A recent health psychology review described this method as: 
‘[t]he process of taking a heterogenous sample of entities […] and 
forming relatively homogenous groups’ through the organisation of ‘large 
quantities of multivariate information. Labels can be assigned to the subgroups, 
making the data more manageable for the individual researcher […]’ This 
technique then allows for ‘identification of groups that might best benefit from 
interventions or further research.’(375, p.330) 
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Clearly, it will be important, both for research and clinical practice, that 
all relevant variables are measurable. With this in mind, it should be noted that 
there is a sound psychometric tradition of psychological measurement that could 
be seemingly adapted to this population. Brief scales measuring coping 
style,(376) self-esteem,(377) personality,(378) relationship intimacy(379) are 
examples that would compliment scales/measurements that are already well 
established to identify the biomedical characteristics of the CPAP user. This 
includes instruments such as the Epworth sleepiness scale (ESS),(5) where 
individuals rate the chances of falling asleep in eight situations. Although the 
ESS has been criticised for its moderate correlation with objective measures of 
sleepiness, like the multiple sleep latency test(380), the message here is that 
the scale is easily implemented and has face validity, and has been effortlessly 
integrated into the care pathway by treating physicians. 
2.5.4 Implications of the model for clinical practice  
To understand the conceptual shift that clinicians will have to make, Figure 5 
describes a typical clinical scenario- tackling nasal stuffiness as a possible side 
effect. The top box, model 1, is an illustration of the multifactorial approach, 
whereas the lower box, model 2, displays an integrative approach. The clinician 
taking an integrative approach may form an understanding of the reciprocal 
effects between biomedical, psychological and social domains. The exploration 
of these interactions will enable the clinician to answers to question left 
unanswered in model 1 or at least to provide a pathway for investigation. Do 
side effects reduce the individuals’ motivation, despite motivational support 
prior to CPAP initiation?  Does the increased frustration with the CPAP machine 
lead to tension between the patient and the partner, resulting in a reduction in 
partner support? Does this in turn leave the individual feeling isolated and 
unable to make use of any remaining resilience?  
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Figure 5: Potential approaches to nasal stuffiness as a side effect. 
Model 1 indicates the simple multifactorial approach to CPAP adherence, adapted slightly 
from Engleman et al 2003.(369) Side effects are eliminated with technological (biomedical) 
approaches. Model 2 highlights a biopsychosocial, integrative approach where side effects, 
when problematic and/or unresolved by technological interventions, are tackled by 
inclusion of psychological (increase personal reliance) and social (increase social support) 
interventions.   This model also indicates the interaction between these domains (two-way 
and solid arrows) as well as one-way relationships  displayed in previous models (dashed 
arrows). The individual’s BPS profile may inform the integration of psychosocial 
interventions prior to the presence of side effects, rather than after problems occur as 
described in model 1. 
Of course, clinicians may be concerned that highly tailored interventions for 
each CPAP patient may not be feasible, or affordable. Therefore it is important to 
recognise that one potential merit of the BPS approach, in contrast to a 
multifactorial model, will be the development of tailored interventions that can 
ultimately be applied at the population level.(381, 382) That is, once possible BPS 
profiles have been conceptualised [at the population level], the clinician may be 
able to match the patient‘s profile [individual level] and so determine best care.  
 
2.5.5 Potential resistance to adopting the BPS model  
There is anticipated resistance to implementing the BPS model: many will surely 
argue it is labour, time and cost intensive, however it is important to remind 
ourselves of the labour, time and cost implications of non-adherence. What is 
currently done equates to sub-optimal adherence rates.  There is currently no 
estimation of the direct cost of CPAP non-adherence, however a recent review 
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estimated that an average non-adherence rate of 24.8 % across the selected 
treatments would, in 2001, have translated to an approximate cost of US$ 300 
billion and the adherence rates for treatments of sleep apnoea were the lowest 
of the reviewed treatments.(169) Additionally there are indirect medical costs of 
untreated OSA linked to cardiovascular events and mortality,(70, 82) and 
increased non-medical costs such as automobile accidents or work 
absenteeism.(383, 384) It is at this time not possible to estimate the exact 
direct and indirect cost of CPAP non-adherence compared with the cost of the 
implementation of a BPS approach in the clinical service. However, it should at 
least be evident that what is currently implemented to improve CPAP use is not 
sufficient, and that a major paradigm shift is now required.  
2.5.6 What has been done so far?  
To date, there has been no reference to an integrative model of CPAP 
adherence; however, there is some evidence in the current literature to be 
reviewed that provides support for the superiority of examining the interactive 
effects of variables from different domains.   
2.5.6.1 Reviews 
A few reviews have previously explored the issue of CPAP adherence and its 
various dimensions. Engelman and Wild presented a clinical practice and 
research formulation for managing problematic CPAP adherence.(369) The 
recurring theme that a reductionist biomedical approach to adherence is not 
sufficient, was also discussed in this review. The authors state that some 
biomedical variables correlate weakly with adherence, however, and more 
importantly, these variables are associated with certain underlying cognitive 
attributions and cost-benefit ratios e.g., the cost-benefit ratio for CPAP 
adherence might differ between males and females. There are indications in the 
text, that the authors of this review advocate a biopsychosocial approach to 
CPAP adherence:  
‘The enhanced value of adherence models incorporating cognitive 
constructs is that variables immutable under a biomedical model, such as AHI or 
Epworth sleepiness score, become plastic [58]. While the biomedical model 
reifies these weak determinants as independent objective entities, within a 
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cognitive model the emphasis is shifted from the numeric value to the patient’s 
perceptions of these values.’(369, p. 92) 
The review does not offer a detailed and/or explicit account of how this 
may occur or even call for a research agenda that incorporates these kinds of 
investigations. In fact, the point made above, does not feature in Engleman and 
Wild’s practice points or research agenda, and has clearly not translated into the 
CPAP literature, where the majority still clearly distinguish between and fail to 
integrate the biomedical and psychosocial domains. Thus by focussing upon the 
sum of the multifactorial parts of their model, the strength of Engleman and 
Wild’s review relates to those parts. However it does not explicitly present a 
biopsychosocial, integrative model of these variables. As a consequence of their 
suggested approach CPAP non-adherence is targeted at the individual level, 
rather than the population level (see above). Furthermore, they argue that 
complex, cognitive interventions are ‘saved’ for difficult or unresponsive cases. 
In contrast the BPS model outlined here will hopefully contribute to the 
identification of BPS profiles that can be implemented before individuals 
encounter problems and possibly prevent them from exiting the system (see 
Figure 5). Lastly, the model presented here does not discard biomedical 
variables that are not univariate predictors of CPAP use, but calls for a re-
evaluation of these variables within a BPS, rather than a univariate framework. 
In contrast, by emphasising only those variables that are univariate predictors, 
Engleman and Wild implicitly discard those that do not. Nevertheless, their 
review offers preliminary support for a BPS model and hopefully this chapter 
extends their attempts, by providing a more detailed and explicit account with 
reference to research studies investigating interactions between all domains.  
In a second review, Sawyer and colleagues(242) describe CPAP adherence 
in the context of age: for example in younger age groups the family context is an 
added factor (positive or negative) in the complex picture of CPAP adherence 
and variables such as parental education, attitudes and beliefs can impact on 
the child’s CPAP use, whereas for older adults any potential reductions in use 
may be mediated by other factors that increase with age, e.g. insomnia. It is 
thus imperative that interventions to improve CPAP adherence are tailored to 
allow for age- and development-specific factors.  Although not explicitly 
mentioned in Sawyer et al.’s review, the authors are drawing upon a 
biopsychosocial framework, by assuming an interaction between age and 
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psychosocial characteristics. Further exploration of these relationships should 
provide an understanding of how variables might have a differential and 
interactive effect on adherence across age groups.  For example, younger CPAP 
users usually have family members/caregivers that can offer support in the 
home, whereas older adults are likely to be living alone. For the older age 
group, there might be a different meaning attached to using a machine to 
control one’s breathing (‘getting old’), which may lead to dysfunctional beliefs 
and attitudes about the disorder and treatment, whereas the younger age group 
might consider wearing a CPAP machine as ‘uncool’. With an increase of 
insomnia symptoms with age, older CPAP users might struggle during the night, 
and increased frustration and worry might further exacerbate the wakefulness. 
This in turn may disrupt the partner’s sleep and potentially reduce the effective 
support they are able to provide. These factors are still very much under 
researched; nevertheless it is clear the psychosocial profile of individuals in each 
age group might vary and adopting a BPS approach could provide insight into 
what factors may be important across these groups.  
  
2.5.6.2 Research studies 
A few research studies have been published with reference (albeit implicit) to an 
integrative model of CPAP adherence. Using an interesting day-to-day study 
design, a recent study asked individuals to complete measures of spousal 
involvement (pressure, support, and collaboration), and examined the daily 
relationship between ratings of spousal involvement and subjective 
adherence.(338) The relationship between adherence and support was 
moderated by disease severity (AHI): support was only predictive of next day 
adherence in those within the highest quartile of AHI scores. The authors 
conclude that perhaps those with lower disease severity experience less daytime 
symptom improvements and any support from the spouse is considered unhelpful 
and might not merit attention from patients. Using the day-to-day analysis, the 
authors were also able to investigate the directional relationship between 
adherence and involvement. Interestingly, spousal collaboration was increased 
after nights with poor adherence, and the authors relate this to possible sleep 
disruption caused by emerging of nocturnal symptoms (e.g. snoring) with non-
CPAP use. Although the caveat of this study is the use of subjective daily 
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adherence, this study highlights the possible intricate relationships between 
spousal involvement, disease severity and adherence.  
A further example of a BPS approach to CPAP can be found in a paper 
published by Olsen and colleagues(301), who expanded on previous attempts to 
understand the relationship between certain health beliefs and CPAP adherence. 
The first study(308) found variables from the Health Belief Model (HBM) 
measured only 1 day after titration were good predictors of CPAP use at 1 
month. This social cognitive model describes the likelihood of the individual’s 
behaviour is influenced by representations individuals have of their illness (in 
terms of severity and their own susceptibility) their treatment (e.g. benefits and 
barriers of engaging in it) and their self (e.g. perceived control). Olsen et al. 
found a similar relationship when the variables of the model were measured 
prior to CPAP initiation. They reported that patients’ outcome expectancies and 
risk perception were independent predictors of CPAP use. The HBM variables 
alone, explained 21.8 % of the variance.  Reflective of previous findings,(308) 
biomedical variables alone were not predictive of adherence. However, when 
these were included in the model alongside the HBM factors, the explanatory 
power rose to 31.8%. Although biomedical variables were included in the original 
Health Belief Model, they have not always been acknowledged. Rosenstock, the 
author of the original HBM article, stressed the importance of considering the 
interactive relationship between health beliefs and demographics and that 
certain cognitive attributions might be differentially distributed across these 
demographic subgroups.(385) 
Other studies have shown when both biomedical and psychological 
variables are included into the same statistical model - albeit sometimes without 
a theoretical underpinning - more variance is explained.(286, 287, 300, 304, 333) 
Interestingly, Poulet and colleagues(300) using a decision tree analysis- by 
nature a method to investigate interactions- were able to correctly predict 86% 
of the non-adherent patients with three baseline variables: emotional reactions, 
age, and maladaptive beliefs. Younger individuals reporting less emotional 
reaction to symptoms and with less accurate beliefs were correctly identified as 
non-adherent to 85.7% certainty. However in the same individuals with more 
adaptive beliefs, the accuracy rates for predicting adherence and non-adherent 
individuals was almost identical (58% vs. 42% respectively). Unfortunately, these 
accuracy ratings at the last node of the decision tree were based on a small 
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number of individuals (i.e., less than 20 individuals from the initial sample of 
122 scored were available in each node of the last stages of the decision tree). 
However, this study does suggest the usefulness of examining variables from 
both the biomedical (age) and psychological (beliefs) domain. The authors 
conclude that this type of analysis might be useful in informing individually 
tailored interventions. 
Lastly, Means and colleagues examined the relationship between ethnicity 
and adherence in a sample of 501 military veterans with and without a comorbid 
mental health disorder.(290) African Americans (AA) had lower CPAP use 
(approx. 1hr) at both one and three months post treatment initiation than the 
Caucasian group (CA). Interestingly, African Americans with a mental health 
disorder had a significantly lower adherence rate than all other groups (AA 
without a mental health disorder and all CAs), indicating an interaction effect of 
ethnicity and presence of a mental health disorder on CPAP adherence.  
These examples illustrate how certain groups of CPAP users might present 
with specific psychological and social attributions. Until now, this review has- 
mainly for simplicity reasons- considered the variables uniquely nested within 
each domain (e.g., AHI is a biomedical variable and not considered within the 
psychological or social domain), however it is important to remember that some 
biomedical variables may overlap with the psychological domain,(369) e.g., side 
effects and symptomatic improvement. That is, these biomedical factors are 
malleable to psychological (placebo) effects and two recent studies provide 
preliminary evidence for this.(1, 251) A recent patient-level meta-analysis of 
three randomised placebo-controlled crossover trials indicated that the effect of 
adherence on improvement in daytime sleepiness might be attributed to both a 
real effect and expectation of benefit. Higher use of CPAP was associated with 
improvements compared to low CPAP users, interestingly though a similar, but 
less extreme pattern was found in the placebo arm, indicating that some of the 
symptomatic improvement might be a result of a placebo effect.(1)  
Likewise, individuals might be more likely to report side effects when 
warned of these in the education session, the ‘nocebo effect’ and this effect 
might be increased by certain personality traits.(386) One study has investigated 
the relationship between personality type and CPAP side effects (e.g. blocked 
nose, dry throat etc.) and their impact on machine use.(251) In this cross 
sectional study 247 OSA patients, who had been using CPAP machine for longer 
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than 6 months, were assessed for Personality Type D (described as a tendency to 
experience negative emotions coupled with inhibiting the disclosure of these 
emotions to important others), the experience of side effects in terms of 
frequency, magnitude and perceived impact on adherence, as well as objective 
machine use. Individuals were then separated into those with and without 
personality Type D. Those with Type D were more likely to report certain side 
effects, judged them as more severe and also indicated the impact on adherence 
was greater than those without Type D. Although there was a significant 
difference in objective use per night (4.8 hrs Type D vs. 6.3 hrs non-Type D, 
p<0.001), no information was given about the interaction between side effects 
and personality type and their influence on objective hours of CPAP usage. An 
additional limitation is the cross-sectional rather than prospective nature and it 
remains difficult to establish whether personality type D was perhaps the result 
of non-adherence (i.e. sleep deprivation).  
In summary, a BPS model of CPAP adherence needs to account for not 
only the multitude of biomedical and psychosocial variables, but also clarify how 
they interact. This would result in a holistic model describing certain individuals 
with a specific biopsychosocial profile and which groups might benefit from 
specific tailored interventions based on these interactions. This might be a 
challenge- a challenge to implement as well as a challenge to convince sleep 
professionals, however if the impact of CPAP non-adherence is considered, it is a 
challenge that seems very worthwhile. With this in mind, it may be helpful to 
highlight how other health services have benefitted from this shift in perspective 
towards a biopsychosocial approach. 
 
2.6 The success of the biopsychosocial model- its 
application in health and illness 
The biopsychosocial model, introduced to the medical domain by Engel, was 
envisaged as an addition to the medical model, rather than its replacement.  
However, the viewpoint that health and illness are defined by biological 
processes, resulting from injury, biochemical imbalances, bacterial or viral 
infections(366, 387) often overlooked important individual experiential 
factors(388) and/or significant social or cultural variables,(389) which merit 
consideration alongside biomedical factors. The adoption of a more integrative 
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framework has facilitated health improvements elsewhere, e.g., peptic 
ulcers(390, 391), antisocial behaviour disorder(392) or chronic pain.(393, 394) 
Chronic pain and peptic ulcers have been selected here as illustrations.  
A peptic ulcer is an ulcerated area within the gastrointestinal tract 
(stomach, duodenum, or oesophagus). The disease exemplifies the 
biopsychosocial problem, initially believed to be a psychosomatic disorder, 
caused predominately by stress and personality,(395) yet with the discovery of 
the bacteria Helicobacter pylori (H. pylori) as the cause of peptic ulcers(396), it 
was then defined as being purely physiological. One reductionist viewpoint had 
been replaced by its mirror image.(397) Much later came the recognition of the 
interplay between these two viewpoints and that H. pylori is one piece in the 
puzzle of a biopsychosocial framework.(391) In fact a recent well designed 
animal model study(398) examined the synergistic relationship of H.pylori and 
psychological stress, by comparing the inflammation in stomach tissue of mice 
between 5 conditions (control, bacterial infection and psychological stress alone 
and in combination as well as psychological stress + treatment). Interestingly, 
psychological stress alone was not statistically different from the control 
condition, but it had additive effects in the combined condition, which is 
suggestive of a possible interaction effect of H.pylori and psychological stress on 
the development of peptic ulcers.  
Chronic pain, in contrast to peptic ulcers, was first considered as a purely 
physical phenomenon. The early Cartesian model offered an explanation of pain 
perception as a biomedical, physiological process, whereby the experience of 
pain occurs as the nociceptive signal travels from the point of injury via the 
spinal cord to the brain. The majority of theories left little room for 
psychological and/or social factors, unable to explain phenomena such as the 
varying relationship between injury and pain, phantom limb pain, and persistent 
pain after tissue healing.(393) With the development of the gate-control 
theory(399, 400) and its successor the neuromatrix theory(400) it was 
understood that pain perception is influenced by top-down processes from the 
brain. The neuromatrix is the connection of different areas of the brain: 
cognitive-evaluative (past experiences, cultural learning, anxiety, attention), 
sensory-discriminative (sensory input) and motivational-affective (hypothalamic-
pituitary-adrenal system, immune system) which, when activated, result in pain 
perception. This integration of multiple domains has made it possible to explain 
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phenomena such as phantom limb or chronic pain as ‘the result of neural 
mechanisms gone awry’.(401,  p. 1678) Today it is understood that psychosocial 
variables such as cognitions, emotions, social support in addition to sensory 
input (nociception) can and do influence pain.(402, 403) A recent review in fact 
highlighted the mind-body interactions in pain with reference to the 
psychological concept of catastrophising. Interestingly, they describe how 
catastrophising is associated with neuro-endocrine, neuro-immune, 
psychophysiologic, and functional neuro-anatomic changes in areas that are 
directly related to sensory pain perception.(404) 
A reductionist view of the aetiology of disease is limiting, whereas 
integrating biomedical and psychosocial perspective has led to a more holistic 
understanding of both PU and chronic pain. These examples provide a 
description of the aetiology of an illness, yet to fully understand the merit of 
adopting BPS framework for CPAP adherence, it is necessary to consider the 
implementation of such a model for adherence in general.   
Engel claimed that all three BPS domains must be taken into account in 
“every health care task”.(405, p.179) Management of adherence is a health care 
task, acknowledged by WHO as more important than any other medical 
treatment for improving patient outcome. Christiansen and colleagues(406-410) 
have utilised an integrative approach for the understanding of adherence to 
treatments for end stage renal failure patients. Their patient-context theory 
states that patient characteristics alone are not associated with adherence and 
it is the interaction between these characteristics and the treatment context 
that is most useful in understanding adherence to haemodialysis. This treatment 
takes many forms and varies in the degree of behavioural control required: 
centre haemodialysis, where the patient takes on a relatively passive role, home 
haemodialysis, where the patient is required to participate in some of the 
decision making, and lastly continuous ambulatory peritoneal dialysis, (CAPD) 
which is the most behaviourally intense in terms of input needed by the 
individual (e.g., bag changes 4 times a day).  Congruence between the patient’s 
preference for involvement and type of treatment is more predictive of 
adherence to treatment than type of dialysis alone.  Patients who favoured a 
more active coping style(409) or were more vigilant with information regarding 
their health,(406, 408) were adherent to dietary and fluid intake requirements 
in the treatment context requiring a more active role (e.g. home or CAPD) than 
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in the more passive context (centre haemodialysis). The opposite pattern was 
found for those preferring a more passive role within their treatment. The 
interaction between patient preference and treatment context is crucial for 
adequate adherence.  
This example highlights how a reductionist perspective, where adherence 
is considered within the treatment context without taking the individual’s 
preference into account, is less beneficial. This would be equivalent to trying to 
make sense of pain perception by considering sensory input only, or 
understanding peptic ulcers through H.pylori infections alone.   
  
2.7 Summary  
This review has provided an overview of how a biopsychosocial model could be 
adopted for the management of CPAP adherence on both a research and a 
clinical level. Following the success of this approach in other disease entities, 
both in advancing knowledge and in improving clinical practice, this chapter 
calls for a biopsychosocial approach to CPAP adherence and perhaps to OSA 
management more generally. CPAP adherence is multifaceted, and that patient-
centred research is vital to advance the field, there is now a need for a 
paradigm shift towards a holistic approach, where consideration of the 
interaction of biomedical, psychological and social factors is the clinical norm.  
 
2.8 Aims of the thesis 
In the context of this narrative literature review three core aims can be 
identified to enable the progression of our understanding of CPAP adherence. 
Firstly, there is a need for identification of the largely under-researched 
psychological and social variables. Secondly, research needs to focus on not only 
the multi-dimensional, but also the holistic nature of CPAP adherence, 
understanding the possible interactions between variables of all domains of the 
BPS model. Lastly, there is a need for developing brief, reliable and valid scales 
to facilitate the identification of BPS profiles within the clinical setting. The 
dearth of information on adherence to CBT-I outlined in the introductory chapter 
highlights how these issues can easily and should be extended to the insomnia 
field. These conclusions provide the basis for the three overarching thesis aims.  
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Aim 1: The first aim is to identify further psychological and social 
variables predictive of adherence to both CPAP and CBT-I. A unique opportunity 
is provided by in depth exploration of the patient’s experience of implementing 
these treatments. The two qualitative studies outlined in chapter 3 and 4, will 
provide greater insight into the psychosocial aspects, real life experiences of the 
treatment of both insomnia and OSA, and direction for further exploration of 
interactions between biomedical and these psychological and social factors.  
Aim 2: The next step is concerned with discovering the full potential of 
the BPS model by considering possible interactions between biomedical and 
psychosocial variables. As described above and in the introduction, the literature 
has reported on the relationship between adherence and outcome; specifically 
revealing that increased adherence may lead to improvements in daytime 
sleepiness. In addition to a physiological basis for this relationship, psychological 
effects might play a role, i.e. the relationship is influenced by an expectation of 
benefit. The identification of both these physiological and psychological effects 
on the dose-response relationship between adherence and outcome was the 
main aim of chapter 5 as a published paper. Three placebo-controlled trials 
were combined to quantify these effects. Most notably, finding improved 
outcome with increased use of both CPAP and placebo would indicate the 
presence of physical as well as psychological effects based on an expectation of 
benefit.  
However, as noted above, the relationship between adherence and 
outcome is likely to be bidirectional; that is, increased use can lead to increased 
improvements, and improvements can also spur on adherence. This has 
implications for the aim of chapter 5 within the context of this thesis. If the 
results of chapter 5 show that sleepiness outcome is affected by an expectation 
of benefit over and above the physiological effects, then sleepiness as a 
predictor of adherence should not only be considered within the biomedical 
domain, but also as a psychological factor, supporting the need for the 
implementation of the BPS model. Furthermore, and keeping in mind that there 
is potentially a bidirectional relationship, if both physical and psychological 
effects affect how increased adherence leads to improvements in sleepiness, 
then ultimately both physical and psychological effects affect how improvements 
in sleepiness also lead to increased adherence. Thus, the aim of this chapter is 
to identify the psychological and physical effects on the relationship between 
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adherence and outcome, to provide evidence for the BPS model of CPAP 
adherence.  
 
 
Aim 3: The last aim considers the seamless translation of a BPS approach 
to clinical care. The development of brief, reliable and valid tools to identify 
psychological and social variables to be added to the already established 
biomedical measures in routine clinical care will facilitate this task. Chapter 6 
will describe this process for a scale assessing components of the 
transtheoretical model (stage of change, self-efficacy, decisional balance and 
processes of change). The insomnia population will provide the context for this 
last aim, however efforts will be made to develop a scale that is easily 
transferable to the CPAP adherence field and potentially other health domains, 
thus providing a holistic approach not only to adherence CPAP and CBT-I, but to 
adherence in general.   
The next sections will be concerned with the evaluations of these three 
aims in the context of four experimental chapters. The aims and conclusions 
that are relevant to each chapter in isolation will be discussed within each 
section. How these results relate to these core thesis aims will be evaluated in 
the overarching discussion in chapter 7.    
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Chapter 3- “It’s logical, it’s rational, and yet I don’t 
want to do it”- A longitudinal qualitative analysis of 
the experience of using Continuous Positive 
Airway Pressure 
3.1 Abstract 
This study set out to examine the experience of patient adherence following a 
diagnosis of OSA. Interviews were conducted with 11 participants, who had 
recently been prescribed a CPAP machine and were attending the sleep clinic for 
their titration study. Six individuals completed three interviews (pre-titration, 1 
week and 3 months after CPAP was introduced into the home). Topics covered in 
the interviews included: the experience of having sleep apnoea and what 
enabled them to use their CPAP machine. Audio files of the interview were 
transcribed verbatim and evaluated using thematic analysis. Three key themes 
emerged in the interviews: ‘internal conflict around acceptance and adherence’, 
‘integration of CPAP into life’ and ‘motivators and resources for CPAP use’. It is 
apparent from this study and previous qualitative work, that CPAP is a 
demanding treatment. Perseverance is vital for the integration of CPAP into 
patients’ lives. Consideration of possible interactions amongst these factors may 
inform service improvement and future research. 
 !
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3.2 Introduction 
In their guidance documents on complex interventions, the Medical Research 
Council (MRC) alluded to the importance of considering qualitative, as well as 
quantitative, methodologies for development and evaluation of complex 
treatments.(411) The qualitative approach has been valuable for undersanding 
adherence to treatments ranging from medication after renal transplants(412), 
home exercise for chronic pain(413) and type II diabetes(414) to name a few. A 
number of studies have investigated the experience CPAP treatment, 
undoubtelbly a complex intervention, using qualitative approaches. The majority 
has focused on one single time point, assessing beliefs and attitudes either prior 
to treatment experience, or after treatment is initiated.  
Broström and colleagues interviewed 23 CPAP users who had initiated 
CPAP between 2 weeks and 182 months prior to the interview.(415) Using a 
qualitative content analysis approach this study identified certain facilitators 
and barriers for CPAP use. Wanting to avoid symptoms and health consequences 
of OSA, fear of disturbing others’ sleep, positive attitudes towards treatment; 
seeing improvements, spousal support and healthcare personnel were aspects 
that facilitated adherence. Negative attitude towards treatment, practical 
problems with CPAP, side effects, negative psychological effects of the 
treatment, insufficient spousal and healthcare team’s support created barriers 
to CPAP use.  
Although this study provides important information about factors that 
influence CPAP use, two limitations were apparent. There was a large variation 
in the time intervals between CPAP titration and interview across individuals (2 
weeks-182 months) adding great variability to the overall results and it is unclear 
which factors might be more/less important at different stages of treatment. 
Secondly, the questions defined a priori were strikingly similar to the 
subthemes. The questions were structured around asking the participant to 
describe a situation that facilitated/ created a barrier for CPAP use at a general 
level and then in relation to situations involving the spouse and healthcare 
personnel. This casts doubts as to whether the emerging themes from were truly 
patient-generated.  
In 2006, Dickerson and Kennedy interviewed 17 CPAP users who had 
attended a CPAP support group.(416) Using a phenomenological approach 
(Heideggerian hermeneutics), individuals described group support as beneficial 
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in facilitating motivation to persist with treatment despite its difficulties, to 
obtain the benefits CPAP could produce. Secondly, individuals described getting 
used to the machine and the need to integrate it into their lifestyle; tips for how 
to do this were provided by the 'expert/long-term' CPAP users. Individuals 
described how they felt empowered by group support, felt less isolated in 
dealing with this illness and treatment; and benefitted from listening and telling 
stories and giving/obtaining practical advice. The support group was defined as a 
community of CPAP users that could encourage, make people feel less isolated 
and was a forum for exchanging advice and providing hope. Overall, the authors 
argued that this format might provide the support and knowledge that could be 
introduced into routine clinical care. One limitation of the study was that 
individuals were recruited by advertisements, thus participants might have been 
biased towards a more open discussion about their difficulties with the machine.  
Smith et al. interviewed 21 CPAP users (3-39 months since initiation) and 
their partners in relation to their learning needs and barriers of use.(417) 
Content analysis of the interview data revealed that both patients and their 
care-givers reported improvements in sleep quantity and quality through use of 
CPAP. Barriers for implementation reported by the caregiver were of a 
psychosocial nature (impact on routines, travel), whereas patient reported 
barriers concerning the practical impact of machine use (i.e. side effects). They 
also asked individuals about the type of information most desired from the 
health care team. Information about sleep apnoea and its consequences on 
health was most frequently mentioned, followed by knowledge on 
implementation of CPAP into everyday life and other more practical issues 
concerning machine use. However, the questions used were similar to the 
emerging themes (e.g. open-ended questions about adherence, benefits, 
problems, current knowledge informational needs) and naturally this type of 
approach might be biased by demand characteristics.  
Veale and colleagues analysed interviews with thirty OSA patients, 15 of 
whom were currently using CPAP.(418) Discourse analysis using the following 
three methods: content analysis, propositional (assessing the proximity of 
words/terms) and lexical analysis, revealed how individuals witnessed 
improvements in their sleep, despite reporting difficulties using the machine, 
especially those who were currently working, or travelled frequently. A number 
of participants considered themselves ‘ill’ as a result of accepting the medical 
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treatment. Unfortunately CPAP adherence was not the primary outcome of 
investigation in this study, but rather how the diagnosis of OSA impacted on 
individual’s quality of life.  
Van de Mortel et al.(275) used grounded theory to investigate the 
experience of the titration night and subsequent CPAP use. Interviewing 19 
individuals, nine of whom reported not using the machine, the authors deduced 
two theories from the data: 1) benefit derived from treatment translates to 
increased use of the CPAP machine and 2) poor experience during the titration 
night leads to poor CPAP adherence.  
Support from the medical team or CPAP suppliers was reported as 
important in the process of accepting and using CPAP in a number of the 
qualitative studies, with some patients experiencing levels of support below 
their expectations.(e.g., 415, 417). Shoukry et al.(419) were interested in the 
experience of a particular type of medical team: pharmacists. Twenty patients 
who had been provided with a CPAP machine from the pharmacy –based CPAP 
service, were interviewed and using phenomenological analysis, the authors 
described the patient’s general experience of from-diagnosis, to the titration 
study and then CPAP use. This overall CPAP experience was similar to the studies 
described above, and most patients were generally satisfied with the service 
provided by the pharmacy. Patients valued the convenient access, and the 
majority considered the personalisation of care offered by the pharmacist 
suitable for their needs.  Unfortunately patients were interviewed between 0.5 
and 84 months of receiving their CPAP machine. Because of such a large variance 
in time intervals and thus heterogeneous sample, specific conclusions are 
difficult.  
In addition to these cross-sectional investigations, a few studies have 
embarked on a longitudinal qualitative investigation of CPAP use. Broström et 
al.(420) presented a longitudinal case study providing in-depth information 
about the experience of implementing CPAP treatment from a patient and his 
partner’s perspective. Semi-structured interviews were carried out with the two 
individuals at four timepoints across 6 months (before CPAP , two weeks, three 
and 6 months after CPAP initiation). Using a phenomenographic approach, this 
study found that CPAP acceptance and adherence was slightly inhibited by the 
lack of initial information given at diagnosis. As treatment progressed further 
emotional and educational support from the CPAP-nurse enabled the couple to 
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fully understand sleep apnoea and its consequences, overcome negative social 
reactions (e.g. strain on the relationship) and stressors (e.g. negative health 
consequences of OSA, side effects of CPAP, fear of being perceived as odd) - 
which increased CPAP adherence in the long-term. This study provides a 
fascinating insight into CPAP adherence from a longitudinal and couple’s 
perspective.  
Another study in 2007 presented data on 20 newly diagnosed OSA patients 
followed through from titration to one and three after CPAP initiation(421). 
Using an interpretive phenomenological approach(Heideggerian hermeneutics) 
the authors identified five themes. The philosophical foundations of this analytic 
approach lay within phenomenology: understanding how people make sense of a 
particular phenomenon; hermeunetics: the theory of interpretation, and 
ideography: the study of the particular both in the sense of detail and a 
particular group or context(422) and in this context allow for a more detailed, 
interpretive account of the individual’s experience of using CPAP. Throughout 
the treatment process, individuals found using the CPAP machine difficult, 
reporting common side effects such air leakage, marks from CPAP straps and 
disrupted sleep (theme 1). Pushing through these difficulties required 
persistence and perseverance on the patient’s behalf (theme 2). Individuals 
seemed challenged by identifying improvements in their symptoms, especially in 
the early stages of treatment. As they progressed through to the 3-month 
interview, changes were more apparent, often endorsed by improvements 
witnessed by family members or non-adherence (theme 3). Problem solving and 
gaining support, especially from family and CPAP providers, facilitated pushing 
through these difficulties. (theme 4).  Based on a cost-benefit evaluation CPAP 
was either integrated into their lives or the device was abandoned (theme 5). 
Lastly the authors describe a constitutive pattern, namely pushing through 
difficulties by obtaining a positive mind-set. Although this comprehensive study 
presents a detailed account of the experience of implementing CPAP, the 
themes are not clearly defined with large overlap in places (e.g. theme 1 
“trouble using CPAP” and 2 “needing to persist through initial and recurring 
frustration”), which hinders the provision of clear directions for treating 
clinicians and future research. Furthermore, the second interview was 
conducted 1 month after CPAP initiation; there is evidence to suggest that 
within the first month, 25 % of individuals stop using CPAP and adherence 
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patterns are relatively well established after 1 month. Interviewing CPAP users 
at a shorter time period after the titration (e.g. 1 week after) might provide 
important information about factors that influence CPAP use.  
In addition to Dickerson’s study, only one working group has evaluated the 
experience of CPAP users in a longitudinal design.(423) This study drew on 
aspects of social cognitive theory as a conceptual framework to further 
understand what factors differentially contribute to adherence and non-
adherence to CPAP. This model describes knowledge, self-efficacy, outcome 
expectations and facilitators of/barriers to change as strong predictors of 
behaviour change. Fifteen newly diagnosed OSA patients were interviewed post-
diagnosis and after a one-week experience of CPAP use. Interviews were firstly 
content analysed, identifying themes at the individual level. The sample was 
then separated into adherers (≥ 6hrs/night CPAP use) and non-adherers (< 
6hrs/night CPAP use). Differences between adherers and non-adherers emerged 
in terms of risk perception, symptom recognition, self-efficacy, facilitators and 
barriers  outcome expectations and treatment goals. Adherers were generally 
considered OSA to be more aware of the symptoms and potential consequences, 
and had increased confidence.  These individuals were also more likely to set 
treatment goals and focus on positive outcome expectancies in order to 
overcome any barriers. The strength of this multi-method study was the blinding 
of the investigators to adherence status, which allowed for minimisation of bias 
in the development of core themes. Two other advantages are also worth 
mentioning were the differential analysis of the adherent and non-adherent 
group and drawing upon components of social cognitive models. These two 
approaches have been also been used by other study groups.(424, 425) 
Valuable information can be obtained when separating adherent from the 
non-adherent individuals, potentially identifying strategies for targeting 
individuals who might be at high risk of non-adherence. Ayow et al.(424) 
conducted a thematic analysis on eight individual CPAP non-users (<1hr use 
nightly use over 7 days) and users (>=5hrs in last 7 days). The same themes 
emerged for both groups: physical (e.g. increased energy, weight loss), 
psychological (e.g. beliefs about OSA, experienced psychological detriment) and 
social influences (e.g. support). However the way these concepts influenced 
CPAP use was different between groups. For example, perceived psychological 
detriment was reported in users when not using the machine: e.g. guilt when 
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snoring impacts on the partner. In non-users, psychological detriment was 
reported when using the machine (e.g. feeling uncomfortable in front of partner 
with the mask on). The authors concluded that two aspects most strongly 
impacted on CPAP use, namely peer comparison (in terms of illness severity and 
daytime functioning) and stigma (feeling stigmatised for not functioning and 
needing to use a CPAP machine).  
One limitation of the study that was not considered by the authors was 
the unequal time elapsed between initiation and interview between the users 
(32 weeks after initiation) and non-users (121 weeks after treatment initiation). 
Factors that emerged in the non-users after 2 ½ years might be inherently 
different from factors emerging after only 8 months in the users.  
The use of a social cognitive model as a theoretical framework for 
qualitative analysis is useful, as it may facilitate translation into interventions 
for improving adherence. Tyrrell et al.(425)  interviewed patients with OSA who 
had recently abandoned CPAP. Using the health belief model as a framework, 
the authors identified that the nine interviewed individuals had a poor 
understanding of their condition and were unsurprisingly not concerned with 
their severity and their susceptibility to health consequences of their sleep 
problem. Additionally, individuals described more barriers to CPAP use than 
benefits and this was considered one of the catalysts for abandoning the 
treatment. Considering individuals who have completely stopped using the 
machine is important, however it is unclear in this study, how these individuals 
were contacted and identified as ‘CPAP abandoners’. A selection bias might have 
occurred, if individuals, who took part were those more content with admitting 
that they had stopped using the machine than individuals who refused 
participation. Arguably these individuals may have displayed a different 
psychological profile.  
In summary, despite the range of study designs, certain commonalities 
can be identified across these qualitative studies. CPAP is a treatment that is 
not easily implemented and users find themselves having to utilise internal 
means such as willpower and self-efficacy often pushing through early resistance 
to this intervention. Some individuals struggle with the concept of using the 
CPAP machine, which they believe identifies them as ill and not able to take 
care of themselves. However, a cost-benefit evaluation whereby advantages 
(especially the elimination of negative consequences of OSA) outweigh these 
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disadvantages potentially translates to increased CPAP use, along with social 
support from spouse/family members and/or health care team. To an extent this 
overlaps with the quantitative studies outlined in chapter 1 and more 
importantly supports the transition witnessed in the literature to increasingly 
focus on psychosocial variables. One limitation of these qualitative studies is 
generalisability; with small sample sizes conclusions can only be made about 
particular samples. There is a need to conduct further qualitative studies with 
similar designs to allow for potential amalgamation at the theoretical level, with 
the goal of increasing the external validity of some of these study findings.(426)  
The aim of this chapter therefore was to investigate qualitatively the 
experience of CPAP adherence using a longitudinal study design. Similar to 
Sawyer et al.’s study(423), a short timeframe of 1 week after the CPAP purchase 
was selected, in addition to a pre-titration and a three months interview. This 
time line was selected because of the frequent abandonment of the machine 
within the first month and because adherence patterns are established within 
the first few days.  
3.3 Methods 
3.3.1 Participants 
Individuals, who had recently been diagnosed with OSA and were committed to a 
titration study, were contacted for participation. Additional inclusion criteria 
were: individuals between 18-75 yrs., English language fluency and willingness to 
comply with the study procedures. Patients who had a co-morbid sleep or 
psychological disorder were not included. Of 11 individuals recruited, 6 
participants were able to commit to three interviews. Two individuals never 
purchased a machine, one was not contactable after the first interview, and two 
individuals were only able to attend two of the three interviews. Therefore, all 
data analysis considered only the homogenous group who were able to complete 
all three interviews.  
 
3.3.2 Procedure 
Ethical approval was obtained by the Sydney Local Health District Ethics Review 
Committee (RPAH Zone). The consent form and patient information sheet are 
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presented in Appendices 2 and 3 respectively. Prior to their overnight titration 
study and upon obtaining consent, eligible OSA patients were invited for the first 
interview, which was conducted in a familiar environment at the sleep centre. 
The study procedures were explained and participants were made aware that 
interviews were audio-recorded with their permission and responses would 
remain anonymous. Participants were briefed about their ability to withdraw 
from the study at any time. To make each participant feel comfortable, the 
interview schedule began with general questions about the history of their sleep 
problem. Subsequent questions covered the individual’s thoughts and feelings 
about diagnosis and introduction to CPAP, and lastly their expectations of how 
the treatment might impact on their daily life. Additional prompts standard for 
semi-structured interviews were included, such as: “Can you tell me more about 
this”, “Can you explain what you mean”. Individuals were asked to contact the 
interviewer after purchasing the CPAP machine. A follow-up phone call was 
made if the individual had not contacted the interviewer within 2-3 weeks post 
titration study. The two post titration interviews (1 week and 3 months after 
purchasing the machine) differed slightly from the baseline interview questions, 
which were phrased prospectively e.g. “How do you think CPAP will affect your 
every day life?”. The second two interviews included questions about 
participants’ initial experiences with the machine and how they felt about using 
the mask at the current time.  Thereafter the topic of adherence was 
introduced, individuals were asked to describe a typical night where they 
used/did not use the machine and what factors they believed influenced 
adherence. The interview schedule is outlined in Appendix 4. Of note, the 
interview schedule for this group was the same for the CBT-I group (presented in 
chapter 4), thus for simplicity reasons, the schedule presented in the appendix is 
a merged version. The two versions only differed in respect to references to the 
sleep problem (sleep apnoea/insomnia) or the treatment (CPAP/CBT-I). 
The interviewer was not involved in any aspect of the care (diagnosis, 
titration study or any follow-up sessions); the sleep unit staff, as part of their 
routine duty, undertook this. 
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3.3.3 Data Preparation and Analysis 
Interviews were transcribed verbatim by the lead researcher, and the data were 
explored using thematic analysis. This approach to qualitative data has been 
used extensively, unfortunately often without explicit reference to its use.(427). 
It has offered a variety of studies- including qualitative explorations of patient 
adherence(428-430) with a flexible technique that is not restricted by ‘pre-
existing theoretical framework[s]’.(427, p. 81) An inductive, descriptive 
approach to analysis was chosen to allow for preliminary exploration of the 
relatively poorly understood topic of CPAP adherence. According to Braun’s 
methodology outline of thematic analysis,(427) each interview was read and re-
read, familiarising oneself with the data set. Subsequently, passages were coded 
at the basic, descriptive level, and these codes were then collated into themes. 
The clustering of codes and identification of themes was refined in an iterative 
process, data extracts were re-read to ensure the themes were internally 
consistent and captured the verbatim evidence accurately.  Lastly, themes were 
organised into a meaningful account of the individual’s experience using 
sufficient verbatim evidence and telling the story in the words of the 
participants. A second reviewer warranted the reliability of the data by assessing 
the analysis at different stages of the process. Themes were also refined by 
discussions with researchers independent from the analysis process. Participant’s 
names and additional identifying information were changed to ensure 
anonymity. Small changes were made in the final report to facilitate legibility of 
the verbal extracts. Brief vocal utterances (e.g. ‘ehm’ ‘oh’) were omitted and 
semantic repetitions (e.g. my partner, you know my partner) or brief tangents 
from the topic, were also transcribed, but replaced in with ‘[…]’ in the final 
write up. Short pauses in the interview were transcribed as ‘…’ and incorrect 
grammar indicated with [sic].  
Additional aspects were considered when dealing with the three time 
points. Participant’s three interviews were examined together, to obtain a sense 
of change within each individual. Emergent themes were then considered across 
individuals to generate a coherent picture of the experience of CPAP treatment. 
In order to describe changes across time and allow for a flow in the description 
of the phenomenon (CPAP adherence), quotes are presented separately, but 
referred to in the text.  
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3.4 Results 
Patient characteristics of the six individuals who completed all three interviews 
are presented in Table 7.  
 
Table 7: Patient Characteristics 
Alias Age 
(yrs) 
RDI 
(events 
per hr) 
Minimum 
Oxygen 
Saturation (%) 
BMI 
(kg/m2) 
CPAP 
pressure 
(cm H2O) 
Marital 
Status 
CPAP use/night 
Matthew 38 11 88 33 13 Married <4hrs 
Benedict 40 23.3 89 25.2 10 Married >6hrs 
Stephanie 48 40 81 35 15 Single 4-6hrs 
Danny 49 29.6 84 34 9 Live-in 
partner 
missing 
Jacob 45 8.5 89 34.5 10 Married >6hrs 
Jim 44 55 71 37 13 Married 4-6hrs 
AVERAGE 44 27.9 82.2 33.1 11.6 - - 
 
From the information provided in the interviews, three themes emerged: 
Internal conflict around acceptance and implementation, integration of CPAP 
into life and motivators and resources. Box 2 depicts these three themes and 
their corresponding subthemes.  
Box 2: Overview of themes and subthemes 
 
3.4.1 Theme 1: Internal conflict around acceptance and 
implementation 
In the interviews CPAP was presented as a challenging treatment and individuals 
were faced with a conflict around acceptance and implementation. Individuals 
were in two minds, knowing on the one side that the treatment would procure 
benefits for them, and on the other hand, CPAP was not something they were 
keen to accept and integrate into their routine. A conflict existed around the 
concept of longing for normalcy, where CPAP embodied the key to regaining 
Theme 1: Internal conflict around acceptance and implementation 
Subthemes:  
• Being in two minds 
• Longing for normality 
• Resolving internal conflict 
 
Theme 2: Integration of CPAP into life  
Subthemes:  
• Integration into nightly routines 
• Integration into personal life 
 
Theme 3: Motivators and Resources 
Subthemes:  
• Intrinsic motivators and resources  
• Extrinsic motivators and resources  
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normal functioning, however was not considered a normal treatment. However 
individuals developed strategies to facilitate the resolution of these conflicts.  
3.4.1.1 Being in two minds 
As an artefact of simply being interviewed shortly before or on the day of their 
CPAP titration study, it was presumed these participants had reached a stage of 
acceptance. Nevertheless, throughout the interviews, it emerged that this 
sample was, battling an internal conflict around acceptance and implementation 
of the machine. Terms used to describe this conflict were having a ‘split 
personality’ [Matthew], seeing the one ‘side/hand’ versus the other [Benedict, 
Jim], showing ‘resistance’ despite known advantages of the CPAP machine 
[Stephanie, Jim].  The latter description is particularly interesting, these 
individuals were fully aware of the potential benefits of using the machine and 
risks associated with not doing so, yet just did not want to use the machine (Box 
3 quote 1-2, 5). This is particularly pertinent in Stephanie’s description of this 
internal conflict (Box 3, quote 3-4). At three months, a few individuals still 
described this conflict, highlighting this potential obstacle for adherence persists 
after these individuals had purchased the machine and were supposedly 
accepting of treatment. (Box 3, quote 5-6) 
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Box 3: SUBTHEME-Being in two minds 
 
3.4.1.2 Longing for normality 
The debilitating daytime consequences of sleep apnoea had proven an 
obstruction to normality in the majority of individuals.    
 
‘what a normal person…what used to take me an hour to do in the 
mornings, it would probably take me a couple of hours to do now.’ [Jim, 1, l.39-
41] 
 
‘I don’t like the sensation of just you know, one minute being you know… 
reading the newspaper or something and then “boom” you are gone, you know 
sort of, fall fast asleep.’ [Stephanie, 1, l. 189-191] 
 
‘there are some days where you get up and you really just cant get going, 
[…] and as a result you waste a day, […] you end up in front of the telly and 
doing all the things that you shouldn’t be doing instead of getting on with life.’  
[Danny, 1, l.56-60] 
 
CPAP presented itself as the key to regaining a sense of normality (Box 4, 
quotes 1-6). Although the treatment was considered as something that would aid 
with the two most basic processes: sleep and breathing. Being unable to do this 
independently, portrayed the individual as abnormal. (Box 4, quotes 7-15) 
Being in two minds 
 
1. ‘I can see the benefits by having the machine, but I am just, in the back of my 
mind, will these benefits stay the same, or will my body get used to having this 
extra oxygen and then become, go back to normal [pre-treatment].’ [Jacob, 1, l. 
200-203] 
 
2. ‘Just a change in your life that you don’t really want to have to implement. You 
know that is basically what it is. “I don’t have to do this. Why should I have to 
do this?” You know, but reality is, you have got to do it.’ [Jim, 2, l. 465-467] 
 
3. ‘Its logical, it’s rational, and yet I don’t want to do it.’ [Stephanie, 1, l. 273-274]   
 
4. ‘I have to do something about my sleep, so, even if I am negative about it, I still 
have to control the feelings.’  [Stephanie, 1, l. 167-168] 
 
5. ‘How it makes me feel is fantastic, but how it makes me feel when I'm wearing it 
is not so great, and it's that sort of thing…all the way along.’ [Danny, 3, l. 247-
249] 
 
6. ‘I try to avoid routine where I can because it’s boring, you know but that is on 
the one hand, but on the other hand this routine is not that much of a problem 
for me, this routine shows me benefits you know. So I am almost a split 
personality when it comes to this.’ [Jim, 3, l. 435-438] 
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It was evident across time points that individuals longed for this sense of 
normality. At the first interview individuals were hopeful in reaching this goal by 
using the CPAP machine (Box 4, quote 1-2), whilst remaining realistic, like 
Danny, who judged normality by what he was able to do prior to developing OSA 
symptoms (Box 4, quote 3). During the second interview, and even more so after 
3 months, individuals began to identify a gradual progression to regaining 
normality during the day (Box 4, quotes 4-6). In conflict with this development 
was the sense of wearing the machine at night was not considered normal; CPAP 
was identified as a treatment for a sleep related breathing disorder. Sleep and 
breathing present two of the most basic human processes. Acceptance and use 
of the machine was equated with being unable to sleep and breathe 
independently, something that set them apart from ‘normal’ people (Box 4, 
quotes 7-10). There was a certain stigma associated with this, and individuals 
identified themselves as ‘old and sick’, akin to an ‘invalid’[Jim], and as if the 
body was ‘giving up’ [Danny]. These terms reflected their own representations; 
individuals also feared the stigmatisation by others (Box 4, quotes 11-12), 
particularly Stephanie voiced her trepidation of accepting the machine, 
assuming others, especially work colleagues, would judge her as not be able to 
function normally.  
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Box 4: SUBTHEME- Longing for normality 
 
Longing for normality 
1. ‘Yeah, hopefully like it will work for me and yeah, like it becomes all good again.’ 
[Matthew, 1, l. 241]  
 
2. ‘If I get, the benefit, the full benefit that I envisage from this thing, I am going to 
have part of my life back, that I haven’t had that…haven’t had for some time.’ 
[Jim 1, l. 234-236]  
 
3. ‘I am not expecting to maybe […], run a marathon or something, but I want to 
have some resemblance of normality back in my life.’ [Danny, 1, l. 328-330] 
 
4. ‘this is a bit like a time warp [...] Back to when it was…to what it was before, or 
how I felt before, I thought that was the norm, but then no it's not.’ [Danny, 3, l. 
113-118]  
 
5. ‘Like just happy and feeling…get back, like just happy, happy that I got it and 
thinking of getting back on track.’ [Matthew, 3, l. 236-237] 
 
6. ‘yeah I have got sleep apnoea, I have still…but by me having the machine, I am 
back to normal.’ [Jacob, 2, l. 443-44] 
 
7. ‘I have something determining my sleeping, you know, how I sleep. You know 
there is …and that is, I have got to follow a particular routine to get to go to sleep 
[emphasis].’ [Jim, 1, l.186-188] 
 
8. ‘Its like you loose your independence as a human being, like you need this machine 
to breathe, you are artificially living.’ [Jacob, 1, l. 281-282] 
 
9. ‘it’s just a stigma, you know, you don’t want to feel that your body is giving up on 
you, or you need assistance, from anybody, especially if you are doing something 
as simple as breathing, we are all supposed to be able to do that.’ [Danny, 1, l. 262-
264] 
 
10. ‘you are doing something that, your doing something that the rest of the 
population is not doing. So, yes, sort of disappointing from that aspect.’ [Benedict, 
3, l. 59-60];  
 
11. ‘like “there is something wrong with him, he has got a machine to breathe you 
know”.’ [Jacob, 1, l. 240] 
 
12. ‘I am a professional person doing a professional job, and I don’t want to be judged 
as somehow not able to do my job properly.’ [Stephanie, 1, l. 347-349]   
 
13. ‘It is not nice, […] at the end of the day, you know, it is a machine, it is an artificial 
thing. It is still in the back of your head, you know, then you are getting the great 
benefits, you can [emphasis] sleep, you can [emphasis] tolerate the noise, you can 
[emphasis] tolerate the heat from the strap; you are feeling good, energy…but why 
can’t you do it by yourself, naturally.’ [Jacob, 2, l.715-719]  
 
14. ‘It [CPAP] doesn't make me feel any different about who I am, other than in that 
one…that one aspect […] I don’t know… father figure, man figure…is that you can 
gather her, flop to your chest and hold them and make everything better, and I 
just feel like this gets…in a way a little bit of that.’ [Danny 3, l. 380-384] 
 
15. ‘At one stage I was thinking ‘if I use this machine for too long, is it going to weaken 
my ability to breathe on my own?’  [Jacob, 3, l.224-225] 
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Interestingly, these concerns were still present at the 1-week and 3 
month interviews, suggesting these concerns might be contributing somewhat to 
the levels of CPAP adherence in these individuals (Box 4, quotes 13-15).  
Seemingly, there is uniqueness about CPAP as a treatment for a sleep 
related breathing disorder. Potentially more so than other disorders, the sense 
of abnormality of receiving treatment is increased by CPAP being a treatment 
for two most basic physiological processes. A quote by Danny highlights how this 
contributes to his internal conflict:  
 
‘I don’t like to feel that I am, you know like I can’t look after myself. 
And you know even with the diabetes you look after yourself because you keep 
your blood sugar levels, so you monitor your blood sugar levels, […] but this you 
are not, essentially it’s a bit different, you are not really in control of this.’ 
[Danny, 1, l. 269-275] 
 
3.4.1.3 Resolving internal conflict 
Individuals described different strategies for overcoming this internal conflict. 
For Jim, the process of simply speaking openly about it during the interviews 
was sufficient to crystallise the root of his resistance and resolve it (Box 5, quote 
1), for others, an effective method was acceptance, being rational about the 
need for change or simply placing mind over matter (Box 5, quotes 2-4). At the 
second and third interview these strategies became more concrete. Considering 
how the benefits of using the machine outweighed the disadvantages for change 
was reported by a number of individuals (Box 5, quotes 5-7). Drawing social 
comparisons was also important, particularly for Jim (Box 5, quote 8), who 
compared his conflict with others who have been through the same process. 
Interestingly, when evaluating the disadvantages against the benefits (Box 5, 
quote 5), it became clear how Jim resolved the conflict around feeling like an 
‘invalid’ (see above): understanding that treatment did not necessarily equate 
to a poor quality of life was a substantial discovery for him.  
There is an implicit assumption in this subtheme, that the resolution of 
this conflict is based on a rational decision-making process. However, there are 
a number of somewhat unconscious processes revealed in the interviews. Firstly, 
a concept borrowed from social psychology: cognitive dissonance; a concept that 
describes the simultaneous presence of two conflicting beliefs; individuals have 
a tendency to want to resolve this dissonance by changing the balance between 
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these two conflicting beliefs. The resolution of conflict, according to the theory, 
occurs largely in the unconscious.(431) This was the case for both Matthew and 
Stephanie (Box 5, quotes 9-10), who seemingly reduced dissonance by attributing 
greater importance to the potential health benefits (compared to the 
disadvantages for change). For Matthew this was accomplished by being 
conscious of the money invested into purchasing the machine; for Stephanie it 
was the belief in her level of intelligence. Secondly, it is important to note that 
the adherence behaviour of interest here occurs during sleep, when certain 
stages are associated with reduced activity in rational/decision making regions 
of the brain, and activity in emotional regions is increased. Waking from REM 
sleep might result non-adherence behaviour (i.e., taking off the mask), which is 
precisely not based on rational decision-making processes. This phenomenon was 
reported by two of the six participants in this sample (Box 5, quotes 11-12). 
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Box 5: SUBTHEME- Resolving conflict 
 
 
3.4.2  Theme 2: Integration of CPAP into life 
At the first interview, individuals had little conceptualisation of the impact CPAP 
would have on their lives. Many raised questions and described expectations 
Resolving Conflict 
 
1. ‘I mean talking about therapy on an emotional level, well it served a great purpose 
on that regard [breaking through resistance]. I guess I wouldn’t really have 
crystallised it, had I not had this interview with you.’ [Jim, 2, l. 565-568] 
 
2. ‘But life isn’t fair anyway as life is, some people are more, their health is better 
than the other people’s health you know what  I mean? But, it’s at the end of the 
day, everybody gets fixed up, it’s the main thing you know. That is how life is you 
know.’ [Matthew, 1, l. 414-417], 
 
3. ‘I need the treatment to have better sleep so that I can function better, so. I’ll just 
get on with it. I mean, that just…you have got to rationally face it.’ [Stephanie, 1, l. 
678-680] 
 
4. ‘So it is definitely there, the downside that is part of the downside. But, I can’t hang 
around thinking; you know thinking about that for too long.’ [Jim, 2, l. 198-200] 
 
5. ‘For me just to feel OK about doing this, it’s a relief to have broken through that 
resistance, It’s a great reminder to take care of my health. It’s made me realise 
there are probably a lot of people out there [...] these people are just carrying on 
with their lives. It makes me realise that the person in a wheelchair who is full of 
life, is living a more fulfilled life that a lot of other people.’ [Jim, 2, l.552-559] 
 
6. ‘It’s more detrimental if I don’t use it, than if I use it. So the benefits and the safety 
are more important than me feeling, you know, a little bit uncomfortable in wearing 
it initially.’ [Jacob, 3, l. 336-339] 
 
7. ‘The feeling of CPAP being unnatural], it’s OK for me, so long as I can see that the, 
the health benefits that I thought of is going to get.’ [Benedict, 3, l. 243-244] 
 
8. ‘There are people that do have problems with it, and it was interesting for me to 
hear that, considering my experience to date with it all. I was kind of “I am not 
alone you know if taking so long to get here. I am not alone in resisting it”, made me 
feel a bit better about myself.’ [Jim, 2, l. 482-486] 
 
9. ‘To use the machine? If I didn’t want the help I wouldn’t come here. If I didn’t want 
the help, from the doctor I wouldn’t come here and spend my money.’ [Matthew, 2, 
l. 356-357] 
 
10. ‘If you know you have a condition and you have therapy that can alleviate it and 
potentially make sure you live an OK length of life, rather than a shorter length of 
life, you’re a bit stupid if you don’t do it. But I don’t think I’m stupid, so I persist.’ 
[Stephanie, 3, l. 537-540] 
 
11. ‘There’s not a rational thinking process going on there. It’s…ahm, you know its an 
un… it’s uncomfortable and that’s the reaction I’m going for […] I don’t think I’m 
really awake enough to [think rationally].’ [Danny, 2, l. 684-690] 
 
12. ‘Oh, it happens every night! I take it off every night. For me not to take it off is quite 
rare. […] Sometimes I remember taking it off, but most times I don’t.’ [Jim, 3, l. 
269-281] 
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they had. For some, their predictions materialised, whereas for others they did 
not. The titration study offered the primary opportunity to experience the CPAP 
machine and what it would mean to integrate this treatment into their life. 
Some described this experience as ‘the worst night sleep’ [Jim] or feeling 
‘jetlagged’ [Stephanie], with no beneficial effect of using the machine upon 
awakening, whereas others again witnessed immediate benefits:  
‘I felt that I didn’t sleep for a long time, but I have [sic] a euphoric 
experience the next day basically, I felt like on top of the world. I felt like, 
wow. “Wow pow catch me if you can.” I was like, “I am heaven” basically, 
“cloud nine,” I felt really good.’ [Jacob, 2, l. 104-106] 
 
Apart from Jim, none of the individuals expressed a positive or negative 
impact of the titration study experience on subsequent machine purchase: 
 
‘it took me a month to get to that point of going and getting the machine 
and I was more ready a month later than I was the day after getting the 
prescription, or the day I received the prescription, so I felt ready to try it out.’ 
[Jim, 2, l. 63-66] 
 
Benedict stated a more detailed focus on the practical experience of 
CPAP on the titration study night would have helped him form most positive or 
helpful expectations around integrating CPAP into his life: 
 
‘a bit more time in the education session with the practical stuff about 
the mask fitting and getting used to the machine. I think that’s, the more time 
that you have with the machine before you actually go home is a good thing, so 
you know what to expect.’ [Benedict, 2, l. 236-238] 
 
Throughout the interviews, individual’s described their initial 
expectations and subsequent experience of the integration of CPAP into their 
life, both at a night-to-night, but also at a more general and personal level, as 
well as considering the impact on family/relationships and their future:  
3.4.2.1 Integration into nightly routine 
Individuals expressed the need to integrate CPAP into their everyday nightly 
routine, moving towards a stage of ‘familiarity’ [Benedict], with the hope that 
the therapy would eventually become ‘second nature’ [Stephanie], almost ‘like 
wearing glasses’  [Jim] or having ‘a ring on your finger’ [Matthew]. They 
described the need to persist until the new behaviour became a habit (Box 6; 
quote 1, 2). Strategies to facilitate this process such as gradual nightly increase 
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in use or anchoring it to existing routines were employed by Matthew and Danny 
respectively (Box 6, quote 3, 4). One particular concern during this process 
however was the potential impact on sleep and the bedtime routine. Being 
accustomed to falling asleep within a few minutes, individuals were 
apprehensive at the baseline interview about the impact this treatment would 
have on their sleep onset (Box 6, quote 5). Interestingly some individuals (e.g. 
Box 6- quote 6, 7) noted the increase in sleep onset latency after using the 
machine at the 1-and 3-month interview. In addition to changes in actual sleep, 
the bedtime routine was affected by the integration of the CPAP machine into 
daily life. Not being able to read a book, have a conversation or be intimate with 
the bed partner were adaptations these frustrated individuals had to make. This 
was not confined to their own routine, as described by Jacob (Box 6; quote 8), 
but concerns extended to the impact on the routine shared with the bed partner 
(Box 6; quote 9).  
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Box 6: SUBTHEME - Integration of CPAP into nightly routines 
 
 
The integration of CPAP was accompanied by unwanted side effects in 
some individuals. Most commonly reported effects were skin irritations, air 
leakages and marks from the straps (Box 6; quotes 10,11). This experience may 
Integration of CPAP into nightly routines 
 
1. ‘I suppose it’s just hoping it just becomes second nature. Part of your routine at 
[sic] going to bed at night is putting that thing on.’ [Stephanie, 1, l. 451-453] 
 
2. ‘getting used to it was uncomfortable at first, so I knew that was going to, you know 
I'd have to adjust to the sensation and the feeling of having a mask both in the face 
and the air going up your nose.’ [Benedict, 3, l. 147-149] 
 
3. ‘Yeah, I would put it on the first couple of hours, that is how much I could do. I 
couldn’t do anymore than that and that is why I took it off. The second day, I did it 
4-5 hours,  that is as much as I could handle. Its good though the 4-5 hours, and 
then I have a break and then I put it on again for the next couple of hours.’ 
[Matthew, 2, l. 399-402] 
 
4. ‘From a daily ahm, point of view, I've just tried to sort of incorporate it. When we 
bath the baby, that's when I sort of bring the stuff out, the machine, I use that as the 
reminder to take the things out.’ [Danny, 3, l. 343-346] 
 
5. ‘I don’t know how uncomfortable its going to be, or whether its going to hinder me 
actually getting to sleep.’ [Bendict, 1, l. 166-168] 
 
6. ‘Like I like to fall asleep in 5 minutes, bang, like I…but I am slowly getting to that its 
taking me like 15-20 minutes to fall asleep.’  [Jacob, 2, l. 141-142] 
 
 
7. ‘I have really noticed in the 3 months, it takes me a lot longer to go to sleep than it 
did in the past. But as people pointed out, in the past I was actually buggered, so not 
surprising I dropped off in 2 seconds.’ [Stephanie, 3, l. 251-254]  
 
8. ‘you want to go to the toilet, it’s a pain in the backside, you understand. You want to 
get up and say read something, you have got to unhook yourself [laughs], so its, you 
are in a way locked in sort of situation.’ [Jacob, 2, l. 88-90] 
 
9. ‘Usually I go to bed after her [partner], when she has fallen asleep, so now if I am 
going to put this thing on and hook this on, and switch it on, I don’t know what I am 
going to do. Might have to do with an extra bedroom.’ [Matthew, 1, l. 177-180] 
 
10. ‘it’s actually seems to have settled down a bit now, but the skin here [points to part 
on nose] has been quite irritating. Ahm, and I’ve actually…I’ve just put it in the 
draw and I’ve done without it for the last couple of hours.’ [Danny 2, l. 470-472] 
 
11. ‘sometimes you have got air blowing in your eye, which isn’t particularly 
comfortable, you know, so you have got to adjust the mask and it is just a hassle,[...] 
and you are back to having broken sleep you know.’ [Jim, 2, l. 336-339] 
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have impacted on CPAP use in the short term, with some individuals reporting 
not using the machine on a few nights as a result. However, generally, these 
individuals re-initiated use by adopting active coping styles such as speaking to 
the CPAP distributor or nurse, or self-experimenting with the mask and machine 
settings.  
3.4.2.2 Integration into personal life 
In addition to incorporating treatment into their nightly routines, individuals 
described the process of integration at a more general and personal level. How 
does CPAP impact on the family and personal relationships? How does CPAP fit 
into the personal outlook? What personal circumstances make integration 
difficult? Before the titration night, concerns were voiced about the potential 
impact of CPAP on family life and new or existing romantic relationships (Box 7; 
quotes 1,2). These were either practical implications, such as the noise of the 
machine disrupting the partner’s sleep or more intimate issues, such as fear of 
embarrassment or interference with closeness. For some, like Jim (Box 7, quote 
3) the concerns did not materialise and CPAP was seamlessly integrated into his 
personal life. Yet for others, even at 3 months the introduction of CPAP resulted 
in sleeping in separate rooms to their partner (Box 7, quote 4), or the machine 
was something that prohibited intimacy.  
Individuals also evaluated CPAP in relation to the future. For the 
majority, at the baseline interview and even at week 1, CPAP embodied a 
treatment that would be integrated in the short term; it was described as a 
crutch, a technique that would help them regain the necessary energy and 
motivation to lose weight and no longer require the machine (Box 7, quotes 5-7). 
Gradually over the 3 months, individuals began to accept that CPAP was a 
treatment for life (Box 7, quotes 8-9) and would require long-term integration. 
For some this step towards acceptance was hindered by their age and the 
thought of implementing this treatment for the next 25-30 years (Box 7, quote 
10). 
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Box 7: SUBTHEME- Integration of CPAP into personal life 
 
  
Unusual personal circumstances provided additional obstacles for this 
process of integration. Travel was frequently noted as a concern in the baseline 
interviews and those who did travel during the first 3 months, noted difficulties 
using the machine. Two other frequently reported events were the presence of 
flu symptoms and shorter nights as a result of social occasions (Box 7, quotes 11-
Integration of CPAP into personal life 
 
1. ‘We don’t have a bogeyman, but maybe there is a bogeyman about to move in you 
know. Kids get freaked out by different things and I am concerned that that may scare 
them a little bit.’ [Jim, 1, l. 199-201] 
 
2. ‘Luckily I am single, I don’t know how it goes, I suppose, the other partners must be 
understanding about the partner needing it, I would hate to be young and getting it, 
because that would really be a passion killer I’d say.’ [Stephanie, 1, l. 437-440] 
 
 
3. ‘The fact that I can sleep in the same bed as my wife, and my kids are OK, if anything 
they tease me about it, [...] And it wasn’t possibly wasn’t as bad as I thought it was 
going to be.’ [Jim, 3, 85-91] 
 
4. ‘We sleep in separate rooms, [...] it can be a problem, if I sleep in the same bed with 
her, because the way I have got it hooked up and I, I wanna [sic] sleep on my side,[...] 
not all the time, but I turn over, and this thing is like rattling on the bedhead.’ [Jacob, 
3, l. 360-365] 
 
 
5. ‘In the back of my positive mind, this is not a life-time commitment for me, even 
though I have been told by the doctor that it is.’ [Jim, 1, l. 114-115] 
 
6. ‘I am still not 100% sure how long you have to be attached to this thing, months, 
years, days weeks, or I don’t know.’ [Danny, 1, l. 249-250] 
 
 
7. ‘I’m assuming that I will get to a stage where I will loose some weight and I will not 
have to use it, ahm every day.’ [Danny, 2, l. 422-423] 
 
8. ‘I am getting this message that this is probably a life thing, you know.’ [Stephanie, 2, l. 
675-676] 
 
 
9. ‘And that is possibly a case of optimism on my part, that I won’t have to use the 
machine anymore […] maybe it was just a bit of a fantasy.’ [Jim, 3, 71-73] 
 
10. ‘they should somehow motivate people, not only to use it, how to get off it, [...] 
especially at 45, you don’t want to be sleeping on a machine for the next 25 years.  
[Jacob, 2, l. 711-715] 
 
 
11.  ‘I think one night when I didn’t use it because I had a heavy cold and I had such a 
shocking night sleep.’ [Stephanie, 3, l. 235-236] 
 
12. ‘We were out late at a party, I think I got home about 2 or 3 in the morning, […]I 
thought […] “it's not worth it”.' [Benedict, 3, l. 412-414] 
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12). Despite these concerns and difficulties experienced, for the majority of the 
sample this process of integration did not seem too onerous, especially at the 
three-month interview. Certainly by this point, individuals described having 
become habituated to using the CPAP machine and integrated it well into their 
life:  
‘I don’t see it as a hardship; if that’s what you’re trying to sort of get at. 
It’s the necessary evil.’ [Danny, 2, l. 285-286] 
 
‘it's not inconveniencing me in doing what I want to do.’ [Benedict, 3, l. 
351-352] 
 
‘That’s me, you know, that’s who I am, I come with the machine and 
mask’  [Stephanie, 3, l. 819-820]  
 
3.4.3 Theme 3: Motivators and Resources 
Individuals described how certain aspects of their sleep problem and potential of 
CPAP in producing benefits for them (internal) and their spouse/family 
(external) embodied motivators for adherence. These goals could be obtained by 
exploiting certain internal and external resources.   
3.4.3.1 Intrinsic Motivators and Resources 
Individuals at all these interviews reflected on the impact their sleep problem 
had on their sleep and daytime functioning and how this motivated them to seek 
treatment. For example sleep apnoea resulted in poor sleep quality, increased 
sleepiness or reduced social functioning (Box 8, quotes 1-3). Improvements in 
daytime symptoms such as sleepiness or reduced energy/motivation were 
significant motivators for continued CPAP use (Box 8, quotes 4-5). Additional 
changes were also witnessed in the following domains: cognition, personality, 
social functioning, road safety, performance, nocturnal symptoms, mood and 
social activities (Box 8, quote 6-7). Apart from these specific changes, 
individuals also reflected on potential improvements in the foreseeable future, 
such as the possibility of enjoying a fulfilled life of good health and wellbeing 
(Box 8, quote 8), in addition to being able to share experiences with family, 
friends and even new arrivals as in Danny’s case (Box 8, quote 9). Moving back 
into the same bed with the partner after a long history of separate rooms, was 
one of these shared experiences individuals longed for. These improvements 
were valued in light of the severity of the sleep problem; some participants 
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described being motivated by how severe they (and others) rated their illness 
(Box 8, quote 10).  
Participants reported accessing a variety of internal resources in order to 
motivate themselves to use the CPAP machine and to gain the above-mentioned 
benefits. Adopting an active coping style was described by a number of 
individuals. Rather than letting frustration with the machine become too 
overpowering, leading to non-adherence or even abandonment of the machine; 
individuals reported using certain strategies to facilitate implementation of 
CPAP. For example experimenting with the machine settings, contacting the 
CPAP nurse for support and delaying the bedtime to increase sleepiness were 
processes that facilitated acclimatisation to the machine (Box 8, quotes 11-13). 
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Intrinsic resources and motivators 
 
1. ‘Because of my snoring my quality of sleep is not that great, so I had come along and have a sleep 
study, you know that is what prompted it.’ [Jim, 1, l. 14-16]  
 
2. ‘It’s a problem, because I feel tired, and I shouldn’t be that tired, you know basically, that is the 
bottom line.’ [Jacob, 1, 457-458] 
 
3. ‘I paid the consequences outside of my working day, so at night and weekends I think, the build-
up over a week, that’s when it whammied at me, and so I think probably more had an impact 
socially rather than work wise.’ [Stephanie, 3, l. 102-105] 
 
4. ‘I have been using it for a week. And I haven’t got this siesta feeling anymore.’  [Jacob, 2, l. 130-
131] 
 
5. ’There’s a few incentives there, but the biggest one is that it works, it’s not a waste of time, it’s 
not just doing something for the sake of doing something. It genuinely seems to do what it’s 
supposed to do, and that’s…give you back you know, some zip, some energy.’ [Danny, 2, l. 233-
237] 
 
6. ‘If the results are good, I will feel more energetic and all that sort of stuff, its just I think its going 
to affect my relationship maybe with my wife a little bit, or I feel it might. I don’t know, I am not 
a 100% about that yet. But if I feel more alert, not as tired, I think it will be good. Good for work, 
good for motivation to do exercise, to do things. Because at the moment, […] I can’t do anything.’ 
[Jacob, 1, l. 464-470] 
 
7. ‘Before I start [sic] doing the therapy, I could wake anytime from…see that is another symptom 
that’s alleviated. And I think somebody here was telling me it’s probably because I was always in 
that shallow sleep, anything going on in my body would disrupt me, and I found I was getting up 
and going to the loo, like anywhere from 1-2 times to 4 times a night. That’s totally gone.’ 
[Stephanie, 3, l. 627-631] 
 
8.  ‘Its not as much the snoring for me, because that doesn’t effect me, it affects others. But the 
health benefits, particularly the blood pressure, are the things were, its all driving me to keep 
going with it.’ [Benedict, 1, l. 235-237] 
 
9. ‘I want to see my son grow up, if I want to enjoy our…you know the relationship for you know 
many years to come, that's what I need to do.’ [Danny, 3, l. 168-170] 
 
10. ‘If I was somebody who had only had mild things, I think I’d probably be more questioning.  
Whereas I know from what people have said “you have got to do something about it- its serious,” 
I will do something about it.’ [Stephanie, 2, l. 736-739] 
 
11. ‘I was telling him [CPAP using friend] about what I had discovered about different machines I go 
“why don’t you go try a different machine” da, da, da. So basically he hasn’t done that. So he 
hasn’t gone to experiment, to try to find a solution to the problem.’ [Jacob, 2, l. 601-604] 
 
12. ‘The first one [CPAP machine] I probably wouldn’t use it, not because I didn’t want to use it, I 
just couldn’t do it, and then I went to the clinic, where there were renting them out, I told the 
person there, to give me like a better one.’ [Matthew, 2, l. 385-387] 
 
13. ‘Normally I go to bed 10-10.30 and I think I have been staying up later to try and make myself 
be tired by the time I go to bed. So that, to try and help them more quickly falling asleep.’ 
[Stephanie, 2, l. 233-235] 
 
14. ‘I think at the end of the day, they can help you, but it is up to you probably to help yourself.’ 
[Matthew, 3, l. 735-737] 
 
15. ‘like I got frustrated the first few nights, whatever, but I am still giving it my best shot, still want 
to do it.’ [Matthew, 2, l. 335-336] 
 
16. ‘that’s what I took it from the medical practitioners the need to keep, you know get help if you 
need it, but keep at it.’  [Benedict, 2, l. 274-275] 
Box 8: SUBTHEME - Intrinsic motivators and resources 
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In these quotes, it becomes apparent that individuals desired active 
engagement in the treatment, rather than blindly following the instructions of 
the physician (Box 8, quote 14). However, some individuals described an 
element of passivity by implementing what they had ‘been told’ to do [Jim].  
Lastly, participants reported intrinsic traits such as willpower and 
perseverance that could provide the necessary resource for continuing to use the 
CPAP machine. (Box 8, quotes 15-16) 
3.4.3.2 Extrinsic Motivators and Resources 
CPAP is a treatment that does not solely involve the individual patient, but is an 
intervention that needs to be integrated within the family context (see the 
above theme ‘integration of CPAP into personal life’), thus extrinsic motivators 
and resources are naturally assumed to influence adherent behaviour. This was 
evident in the present sample. The impact of OSA on the family and close 
relationships was a large motivator for these individuals to seek and adhere to 
treatment. Participants wanted rid of both night time (e.g. snoring) and daytime 
(e.g. sleepiness, irritability) symptoms that were affecting the individual’s 
partners, family or friends (Box 9, quotes 1-2) and in Jacob’s case the public 
(Box 9, quote 3). Witnessed and potential further improvements in these 
domains were considered and played a role in motivating these individuals (Box 
9, quotes 4-6). 
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Box 9: SUBTHEME - Extrinsic Motivators and Resources 
  
Extrinsic resources were available to these individuals. Support obtained 
from the spouse/family was reported as advantageous for increased CPAP use 
Extrinsic motivators and Resources 
1. ‘We went out one time and I fell asleep in the restaurant. I was tired, I mean I had been up all 
night and all day and out in the evening and… but that shouldn’t be happening, its really 
embarrassing her, and I don’t want to embarrass her, I want that to be gone.’ [Danny, 1, l. 
325-328]  
 
2. ‘That is something I am always conscious of when I go away with friends, is that I know I 
snore loudly. And all that sort of thing, so….sometimes that does put me off.’ [Stephanie, 1, l. 
107-109]  
 
3. ‘So that I don’t feel tired and don’t become a danger to the public and myself, when driving.’ 
[Jacob, 3, l. 436-437]  
 
4. ‘just be able to I suppose just lie and have a chat with my wife in bed is a nice thing rather 
than her having to go to sleep before me, you know because of my snoring.’ [Jim, 2, l. 211-
213] 
 
5. ‘She will probably be happier if I am not as grumpy, you know if I am not as tired. If those 
things improve I think she will be happy in that respect.’ [Jacob, 1, l. 189-190]  
 
6. ‘that's also having benefits for those other people, so you know my wife doesn't have to hear 
me ah snore as loud. My wife doesn't have to hear me gasping for breath. So I feel good about 
that.’ [Benedict, 3, l. 335-338] 
 
7. ‘It feels good that she is standing by me you know. She is the one that wanted me to do all this 
kind of stuff. Yeah, cos [sic] I would probably, I wouldn’t…not think about doing it you know.’ 
[Matthew, 2, l. 77-179] 
 
8. ‘My sister has been brilliant, she has been ringing me on a regular basis saying “how’re we 
doing” and she talks about what she does, or she gives me suggestions like with the air 
blowing on my face, she said “oh well try turning the tube up over your head”.’ [Stephanie, 2, 
319-323] 
 
9. ‘The staff here have been great, you know taking the time that has been spent here, you know, 
I was comfortable doing it, so that was great. And they helped you pretty well every step of 
the way.’ [Jim, 2, l. 641-643]  
 
10. ‘I think they should be doing more, or better fitting of the masks, or really, really walking you 
through with the mask. Because you don’t really…when you first start using it, you don’t 
really know if you’ve fitting it right.’ [Stephanie, 2, l. 215-218] 
 
11. ‘I think it would have been better to spend less time in that session in before hand about what 
sleep apnoea is, because I think we covered that, particularly in the first two consultations 
with the clinicians and more time on saying, you know this is what it involves.[....] And 
maybe, you know some tips about how to help you, you know stick at it, so to speak, 
particularly in the old days.’ [Benedict, 3, l. 111-122]  
 
12.  ‘I think it’s sort of been like "this is your diagnosis, this is what the treatment is" its not like 
[...] "how can we keep you on this, or what can we do to help you be on this treatment".’ 
[Stephanie, 2, l. 856-859]  
 
13. ‘I feel in that respect I feel I have had better follow-up or more care, if I can use that word, for 
the person I bought the machine from, then from here (sleep centre).’ [Benedict, 2, l. 289-
291]  
 
14.  ‘I got married about 5 years ago, ahm, it was getting worse and worse, and the first 3-4 years, 
she could cope with it, about 2 year she couldn’t cope no more. “Yeah, fix yourself up, or I 
leave you” [laughs].’ [Matthew, 1, l. 42-44] 
 
15. ‘It is not always good to push me, because then I will just say “oh stuff that, I don’t want to do 
it”. So I…probably I did resent being pushed.’ [Stephanie, 1, l. 67-68] 
 
16. ‘He [physician] basically said this is it and that is it. Basically he was pretty blunt about it, I 
am a bit different, [...] I explain things to them a bit more compassionately.’ [Jacob, 1, l. 326-
332].  
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(Box 9, quote 7). Support from the medical team (physician, CPAP nurse, contact 
at CPAP distributor) or peers (other CPAP users) were vital for troubleshooting as 
well as emotional support (Box 9, quotes 8-9), however some rated the input 
from the medical team below their expectations. Stephanie and Benedict for 
example desired increased opportunity during the education session (prior to the 
titration study) for getting to grips with the practicalities of the machine (Box 9, 
quotes 10-11). There was a consensus amongst these two individuals that there 
was increased focus on sleep education and less on concrete implementation of 
the treatment (Box 9, quotes 11-12). For Benedict this type of support was 
optimally provided from the CPAP distributor (Box 9, quotes 13). It is important 
to note that for some individuals there was a fine line between support and 
external pressure. Well-meant support from the spouse could often be 
interpreted as pressure, described by Matthew in a joking manner (Box 9, quote 
14), however for Stephanie the pressure experienced from her mother was more 
serious situation and actually led to increased resistance towards seeking 
treatment (Box 9, quote 15). Jacob underwent a similar experience from the 
medical team (Box 9, quote 16) envisaging a more co-operative, patient-centred 
style than was offered by the physician.  
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3.5 Discussion  
CPAP, the current treatment of choice for OSA is undoubtedly a demanding 
intrusive treatment. Although the literature has predominantly focused on 
biomedical factors as discussed in chapter one and two, a handful of studies has 
investigated psychosocial variables using both quantitative and qualitative 
methodologies. The qualitative studies have drawn upon a wide variety of 
methodologies and analyses and themes emerging in these studies can be 
compared to the results reported here. This chapter provides a longitudinal 
perspective upon CPAP use, highlighting important experiences from pre-
titration through 1 week and 3 months post-treatment initiation. Figure 6 is a 
visual representation summarising the emerging themes; how they relate to one 
another is explained below.  
 
Figure 6: Summary of Results 
3.5.1  Conflict 
The results presented in this chapter highlight how individuals experience a 
conflict around initial acceptance and subsequent adherence to the machine, 
describing a state of being in two minds, influenced by their knowledge of OSA 
and its consequences, and on the other hand being held back by simply not 
wanting to use the machine. What individuals longed for was to obtain a sense of 
normality; which often created further conflict as CPAP is not a normal 
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treatment, but is the key to normal functioning. This conflict was less evident in 
the 3-month interview, potentially as a result of the conflict being resolved, 
using various different strategies, such as focusing on the benefits or acceptance 
of the situation. This theme highlights how CPAP adherence can be a very 
dynamic process, with individuals potentially moving back and forth between 
seeing the necessity for change, but also being reluctant to engage in change. 
Some individuals seem to resolve this conflict early on and succeed in integrating 
the treatment into their lives; others are delayed and even at 3 months after 
purchasing the machine still describe a certain resistance to using the machine. 
A model that has acknowledged this very dynamic process is the transtheoretical 
model. This theory (described further in chapter 6) states individuals pass 
through five distinct stages of change, and throughout this transition weigh up 
the pros and cons for change. Their belief in their abilities to make the 
behaviour change (self-efficacy) can vary as a function of the transition through 
these stages, with self-efficacy being increased in the theoretically higher 
stages. Lastly, the transition is facilitated by the adoption of certain strategies; 
cognitive approaches encourage movement through the earliest stages whilst 
behavioural approaches predominate in the transition through the later stages.  
This assumption differs significantly from the view commonly adopted in 
the literature that change (i.e. adherence) is a static entity. Earlier reports 
dichotomised CPAP adherence using the cut-off of 4hrs on 70% of nights(181) and 
evidence for the stability of these dichotomous patterns after only a few 
days.(203, 204) However, a recent time-series analysis of 71 CPAP users over 365 
days, revealed seven behavioural patterns, five of which were identified as non-
stable (slow improvers, slow decliners, variable users, occasional attempters and 
early dropouts), supporting the notion that adherence is a dynamic process.(205) 
Additionally, the components of the transtheoretical model assessed early in the 
treatment stages predict subsequent CPAP use(237, 286, 287) and motivational 
interviewing/enhancement therapy (MI/ME) has indicated improvements in CPAP 
use, with one study reporting small to moderate effect sizes(Cohen’s d of 0.3-
0.6(354) and another study revealing a 2hr increase in median nightly CPAP use 
in the intervention arm compared to the placebo control group at 12 
months.(355) MI/ME approaches acknowledge that some individuals will present 
with ambivalence towards change and require the therapist to ‘role with 
resistance’.(432, 433) 
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In this theme, it also emerged that CPAP embodied an obstruction of 
normality of two basic processes: sleeping and breathing. Individuals described 
feeling stigmatised by others and to an extent internalising these beliefs 
themselves. CPAP as a treatment for a sleep related breathing disorder was 
equivalent to showing vulnerability, feeling old or sick. Both an internal(419) and 
external(424) stigmatisation has been reported by other qualitative studies. This 
highlights the increased importance of psychosocial interventions in improving 
CPAP adherence. Wearing a machine every night to go to sleep is different from 
simply ‘popping a pill’, which is indisputable. However, it might also differ from 
other complex treatment interventions. As explained by one of the participants, 
CPAP was different from controlling his blood sugar levels for his diabetes. The 
question arises, is there something unique about this treatment for a sleeping 
and breathing related problem that requires specific attention over and above 
what is addressed through basic medical interventions. This aspect has not been 
explicitly targeted by any of the existing interventions. One study interested in 
the effects of cognitive behavioural therapy in increasing CPAP use, did however 
include role models (existing CPAP users), who described their positive (and 
negative) experience with the CPAP machine, emphasised the potential benefits 
of adhering to the treatment and the importance of pushing through early 
resistance.(351) The intervention devised by Richards and colleagues took part 
in a group format including up to 10 individuals and their partners. These 
aspects although not explicitly targeting stigma, might have effectively reduced 
the individual’s and partner’s dysfunctional beliefs about the CPAP machine. 
Future interventions aimed at increasing CPAP adherence might benefit from a) 
explicit targeting of potential stigma of using the machine b) inclusion of 
spouse/important family member c) include other CPAP users in a group format 
to somewhat normalise the CPAP experience.(see 416)  
The participants in this study also described using techniques to resolve 
the conflict they faced. One strategy that was mentioned by a number of 
participants was to focus on the benefits CPAP provided. This sense of weighing 
up the advantages against the disadvantages of change emerged in numerous 
qualitative studies described in the introduction.(421, 423-425) This cost-benefit 
evaluation has also been described in some quantitative studies that have 
evaluated this process as a component of social cognitive and behaviour change 
models (e.g. health belief model, transtheoretical model). The health belief 
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model for example describes how individuals engage in a cost benefit evaluation 
‘wherein the individual weighs the action’s effectiveness against perceptions 
that it may be expensive, dangerous (e.g., side effects, iatrogenic outcomes), 
unpleasant (e.g., painful, difficult, upsetting), inconvenient, time-consuming, 
and so forth’(434, p. 2) and the transtheoretical model explains how a balance 
between the pros and cons differ at different stages of the change process 
(decisional balance). Additionally, the process of consciousness raising, a 
cognitive strategy that facilitates the transition through the earliest stages of 
change, may help individuals focus on the benefits and how these outweigh the 
costs.  
A second strategy to resolve this conflict involved acceptance of the need 
for treatment, despite its difficulties. Acceptance and commitment therapy 
(ACT) can be considered a third-wave therapy successful in producing significant 
improvements for a variety of psychological disorders.(435) Although not 
extensively adopted for the use of improving patient adherence, and not at all 
investigated as a potential intervention for CPAP use, some attempts have been 
made to investigate the usefulness of ACT in improving patient adherence. For 
example, a recent paper presented at the 9th Annual Conference of the 
American Psychosocial Oncology Society reported that men, who experience 
frustration and embarrassment about erectile dysfunction after prostate cancer 
surgery, might be poor adherers to treatment. The authors further describe the 
potential implementation of ACT to increase their levels of adherence; a clinical 
randomised control trial is currently ongoing.(436) Because similar feelings of 
embarrassment and shame of using the CPAP machine were voiced in this 
sample, the development of a CPAP specific intervention including elements of 
ACT might be useful.  
One participant also mentioned the value of the interview in reducing the 
resistance to treatment. The possibility of simply expressing one’s thought might 
be as beneficial as other successful psychological interventions. Creative 
strategies of how this could be cost-effectively introduced to clinical care might 
be worth investigating. For example, simply asking the individual to keep a diary 
(written or audio) during the early phases of treatment might present itself as an 
inexpensive strategy for guided patient discovery and may contribute to 
improvements in treatment acceptance and adherence.  
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3.5.2 Integration of CPAP into life 
The titration night gave individuals a first experience of what it would mean to 
integrate CPAP into their life. Some individuals had a negative experience of this 
overnight study and although there were no explicit references to the potential 
impact on subsequent adherence, this relationship has been reported by both 
qualitative(275) and quantitative studies.(276-278)  
Following machine purchase, individuals described integrating CPAP into 
their nightly routine and at a more general level, into their personal life. This 
process has been outlined in other qualitative studies.(416, 417, 419, 420) 
The integration at the nightly level involved habit forming, slowly getting 
used to the machine and mask and some generated specific techniques to 
facilitate this process (gradual increase of time on machine, anchoring to 
existing routines) Adherence is akin to any behaviour change that needs to be 
practised in order for the action to become habitual and largely an unconscious 
process. Smith et al. based their music and habit-forming intervention on 
Triandis Theory of Behaviour, which claims adherence is largely enforced by 
knowledge of the consequence of not following the recommendations, and 
practicing the behaviour until it becomes habitual.(437)They randomised 97 
patients with OSA to either a music and habit-forming intervention or placebo 
control (instructions on daily vitamin intake). The active component included an 
audio-tape supported with relaxing music, instructing the patient on how to fit 
the mask comfortably and then introduced some relaxation strategies. The 
intervention also included the provision of details on the consequences of 
untreated OSA, CPAP reminder placards and a 4-week diary. The placebo 
intervention was matched for time, effort and healthcare contact. The active 
intervention was related to increased adherence, 89% were considered adherent 
(≥4hrs on 64% of nights) in the intervention group compared to only 55% of the 
placebo controls after 1 month, however there were no differences at 3 and 6 
months. These results indicate that this type of habit-forming technique might 
be useful in the short-term, and might benefit from supplementation with other 
interventions to increase long-term CPAP use. A possible limitation of this study 
was that the intervention included a number of components: relaxation that 
might have led to improvements in sleep, audio instructions and reminder 
placards that would have increased habit forming and keeping a diary to note 
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their experiences, might have made individuals more aware of their situation 
and actively contemplating reasons for and against adherence.  
Integration of CPAP into the nightly routine impacted on some individual’s 
usual nightly habits; especially interesting was the perceived disruption to sleep 
onset latency. Although some were aware that they were comparing the status 
quo to a time of increased sleepiness, these responses indicate an increased 
attention towards sleep, which might further develop into a chronic 
problem(135, 136) The prevalence of co-morbid insomnia in this population is 
still very much under researched, despite its high rates of comorbidity of 
approx. 40-50%(343, 344) and effects on adherence.(334) 
Side effects that were commonly reported in the literature (such as skin 
irritations, air leakages and marks from the straps) were also described in this 
sample and this was not confined to those who were not adherent, similar to 
what is reported in other studies, one needs to use the machine in order to 
experience adverse events related to CPAP.(322) It seems in this sample 
individuals did experience side effects, however with the appropriate 
psychological and social resources available to them were able to persevere 
despite these experienced difficulties, similar to the interviewed samples in 
other qualitative studies.(419, 421) These results indicate a possible interaction 
between presence of side effects and psychosocial factors, which might explain 
the conflicting results found in the literature.  
The integration of CPAP also occurred at the level of the individual’s 
personal life, most specifically the potential impact on social relationships was 
noted as a concern. Noise of the machine could disrupt partner’s sleep and 
intimacy difficulties were often mentioned. This might have been more 
prominent in those whose bed-partner was more easily aroused by external 
stimuli. One study indicated in a 2-week period post CPAP initiation, the number 
of nights of co-sleeping was positively and strongly related to mean hours of CPAP 
use on days used (r=.74) in 10 male OSA patients.(336) History of co-sleeping 
(prior to CPAP) with wife was also related to adherence, with only 43 % of those 
sleeping separate from their wives using CPAP more than 4 hrs per night, 
compared to 74% of those co-sleeping. One can only hypothesise that this is a 
result of fear of arousability from sleep.  Unfortunately the two-week assessment 
period is too limiting to determine whether an actual increase in co-sleeping events 
predicts increased CPAP use (with increased co-sleeping potentially being a 
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marker of improvements in wife’s sleep quality). Larger longitudinal studies are 
needed to understand the direction of these relationships.   
Interestingly in this sample, individuals conceptualised integration of 
CPAP also in terms of the future, and through the course of the study a certain 
cognitive shift became apparent. The initial understanding for some individuals 
was that CPAP was a “cure”, with more energy they would be able to exercise 
and eventually come off the machine. This was especially pertinent for younger 
participants, who described a fear of having to use this machine for the rest of 
their lives. There is some evidence, albeit weak, of a positive relationship 
between increasing age and CPAP adherence.(195, 199, 277) These results 
support the hypothesis outlined in chapter 2, an interaction between age and 
psychological factors, potentially younger individuals will have different 
thoughts about/attitudes to the machine than their older counterparts. Towards 
the end of the study, however individuals saw CPAP as a crutch for a chronic 
problem and at the end of the three months, most participants accepted that 
this was a treatment for life, and had fully integrated the treatment into their 
life. 
3.5.3 Motivators and Resources  
Individuals described how their improvements in daily and nightly symptoms 
represented a significant motivator for CPAP adherence, a finding that has been 
reported in a number of other qualitative studies.(275, 415, 417, 419, 420, 424, 
425) Interestingly, one qualitative study reported that individuals described 
initial difficulties with interpreting subtle improvements and often used their 
families’ feedback and experimentation with non-adherence as evidence for 
improvements.(421) Changes in OSA symptoms (e.g. decreased sleepiness, 
increased daytime functioning) post treatment is a strong predictor of CPAP 
adherence in quantitative studies(179, 181, 182, 193, 195, 200, 325), and this 
relationship presents itself in a dose-dependent manner.(1, 57, 59) Interestingly, 
Crawford and colleagues reported, based on results from merging three 
randomised placebo controlled trials, approximately 29% of the symptomatic 
improvement is a result of an expectation of benefit.(1) This indicates that the 
relationships reported between adherence and symptomatic improvement, might 
not only be based on physiological, but also psychological effects.  
Chapter 3 Qualitative Exploration of CPAP adherence 146 
 
This study also reported a strong correlation between CPAP and placebo 
use, which might be indicative of an “adherent-patient characteristic” (see 
chapter 5). This trait might extend to concurrent adherence to pharmacological 
treatments, which might be partly contributing to the benefits observed in these 
individuals, however this is subject of conflicting reports.(438-440). This 
potential trait might also be representative of an individual’s willingness and 
determination to ‘comply’ with treatment. This was certainly described by some 
individuals in this chapter as a resourse for adherence. Additional resources 
included an active coping style and active engagement with the therapy (e.g. 
experimenting with the machine). The former has been reported in one of the 
qualitative studies(419) and one quantitative study has highlighted the link 
between active coping measured prior to treatment initiation and increased 
CPAP adherence at week 1.(333) Active engagement (e.g. experimenting with 
the machine) seemed to be an important facilitator of adherence. This is similar 
to the theme that emerged in Dickerson and Kennedy’s qualitative study of 
individuals taking part in a CPAP support group.(416) Experts in the group 
encouraged empowerment and ownership, being involved in problem solving. 
These findings fit well with recent developments towards the notion of 
adherence/concordance versus compliance, the former encouraging much more 
patient invovlement in care.(173, 441)  
Importantly though, some expressed a reason for adherent behaviour was 
because the doctor had “told them so”.  This potentially highlights the need for 
tailoring approaches to individual patients’ preferences. Pioneering work from 
Christensen and colleagues has been described in chapter 2, which reports an 
interaction between the complexity of treatment for renal failure and patient 
preference for level of involvement in the treatment is a useful predictor of 
patient adherence.(407) 
OSA not only impacts on the actual patient, but also on the surrounding 
individuals. Thus, in this sample, the impact of OSA on the spouse/family and 
potential improvements as a result of CPAP use, were noted as significant 
motivators for adherence. Nocturnal symptoms like snoring and apneas may 
contribute to a reduction in the bed partner’s sleep quality.  Daytime symptoms 
(e.g. irritability, sleepiness, low motivation) might negatively impact on social 
relationships/marital satisfaction and potential (and actual) reduction of this 
impact might motivate individuals to use (and continue using) the machine. This 
Chapter 3 Qualitative Exploration of CPAP adherence 147 
 
has been reported by both qualitative(415, 420, 423) and quantitative 
studies.(307, 336) For example, in a parallel trial comparing 44 individuals 
treated with CPAP with 25 on conservative treatment (weight loss, sleeping 
posture and reduced alcohol intake), McFadyen reported both increase in 
partner reported marital satisfaction (r=.3) and decrease in disagreement 
frequency in the relationship (r=-.4), were related to increased CPAP 
use.(307)The direction of this relationship remains unclear from these 
correlational results: however it supports the possibility of a complex 
relationship between use and marital functioning. However, because baseline 
assessments of these measures were not significantly related to CPAP use at 3 
months, it might be the potential/actual improvement in marital satisfaction 
that results in increased motivation for CPAP adherence. In Cartwright et al.’s 
study outlined above,(336) co-sleeping was associated with improved adherence. 
It was not possible to determine improvements in co-sleeping habits, however 
one could hypothesise that this indicates that the impact on the wife’s sleep 
quality (lowered arousability) might be related to adherence and subsequent 
spousal support might be moderated by the impact on the partner’s sleep.  
Support provided a vital external resource for the participants in the 
current study. Support from the spouse/family, other CPAP users and medical 
care team was described as facilitating CPAP use, and is in concordance with 
reports from the current qualitative studies outlined in the introduction.(415-
417, 419-421, 423, 424) This corroborates the findings in qualitative studies that 
have highlighted the association between improved adherence and spousal 
support and/or relationship quality(298, 338) and augmented medical support in 
some(345, 437), but not all studies, which might have been a result of 
sophisticated ‘treatment as usual’ groups(442) or small sample sizes.(186, 443).  
A few individuals however reported well-meant support from either a 
family member or the physician was interpreted as pressurising, which might 
have negative effects on adherence, as reported by Baron and colleagues, who 
found a negative correlation between spousal pressure and CPAP adherence at 3 
months.(338) Additionally, individuals referred by their spouse are reported to 
present with lower adherence rates compared to self-referred patients.(345) An 
empathic, non-judgmental and supportive therapist style is associated with 
increased motivation to change(444) and CPAP interventions that support this 
style (motivational interviewing/enhancement strategies) have been successfully 
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explored as techniques for improving CPAP adherence.(353-355, 358) It might 
therefore be useful to encourage the spouse (and physician) to be more 
supportive and empathic and less confrontational.  
Some participants described being dissatisfied with the educational 
support provided by the health care team. The education session included 
information about OSA and the consequences of this sleep problem, knowledge 
some individuals had obtained on their own account prior to the overnight 
titration study. These individuals noted a desire for more detailed instructions 
and guidance on how to implement the treatment to the CPAP machine. This is 
similar to Smith et al.’s qualitative study, where although individuals most 
frequently desired information about OSA, this theme was closely followed by 
need to learn about how to successfully integrate CPAP into everyday life.(417) 
Goal setting has been successfully established as a strategy for increasing 
performance in organisational settings, and setting goals that are specific and 
challenging result in superior performance compared to a lacking of or vague 
goals e.g. ‘do your best’.(445) This might be applicable for CPAP users, where 
specific goals that are explicit about how to facilitate adherence e.g. ‘speak to 
partner about how CPAP might impact on your nightly routine’ and difficult, but 
achievable goals ‘use the machine for the full duration of your sleep time’, 
might lead to increased adherence compared to ‘try to use the machine for at 
least 4 hours a night to avoid potential health consequences of OSA’. Goal 
setting techniques have recently been adapted for improving health behaviour 
change, e.g. adherence to lower back pain rehabilitation program,(446) dietary 
behaviour change,(447) and exercise(448) to name a few.  
 
3.5.4 Summary of themes and their interrelations 
Figure 6 highlights each of the three themes, their associated subthemes as well 
as their interrelations. The themes “conflict”, “integration” and “motivators 
and resources” are represented across two categories: 1) internal and external 
to the patient and 2) more global and nocturnal issues. The internal conflict 
between wanting to feel normal during the day and feeling abnormal with the 
mask at night, and trying to resolve this conflict is characteristic of the process 
of early CPAP acceptance. However these feelings may persist long into 
treatment for some individuals and influence adherence. Thus the theme 
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conflict is presented in the top left corner with amber coloured arrows crossing 
both dichotomies of each categories; representing conflict as an overarching 
theme that underlies the other two. Once the CPAP machine has been accepted, 
the individual will evaluate how this intervention is best integrated into both 
their personal life and their nightly routine. In order to accomplish this task, 
both internal and external motivators and resources are utilised. The ease of 
integration might then encourage increased motivation and the utilisation of 
certain resources and the red arrows drawn between these two themes indicate 
this reciprocal relationship.   
 
3.5.5 Limitations and Future Directions 
The major limitation of this study was the small sample size with only six having 
completed all three interviews. Although, no new emerging themes were present 
in the baseline interviews of the individuals who did not complete all three 
interviews (n=5), it is difficult to gauge whether the content of these themes 
was different, as described in Ayow et al.’s study(424). The analysis of the six 
completers was the most appropriate approach to ensure homogeneity of the 
sample, as required for qualitative studies.(422) 
One further limitation is the largely male sample, which is representative 
of most studies of OSA, because of the approximate two-fold increase of sleep 
related breathing prevalence in males compared to women.(10) Any comparisons 
across gender are not possible here, thus future qualitative studies might benefit 
from including larger female samples to understand further potential gender 
differences in CPAP experience.  
For reasons of convenience and feasibility, interviews were completed at 
the sleep centre; it was familiar to patients and most interviews coincided with 
the titration/follow-up appointment. However, this might have increased the 
demand characteristics, so although individuals were briefed before the 
interview that all response would remain anonymous, they might have linked the 
interviewer with the care provision team and feared any transmission of 
information, especially about non-adherence. A related consideration is the type 
of individual who is most inclined to take part in (qualitative) research. These 
individuals might be more outspoken and willing to discuss their experience with 
treatment. Future qualitative studies might benefit from the use of audio 
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diaries(see 139) completed at home on a nightly basis, which could reduce the 
impact of these limitations on the emerging themes.  
As with all qualitative studies, the aim is not to generalise, but to draw 
conclusions about the particular group of individuals. As described in the 
introduction, there are a number of qualitative studies that have been 
conducted, thus this study adds to the “database” of accounts of individuals 
undergoing CPAP treatment and supports the commonalities outlined above. 
CPAP isn’t something individuals want to do, is associated with a stigma of being 
ill, and helpless; integration is difficult, but individuals’ find ways to push 
through that resistance, if the benefits outweigh the costs and they have a good 
support system. However this study has to an extent highlighted the need for 
examining an interaction between more biomedical/treatment specific factors 
and psychosocial profile of the individual as described in chapter 2. Future 
qualitative and quantitative studies might benefit from further investigations of 
possible interactions outlined from the results in this chapter: side effects, level 
of involvement, age and their interaction with various psychosocial factors.  
 
3.6 Summary 
In summary, this study reveals that CPAP remains a difficult treatment, which 
needs specific consideration of how to integrate into nightly routines and 
personal life, and this process relies on internal and external resources and 
motivators. CPAP adherence remains a complex issue with possible interacting 
factors, yet it is suffice to say: CPAP remains logical, rational, and yet people 
just don’t want to do it. 
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Chapter 4- A thematic analysis of patient 
experience of cognitive behaviour therapy for 
insomnia (CBT-I)  
4.1 Abstract  
Despite established evidence for the efficacy of Cognitive Behavioural Therapy 
as the treatment choice for chronic insomnia, the experience of patients 
implementing the therapeutic components remains relatively unexplored. 
Patient adherence forms a large part of this treatment experience and thus, this 
chapter offers a holistic and qualitative perspective on patient adherence to 
CBT-I. Semi-structured interviews were conducted with individuals with 
insomnia, who had completed a cognitive-behavioural programme for the 
treatment of their sleep problem. A total of eleven individuals took part in this 
study (female n=8). Using thematic analysis, three themes emerged that 
portrayed the experience of adhering to CBT-I: ‘Making sense of CBT-I’, ‘Ongoing 
evaluation of components’ and ‘Obstacles to implementation’. Each theme was 
associated with three subthemes that provide a more nuanced and interpretive 
account of how individuals experience the implementation of cognitive 
behavioural strategies. These results offer unique insight into the issues these 
individuals faced during CBT-I, and contribute to our understanding of adherence 
in this population. 
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4.2 Introduction 
 
Despite the substantive evidence for the efficacy of cognitive behaviour 
therapies for insomnia only few have explored the patient’s experience of 
implementing CBT-I components. The relatively limited exploration might be a 
result of the nature of the intervention itself.(206) Chapter 1 has outlined 
quantitative studies that have identified variables that might be predictive of 
adherence to this multi-component therapy as well as individual treatment 
strategies.  Although these studies add to our knowledge of what influences 
adherence, they provide little information about the treatment perceptions, 
which can be valuable, as they have been associated with treatment choice(449, 
450) and more importantly, patient adherence.(451-453) 
The quantitative exploration of treatment perception and experiences has 
been examined in sleep research. In fact, a study conducted as part of this post-
graduate research project, but not included in this thesis, found that, in a head-
to-head study comparing CPAP therapy with a mandibular advancement device 
(MAD), individuals diagnosed with sleep apnoea rated MAD as more convenient. 
Additionally, treatment acceptability predicted CPAP adherence, but not use of 
the mandibular device. However, the sample size in this study was small (n=34) 
and treatment perceptions were measured after a 2-week acclimatisation 
period, rather than at baseline.(454) This study was presented at the Associated 
Professional Sleep Societies Conference in Minneapolis 2011 in poster format and 
is included in Appendix 5.  
In the insomnia literature, treatment perception has been established as 
an important feature at various stages of treatment. Certain beliefs prior to any 
implementation might have implications for subsequent behaviour.(120, 230, 
455, 456) Stinson and colleagues showed that endorsement of certain beliefs, 
such as poor efficacy and attractiveness ratings, or lack of awareness of possible 
options, might act as barriers for treatment seeking behaviour(455) 
Unfortunately, this was a retrospective study and differential beliefs towards 
types of treatment were not obtained. Other studies have examined pre-
treatment perceptions towards different psycho-behavioural options(456) and 
psychological versus pharmacological options(120, 230)  
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In 431 individuals with primary insomnia, pre-treatment perception 
(suitability, appropriateness, effectiveness and willingness to adhere) was 
related to treatment choice (sleep hygiene, stimulus control, sleep restriction or 
multi-component treatment with these three interventions).(456) Results in this 
study indicated that individuals preferred multi-component options and stimulus 
control, and preference was influenced by the perception of the acceptability of 
each treatment. In one of the earlier studies on pre-treatment perception, Morin 
and colleagues presented 39 individuals with chronic insomnia and their 
significant others (n=32) with descriptions of both behavioural and 
pharmacological treatment options.(120) Results indicated both groups rated the 
former as more acceptable than medication in all areas assessed, apart from 
perceived effectiveness in alleviating problems in the short term. These finding 
were largely replicated in a similar study of 43 individuals with primary 
insomnia. Pre-treatment perceptions were also found to be a strong predictor of 
subsequent attrition rates, but not treatment outcome in 37 participants who 
completed a CBT-I program.(230) The studies so far have not differentiated 
between insomnia phenotypes; however this might be important factor involved 
in treatment perception and experience. A recent study expanded this line of 
investigation to group of individuals diagnosed with psychophysiological and 
idiopathic insomnia.(457) Replicating the studies above, descriptions of 
psychological treatments (acceptance-based and behavioural intervention) were 
preferred over a pharmacological option by both groups; however the idiopathic 
group rated acceptance treatment more favourable in treating their sleep 
problem.  
These studies highlight the importance of pre-treatment perceptions; a 
number of studies has also investigated treatment appraisal after completion of 
the intervention.(209, 230) In the previously mentioned study, Vincent and 
colleagues asked patient to report on their satisfaction (usefulness and likability) 
of different components of CBT-I. Perhaps not surprisingly, sleep restriction was 
rated the least, and sleep hygiene the most favourable. However, strong 
correlations were reported between satisfaction with sleep restriction and 
improvements in sleep (r=.6) and quality of life (r=.66-.85); this relationship 
might have been a marker of increased adherence in those who favoured this 
option. These results stood in contrast to earlier reports where 65 individuals 
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with sleep maintenance insomnia, sleep hygiene was rated the least likable 
compared to the meditation and stimulus control options.(209) 
Despite evidence for long-term effectiveness of CBT-I,(458-461) only one 
study has examined individual’s long-term use of CBT-I components.(206) Here, 
patients were asked to complete a questionnaire in regards to their use of 10 
core components. Mirroring some of the results above, relaxation strategies 
were most often used (70% of respondents), whilst stimulus control/sleep 
restriction and cognitive restructuring were only used by about 40% of the 
respondents. The lowest reported use was for imagery techniques at 19%. 
Largest improvements were however witnessed in those implementing stimulus 
control and sleep restriction.  
Overall, these studies allude to the importance of pre- and post-
treatment perception for treatment choice and adherence to CBT-I. In summary, 
it is evident that individuals find psychological treatments more acceptable than 
pharmacological options. Conclusions on comparative perceptions across 
different CBT-I components are less definitive, however there seems to be a 
tendency for sleep restriction to be least liked amongst these individuals, but its 
implementation is predictive of clinical improvements. One possible, but very 
speculative interpretation of these results is, that after a long history of having 
tried or been offered a variety of pharmacological options, individuals present to 
the behavioural sleep medicine expert extremely motivated to embark on the 
psychological route. However, once introduced to the individual components- 
some of which are behaviourally quite demanding and require significant 
behaviour change- motivation might be reduced for the following reasons: sleep 
restriction and stimulus control (1) appear at least initially, to be counter-
intuitive, even paradoxical to the individual’s goal of increasing their total sleep 
time(139) (2) they inflict slight sleep deprivation as homeostatic pressure for 
sleep is increased(462), which can lead to amplified daytime sleepiness and low 
mood(139) and (3) they include curtailing certain behaviours (e.g. spending 
longer in bed) that have become engrained during the chronicity of their 
condition. This might explain why in the some studies these behavioural 
components are least preferred and implemented. For a more nuanced insight 
into these perceptions especially in regard to treatment adherence, there is a 
need to move beyond the top-down approach, where individuals are asked to 
indicate a level of agreement with researcher imposed statements, and 
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corroborate the present knowledge with patient-generated perceptions 
especially on treatment adherence using qualitative, bottom up methodologies. 
Furthermore, this will allow to expand on these quantitative accounts of 
treatment perceptions, which constitutes a small part of the overall treatment 
experience. 
To date, only two such studies have been conducted.(139, 463) One study 
embarked on a systematic investigation of patient’s perceptions and experiences 
of implementing a sleep restriction programme(139). Using both validated self-
report measures and qualitative accounts of the treatment through audio diaries 
twice a day and interviews, Kyle and colleagues were able to map, in detail, the 
patient’s general experience of sleep restriction therapy (SRT) in 18 individuals 
with primary insomnia. Explicit evaluation of treatment adherence was obtained 
through the diary entry approx. 30 minutes after awakening and questions on 
implementation at the 4-week post-treatment interview. Of the total sample, 14 
individuals completed the qualitative component of this study. Adjustment 
issues and difficulties implementing the program was frequently recorded in 
both the audio-diaries and interviews. Particularly problematic was the impact 
sleep restriction had on daytime functioning and dealing with the sleepiness. 
Individuals were concerned over the impact on functioning the following day and 
boredom or loneliness that were induced by the extended wake period. Certain 
coping strategies were employed to counteract these effects (e.g., engage in 
wakefulness promoting activities), however giving in to these effects (e.g. by 
napping) led to unwanted effects (increased sleep onset latency) that spurred on 
continued adherence. This study highlights the complexity and effort associated 
with the implementation of sleep restriction, and provides further information 
of patient’s experience of adhering to this behavioural intervention. Although 
useful in contributing to the understanding the potential mechanistic principles 
of SRT, the presentation of SRT in isolation is not routine clinical practice. The 
common presentation of sleep restriction alongside other behavioural and 
cognitive components might drastically alter the experience of individual 
components, with patients on the one side allowed to “pick and choose”, but 
also the combination of components may exacerbate the effects of individual 
treatment. For example, the repeated getting up after 15 minutes of 
wakefulness with a restricted window of about 5 ½ hours could be challenging.  
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Currently only one study has investigated the experience of completing to 
a multi-component package CBT-I from a qualitative perspective.(463) Open-
response feedback forms with questions regarding their treatment experience 
were completed by 43 of the total 52 participants with chronic insomnia after 
completion of the 7-week CBT-I program. The responses were subsequently 
coded into themes, indicating that about half of the participants reported the 
completion of CBT-I in a group format and sharing the insomnia experience with 
others was most helpful. Although the strength of this study was the qualitative 
analysis of patient generated responses, there are some shortcomings of this 
study. Firstly, it did not provide an in-depth qualitative analysis of the patient 
experience and secondly, there was no explicit focus on treatment adherence.  
The undeniable benefit of such qualitative exploration is to provide rich 
insight into patient’s perceptions and experience of implementing components, 
which are not fully obtainable through the previously outlined quantitative 
approaches. This aim of this chapter is thus to expand on these investigations 
and present an in-depth qualitative exploration of patient’s experience to CBT-I. 
With a particular focus on adherence, this study investigates some of the 
complex issues individuals are faced with when implementing components of 
CBT-I, which will not only advance our understanding of adherence to this 
treatment, but potentially provide information about treatment delivery and 
interventions to facilitate implementation.  
4.3 Methods 
4.3.1 Participants 
Individuals with insomnia, who had partaken in research studies that included a 
manualised form of CBT-I (either as part of the core research protocol, or as a 
good-will gesture for participating in other research), were approached. To 
reduce the variability in treatment delivery, only those who had undergone 
manualised CBT-I as described elsewhere(207, 464, 465) were included in the 
study. This format encompasses five sessions covering sleep hygiene/education, 
stimulus control, sleep restriction and cognitive restructuring components. A full 
description of this CBT-I program can be found elsewhere.(207, 464)  
Further inclusion criteria were:  
1. Participants had to be aged between 18-65 years  
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2. have completed treatment within the last 24 months (this 
was decided to minimise effects of recall bias; however all eligible 
participants had completed the treatment within the last 1-4 
months) 
3. have had a diagnosis, prior to CBT-I initiation, of primary 
insomnia according to the research diagnostic criteria [RDC(92), see 
Appendix 1]. (As all participants had completed the CBT-I 
intervention as part of other research projects, this information was 
obtained from the research data base) 
4. fluent in the English language 
 
Those with co-morbid psychiatric or medical disorders were excluded 
unless there was a temporal and causal separation from their primary sleep 
concern, in concordance with the research diagnostic criteria.(92) The presence 
of a co-morbid sleep disorder (e.g. sleep apnoea, restless legs, parasomnia) was 
a further exclusion criterion. Individuals who were also using other forms of 
treatment for their insomnia (e.g. pharmacotherapy) were not excluded (as 
above, this information was obtained from the information on the research 
database). 
Twelve eligible individuals were identified and approached, of which one 
was unable to attend the interview because of travel distance to the research 
centre. This is an adequate sample size for this type of study.(422) 
 
4.3.2 Procedure 
Ethical approval was obtained from two committees NHS Greater Glasgow and 
Clyde and Sydney Local Health District Ethics Review (RPAH Zone) Committees to 
conduct this study at two separate sites (University of Glasgow Sleep Centre, 
Glasgow, UK and Woolcock Institute of Medical Research, Sydney, Australia). 
Information sheet and consent form are presented in Appendices 6 and 2 
respectively. 
Once contacted and their consent obtained, participants were invited to 
the research centres for a face-to-face interview. All interviews were conducted 
by the lead researcher during 2009-2010, and questions and prompts were pre-
determined (see Appendix 4). This enabled the interviewer to entirely focus on 
the responses, permitting each individual to speak freely and with as little 
guidance from the interviewer as possible. Thus the direction of the interview 
was malleable depending on issues that were generated by the respondent. 
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These types of semi-structured formats enable the exploration of the 
individual’s experience, thoughts and beliefs in rich detail.(422) 
After explaining the study rationale (see interview schedule in Appendix 
4) the participant was reminded that the interview would be tape recorded. 
Suggested topics covered in the earlier parts of the interview were mainly 
descriptive in nature e.g. ‘history of the sleep problem’, allowing the 
interviewer to establish rapport with the participant. Once the interviewer felt 
the participant was comfortable, more sensitive topics were discussed ‘feelings 
when treatment was suggested’ or ‘impact CBT-I has on every day life’. Table 8 
highlights the topics covered in the interviews. Duration of the interviews was 
between 40-90 minutes. Each interview was transcribed verbatim and 
subsequently analysed using thematic analysis.  
 
Table 8: Topics covered in semi-structured interviews 
 
The experience of insomnia and participation in CBT-I 
Factors that influenced their decision to adhere/not adhere 
What factors they believed influenced adherence to other treatments, 
and relating this back to their experience with CBT-I 
What they would have changed in the process to facilitate adherence 
4.3.3 Data preparation and analysis  
Interview data were analysed using thematic analysis (Braun and Clarke 2006) as 
outlined in chapter 3. The results in this chapter are presented slightly 
differently from chapter 3. Because individuals were only interviewed at one 
time point, quotes are presented within the text forming a narrative account of 
the individuals’ experience of adhering to CBT-I.   
4.4 Results 
4.4.1 Patient Characteristics 
The group of 11 participants was relatively homogeneous. The majority 
were female (73%), and well educated. For the 10 participants who provided this 
information, the mean years of education was 16 (SD=3). All individuals gave 
details about their ethnicity; the largest proportion described themselves as 
White (British/Scottish, Australian or Canadian, n=10, 91%) and followed by 
Asian (n=1, 9%). Individuals considered themselves to have had their sleep 
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problem for an average of 10 years (SD=8). Approximately half were married or 
had a live in Partner (55%), whilst others were single, divorced or separated 
(45%).  
Table 9 presents the characteristics of each participant.  
Table 9: Participant Characteristics 
Participant 
Alias 
Age (Yrs) Education  
(Yrs) 
Marital Status Insomnia 
Duration 
(Yrs) 
Post CBT-I 
Insomnia Severity 
Index (/28) 
CBT–I 
Group 
Belinda 63 10 Divorced, living alone 20 16 1 
Ben 45 17 Separated, living alone 7 8 1 
Sally 58 17 Live-in Partner 13 - 2 
Mike 44 19.5 Live-in Partner 10 12 2 
Jonathan 47 16 Married 6 11 2 
Caroline 58 11 Married 4 12 3 
Madeline 51 - Single 6 18 3 
Abigail 22 16 Single, living with 
friends 
.7 3 4 
Polly 49 16 Divorced, Living alone 9 4 4 
Rachel 43 16 Married 30 - 4 
Karen 48 19 Live-in Partner 4.5 2 4 
4.4.2 Qualitative Results 
Three themes emerged from the thematic analysis of the interviews: “Making 
sense of CBT-I”, “Ongoing evaluation of components” and “Obstacles to 
implementation’. A summary of these and their associated subthemes are 
detailed in Table 10 below. In the following, each theme is presented with the 
respective subthemes and patient quotes embedded in the text to feature the 
experience of patient adherence to CBT-I in a narrative style.  
4.4.2.1 Making sense of CBT-I 
Individuals described their initial impressions at the initiation of treatment. Very 
few had concrete conceptualisation of what CBT-I actually really was, and 
individuals were willing to “give it a go” as CBT-I presented itself as the last 
resort. CBT-I was also conceptualised in reference to the meaning of their 
insomnia.   
4.4.2.1.1 What is CBT-I really? 
At initiation of CBT-I, it was uncommon for participants to have a tangible 
understanding of the treatment. Very few had further investigated this type of 
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therapy and many even described entering treatment with a ‘blank canvas’. 
Individuals, like Belinda, were mostly concerned with the prospect of improving 
their situation: ‘I don’t know that I really had any expectations, I think I just 
hoped that, you know, I would learn things and at the end of the day, put them 
into action and would learn how to sleep a bit better’ [Belinda, lines 139-141].  
Apart from identifying CBT-I as “talking therapy”, individuals were unsure 
of the content of the therapy: 
 
‘I thought it might have been like therapy of some sort, like talking 
about your problems, how you got them, what we can do about them.  I 
wasn’t sure what, in what format though. […] I thought it was a short 
thing, I thought “oh I will just go for some tips […] and I can take them 
away for me and try and work them you know”.’ (Polly, l. 93-99) 
 
‘well I wasn’t sort of sure, I guess, what we were going to go into, 
like I said, I have never looked into doing anything for my sleep before […] 
so I didn’t know… I assumed…I guess now it makes sense that there are 
things like sleep diaries and thing, but I never considered I might be filling 
one of those out, so not in terms of content, not a lot, particularly.’ 
(Abigail, l. 136-139) 
 
The simple distinction from the familiar pharmacological options seemed 
to be a motivator to take part in something individuals had little knowledge 
about:   
‘I didn’t really know what to expect I think it was just going in 
there almost, like with a sort of blank canvas, open minded, willing to 
try and take on… I wouldn’t have been willing to take on any medication 
as such, ah, as I said, I’ve, I just don’t like taking medication basically.’ 
(Ben, l. 205-210) 
 
‘when you approached me and it was non-drug, I thought “why not 
give it a go… can’t lose anything”.’ (Rachel, l. 85-86) 
 
‘there was no harm in trying, it was not like I was going to you 
know, like if you are taking drugs get addicted to it, and not have 
anything, not having a result out of it, so I wasn’t loosing anything, there 
was only something to gain. So, that was motivation for me.’ (Rachel, l. 
390-393)  
4.4.2.1.2 CBT-I as the last resort  
In the interviews it emerged that, for the majority, CBT-I was their last hope for 
improvement; having tried various other treatment options (pharmacotherapy, 
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hypnotherapy and herbal remedies) individuals were willing to engage in this 
treatment that was, as Karen describes, the “last port of call” [l.154]’: 
 
‘I either do this, or I…see I didn’t see that not sleeping anymore 
would actually get better, so it was get worse or get better.’ (Karen, l. 
154-156) 
 
Individuals described the emotional impact of sleeplessness; feeling 
“depressed” and “fed up”, at the end of their tether, which resulted in a sense 
of emotional “relief”, when the treatment was suggested: 
 
‘When I got the chance of this, I thought well, I can’t go on like this. 
Not sleeping or sleeping for a week, you know, and I find sometimes [sighs] 
sometimes, it really gets you down, you feel quite tired and depressed; 
because you are not sleeping you know.’ (Belinda, l. 54-58) 
 
‘I was fed up, I couldn’t, well you can’t say you couldn’t go on, I was 
just like, every day was getting worse and I was fed up and you know I 
thought I tried all these herbal remedies and they were like not really 
working, so I thought, well “I will go to the sleep clinic”.’ (Madeline, l. 
217-220) 
 
‘I think it was a bit of a relief once I started coming here, wouldn’t 
say I saw immediate benefits, but I think you felt as though, yeah, well 
there is a way out of this. [...] there is a light at the end of the tunnel 
here.’ (Ben, l.123-129)  
 
CBT-I was seen as the solution- both in terms of leading to improvements 
in sleep, and in providing an acceptable alternative to pharmacotherapy, a route 
they were less comfortable in pursuing. The combination of feeling helpless /at 
the end of their tether, and CBT-I taking shape as an option that wouldn’t 
produce any side effects, or would not be something they were in danger of 
becoming addicted to, proved a catalyst for engagement in this therapy:    
 
‘I wanted to see it [CBT-I] through, I wanted a positive outcome, I 
mean and this was a chance like I said, I can’t see any other avenues to go 
down, so if this didn’t work, I didn’t know what else to do. And I can’t…I 
think I would have ended up taking more pills.’ (Caroline, l. 1098-1100) 
 
‘You know that everything was worth a try, I mean obviously I 
hadn’t gone the sort of medication route, as it was, which is something I 
could have discussed with my GP, if I had wanted to. So on some level, I 
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have always avoided that, so you know, sort of doing therapy for it, 
seemed like a good idea.’ (Abigail, l. 46-49) 
 
Table 10: Themes and Subthemes that emerged from the interviews using thematic analysis  
Themes Subthemes 
Making sense of CBT-I  
What is CBT-I really? 
CBT-I as the last resort 
The meaning of insomnia  
Ongoing evaluation of 
components  
Evaluation against past, present and future self  
Using what works 
Comparing self to others 
Obstacles to implementation 
Is the timing right? 
Beliefs about sleep  
Negative/Unwanted Consequences 
4.4.2.1.3 The meaning of insomnia  
Making sense of CBT-I occurred in light of how these individuals conceptualised 
their insomnia. Although many described the frustration, helplessness and 
hopelessness of having insomnia and were ready to embark on the changes 
outlined in the treatment; some participants described an initial disbelief in the 
potential effectiveness of CBT-I, based on the meaning insomnia had for them. 
What emerged in some interviews is that for CBT-I was seen as too simple to 
deal with their complex, chronic problem. An excerpt of the interview with 
Rachel highlights how she defined her insomnia as a chronic problem- chronic to 
the point she had accepted it was just the way she slept. This perception 
influenced how she made sense of CBT-I:   
 
Rachel: I didn’t think it would work. 
  
Interviewer: Why was that?  
 
Rachel: When you first called I thought ‘oh this might be a waste of time’ 
[laughs]  
 
Interviewer: What was the reason for that?  
 
Rachel: I don’t know, maybe because I have had this problem for so long, 
then I just thought it was the way I slept, or lack of sleep. I just thought 
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it was me. And I guess you get to a point where you just accept what you 
have and just get on with it.     
(Rachel, 130-140) 
 
Others defined their insomnia in terms of the complexity of their 
problem. For Karen, CBT-I components seemed ‘too simple’ for her complex 
problem, whereas for Ben it was the process of sleeping that was too simple to 
deserve treatment: 
 
‘some of the basic techniques of not turning the lights on at night, 
of you know winding down before I go to bed, of when I do wake up going 
“it’s not such a big deal and I will cope tomorrow and I will be fine.” They 
sounded too simple to actually work.’  (Karen, l. 90-93) 
 
‘I suppose I was a bit apprehensive, ‘cos [sic] it’s something new and 
you feel as though a bit stupid, really, thinking you know, “how can you 
not get to sleep?” […] surely you can resolve this yourself without 
somebody having to tell you.’ (Ben, l. 114-119) 
 
Interestingly though, when the attempt was made to implement these 
techniques, individuals realised how difficult some of the components actually 
were. Karen, who had initially understood CBT-I as too simple, made this 
discovery:  
 
‘Putting them into practice was actually harder than I had expected. 
You know the getting up after the 15 minute rule was really hard, and you 
know a couple of times I have slipped on the waking up at 6 o’clock 
especially in the mornings.’ (Karen, l. 93-96) 
 
In contrast, other’s felt CBT-I was a suitable option for their chronic 
complex sleep problem:  
 
‘It [CBT-I] wasn’t something synthetic, and the…there were going 
to be skills, like, you know presumably would you know last a life time, 
in terms of being helpful. It didn’t seem like such a, what would you say, 
like a band-aid, you know it was more of a long term solution.’ (Abigail, 
l. 67-70) 
 
‘So that is how I look on this treatment too. So it’s not- it will, it 
may not help me in the shor…well does help me in the short term, but 
the long-term is what I am looking for. Yeah, long-term benefits.’ (Polly, 
l. 827-829) 
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On the one side, insomnia was defined as a debilitating, chronic condition 
affecting daytime functioning and quality of life; however participants also 
described an alternative meaning of insomnia. For a small number of 
interviewees, insomnia was defined as was part of one’s identity; an excuse; or 
even a blessing in disguise, providing the individual with more opportunities 
during night-time hours, which led to the initial ‘trepidation’ or resistance 
towards CBT-I.  
 
‘Trepidation [described feeling when treatment was suggested], 
because I was thinking “oh gosh”, you know “will this work really? “Am I”, 
you know, “am I going to be able to get out of it” because I realise that it 
was a habit, and I kind of even sometimes looked, not sort of looked 
forward to being up all night, but I thought, “well I can always do that 
when I go to bed”.’ (Sally, l. 101-104) 
 
 ‘it’s shedding those things that make you different, and having the 
badge of being an insomniac, it’s like “oh no, shedding that one too”.’ 
(Karen, l. 121-123) 
 
‘before it was quite easy to say “oh look”, you know “leave me 
alone, I have had a bad night” or “the reason I, I am not thinking straight 
is because I had a bad night”. so there is no more blame, to having a 
problem with sleep, because it is not there now.’ (Rachel, l. 395-396) 
4.4.2.2 Ongoing evaluation of components 
It emerged in the interviews that individuals did not simply comply with what 
was outlined in the programme, but experienced a process of evaluation of the 
components on which they based their subsequent adherence behaviour. Each 
aspect of CBT-I was continuously evaluated in terms of efficacy: individuals used 
what worked; what worked for them; and in terms of what worked for others. 
4.4.2.2.1 Evaluation against past, current, future self 
Once initial impressions had been made and the treatment was established as an 
option that was in concordance with the way individuals perceived their 
insomnia, there was a more detailed evaluation of the treatment components in 
respect to the image they had of themselves. Treatment components were 
deemed valid when there was concordance with individuals’ past, current and 
future self-image.  
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Newly imposed routines were compared to how they used to be, or seen 
as a mechanism to establish the old sleep patterns:  
 
‘that’s what I used to do, so maybe, maybe if I start trying that 
again, and its really just, re- its sort of like, it reaffirms the “yes, I have 
been on the wrong track and there is a way back.’  (Sally, l. 460-462) 
 
I thought “oh this is great maybe they can come up with some 
different strategies, or ideas that would help me re-establish my old sleep 
pattern”.’ (Polly l.74-76) 
 
Participants also continuously assessed whether or not there was an 
alignment between the treatment components and their current habits and 
preferences. This could either encourage or discourage their continued use of 
the particular components: Abigail, who described herself as not having ‘whole 
lot of negative thoughts’ found using the cognitive strategies very difficult. 
Similarly, Mike who disliked ‘routine imposed upon’ him sometimes struggled to 
stick with the sleep restriction programme. For Belinda, Abigail and Madeline, 
there was congruence between what was required of them and the description 
of their “self” as someone who ‘doesn’t lie in bed any length of time’ ‘ha[s] 
never been someone to snooze the alarm’ or ‘would try anything’ respectively. 
Others again identified their present circadian preference or insomnia 
subtype when evaluating treatment components:  
 
‘I still am a night person, but I think I realise also there is better 
things, there is opportunities at the other end of the scale, other end of 
the day as well. Yeah, it’s [sleep restriction] sort of opened my eyes a bit 
really.’ (Polly, l. 443-446) 
 
‘my problem doesn’t seem to be going to sleep, my problem is 
staying asleep. So it is difficult to stick to the 15 minute rule you know, 
when you are lying there at 2 o’clock in the morning and you are feeling 
shattered, it is difficult, although I have done it.’ (Belinda, l.247-250) 
 
 
In addition to their image of their past and current self, patients also 
described their future self and the goals they aimed to achieve in terms of their 
sleep: ‘I still see the challenge to get over that because its not quite where I 
would want to be, but at least there is like a direction to go.’ (Jonathan, l.154-
156). The prospect of reaching these goals provided added motivation to adhere 
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to the treatment components. For some it was also the image of what they could 
become, if they failed to initiate change that provided a push to continue:  
 
‘With older people, like my mum is in a nursing home at the 
moment, and when I get there, it doesn’t matter what time I go there, 
they are all asleep, a lot of them are napping, I thought “crikey if I fall 
into that category now, what hope have I got when I am that age” I don’t 
what to get into that.’ (Polly, l.397-400) 
 
4.4.2.2.2 Using what works  
Of components that were deemed appropriate for themselves, individuals used 
what proved effective in improving their sleep patterns. The following quotes 
reflect how this involved an ongoing process:  
 
‘It’s like “ok I will test that bit out, no that doesn’t work, I will 
test…no that doesn’t work, oh that works, ok I will keep doing that one” 
so yeah for me it’s really about trial and error and about what works and 
doesn’t work.’ (Karen, l. 664-667) 
 
‘I just went through the processes of what you told us, and if one 
didn’t work, I would do the other, and eventually one would work.’ 
(Rachel, l.200-201) 
 
Some individuals identified the specific components that worked for 
them. Interestingly, no single component emerged as the most useful and it 
becomes evident, that these individuals used what worked best for them.  
 
‘the relaxation tape to help you relax before going to bed … I found 
that useful you know, I found that did help me get to sleep quicker.’ 
(Jonathan, l.94-95)  
 
‘Building up that sleep drive and sticking to a sleep window has 
been…I felt really good about that, that it works and can be something 
that one can use.’ (Mike, l.144-145) 
 
‘the relaxation tape, I tried that, but I couldn’t be bothered with 
it, it just, I think, I thought it was too long winded, so I got frustrated 
with that, so I didn’t like to use that. But I like the fact of having stories, 
creating yourself a story and the picture in your mind, and setting 
yourself somewhere else I liked that. And the chanting the name and 
writing off all your thoughts before you go to sleep, that worked for me.’ 
(Rachel, l.459-462) 
Chapter 4  Qualitative Exploration of CBT-I adherence 167 
 
 
‘I don’t imagine anything, I just don’t let my mind wonder, if it 
starts wondering, I think that is when you start thinking, so its just 
something that I haven’t used, but I don’t think I would use it, because 
the other things are working for me.’ (Caroline, l. 732-734) 
 
There was a dissonance between using what worked and the actual 
difficulty in adhering to the components. Individuals described almost a cost-
benefit evaluation when deciding to follow recommendation. In the majority of 
cases, like for Madeline, the effectiveness seemed to outweigh any difficulties 
individuals were having and provided the motivator for continued use.  
 
‘I don’t want to get up and get out of bed, when you don’t have to 
and you know you are going to go back there shortly, so I would rather not, 
but I mean it does work, you get up and you go have a little wonder and 
then you go back.’ (Madeline, l.778-781) 
 
Seeing the effects of non-adherence provided a form of validation for the 
efficacy of components and this increased their motivation to be more rigorous 
with the treatment routine. Seemingly testing the boundaries is imperative in 
increasing their awareness of how treatment works and how non-adherence 
affects outcome.  
 
‘I woke up at about half past 5, I could have got up then quite easily 
and went, “no I will just sneak some more sleep in” […], then I felt pretty, 
not as alert all day, just a bit sort of lethargic, and then that night, I just 
had so much trouble getting to sleep, […] thinking “I don’t want to do that 
again, see a direct causal relationship between when I get up in the 
morning and when I go to sleep the night before”.’ (Karen, l.511-517) 
 
‘Saturday night, come bedtime I wasn’t tired, I didn’t feel tired, […] 
but that was my bedtime, so I kind of footed about and went to bed, which 
was a big mistake because I didn’t sleep all night.’ (Belinda, l.440-445) 
 
4.4.2.2.3 Comparing self to others 
Lastly, patients also evaluated components after comparing their behaviour with 
others. This could be others in the treatment group, or reports of previous 
success stories. Seeing how components led to improvements for others in the 
group or hearing about the effectiveness of CBT-I from the current literature 
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provided a source of validating the effectiveness of these components and 
encouraged continued use: 
 
‘I didn’t think the thought blocking… I didn’t actually think would 
be that helpful to be honest. And then one day, I remember I have 
forgotten her name, who had done the ‘2’ instead of the ‘the’ and she 
had said you know that that had been really helpful, so then I thought 
‘oh I might as well give it a go.’ (Abigail, l. 441-445) 
 
‘it helps with […] listen to someone who is similar, but approaches 
it in a different way and going “oh, ok if they are similar to me and then 
if I approach it their way, it might work for me too”.’  (Karen, l. 881-884) 
 
These comparisons also gave hope that the improvements would been 
seen if they continued to adhere to components: 
 
‘And I think it was just getting that sort of reassurance; this and 
this worked for all these different people, there is every chance that it 
will work for me too.’ (Ben, l. 548-550)  
 
In this process of comparing themselves to others, individuals also 
recognised dysfunctional behaviour or thought processes, they were also trying 
to change. As both Sally and Karen describe, this process helped them 
internalise the underlying treatment rationale to provide validation of the 
treatment components:    
 
‘It’s like me giving the advice that I don’t take myself really, […] 
and it’s a kind of re-affirmation, yeah, when I am trying to say, “well you 
try this and if you try thi...” it’s as if I am trying to convince myself that 
these things will work and then by explaining to someone else, it helps me 
get it straight in my head really.’ (Sally, l. 216-220) 
 
‘I do really like the group thing and hearing how other people going, 
and hearing myself in other people who aren’t going so well, and 
recognising parts of me, but I think it’s not judging them, but it’s going 
“they are still hanging on to that bit, I am too”, if you know, and learning 
that, that reflective thing of “if it is not working for them, why do I think 
it is going to work for me?”.’ (Karen, l. 868-872) 
 
4.4.2.3 Obstacles to implementation 
Throughout the CBT-I programme, individuals were faced with certain obstacles 
that made implementation of the treatment components challenging. Trying to 
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implement components at the wrong time, remaining dysfunctional beliefs and 
the presence of unwanted consequences were obstacles described by these 
individuals: 
  
4.4.2.3.1 Is the timing right? 
Optimal behaviour change occurs at the correct time. This could be at the day-
to-day level with adherence issues occurring on difficult days, or at the broader 
contextual/motivational level- individuals have to be ready for change with 
treatment initiation occurring at the right time in life. Unfortunate timing might 
then result in practical or motivational obstacles for implementation.  
Implementing the sleep restriction programme on the weekends or during 
holidays was particularly challenging for many individuals in this study. Karen 
describes the reason she found this difficult was because it is “traditional” to 
stay in bed longer on the weekends. As the following quotes highlight, partners 
and families were also impacted during these times:  
 
‘as my partner pointed out, how can you do this during the 
holidays, why are they meaning you doing [sic] this in the middle of the 
holidays. So […] given the opportunity, I guess I would do it at a different 
time’ (Mike, l. 534-537) 
 
‘you’ve got weekends and your partner is there, […] you can’t just 
dictate your sort of sleep pattern to yourself, you cannot just be up, I 
mean you can be, but I generally you not being that selfish, […] so you’re 
sort of you’re not really adhering to… in those occasions because you 
want to spend time together.’ (Ben, l. 368-373) 
 
The sub-theme timing was also considered in terms of the broader 
contextual level. Both Jonathan and Sally described the timing of CBT-I initiation 
in terms of their current lifestyle; Jonathan’s relatively free schedule facilitated 
effort in implementing components, whereas Sally’s hectic life-style produced 
obstacles for adherence:  
 
‘I think I probably had the advantage, that because I am not 
currently working, it was probably easier for me to organise my time to 
fit in to the programme, and the steps of the programme, it might have 
been slightly more tricky for the people who were in work.’ (Jonathan, 
l.80-83).  
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‘it’s been […] not a normal period of time sort of thing, so if I had, 
just like a normal […] if my life had been running normally, then I …it 
would have been different definitely, but in a way, I might not have been 
as determined to try and see it through.’ (Sally, l. 673-676) 
 
Individuals also acknowledged that importance of timing in reference to 
their internal motivation and whether they were ready for change, as Polly 
denoted, one of the biggest things was ‘that we are willing to change, I think, 
[…] that we are actually willing to.’ (l. 936-937) Some individuals described at 
the start being ‘resistive’ ‘having trepidation’ or thinking the treatment 
wouldn't work. Karen explains how this prevented her from initially seeking 
treatment:    
 
‘I was really resistive [when CBT-I was suggested], because 
someone had suggested it when I came for the sleep apnoea test here. 
And I just put it off and put it off and put if off and put it in the too hard 
basket.’ (Karen, l.86-88) 
 
4.4.2.3.2 Beliefs about sleep  
 Beliefs about sleep needs provided a further obstacle for implementation. One 
belief that prevented many from implementing the behavioural components was 
aspiration to obtain more sleep, or the magical ‘8 hours’:    
‘I couldn’t sit up till 11.30 anyway and get up when I have to get up, 
I find that I just needed that sleep, but then I then I’d be counting up the 
hours, so that is a long time I do spend in bed sometimes, when you say 
you only need 8 hours a night sleep, I must need 8 hours a night sleep.’ 
(Caroline, l. 423-426) 
 
‘once I sleep [sic] in […], I could have got up at 7, but I just decided 
that it wasn’t going to do me any good and, and so my sleep window ended 
at 7, I got up at something like 9.’ (Mike, l. 283-286) 
 
Karen even describes this experience of wanting more sleep as ‘an old 
voice’ that felt validated when she did decide to stay in bed past her rising time- 
‘”see you did get an extra hours sleep”.’: 
 
‘it’s like when you wake up in the morning you have got a vulture 
sitting on the end of your bed going “glad you are awake, I want to have a 
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word with you”’ so it’s a nag, a little voice in your head all the time.’ 
(Karen, l.359-361) 
 
For others, it was the understanding (or misunderstanding) of the 
treatment rationale that was an obstacle: 
 
 ‘if you don’t fall asleep you know sometimes I find too, if I do get 
up and I sit, I become more wide awake and that kind of defeats you 
know you can be sitting there for a long time before you’re feeling 
tired.’ (Belinda, l.253-255) 
 
Interestingly, individuals explain how ‘getting their head’ round the 
treatment rationale, facilitated the rebuttal of these dysfunctional beliefs. For 
some this process was about truly understanding the rationale of the 
components and comprehending the consequences this had on their behaviour. 
Yet again for others, like Karen it was about re-defining the rationale, to make 
sense of it on a personal level. Rather than taking it literally, people 
individualised the treatment components to get their head around them and 
fully internalise the rationale.  
 
"I really need to get my head round this as well, if I don’t feel 
tired when I should be going to bed, then I just don’t go” (Belinda, l. 443-
445) 
 
‘the effort of physically getting up, I just think “augh, no I will 
just lie here and I will fall asleep eventually”, whereas generally 
speaking that’s not what happened, you do drop off, but I felt as though 
in those occasions, you weren’t getting a proper sleep.’ (Ben, l. 335-358) 
 
‘Well, it has been working a bit better, because you are going to 
bed late, you are not going to bed because you are just like ‘oh might as 
well go to bed, I am tired”, but you really aren’t as tired as you should 
be, you got [sic] to get that sleepy tired. So that is quite good, that 
window of sleep, I think and it does make you, I think it makes you sleep 
a bit more too.’ (Madeline, l. 144-148) 
 
‘the 15 minute rule, its kind of good, but for me its more about 
the point at which the frustration sets to start in, that is, and that can 
happen after 5 minutes, so that for me is the more important part of 
that bit, because that is when the anxiety and the distress start to 
happen, so if I get up at that point, and break that thought cycle.’ 
(Karen, l. 762-766) 
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For Karen it wasn’t solely about internalising the rationale, but also 
internalising sleep and accepting sleep as part of her self, which made the CBT-I 
experience less fearful: 
 
‘Well, is it [sleep] something to be conquered? That is the thing, its 
just, I don’t conquer being awake […] but for me sleep actually has to be 
so normal, that is part of who I am and part of what I do, rather than this 
almost external entity that has to be gotten better of. […] So to normalise 
sleep, makes it less of a foe, less of something to be afraid of, yeah I think 
that works for me.’ (Karen, l. 384-393) 
 
4.4.2.3.3 Negative/Unwanted Consequences  
Individuals described difficulties implementing the behavioural components- 
especially sleep restriction and stimulus control- when these produced unwanted 
or even unexpected consequences. One of the most frequently noted adverse 
effect was increase in sleepiness. Despite their willingness to adhere, they found 
it progressively more difficult to ward off these feelings that emerged during 
treatment.  
 
‘I was tired. I struggled with the sleep restriction on the basis, I… 
it was suggested that I shouldn’t be going to bed until about 1 in the 
morning and I just physically couldn’t stay awake until that time.’ (Ben, 
l. 149-151)  
 
‘it was really slow mornings then a period of feeling fine and then 
early evenings starting to get really tired and, having to stick with it and 
stay up and stay out of bed and so it was challenging.’ (Mike, l.154-157) 
 
‘I was quite tired most of the nights, like that I had out, I couldn’t 
actually stay out as late as I used to, because I was feeling more tired.’ 
(Abigail, l. 269-270) 
 
Apart from more physiological consequences, the presences of unwanted 
practical consequences inhibited implementation of treatment components. 
Individuals felt that some components impacted on daily activities and especially 
on others in the household:  
 
‘sitting up at night, and getting up early in the morning, when you 
live in a small house, with people, who were a bit sensitive to noise, at 
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first I was like “oh, what am I going to do”, kind of, you can’t turn the 
telly on, because the noise.’ (Karen, l.209-211) 
 
‘then she [partner] was on holiday for a week after and I wanted an 
alarm going off at 7“.’ (Mike, l. 187) 
 
In order to overcome these side effects, participants described the need 
to develop certain coping strategies. For many participants implementing change 
was more difficult that expected and side effects like tiredness or boredom had 
to be counteracted by these strategies. For example countering sleepiness by 
staying active, changing habits like sitting on the couch, or finding activities that 
would encourage rising in the morning, facilitated adherence. Likewise, 
individuals had to develop strategies to prevent the more practical unwanted 
side effects that disrupted others in the household:   
 
‘In the evening, I had to stay physically active to be able to… you 
know, if I’d sit down for a long time, I would really get sleepy, so I had to 
stay physically active to…, in order to stick to the programme.’ (Mike, 
l.176-178) 
 
‘Ah if I don’t sit in the lounge, I think I am just too exhausted, I 
have to sit somewhere, because I have been going and going, if I sit at the 
dinning table, which is a nice firm chair, then I definitely stay awake.’ 
(Polly, l.348-350) 
 
And my partner did suggest that I do the laundry and other things 
and I said ‘no’ the motivation to get up at 6 would just disappear instantly 
of course. You know to do the housework, so, yeah it had to be something 
that I actually enjoy doing. (Karen, l.224-226) 
 
 “How to set the alarm and finding something that wouldn’t wake 
the whole house up- just an ipod under the pillow with a low volume, it 
woke me up, but not my partner” (Karen, l. 258-260) 
 
 
4.5 Discussion 
In 2006, a review on the use of psychological and behavioural treatments for 
insomnia concluded that effectiveness studies were lacking.(466) Behavioural 
adherence is a significant component of effectiveness of any treatment, yet our 
understanding of adherence to CBT for insomnia is equally narrow. This study 
aimed to explore the experience of individuals undergoing CBT-I in order to shed 
light on this phenomenon. Interviews were conducted to investigate how people 
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follow recommendations to overcome their insomnia and the salient issues that 
influence their behaviour.  
Three superordinate themes were extracted from the analysis that 
reflected the overall experience of implementing CBT-I components: “making 
sense of CBT-I”, “ongoing evaluation of components” and “obstacles to 
implementation”. Figure 7 provides a summary of the themes and their 
respective subthemes. How these themes are related is explained further below. 
 
Figure 7: Themes and Subthemes and their Interrelations 
 
4.5.1 Making sense of CBT-I  
This theme reflected how individuals obtained a global sense of what CBT-I was. 
At the start of treatment, these individuals had little conceptualisations of the 
content of CBT-I, having entered the treatment with no prior knowledge or 
research into this type of intervention. They were willing to engage in 
treatment, potentially because it offered a solution that was different from all 
other options previously experimented with (pharmacotherapy, herbal remedies 
etc.) Little awareness of sleep and available treatments, as reported in our 
sample, is potentially a function of sleep having little presence in public health. 
A study conducted in the UK by Stores and Crawford found that sleep is 
acknowledged merely 5 minutes in undergraduate medical student’s 
curriculum(467) With general practitioner appointments, certainly in the UK and 
Australia, limited to around 15 minutes, the opportunity to speak about sleep 
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during consultations is even further reduced. The consideration of increasing 
awareness and availability of CBT-I has been addressed elsewhere(121) and there 
is evidence to show that lack of awareness can act as a barrier to seeking 
treatment for insomnia,(455) however the concrete relationship between 
awareness/knowledge and subsequent adherence to CBT-I remains unclear in 
this population. In the majority of respiratory sleep clinics, sleep education 
plays a large role in introducing continuous positive airway pressure (CPAP) to 
individuals with obstructive sleep apnoea (OSA) however educational 
interventions have not been associated with or produce only small improvements 
in CPAP use, see chapter 1. Further research might benefit from investigating 
how psychoeducation in CBT-I is related to adherence to other components.  
In this sample, individuals described a debilitating history of trying to 
manage their sleep problem prior to the start of CBT-I. It was common for 
individuals to have tried a variety of alternative options prior to seeking 
professional help with their sleep, which has previously been reported in the 
quantitative literature(107) also in qualitative studies.(139, 468) Many described 
their insomnia as debilitating condition, which corroborates previous qualitative 
investigations of the emotional and psychological effect of chronic poor 
sleep(468-470). This sense of being at the end of their tether, coupled with the 
ineffectiveness of previous pharmacological and self-help attempts, led to a 
sense of relief when CBT-I was suggested. CBT-I was described as ‘light at the 
end of the tunnel’, however this also translated into this treatment being 
identified as their last resort. If taking part in this opportunity did not prove 
effective, there was no other option. It is difficult to draw conclusion on how 
exactly this might have impacted on individual’s adherence, however one 
possibility is that the effect of CBT-I being scarce might have encouraged 
individual’s motivation to initiate and adhere to treatment (perhaps even more 
so than if these treatments were readily available). This suggestion is 
speculative; however the scarcity effect is well established in the social 
psychology/marketing literature.(471) This is not to say that CBT-I should remain 
scarce and recent efforts to develop strategies to improve the availability of 
CBT-I(121) are laudable, however therapist might strategically draw on this in 
their efforts to improve adherence.    
Lastly, individuals made sense of CBT-I in light of how they defined their 
insomnia. For some their sleep problem was defined in terms of its chronicity or 
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complexity and the anticipated level of effectiveness or suitability of the 
treatment was contrasted with this view. There is a large body of evidence that 
has revealed the relationship between illness perceptions and health 
behaviour.(472) Leventhal’s self-regulatory model suggests that an individual 
processes information about the illness and forms a cognitive representation 
thereof on the basis of 5 dimensions: identity (what are the symptoms, labelling 
the illness), cure/control (curability and controllability of the illness), cause, 
consequences and timeline (potential duration of the illness).(473) Whether 
these types of perceptions are related to adherence to CBT-I is relatively under-
investigated. One study however found that the perception of insomnia as a 
trivial condition that does not to be addressed within a therapeutic framework 
was an obstacle for seeking treatment.(455) Using the Illness Perception 
Questionnaire (derived from Leventhal’s model), Morgan and colleagues(232) 
found no relationship between perceptions about the curability/controllability of 
the sleep problem and adherence (personal communication). However, this 
study did not investigate the other illness perceptions and had used the crude 
measure of attendance as a marker of adherence.   
4.5.2 Ongoing evaluation of components 
Patients described how they continuously evaluated their self, the components 
and others throughout treatment. This theme portrays not only how dynamic the 
process of adherence is, but that for these patients, treatment implementation 
is not merely about complying/not complying, but an active decision making 
process to adhere or not to adhere.  
Firstly, patients critically evaluated the components against their self in 
past, present and future form. Past and future images of self reflected either a 
healthy sleep pattern they were hoping to return to/achieve or the downhill 
spiral into poorer sleep habits they recognised from pre-treatment times and 
hoping to avoid. The image of their present self took on many different facets, 
from general habits to more sleep related perceptions of the self (type of 
insomnia: onset versus maintenance, or circadian preference). A dissonance 
between the treatment and the image of their self led to a poorer evaluation of 
the treatment components, which were subsequently not implemented. If 
patients are choosing the aspects that overlap with the image of their self, there 
might be value in matching treatment components across assessed criteria. The 
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few efforts to individualise treatment have, however been unfruitful.(474, 475) 
Unfortunately, these treatments were tailored according to poorly established 
methods of subtyping (e.g. using questionnaires to match cognitive intrusion or 
physical tension with cognitive therapy or relaxation therapy respectively). 
Efforts to match treatment against relatively more robust diagnostic distinctions 
of subtypes of insomnia (paradoxical, idiopathic, psychophysiological insomnia) 
could be more fertile for the possibility of individualised treatment. For 
example,(457) reported that individuals with idiopathic insomnia rated 
acceptance-based therapies as more preferable than their psychophysiological 
counterparts.   
Patients made further inferences about the individual treatment 
components – selected for implementation were components that were effective 
and easy for them to use. There was a selective decision to use some 
components, whereas others were discarded, rated as less suitable or effective. 
Treatment preference and attribution has been given relatively little attention 
in the insomnia literature. Although some studies have reported that 
psychological/behavioural treatments are preferred over pharmacological 
options when assessed prior to treatment(120, 230, 456), there are only a few 
studies that have attempted to establish which of the actual treatment 
components are rated most acceptable and thus most often used.(206, 209, 230) 
It is difficult to draw conclusions from these studies-with different research 
designs- about individuals differential preferences for each aspect of CBT-I. This 
study certainly was not able to gauge which components were most favoured by 
individuals, and it was also not the intention of this study to investigate in detail 
perceptions about each component, however it seems that individuals used the 
elements they perceived as most effective for them.  
The experience of occasional non-adherence was used as an important 
marker in determining what worked and this inadvertently increased their 
willingness to comply. Failure to implement medical recommendations is 
inherent to most treatments, even behaviour as simple as pill taking is 
associated with poor adherence rates.(169) This experience provided patients 
with a strategy to validate the treatment: non-adherence lets them re-discover 
how their sleep had been before treatment initiation. To avoid individuals 
abandoning treatment entirely, preparation for relapse should be an integral 
part of CBT-I.(see 207) Currently, motivational interviewing/ enhancement 
Chapter 4  Qualitative Exploration of CBT-I adherence 178 
 
therapy (MI/ME), which acknowledges relapse as an important part of change, 
has been proven useful for problem behaviours like substance abuse.(476) Some 
studies have provided preliminary evidence for the effectiveness of MI/ME in 
improving CPAP use.(354, 355, 358)  
Lastly, witnessing the effectiveness of components in other group 
members or hearing of previous success stories, led to a re-evaluation of the 
suitability of treatment components for individuals. Bandura’s social cognitive 
model states that people form knowledge about their environment from 
observing and modelling other’s behaviour.(340) It has yet to be explored 
whether this phenomenon plays a role in adherence to CBT-I. Group 
administration of CBT-I is well-established and leads to clinically meaningful 
improvements in sleep outcome variables(140) even when compared to the one-
on-one delivery option.(477, 478) Despite the consensus that group therapy 
might increase adherence to treatment components,(477-479) and one 
qualitative study reported that individuals valued meeting others like them 
during group CBT-I(463), there has been no systematic investigation of 
adherence across these different delivery modalities.  
Similarly, the incorporation of previous treatment completers has not 
been considered, but the effectiveness of including such strategies in a CBT-I 
program to improve adherence could be investigated. A recent study in OSA 
reported that the incorporation of short 15-minute video of current CPAP users 
in a cognitive behavioural intervention, displaying both treatment success and 
failure, provided an increase in average nightly machine use of 2.9 hours 
compared to treatment as usual.(351)  
4.5.3 Obstacles to implementation  
Despite the extensive literature on the effectiveness CBT-I, few studies have 
studied potential obstacles for adherence to this treatment. In this study despite 
having made sense of CBT-I and evaluated which treatment components were 
most suited to their needs, individuals identified certain features of the process 
that created obstruction to implementation. The practical, motivational and 
external obstacles overlap to an extent with what has been established in the 
literature: increased initial wake periods caused by stimulus control or sleep 
restriction may lead to boredom and annoyance(139, 208), or increased 
sleepiness.(139, 218)  
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 In this study timing was identified as one of these obstacles, with 
individuals describing weekends or holidays as the most difficult times to adhere 
to the sleep scheduling practices. The social norm of ‘sleeping in’ or additional 
social activities on weekends and holidays might make adhering to the get-up 
time increasingly difficult. To date the self-report scale that have been used to 
measure adherence to the behavioural components has not included separate 
items for week versus weekdays.(208, 214) However, considering that this 
subtheme emerged in both this and Kyle’s qualitative investigation(139) of the 
experience of sleep restriction therapy, the differentiation of weekday and 
weekend in future adherence scales might be fruitful. Of note, this type of 
adherence self-report measure has been developed at the University of Glasgow 
research group and is considered in more detail in chapter 6.  Participants in this 
sample also identified how an important facilitator for treatment adherence was 
the implementation of CBT-I at the right time in life, both from a practical, but 
also motivational perspective. The motivation or readiness to change has been 
extensively studied in the framework of the transtheoretical model. This theory 
describes behaviour change can only occur when the individual is at a stage 
ready for change (see chapter 6 for a detailed outline of the transtheoretical 
model). The consensus in the literature is that individuals with insomnia are 
ready for change once treatment is sought; however when faced with the 
behavioural components and the prospect of reducing the time they spend in 
bed, which might seem counter-intuitive, motivation might be altered in some 
individuals. Certain dysfunctional beliefs that remain despite cognitive 
restructuring elements of CBT-I might play a role in this reduction in readiness to 
change.  
Beliefs about sleep (especially sleep needs) emerged in this study as a 
further obstacle for treatment implementation. If the dysfunctional belief of 
needing 8 hours of sleep is still heavily endorsed, removing oneself from bed in 
accordance with sleep restriction and stimulus control will be challenging. Their 
goal of increasing their sleep might seem counter-intuitive with what is asked of 
them. This experience was also highlighted in Kyle’s qualitative study(139). The 
themes termed ‘this is a sleep restriction programme’ and ‘adherence and 
adjustment’ highlighted participants’ frustration with limiting (at least initially) 
their sleep opportunity, when their goal is paradoxically to increase this. A 
successful restructuring of individual’s thought processes prior to 
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implementation of the behavioural components might be an interesting avenue 
to pursue. Unfortunately, to date there has been no systematic investigation of 
the order of cognitive and behavioural elements of CBT-I. Most packages will 
provide the behavioural prior to cognitive components. However, this and the 
previous subtheme (timing at the motivational level) suggest it might be useful, 
at least in some individuals, to offer the cognitive components first. 
Randomising individuals to either pathways, or matching the pathway according 
to individuals’ beliefs and readiness to change could be useful, as has been 
shown for alcohol dependence.(480)  
In terms of dysfunctional beliefs, research has indicated that these are 
subject to change across the treatment of CBT-I; additionally, improvements in 
certain cognitions- such as needing 8 hours of sleep- were associated with 
improvements in outcome(146, 481). Whether this process is important for 
adherence should be subject to further quantitative and qualitative 
investigations.  
Finally, the experience of negative/unwanted consequences emerged as 
an obstacle to implementation. The more practical impacts on the family or 
daily activities were seen as frustrating side effects of adherence, however even 
more potent were the physiological consequences of acutely increasing their 
homeostatic drive for sleep. Mounting feelings of sleepiness- an experience 
individuals with insomnia are often unfamiliar with- left individuals challenged in 
adhering to the behavioural components of CBT-I. This phenomenon of adverse 
effects has largely been neglected in the research of psychological-/behavioural 
treatments for insomnia.(123, 139) Kyle et al. indicated that in the acute stages 
of a sleep restriction programme side effects -especially extreme sleepiness- 
emerged in both the qualitative and quantitative measures of this study.(139) As 
described in chapter 1, interventions that target these obstacles e.g. 
introduction of modafinil, might have a positive effect on adherence.(see 218)  
 Individuals in this study identified coping strategies, such as finding 
activities or eliminating sleepiness inducing environments, to overcome the 
physiological consequences and found solutions to reduce the impact of the 
more practical consequences. Evidently these individuals are successfully 
developing active problem solving techniques to overcome these obstacles. Both 
the presence of an active coping style and increasing self-management has been 
associated with increased adherence to CPAP,(333, 482) whether improving 
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these strategies along side the implementation of CBT-I components remains to 
be investigated.  
4.5.4 Summary of themes and their interrelations 
Figure 7 summarises the themes and their respective subthemes. Making sense of 
CBT-I at the global level is core to the process of implementing the components, 
as indicated by the framed box in Figure 7. Establishing the meaning of this 
treatment is fundamental and with this in place, individuals begin to focus their 
concerns on the individual component. This incorporates both the evaluation of 
each component against several criteria and also how certain obstacles may 
complicate the implementation. These themes “ongoing evaluation” and 
“obstacles” might inform each other (as indicated by the dashed arrow in Figure 
7). For example, beliefs about sleep as an obstacle might cloud the evaluation of 
the component’s effectiveness. Likewise, something valued as effective might 
facilitate the continued implementation despite marked obstacles. However, 
this was not entirely clear from the data and remains a speculative 
interpretation.  
4.5.5 Limitations and Future Directions 
It is important to evaluate this study in light of its limitations. The aim of this- 
akin to all qualitative studies- was not to produce results that are generalisable 
to the population, but to describe the experience of this particular sample. 
There is a need for further qualitative and quantitative studies to explore the 
themes highlighted here, for us to make generalisable statements about the 
experience of CBT-I and important factors that influence adherence. One 
limitation of this study is it sampled participants from both the UK and Australia. 
Samples in qualitative studies are generally comprised of a homogenous group. 
Recruiting participants from only one cultural background might have generated 
different qualitative data; on the other hand, themes emerged in this qualitative 
investigation, are reflective of experiences across both settings, relatively 
uninhibited by effects of different cultures and health systems. Only individuals 
who had completed the same manualised form of CBT-I were included, which 
minimised effects of using a culturally heterogeneous group. There were no 
apparent differences in themes emerging across these two sites.  
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One further limitation is the largely female, well-educated sample of 
individuals with primary insomnia, selected from previous research studies. 
Although this is quite representative of research samples within the insomnia 
literature, it will be imperative to investigate experiences of a real-world 
clinical sample that in addition to insomnia, might be dealing with a co-morbid 
sleep disorder like sleep apnoea, or other physical (e.g. pain) or psychological 
conditions (depression)- exclusion criteria in the present study. Some of these 
conditions have been associated with decreased adherence to CBT-I(215) and 
qualitative investigations in these subgroups might provide further insight into 
adherence to CBT-I. Furthermore, the experiences of a largely motivated, health 
literate research participant might differ gravely from the journey of someone 
who is presenting to their GP in their first treatment-seeking attempt. 
Interestingly though, even this motivated group of research participants, who 
largely responded to treatment, found CBT-I challenging.  
This qualitative investigation relied largely on the recall of experiences in 
these individuals. All participants were interviewed between 1-4 months after 
completing the treatment protocol, thus recall effects might have biased 
retrospective accounts of the experience of implementing components. 
Additionally, the retrospective nature of the study resulted in the exclusion of 
treatment drop-outs, this might have led to the omission of important 
experiences related to the early phases of CBT-I unique to this group.  Future 
studies might want to follow individuals through the entire CBT-I process to 
obtain a more detailed account of individuals experience in real time. 
Techniques such as audio diaries, with which individuals can record their 
experiences on a daily basis, has successfully been used in a previous study 
involving insomnia population(139) and might provide a valuable resource for 
this endeavour.  
Lastly, for reasons of feasibility, the interviewer in this study was also the 
therapist or shadowed the therapist in all CBT-I groups. This might have led to 
the interviews being biased by demand characteristics. However, there was no 
evidence of this bias in the results as presented. . 
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4.6 Summary  
This present study is the first to extensively explore the patient’s experience of 
Cognitive Behavioural Therapy for insomnia. This has provided us with valuable 
information about how, within this group of patients, adherence is a very 
dynamic process: patients continuously evaluated CBT-I and the components. 
This started as early as at treatment initiation, and continued throughout 
treatment. Patients engage in various thought processes in determining which 
treatment components to implement and do not simply comply. Additionally, 
this study provides further evidence that the implementation of some of the 
behavioural components is far from simple and this needs to be considered in 
future studies trying to understanding the treatment experience and important 
factors that influence behavioural adherence to CBT-I. 
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Chapter 5- The effect of continuous positive airway 
pressure usage on sleepiness in obstructive sleep 
apnoea: real effects or expectation of benefit? 
5.1 Abstract  
Rationale: Placebo responses are complex psychobiological phenomena and 
often involve patient expectation of benefit. With continuous positive airway 
pressure (CPAP) treatment of obstructive sleep apnoea, greater hours of CPAP 
use are associated with reduced sleepiness. However, these open label studies 
have not controlled for patient expectation of benefit derived from their 
knowledge of their hours of device use. Objectives: To investigate the relative 
effectiveness of the use of real or placebo CPAP on daytime sleepiness. 
Methods:  Patient-level meta-analysis combining data on sleepiness measured by 
the Epworth Sleepiness Scale from three randomised placebo-controlled 
crossover trials (RCTs). Mixed model analysis of variance was used to quantify 
the effects of real vs. placebo-device treatment, usage, their interaction, and 
regression to the mean. Measurements and Main Results: Duration of real and 
placebo-CPAP use was correlated within patients (r=0.53, p<0.001). High use of 
real CPAP reduced sleepiness more than high use of placebo (difference 3.0 
points; 1.7 to 4.3, p<0.0001) and more than low use of real CPAP (difference 
3.3; 1.9 to 4.7, p<0.0001). High use of placebo was superior to low use of 
placebo (difference 1.5; 0.1 to 2.8, p=0.03). Twenty-nine percent of the effect 
of high usage of CPAP (4.2 points; 3.3, 5.1) was explained by the expectation of 
benefit effect associated with high use of placebo (1.2; 0.2, 2.3).Conclusions:  A 
clinically significant proportion of the effectiveness of high CPAP use in reducing 
sleepiness is probably caused by patient expectation of benefit. 
 
5.2 Introduction 
Poor compliance with medical treatments is a major barrier to clinical 
effectiveness for many chronic conditions.(483, 484)  Recent studies suggest that 
placebo effects may involve crucial psychobiological factors influencing 
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treatment effectiveness and clinical practice.(485) Placebo treatments are not 
necessarily inert; one principal component is the expectation of future benefit 
responses following administration of a placebo.(485, 486) Patients who accept 
treatment are expecting that it will help them. These observations have 
primarily been made in a range of pharmaceutical and other therapeutic 
interventions. However, the availability of real and placebo continuous positive 
airway pressure (CPAP) for obstructive sleep apnoea (OSA) provides an almost 
unique opportunity to examine the relationships between treatment usage, 
expectation of benefit, relief of symptoms and the placebo effect including 
expectation of benefit.  
Unblinded cohort studies have shown a dose-response relationship where 
greater usage of CPAP was associated with better symptomatic outcomes for 
patients.(57-59, 487) However, because those were open-label studies patients 
were largely aware of how many hours a night they had been using CPAP. 
Therefore it is possible that some of the symptomatic benefit associated with 
greater use might have arisen from an expectation of benefit.  
Randomised placebo CPAP-controlled crossover trials provide a method to 
determine whether the symptomatic response to higher use of CPAP is related to 
a real effect or expectation of benefit from their high use. Given the complexity 
of human psychobiology, cross-over trials offer a better comparison as patients 
act very well as their own controls, because usage of real and placebo CPAP 
seems to be highly correlated.(488)  Placebo control via an almost identical 
sham device also helps to quantify the size of the expectation of benefit effect 
associated with using CPAP therapy. We combined 3 crossover trials(488-490) in 
an individual patient-level meta-analysis in order to quantify the relative effects 
of real and placebo CPAP compliance on sleepiness measured using the Epworth 
Sleepiness Scale. 
 
5.3 Methods 
5.3.1 Participants 
We combined data from the 91 patients who completed one of the crossover 
trials. Detailed descriptions of the study designs, patient’s characteristics, and 
primary outcome findings of both studies can be found in the original 
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publications.(488-490) Table 11 briefly describes the patients included in this 
analysis from these studies.  
Table 11: Patient Characteristics across the three trials 
 Trial 1 
(Marshall et al 2005) 
Trial 2 
(Coughlin et al 2006) 
Trial 3 
(Phillips et al 2011) 
Gender 
(Female) 
7/29 (24% female) 0/34 (0% female) 3/28 (11% female) 
Age (Median 
Years) 
50.6 (range 25-67) 49.0 (SD 8.3) 48.8 (range 25-72) 
Apnoea 
Hypopnoea 
Index 
21.6 (SD 7.5) 39.7 (SD 13.8) 38.68 (SD 24.04) 
Body Mass 
Index (kg/m2) 
31.5 (SD 6.0) 36.1 (SD 7.6) 31.7 (SD 4.1) 
Baseline 
Epworth Score 
12.5 (SD 4.1) 13.8 (SD 4.9) 10.3 (SD 4.8) 
Prescribed 
CPAP Pressure 
(cmH2O) 
7 (range 5-10) 10.0 (IQR 8-10) 11 (range 7-18.5) 
  
5.3.2 Study Design and Procedure 
Trials were combined as they had congruent study designs with all patients 
receiving in random order both standard individually titrated real CPAP and 
placebo CPAP (sometimes called ‘sham CPAP’ and hereafter simply described 
here as placebo). The placebo was identical, in all trials to the CPAP machine in 
terms of noise, mask temperature, mask humidity, and airflow through the 
exhalation port. To create a sub-therapeutic treatment, the placebo machine 
was set to 8 cm H2O, yet delivered <1.0 cm H2O pressure. The datasets were 
merged and we analysed the effects of real and placebo treatment and the 
effects of greater use of both these devices on sleepiness as measured by the 
Epworth Sleepiness Scale (ESS).(5) The ESS was the only outcome in common 
among the trials. 
 
5.3.3 Data Preparation and Statistical Analyses 
Statistical analyses were performed using SAS (v. 9.2; SAS Institute, Inc., Cary, 
North Carolina, USA) and SPSS for Windows (v. 17; SPSS, Inc., Chicago, Illinois, 
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USA). Continuous variables were presented as mean ± standard deviation (SD) or 
95% confidence intervals (CI) and p-values of <0.05 were considered statistically 
significant. We considered the interaction of compliance-by-treatment to be 
significant when p<0.1 because this was the primary screening method for our 
hypothesis– the specific group-by-group analyses arising from such an interaction 
were then judged by the p<0.05 criteria.  
We used mixed model analyses of variance (using variance components 
structure of covariance) to quantify the effects of usage (High vs. Low cut at 4 
hours/night) and the interaction between treatment and compliance. These 
models also included the effects of treatment (CPAP or placebo) and regression 
to the mean (the baseline severity in ESS). A priori we specifically tested the 
following comparisons: 1, the superiority of high use of CPAP to high placebo 
use: 2, the superiority of high CPAP use to low CPAP use and 3, the superiority of 
high placebo use to low placebo use (all using p<0.05 as the critical threshold 
level). Inter-trial and inter-individual variability were classified as random 
effects; all previous variables (treatment, compliance, regression to the mean, 
and the interaction between treatment and compliance) were fixed effects. We 
also estimated the proportion of improvement associated with high use in 
clinical practice that is probably attributable to expectation of benefit by 
dividing the effect associated with high placebo use by the effect associated 
with high CPAP use. Effect sizes were calculated by dividing mean effects by the 
standard deviation of the Epworth Sleepiness Scale, which is very often around 4 
points in both clinical and population samples. Small effect sizes are between 
0.20 and 0.50, medium 0.50 and 0.80, and large effect sizes .0.80.(491) 
These main analyses were conducted using compliance as a dichotomous 
variable based on compliance cut at the standard 4 hours/night; in a second 
model we investigated the relationship between outcome and compliance as a 
continuous variable using the mixed model analysis described above. In 
sensitivity analyses we tested different dichotomous cut-points for use and 
whether the order the treatment was given may have influenced our final 
conclusions by using an order and an order by treatment interaction in our final 
model. We also examined the correlation between CPAP and placebo use. 
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5.4 Results 
5.4.1 Correlation between placebo and real CPAP compliance: 
Real and placebo device usage was correlated (r2 = 0.53, p<0.001; see Figure 8). 
Individuals who used placebo more than 4hrs/ night were also very likely to be 
high CPAP users with only 3 of those patients having compliance below 4 hours 
when on CPAP (see Figure 8).  
 
 
Figure 8: Correlation between real and placebo use 
Patient use of treatment is stable between a real CPAP device and a placebo version of the 
same device (r2=0.53, p<0.001).  X and Y axes are in units of average hours per night of use. 
 
5.4.2 Epworth Sleepiness Scale (ESS) 
High use was associated with superior improvement in the ESS across both 
treatments (mean difference =2.2 points; 95% CI=1.0 to 3.3, p<0.001; effect size 
(ES) based on a SD of 4 points =0.55). Real CPAP improved sleepiness more than 
placebo irrespective of usage (2.1; 1.1 to 3.0, p<0.001; ES=0.53). The 
interaction between hours of usage and type of treatment (real or placebo) was 
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significant (p=0.056), using a significance threshold level of 0.1 for investigating 
the specific comparisons of interest. The effect on ESS of high use of real CPAP 
was greater than higher usage of placebo CPAP (difference=3.0 points; 1.7 to 
4.3, p<0.001; ES=0.75) and low use of CPAP (3.3; 1.9 to 4.7, p<0.0001; ES=0.83). 
Additionally, high placebo use was better than low placebo use (1.3; 0.1 to 2.8, 
p=0.03; ES=0.33). These effects were not influenced by order or order by 
treatment interaction. These results are presented in Table 12 and Figure 9.  
 
Table 12: Effects of high and low CPAP and placebo use on Sleepiness 
 
 
High vs.  
Low Use 
[Mean (95%CI), 
p-value]  
CPAP vs. 
Placebo 
 [Mean 
(95%CI), 
 p-value]  
Interaction  
Treat*use 
[p-value]  
High CPAP vs. 
High Placebo  
[Mean (95%CI),  
p-value]  
High Placebo vs. 
Low Placebo 
[Mean (95%CI),  
p-value]  
ESS  
(24 points) 
2.2 (1.0-3.3), 
p<0.001  
2.1 (1.1-
3.0), 
p<0.001  
p=0.056  3.0 (1.7-4.3), p<0.001 
1.4 (0.1-2.8), 
p=0.03 
Data are presented as Mean Points of improvement from baseline, (95% CI), p-value. This 
table presents the effects of compliance, treatment and the interaction between treatment 
and compliance. The compliance effect tests whether high use is better than low use. The 
treatment effect tests whether CPAP was better than placebo and the interaction tests 
whether the effect of high use differs between CPAP and placebo. CPAP=Continuous 
Positive Airway Pressure; ESS=Epworth Sleepiness Scale; CI=Confidence Intervals 
 
 
High use of CPAP was associated with a 4.2 point reduction in Epworth 
(95% CI = 3.3, 5.1 points, p<0.0001) and high use of placebo was associated with 
a 1.2 point reduction in Epworth (0.2, 2.3 points, p=0.03). As such, we estimate 
about 29% of the improvement in Epworth scores associated with high CPAP 
compliance seen in clinical practice is probably attributable to expectation of 
benefit in patients who are high users of CPAP (i.e. 1.2 points on high use 
placebo divided by 4.2 points on high use CPAP). 
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Figure 9: Effects of different treatment type and use on improvements 
measured by the Epworth Sleepiness Scale 
(y axis is in points of improvement from baseline in the 24 point Epworth Sleepiness 
Scale). Diamonds indicate the estimated mean effects (bars the 95% CI). High use (>4 
hrs/night) of either machine confers greater benefits but the symptomatic benefits accruing 
to high users are greater when using real CPAP than placebo CPAP. CPAP=Continuous 
Positive Airway Pressure. 
 
We also investigated usage as a continuous linear variable. In these 
models, both treatment and usage were significantly related to Epworth 
improvement in the expected direction (mean estimate=2.1 points (95% CI 1.2, 
2.9) and 0.6 points per hour, 95% CI 0.3 0.9, respectively, both p<0.0001). In 
contrast to the findings in the dichotomous model, there was no significant 
interaction between treatment type and usage duration (p=0.54).  In other 
words, the effect of duration of use, measured as a continuous linear variable, 
on ESS did not significantly differ between CPAP and placebo devices.  
In sensitivity analyses we analysed the cut points for high and low use 
using 5, 6.5 and 7.5 hours/night. The combination of these analyses plus plotting 
raw data and fitting curves to it indicated the likely existence of no additional 
benefit beyond about 5.5 hours, but with significant uncertainty about the exact 
location of the asymptote (See Appendix 7). 
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5.5 Discussion 
Using data from 3 randomised placebo-CPAP controlled crossover trials, we 
estimate that 29% of the reduction in sleepiness seen in patients with OSA who 
use CPAP over 4 hours a night is probably caused by an expectation of benefit. 
The expectation of benefit is one of the components of the placebo effect and is 
caused by patients inferring benefit from treatments they choose to use. 
Conversely, patients who do not use treatments do not expect to feel better. 
Because clinical interaction is such a complex psychobiological phenomena, 
these effects are best quantified in randomised cross-over trials where patients 
act as their own controls and tend to use the active treatment (CPAP) about as 
much as they use the placebo. 
Previous open label cohort studies(57-59) and parallel design clinical 
trials(492, 493) have shown that there is a dose-dependent association between 
greater use of CPAP and better patients outcomes.(370) Instead, we analysed 
three placebo-CPAP controlled randomised crossover trials in order to separate 
real treatment use effects to symptom improvement related to this placebo-like 
expectation of benefit within each patient (see Figure 9 and Table 12). As 
expected real CPAP had a beneficial effect over placebo as did high use of either 
device compared to low use. Fortunately, not all of the benefits of high use 
were driven by expectation of benefit as patients using CPAP more than 4 hours 
a night had greater reduction in sleepiness than patients using placebo more 
than 4 hours/night. We infer expectation of benefit effects because patients 
using placebo for more than 4 hours a night exhibited greater reduction in 
sleepiness than patients who used placebo less than 4 hours a night, despite this 
device having no physiological effect on OSA. These high users of placebo were 
also 94% likely to be high users of CPAP (46 out of 49, see Figure 8) indicating 
the existence of a compliant patient phenotype who will use the device 
regardless of its ability to control OSA. Conversely, there were also patients who 
used placebo CPAP less than normal CPAP (see the lower right quadrant of Figure 
8). This may be further evidence that patients who feel benefit from CPAP 
treatment tend to use it more.(59) 
The main effect we report here cannot be observed in clinical practice 
because patients in routine clinical care are not given placebo CPAP therapy. 
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Additionally, placebo devices are not commonly employed in cross-over trials 
due to a fear of unblinding,(494) so the number of clinical trials available for 
this sort of analysis is limited.  
The uncertainty about whether the dose effect is linear, stepped or 
asymptotic led us to treat compliance as both a dichotomous (the widely used 
4hrs/night threshold value) and a continuous hours of use variable.(57) When 
compliance is treated as a continuous linear variable in these same models both 
treatment with CPAP and high usage confer significant benefits. However, the 
non-significant interaction term in that linear model indicates that the use 
effects of CPAP and placebo do not differ in a way that is consistent with a 
linear-dose response. In sensitivity analyses we dichotomised hours-of-use data 
at different cut-points (5, 6.5 and 7.5 hours) and additionally visually plotted 
the raw data (see supplemental figures). These raised questions about the 
linearity of the relationship between compliance and symptomatic improvement. 
Thus we can also confirm previous reports that after controlling for placebo 
effects the association between compliance and better patient outcome is 
weaker than expected(59) and may not be linear(57) as benefit ceases to accrue 
at an asymptote of about 5.5-6.5 hours per night. 
Figure 8 shows patients using either the real or placebo device in similar 
amounts. Whether this ‘high-use’ trait might generalise between CPAP and 
pharmacological compliance is the subject of conflicting reports.(438-440) 
Additionally, the possibility of modifying psychological characteristics of non-
compliance with CPAP treatment should continue to be the subject of clinical 
trials (e.g. (351) and ACTRN:12606000065594). The characterisation of patients 
into ‘high’ and ‘low’ users is defensible because CPAP compliance is often 
bimodally distributed (see Figure 8 and the relative paucity of data points 
centred around 4 hours compared to 0-2 hours and 6 hours). However this 
classification may still be flawed as recent investigations of both 
pharmacological treatment of epilepsy and CPAP indicate there may be more 
than 2 compliance phenotypes.(205, 495) 
The use of crossover trials with placebo control offers only a partial 
solution to the problem that patients are aware of (unblinded) to their ‘dose’ of 
treatment. A trial where patients are randomised to 2, 4, 6, or 8 hours/night of 
effective treatment might offer superior data to what we are currently able to 
present here. Our approach of using each patient with their highly 
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correlated(488) use of CPAP and placebo to act as their own control offers an 
advance on previous analyses. However, such highly selected and motivated 
patients may not be generalisable to normal clinical populations. Data from both 
clinical trials and unselected cohorts provide useful clinically applicable 
information when employed together. We were also limited by the availability of 
only one subjective outcome variable and by the limited numbers of patients 
(n=91) available from these technically challenging clinical trials. Two of the 
trials did not have 2nd arm baseline measurements(489, 490) and one did not 
have a washout period(490) which might have affected our results. The 
Australian-based study10 also had lower baseline ESS scores than would be 
expected for a symptomatic clinical sample and this may have made detecting 
treatment and use differences harder because of a possible floor effect. One of 
the implications of this is that in clinical practice with patients who have very 
high ESS scores the dose-effect may be stronger than we report here and the 
dose-benefit may extend well beyond the asymptote we may have detected. We 
may have had more accurate treatment estimates if we had used some measure 
of percentage of sleep with CPAP rather than the more crude hours per night- 
however we lacked a good objective measure of sleep duration. Nevertheless, 
these rare data provide opportunity for understanding aspects of CPAP 
compliance that have not yet previously been investigated.  
Longstanding efforts to improve compliance to CPAP by employing 
technological solutions aimed at reducing pressure may be questionable as 
Figure 8 also suggests compliance has little relationship to pressure. This also 
explains why the two most recent meta-analyses of pressure modification 
approaches to improving PAP compliance show little or no compliance benefit 
and no symptomatic benefit.(177, 245) In this context it is not surprising that 
the largest effect of any treatment intended to increase use of CPAP therapy 
tested in a randomised trial has been cognitive behavioural therapy.(351)  
5.6 Summary 
This patient-level meta-analysis of 3 randomised placebo-CPAP-controlled 
crossover trials for sleep apnoea patients confirms that high use of CPAP 
provides greater sleepiness reduction benefits than high use of a placebo device. 
Interventions that improve CPAP use from low levels (i.e. below 4 hours/night) 
are likely to cause real benefits for patients. 
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Chapter 6- The Stage of Change Scale for Insomnia 
(SOCSI) - A new scale to monitor stage of change 
during sleep restriction therapy for insomnia 
‘Patterns)of)behavio[u]r)are)not)usually)created,)modified,)or)stopped)in)a)single)moment)in)time)
or)with)a)single)flick)of)a)switch.’))
) DiClemente)2006(496,)p.25)))
6.1 Abstract 
A number of patient reported-questionnaires based on the Transtheoretical 
Stage of Change (SOC) Model have been developed to identify adherence issues 
in other sleep populations (e.g. CPAP users). However rigorous psychometric 
testing of these questionnaires is usually lacking. Additionally, no such scale 
exists to predict adherence to behavioural treatments for insomnia.  This study 
set out to develop a measure to assess individuals’ stage of change during a 
sleep restriction programme for their insomnia. The stage of change scale 
specific for insomnia (SOCSI) using cognitive interviewing techniques (Study 1) 
was firstly developed and face validity assessed. Interview responses from 
individuals who had completed CBT-I treatment (n=13) indicated good face and 
content validity; participants indicated no missing responses. Some amendments 
to the scale were recommended by participants and adopted in the final version 
of the scale. Further psychometric evaluation of the scale considered the 
validity in predicting adherence to a sleep restriction programme (Study 2). The 
SOCSI was administered to twenty-seven individuals with primary insomnia who 
completed the 4-week intervention. Adherence was measured using a self-report 
questionnaire, sleep diaries and actiwatches, however only data from the latter 
were correlated with significant sleep-related improvements. Stage of Change 
was skewed with the majority scoring in the action/maintenance stage at all 
points throughout the treatment and 3-month follow-up. Stage of Change status 
and self-efficacy ratings were highly reliable when re-assessed after a 10-minute 
distractor task. Those who scored in the action stage had better rates of 
concurrent adherence, motivation and self-efficacy (concurrent validity) and 
subsequent adherence throughout the 4-week intervention (predictive validity) 
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period than those in the pre-action stages (contemplation/preparation). Sleep 
improvements and impaired energy/motivation were most often reported as the 
pros and cons for change respectively although the majority indicated no 
disadvantages with the therapy. Behavioural strategies (e.g. self-liberation) 
were most often reported to help implement change compared to cognitive 
strategies (consciousness raising). Although the results need to be interpreted in 
light of the study limitations, documenting stage of change at early periods 
during therapy seems to provide useful information about adherence using the 
reliable and valid SOCSI.  
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6.2 Introduction 
There has been a considerable surge of adherence research in the last 
decade(497), yet some have cautioned against behaviour change studies that are 
not based on theoretical models.(411, 498, 499) Based on the researcher’s 
intuition or implicit theory, these studies’ results are often not reproducible, 
furthermore evaluating efficacy of interventions based e.g. exclusively on 
behaviour rather than theory, is problematic.(498) There is mounting evidence 
in other health domains that corroborate these claims: for example, two recent 
reviews indicated the effect of behaviour change was increased when 
interventions were based on theoretical concepts.(381, 500) Although adherence 
to sleep therapies is still in its infancy, there is emerging evidence to suggest 
the superiority of theory based studies and interventions in this field. A handful 
of studies in insomnia and sleep apnoea research have successfully examined the 
predictability of variables from social cognitive and stage based models.  
 
6.2.1 The use of behaviour change theories in sleep research  
A number of behaviour change theories have been examined in sleep research to 
date. Adherence to CPAP and CBT-I has been predicted by components of 
Wallston’s social learning theory adapted for health,(304) and Bandura’s social 
cognitive theory(231, 237, 286, 287, 296)  
Two theoretical models that have been quite thoroughly explored within 
the CPAP and CBT-I adherence literature are the health belief model (HBM) and 
the transtheoretical model (TTM)/ stage of change model.  
 
6.2.1.1 The Health Belief Model (HBM) 
The HBM, developed in late 60s/early 70s(385, 434, 501), describes 6 distinct 
constructs as important in predicting implementation of new behaviour. The 
likelihood of the individual’s behaviour is partly influenced by illness 
representations, such as the susceptibility to and severity of an illness and the 
evaluation of the perceived benefits of and barriers to change. Cues to action, 
which might be internal (e.g. the symptoms) or external (e.g. advice of health 
practitioners), might also lead to behaviour change. Two factors that have 
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recently been added to the model are health motivation and perceived control 
of the situation. This model has been utilised for predicting adherence to both 
CPAP(301, 308) and CBT-I(208) 
Sage et al. 2001(308) and Olsen 2008(301) examined HBM variables 
adherences post and pre CPAP initiation respectively as outlined in chapter 1. 
Perceived benefits, when assessed before and after CPAP titration, were 
predictive of later CPAP use. Barriers and cues to action were only measured in 
Sage et al.’s study but only the former was an independent predictor of 
adherence. Self-efficacy and severity were not independent predictors in either 
study and susceptibility was in Olsen et al.’s, but not in Sage et al.’s study a 
predictor of later use.  
Vincent, Lewycky and Finnegan applied this model to insomnia and CBT-I 
adherence.(208) They explored variables of the HBM and their predictability of 
adherence to stimulus control and sleep restriction (SC/SRT) components of 
CBT-I. In a sample of 53 individuals with insomnia undergoing a 6-week CBT-I 
program, the authors reported that fewer barriers to implementation of SC/SRT 
and less pre-treatment sleepiness were associated with increased subjective 
adherence based on sleep diary data. Again, lack of validated measures, 
resulted in not all constructs of the HBM being investigated.  Furthermore, 
assessment of adherence to the treatment program was limited to self-report 
measures and sleep diary; both subject to bias by demand characteristics, if 
participants were aware that adherence was the main research focus.    
 
6.2.1.2 The Transtheoretical Model (TTM) 
With the call for increased attention towards psychological variables(369 see 
also chapter 2) and the shift in conceptualising adherence as a dynamic rather 
than dichotomous principle,(205, 495) the CPAP adherence field has welcomed 
the use of the transtheoretical model (TTM). Initially developed to understand 
behaviour change in smokers,(502-504), the application of this dynamic stage-
based model is expanding to the contexts of other behaviour- particularly the 
cessation of unhealthy behaviour, such as substance use,(505) or unsafe sexual 
behaviours,(506) but also the implementation of healthy behaviour like 
exercise,(507, 508), mammography screening(509) or medication 
adherence.(510) With the intention of developing an integrative framework, 
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Prochaska and DiClemente identified concepts involved in behaviour change that 
were common to psychotherapies at the time. They suggested that individuals 
pass through five stages of change: pre-contemplation (no awareness of the 
need to change), contemplation (thinking about change), preparation (planning 
change), action (implementation of change) and finally maintenance (long-term 
implementation of change). These stages are associated with different profiles 
on the measures of decisional balance (pros vs. cons for change), processes of 
change (cognitive vs. behavioural strategies that are employed to move through 
the earlier and later stages of change respectively), and self-
efficacy/temptation. In the early stages of change, self-efficacy and temptation 
are low and high respectively. Transition to higher stages witness as increase in 
self-efficacy and decrease of temptation. The transtheoretical model is 
described in greater detail in Appendix 8.   
A number of studies have applied the transtheoretical model to the sleep 
field. One particular research group has scrutinized the utility of the TTM model 
in predicting CPAP use in both naïve patients in the short(286) and long 
term(237) and experienced CPAP users.(287) The first study in 2002(286) 
examined behaviour change variables prior to CPAP titration (baseline), 1 week 
and 1 month, and found that all but the baseline TTM variables were predictive 
of post treatment CPAP use. The same working group replicated these results 
with long-term CPAP use of 6 months.(237) Again, baseline measures explained 
little of the variance in subsequent adherence. In 2006, Stepnowsky and 
colleagues conducted a retrospective study examining TTM variables in 
experienced CPAP users (mean 2 years).(287) Despite measuring all concepts of 
the TTM (stage of change, decisional balance and processes of change), the 
authors seem to consider only the process of change and decisional balance 
index in their analyses, providing no information about stage of change and how 
this relates to CPAP adherence. This limitation makes it difficult to evaluate the 
use of the transtheoretical model in predicting CPAP use.  
In the insomnia field, two studies to date have investigated the use of the 
TTM.(223, 511) One well-designed study explored the relationship between TTM 
variables and hypnotic discontinuation, providing insight into the usefulness of 
this model in understanding hypnotic tapering in individuals with insomnia.(511) 
As part of a larger randomised control trial (assessing hypnotic tapering 
with/without self-help non-pharmacological treatment for insomnia), the 
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authors evaluated the stages of change using an algorithm [see Appendix 8 for 
details on measurements], readiness to change with the University of Rhode 
Island Change Assessment,(512) decisional balance and self-efficacy in 53 
participants over a 6-month study period.  Baseline measures of all TTM 
variables (self-efficacy, readiness to change, and decisional balance) were not 
predictive of taper outcome group allocation. When comparing across groups, 
self-efficacy was the only measure that was significantly different between 
drug-free and non-drug free participants when measured mid-and post-
treatment. When comparing those who were able to maintain their drug free 
status at 6-months and those who relapsed in the interim period between post-
treatment and follow-up, self-efficacy and readiness to change were increased 
in the former group. At months 1, 3, 6, readiness to change was higher in those 
who did not relapse, as was self-efficacy at months 6. Of the 50 individuals 
analysed, 1 participant scored in the pre-contemplation, 17 in the 
contemplation, 32 in the preparation stage. Contrary to their hypothesis, there 
was no relationship between stage of change and group allocation. As the 
authors noted, this might be a result of both methodological and conceptual 
issues. The adapted measurements for stage allocation and readiness to change 
had not previously been validated in this population. Additionally, the 
transtheoretical model has been well described for ‘problem’ behaviours such as 
substance abuse, however hypnotics might not have the same negative 
connotation and the participant might have interpreted the term ‘problem’ to 
be the ‘sleep problem’.  
One other study has explored the use of the TTM in explaining adherence 
and attrition rates to an online CBT-I program.(223) Using an adapted version of 
a pain stage of change questionnaire, readiness to change was measured in 47 
individuals with chronic insomnia to predict treatment attrition and adherence 
(defined as the percentage of participants using homework for at least 4 nights 
of the week). There was no significant correlation between readiness to change 
and attrition; the contemplation subscale was positively related to adherence to 
exercise recommendation and tapering of caffeinated beverages: both sleep 
hygiene components. Contrary to predictions, no other relationships were 
reported.  The authors failed to mention an important conceptual issue with the 
readiness to change items used in their scale that might explain these negative 
results. It is important when considering readiness to change to acknowledge the 
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difference between motivation for change (or improvement) and motivation to 
participate in a particular treatment.(513) The following example from the 
contemplation subscale used by Herbert and colleagues, is more reflective of 
the former:  ‘I have recently figured out that it's up to me to deal better with 
my insomnia’. Whereas a hypothetical item, such as ‘I don't think making 
changes to my bedtime routine will lead to any improvements in my sleep’, 
might highlight the individual’s readiness (or lack of) to engage in the cognitive-
behavioural intervention and reflect a stronger relationship with adherence. In 
addition, attrition rates and adherence were only related to a baseline measure 
of readiness to change. As explained above, measuring TTM variables prior to 
implementation of treatment, as seen in the CPAP trials, might be futile, if 
individuals have not been provided with ample opportunity to formulate beliefs 
and attitudes that might moderate their motivation. Lastly, of all 
transtheoretical model variables, this study was limited only to assessing 
readiness to change. Stage of change, decisional balance, process of change and 
self-efficacy are important constructs of the transtheoretical model that need to 
be assessed individually alongside important relationships between each 
constructs, to evaluate fully the transtheoretical model in predicting adherence 
to CBT-I.   
In summary, there have been a number of studies that have perused 
theoretical health behaviour models to shed light on adherence to CPAP and 
CBT-I. However, several limitations can be identified with the above outlined 
studies:  
 
1. Studies have fallen short of examining the overall impact of these 
theoretical models. Future studies should take care to include all 
components of the relevant theoretical model.  
2. Insomnia or Sleep apnoea-specific scales that have been developed for 
this purpose have failed to include rigorous psychometric evaluation, 
especially patient-feedback, despite recent guidelines for patient 
reported outcomes to include assessment of patient understanding and 
readability of the questionnaire.  (e.g. PROMISE(514)and FDA 
guidelines(515) 
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3. Adherence measures for CBT-I rely solely on self-reported questionnaires 
or sleep diaries (see also chapter 1). An objective measure of adherence 
to the behavioural components to CBT-I is required.  
 
Although the health belief model and the transtheoretical model have 
most likely received equal amounts of attention in both health psychology in 
general and sleep research specifically, the use of the latter model might be 
more applicable for adherence research because of the natural transition to 
stage matched interventions for improving adherence.(500) Additionally, a more 
dynamic model, such as the TTM, might be more valid for understanding 
adherence to treatments for sleep disorders, when considering the 
characteristics of sleep and its disorders, such as insomnia.  
Firstly, sleep is a dynamic process in itself. Some individuals with 
insomnia will present with extensive night-to-night variability in both the 
quantity and quality of sleep compared to good sleepers.(516, 517) Although this 
variability is targeted and effectively reduced during CBT-I,(233, 460, 518) any 
residual variability might influence participants’ perceptions of treatment 
effectiveness. This might impact further on their motivation/readiness to adhere 
to treatment components. A model- such as the TTM- that accounts for these 
potential dynamic fluctuations might have greater potential in explaining 
variability in adherence.  
A second important characteristic of the insomnia disorder is 
dysfunctional beliefs and attitudes about sleep (DBAS).(519) A strong 
endorsement of beliefs such as ‘poor sleep is a result of a chemical imbalance’ 
might be associated with reduced willingness to embark on non-pharmacological 
treatment options such as CBT-I. In this instance individuals might be less likely 
to recognise the problem as a result of poor sleep habits and less motivated to 
change these using strategies such as sleep restriction or stimulus control. This 
assumption is supported by a recent, thorough investigation into these 
cognitions. Carney and Edinger identified six of the 30 DBAS scale items that 
were amenable to change after treatment for primary insomnia, but had no 
‘good sleeper/insomnia patients’ discriminative value. One possible reason for 
this paradoxical finding, as suggested by the authors, is that these beliefs are 
‘mediators of treatment change through increasing treatment adherence’.(146, 
p.452) Again, a dynamic model, that accounts for some individuals not being 
Chapter 6 The Stage of Change Scale for Insomnia  202 
 
ready for change- potentially because of residual dysfunctional beliefs- might be 
useful in understanding adherence to non-pharmacological treatment options for 
insomnia.  
Lastly, it is also important to highlight the subtleties of the insomnia 
specific behavioural/psychological interventions per se, when advocating the use 
of the transtheoretical model for our understanding of adherence. Behavioural 
components such as sleep restriction therapy and stimulus control require a 
patient to reduce initially their time in bed.(137, 520) This may seem 
counterintuitive to someone whose treatment goal is to increase the amount of 
total sleep time, especially when considering potential residual beliefs outlined 
above. Additionally, there is a general consensus that non-pharmacological 
treatments are ‘safe’ and are not associated with side effects like their 
pharmacological counterparts.(521) However, a recent study highlighted that 
individuals undergoing sleep restriction therapy may incur side effects, such as 
extreme sleepiness, fatigue and reduced motivation.(139) These debilitating 
experiences might negatively impact on individual’s readiness to engage with 
treatment.  
In summary, understanding adherence to non-pharmacological treatments 
for insomnia using the transtheoretical model seems logical after considering the 
characteristics of the disorder and its treatment.  
6.2.2 Aims of this chapter 
With the considerations outlined above, the goal was to develop an insomnia-
specific SOC questionnaire that can be used to predict adherence to one single 
component of CBT-I: sleep restriction. After development of any instrument, 
cognitive pre-testing is a necessity in a sample of participants representative of 
the end-users. This will ensure that the questionnaire is comprehensible, that 
the intended cognitive processes are used in answering the questions, and that 
items generate a correct response (i.e. responses are correctly mapped onto the 
response categories presented). No previous author has published cognitive 
pretesting or any form of patient pre-testing for any existing stage of change 
questionnaire development. Patient involvement in psychometric validation 
instruments is essential(515, 522) to ensure the questionnaire measures what 
the developer intended. The next step was to establish further the psychometric 
reliability and validity of this scale in individuals undergoing treatment for their 
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insomnia. With limited information on optimal measurements of adherence, 
outlined in chapter 1, this study also investigated the use of novel techniques to 
assess adherence. 
 
Thus, the following studies aim to  
• Develop and cognitively pre-test a questionnaire to measure the 
components of the TTM (STUDY 1)  
• Determine the concurrent and predictive validity the scale when applied 
to an insomnia population completing a sleep restriction program  (STUDY 
2) 
• Test further subjective and objective measures of adherence to sleep 
restriction therapy adding to the currently limited information available  
(STUDY 2) 
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6.3 Study 1: Development and Preliminary Validation of 
the Stage of Change Scale for Insomnia(SOCSI)  
6.3.1 Aim of study 1 
The aim of study 1 was to develop and then specifically investigate patient-
perceived validity of a stage of change scale specific for insomnia (SOCSI) .  
6.3.2 Methods 
6.3.2.1 Questionnaire Development 
A team, which included two clinical psychologists specialised in sleep, and one 
research psychologist experienced in questionnaire development and 
psychometric evaluation, developed the questionnaire. Throughout this process 
three desired purposes of the questionnaire were discussed and agreed upon by 
the team during regular meetings. This scale should:  
1. Assess all aspects of the transtheoretical model: stage of change, self-
efficacy, pros/cons for change and processes of change.  
2. Be generic, so it could potentially be applied to other fields of sleep 
(in addition to insomnia).   
3. Be applicable to both research and clinical settings, thus it needed to 
be short and have good face validity.  
 
The initial version of the SOCSI, was modelled on existing adherence stage 
of change questionnaires used in different clinical domains.(286, 523) Specific 
considerations for each component of the transtheoretical model were 
discussed: 
6.3.2.1.1 Specifying the change of interest 
In order to develop a scale that could be utilised as both a clinical as well as a 
research tool, open boxes were included for individuals to enter the specific 
behaviour to be changed (e.g. changes in get up and bed time). This enabled the 
scale’s generalisability to other domains of interest, both within insomnia as 
well as other health areas.  
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6.3.2.1.2 Stage of change  
As outlined above, a variety of formats have been used to assess stage of 
change, these vary from continuous scale measures, to single item (forced 
choice) format and algorithms. There was consensus that the latter options 
(single item/forced choice and algorithm) would be most appropriate, because 
of their simplicity, in accomplishing the aims outline above. Thus two versions of 
the scale were developed to accommodate both the single item and algorithm 
option. These were then subjected to further scrutiny by the participants in this 
study (see below). Figure 10 shows the difference between these two options 
(note, this is taken from the final versions post cognitive pre-testing).  
 
Figure 10: Forced Choice vs. Algorithm 
 
One consideration discussed, was the use of a baseline measure, which 
assessed stage of change before treatment had been initiated. Previous stage of 
change scales e.g.(286) have included the action and maintenance stage at 
baseline assessment. This seems inherently redundant, if an individual, who has 
not yet had a titration study or even seen the machine , is asked to make a 
forced choice between ‘I currently do not use CPAP, but I am thinking about 
starting to use CPAP in the next 2 weeks’ [contemplation] AND ‘I currently use 
CPAP nightly and I have begun doing so within the last 2 weeks’ [action]. The 
1"item'forced'choice'
STEP'2.'Please'circle'the'response'that'best'
describes'how'you'feel'about'your'ac=on'
plan'right'now?'Please'circle'ONE''op=on'
only.!
'!
1.   'I!am'not'consistently!s.cking!to!the!
ac.on!plan!and!I'am!not!considering!
doing!so!in!the!future!
2.  I!am'not'consistently!s.cking!to!the!
ac.on!plan!but!I'am!considering!
doing!so!in!the!future'!
3.  I!some.mes!s.ck!to!the!ac.on!plan,!
but!I!will!start!doing!so!consistently!
from!now!on!
4.  I!am!consistently!s.cking'to!the!
ac.on!plan!and!have!done!so!!
!'!
a)  within!the!last!4!weeks!
b)  for!longer!than!4!weeks!
'!
Algorithm'
STEP'2.'Please'follow'through'the'next'set'
of'ques=ons.!
'!
!!
Q1.!Do!you!currently!consistently!s.ck!to!the!
ac.on!plan?!
a)  Yes!(Go!to!Q2)!
b)  No!(Go!to!Q3)!
!!
!!
Q2.!Have!you!been!consistently!s.cking!to!the!
ac.on!plan…!
!!
i.  within!the!last!4!weeks!
ii.  and!for!longer!than!4!weeks!!
!!
!!
!!
Q3.!Are!you'thinking!about!consistently!
s.cking!to!the!ac.on!plan?!!
a)  Yes,!I!will!start!doing!so!from!now!on!!
b)  Yes,!I!am!considering!doing!so!in!the!
future!
c)  No,!I!am!not!considering!doing!so!in!the!
future!!
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baseline SOCSI (to be administered before treatment initiation) therefore only 
included three stages: pre-contemplation, contemplation and preparation. All 
other items remained identical.   
Lastly, decisions were made in terms of what constituted each stage in 
this population.  These decisions were based on existing descriptions of the 
stages as well as clinical experience with the insomnia population. The pre-
contemplation stage described an individual who was not willing to consistently 
adhere to components of CBT-I. Contemplation and Preparation were described 
as individuals who were not consistently adhering to the treatment, but thinking 
and planning on doing so respectively. Some scales separate these stages by 
indication of some behavioural changes in the preparation change (e.g., 286) 
however because there is little information about what optimal/partial 
constitutes adherence to CBT-I, it was decided to remain with a more 
intentional/temporal distinction (considering doing so in the future vs. will start 
doing so from now on). Lastly, action and maintenance stages were separated by 
the temporal distinction of 4-weeks, despite the original description of 6 months 
as a differentiating time between the action and maintenance stages. This time 
frame reflects, more appropriately than 6 months, the relatively immediate 
improvements in sleep reported in most clinical trials of CBT-I.  Additionally, 
some have described the implementation of a booster sessions after CBT-I within 
these short time periods, to prevent relapse(e.g., 233, 524) 
6.3.2.1.3 Self-efficacy 
Because one of the aims was to develop a short questionnaire with good face 
validity, easily administered within the clinical setting, a single 5-point item for 
self-efficacy was used. Although this concept is considered multi-
dimensional,(340) a 1-item scale has been shown to be a reliable predictor of 
adherence to CBT-I.(231) 
6.3.2.1.4 Pros/Cons for Change and Processes of Change 
As there are currently no validated measures of decisional balance and process 
of change for adherence to CBT-I, the questionnaire was designed to generate 
patient’s accounts of the pros and cons, and processes of change, using the open 
box response format. The secondary gain of this patient-generated information 
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is the further development of psychometrically more reliable measures to assess 
the decisional balance and processes of change. 
6.3.2.2 Participants 
Participants were recruited if they were currently, or had previously completed 
a CBT-I program at the Woolcock Institute for Medical Research, Sydney and 
University of Glasgow Sleep Centre, UK. Participants included a mixture of both 
clinic patients and research participants. Only individuals who were between 18-
65 years and proficient in the English language were approached for 
participation in this study. Ethical approval was obtained from the local ethical 
committees NHS Greater Glasgow and Clyde, and Sydney Local Health District 
Ethics Review (RPAH Zone).   
6.3.2.3 Cognitive Pre-testing  
Cognitive pre-testing is a methodology, which can assess patient acceptability 
and comprehension of survey questionnaires as part of face validity testing.(525) 
Two main methodologies can be used in isolation or combination, think-aloud 
and probing.  
6.3.2.3.1 Think-aloud process: 
This methodology can be administered in concurrent and retrospective fashion. 
Within this approach the individual thinks-aloud during or after filling out the 
questionnaire. Rather than just responding to an item, the individual is asked to 
verbalise all thoughts involved in the process of responding to a particular 
questionnaire item.  The interviewer takes note and records the responses with 
no or little probing.  
 
6.3.2.3.2 Probing:  
With this methodology, the interviewer uses certain probes to follow the 
responders thought processes from reading and processing a question (or 
instruction) through to formulating a response. Probes can be proactive or 
reactive. Proactive probes are generated by the interviewer and can be 
anticipated, hence prepared beforehand, whereas spontaneous probes are 
devised in reaction to novel and important responses or themes emerging during 
the interview. Both proactive and reactive probes can be standardised i.e. 
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elicited in response to certain behaviour of the interviewee (e.g. if subject 
pauses before answering, the interviewer might ask about the reason for the 
pause) or unstandardised, i.e. emergent (spontaneous responses to the 
interviewee’s unique behaviour). The current study involved a mixture of both 
procedures to cognitively pre-test this insomnia specific SOC questionnaire using 
the following procedure: 
 
6.3.2.4 Interview Procedure: 
After obtaining consent (consent forms and patient information sheets are 
similar in format and content to those in Appendices 2, 3 and 6), general 
procedures of cognitive pretesting were explained. The participant was then 
asked to fill in each questionnaire (all 3 versions: baseline, forced-choice, 
algorithm) without input from the interviewer and encouraged to mark any 
comments on the questionnaire. To minimise order effects, the presentation of 
the forced-choice and algorithm order was randomised. The interviewer then 
progressed through through each questionnaire step by step (see Appendix 9 for 
an excerpt of the interview protocol), encouraging the individual to think aloud 
as much as possible. Conditioned probes (Appendix 10) were prepared prior to 
the interview. After the semi-structured interview, the individual was 
encouraged to make any general comments regarding the questionnaires. All 
interviews were audio-recorded.  
6.3.2.5 Data analysis  
A detailed review of the audio-recorded responses to each instruction, question 
and each response option was conducted at the end of each interview. The semi-
structured interview schedule and questionnaire were changed in an iterative 
process as novel themes emerged that required further exploration with 
subsequent participants or as changes were made to the questionnaire (i.e., 
rewording or reformulation due to comprehension problems, alternative wording 
suggestions by patients, or restructuring of the instrument).(525) No individual 
change was made that was not subsequently cognitively tested by at least 2 
participants. The SOCSI was amended iteratively by two researchers of the 
development team, with the theoretical underpinnings of the model in mind, 
and interviews continued until no new issues emerged (saturation).  
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6.3.3 Results 
Saturation was reached after 13 individuals (mean age=39, mean education 
level= 16, range12-19) were interviewed. Minor changes to the questionnaire 
were confined to issues with layout, confusing wording, and the use of jargon.  
The more substantial changes made to the questionnaire were 1) the term 
used to describe the behavior change of interest and 2) the time frame and 
distinction between stages of change items 3) terms to describe pros/cons and 
processes and 4) the term to describe ‘adherence’, see Table 13 for further 
descriptions. 
Chapter 6 The Stage of Change Scale for Insomnia  210 
 
Table 13: Major Changes to SOCSI after Cognitive Pretesting 
Changes Changed from   Changed to Rational for Change 
1. Term used to describe the 
behavior change of interest 
are you sticking to ‘the above’ 
(in reference to the patient’s 
response in the open box format) 
are you sticking to the action 
plan 
The use of the word action plan was suggested by 
one participant, and preferred by subsequent 
participants over vague alternative options (e.g. 
’the above’ or ‘sleep strategy’). This term was 
better understood and generally reflected better 
the notion of actively doing something.  
2. Distinction between the 
preparation and 
contemplation stage 
‘Planning to consistently stick to 
the above in the near future 
‘(preparation) vs. ‘considering 
consistently sticking to the 
above’ (contemplation) 
‘I will start doing so from now 
on’ (preparation) vs. ‘I am 
considering doing so in the 
future’ (contemplation) 
The poor distinction between the two stages is 
often quoted as a possible reason limited 
difference in behavior change between these two 
stages. This was also reflected in the cognitive 
interviews, and individuals struggled to identify 
differences between these two items. One 
participant suggested the addition of ‘from now 
on’ and the use of the word ‘will’ rather than 
‘plan to’ would reflect a more stark contrast to 
the contemplation stage.  
3. Terms used for  
 Pros/cons Advantages/Disadvantages Advantages/Disadvantages Some participants suggested changing this to 
pros/cons, however the majority of individuals 
preferred the advantage/disadvantage distinction.  
 Processes ‘what strategies do you have to 
help you…’ 
‘what can you do to help you 
stick to the action plan’ 
This change was more comprehensible to 
individuals, and also reflected a more dynamic 
nature underlying these processes, which is in line 
with the TTM model.  
4. Terms used to describe 
adherence  
Sticking to Sticking to Although this term remained unchanged, it was 
important to determine the most acceptable term 
for adherence. All participants favoured this term 
over alternative suggestions (adherence, 
compliance, follow the treatment regime etc.)  
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One individual felt the need for a response reflecting a stage between the 
preparation and contemplation stage. However this was inconsistent with the 
transtheoretical model, and thus this was not considered in this adaptation 
phase of the questionnaire.  
Overall, interview responses indicated good face and content validity, and 
no other missing responses were indicated by individuals. Interestingly, three 
participants remarked that completing the questionnaire made them more 
aware of their motivation to use sleep strategies.  
‘I didn’t answer straight away, I had a little think about generally how 
confident I was…and thought about how I had been performing thus far, which 
is not very good, so that has made me less confident’ 
 
‘it’s good, it’s a challenging question [on the decisional balance], it’s 
always good to think about why you are doing these things that you are doing’ 
 
‘Its a great idea to have this sort of questionnaire, because it does get 
you to look into the deep dark tea time of the soul and think, well hang on it is 
all up to me’ 
 
These quotes provide preliminary evidence for the accomplishment of one of the 
aims: to develop a tool that could be used in clinical setting to monitor and 
potentially improve stage of change.  
At the end of each cognitive interview, the participants were asked which 
version they preferred. The algorithm version was the preferred questionnaire 
format (n=8/13) and this was used to further validate the SOCSI.  
6.3.4 Preliminary Conclusions  
This cognitive pretesting study presents important patient-reported validity 
data. Results suggest that the SOCSI is valid and comprehensible to individuals. 
The brevity and easy of administering the SOCSI suggests it’s potential for being 
an integral of the therapeutic process in daily clinical practice. The final 
questionnaire is presented in Appendix 11 and further validated in Study 2.  
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6.4 Study 2: The Stage of Change Scale for Insomnia 
(SOCSI)- A new scale to monitor stage of change 
during sleep restriction therapy for insomnia 
6.4.1 Aim of study 2 
Based on the results of the previous study, the final questionnaire was used with 
a group of individuals with insomnia undergoing a sleep restriction program. The 
primary aim of this study was to assess further the reliability and validity of the 
SOCSI: is the questionnaire measuring what it is set out to measure and can it 
reliably do so. In order to examine the scale in relation to these criteria the 
following study was conducted.  
 
6.4.2 Methods 
6.4.2.1 Participants  
Participants for this study were recruited at the University of Glasgow Sleep 
Centre using routine recruitment methods: posters were distributed in public 
areas (such as libraries, GP surgeries, sport and community centres). 
Additionally individuals who were on the sleep centre’s research database and 
who had consented to being contacted for research purposes were approached 
about participation in the study. Suitable individuals- as determined by 
preliminary screening interview used at the UGSC (see Appendix 12)- were 
followed up by the principal study investigator for a thorough screening 
interview as outlined elsewhere.(465) Inclusion was evaluated against 
established research diagnostic criteria for primary insomnia, see appendix 
1.(RDC 92) Individuals had to present with a difficulty falling asleep, staying 
asleep or waking too early, despite adequate sleep opportunity. The sleep 
problem, lasting for a minimum duration of 1 month, was also associated with 
difficulties in one of the core daytime functioning areas outlined in the RDC 
criteria. Further requirements for inclusion were:  
• Between 18-65 years 
• Naïve to behavioural treatments for insomnia and currently not 
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receiving any pharmacological treatment for their insomnia (those 
who had successfully tapered off their hypnotic medication for 
longer than 2 weeks  [under guidance by their general practitioner] 
were eligible for the study.)  
• Fluent in English and able to understand, participate and comply 
with the requirements of the study procedures.  
Participants who had a co morbid psychiatric or medical disorder, which 
was temporally related and/or attributed to their sleep problem(92), were 
excluded.  Additional exclusion criteria were suspected co-morbid sleep disorder 
(circadian rhythm, sleep apnoea, narcolepsy, restless legs syndrome) and an 
irregular sleep/wake pattern that would interfere with the treatment program 
(e.g. nightshift).   
6.4.2.2 Study Procedure:  
This study was approved by the NHS Greater Glasgow and Clyde ethics 
committee (consent forms and patient information sheets are similar in format 
and content to those in Appendices 2, 3 and 6). After obtaining participant 
consent, individuals were asked to complete a sleep diary for 7 days prior to 
arrival at the sleep centre, where the sleep restriction treatment was then 
delivered to groups of 2-3 people. The sleep restriction treatment protocol (see 
Appendix 13) was adapted from the original treatment description(137) and the 
University of Glasgow CBT-I protocol, described elsewhere.(207, 464, 465). Sleep 
Restriction (or perhaps more accurately bed restriction and from hereon 
referred to as such), involves curtailing the time spent in bed to the individual’s 
average sleep time obtained from the diary. A morning rising time is set 
according to personal and circadian preference. The average sleep time is 
subtracted from this rising time to establish the threshold time, when or after 
which individuals were allowed to retire to bed. Individuals are instructed to 
only be in bed between these allocated times.  Subsequent weekly titrations are 
made to the window according to the following criteria: 15 minutes increase to 
the bed window if weekly sleep efficiency ratings is more than 90% [sleep 
efficiency being the percent of time spent in bed asleep]; no change if sleep 
efficiency was 85-90% and a downward titration by 15 minutes if sleep efficiency 
was below 85%. The minimal bed window was 5 hrs.  
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The acute treatment phase in this study was 4 weeks. In the first session, 
participants were introduced to the bed restriction program, along with a brief 
introduction to sleep/wake processes and treatment rationale. Individual bed 
windows were calculated based on the 7-day baseline sleep diary and 
subsequent titrations were made each week. The first 3 sessions included 
discussion of the sleep restriction rationale, calculating sleep efficiency and 
titrating the bed window, potential trouble shooting and questionnaire 
completion. The content of the last two sessions and 3-month follow up session 
was reduced to bed window titrations and questionnaire completion. Figure 11 
and Figure 12 for an outline the study and treatment sessions respectively. 
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Figure 11: Study Outline 
 
Figure 12: Outline of treatment sessions
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only 
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Follow-Up 
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Baseline: 
7 days sleep 
diary 
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6.4.2.3 Measures:  
6.4.2.3.1 Outcome measures of sleep and mood  
The following measures were administered to assess sleep and mood outcomes:  
6.4.2.3.1.1 Sleep Diaries:  
The Sleep Diary for insomnia(465) is a daily assessment of the quality, quantity, 
and timing of sleep episodes. The sleep diary in this study was slightly adapted 
from the original to include information on napping, overall sleep quality and 
early morning awakenings (EMA) in addition to the usually reported subjective 
sleep outcome variables: Wake-after-Sleep-Onset (WASO), Sleep Onset Latency 
(SOL), Total Sleep Time (TST), Sleep Efficiency (SE), Time in Bed (TIB) and Sleep 
Quality (SQ), see Appendix 14. 
 
6.4.2.3.1.2 Insomnia Severity Index (ISI) 
The ISI(102) is a 5-item questionnaire used to assess the severity of the insomnia 
symptoms (onset, maintenance and early morning awakenings); daytime and 
quality of life impairment attributed to the sleep problem, as well as 
dissatisfaction with sleep and distress associated with insomnia. Used as both a 
clinical assessment tool and research outcome measure, the total score can be 
used to classify individuals into varying degrees of severity: No clinically 
significant insomnia (0–7); Subthreshold insomnia=  8–14; Clinical insomnia 
(moderate severity)= 15–21; Clinical insomnia (severe)= 22–28. The reliability 
(Cronbach’s coefficient alpha=.74) and validity (moderate correlations with 
sleep diary measures and established sensitivity to change with cognitive 
behaviour therapy) have been established,(526) justifying its widespread use. 
6.4.2.3.1.3  Pittsburgh Sleep Quality Index (PSQI) 
The PSQI(105)] is a measure of sleep quality and sleep disturbances over a 1-
month period. It has been used as an outcome measurement in insomnia studies 
as well as a valid tool for distinguishing good and poor sleepers. The total score 
(0-21) is made up of 7 subscales (Sleep duration, sleep disturbance, sleep 
latency, daytime dysfunction due to sleepiness, sleep efficiency, overall sleep 
quality and medication use). Higher scores indicate poorer sleep quality. In a 
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validation study Backhause et al. used the cut-off for poor sleep quality (total 
score>5) on the PSQI to correctly identify individuals primary insomnia with a 
sensitivity of 98.7% and good sleepers with a specificity of 84.4%. In the primary 
insomnia group, test-retest reliability was good, as was the internal consistency 
of the scale, with a Cronbach’s alpha of 0.85. Items of the PSQI correlated with 
the respective sleep diary entries.(527) 
6.4.2.3.1.4  Hospital Anxiety and Depression Scale (HADS) 
Originally developed by Zigmond and Snaith, the HADS was developed as a tool 
for identifying and quantifying depression and anxiety symptoms in hospital 
patients.(528) It has now become a well-used scale extending beyond the initial 
patient group. The questionnaire consists of 14 items from which the 7 anxiety 
items and 7 depression items make up the respective subscales. A review of 
validation studies indicated a mean Cronbach’s alpha of 0.83 for the anxiety 
subscale and mean internal consistency ratings of 0.82 for the depression scale. 
Across studies the scale showed good sensitivity and specificity (around 0.8) and 
strongly correlated with other validated depression and anxiety scales.(529) 
 
6.4.2.3.1.5 Dysfunctional Beliefs and Attitudes about Sleep Short Form (DBAS-16) 
The DBAS-16(530) is a measure of sleep-related dysfunctional thinking, adapted 
from the original 30-item scale.(519) Individuals are asked to indicate the level 
of agreement on sixteen statements; a strong endorsement of these statements 
is suggestive of dysfunctional beliefs and attitudes about sleep. This 16-item 
version is comprised of 4 subscales that reflect individual’s misconceptions about 
1) perceived consequences of insomnia 2) worry/helplessness about insomnia 3) 
sleep expectations and 4) medication. The scale has acceptable internal 
consistency (Cronbach’s alpha between 0.77 and 0.79) and adequate test-retest 
reliability across a 2-week interval (r= .83)(530). 
6.4.2.3.2 Stage of Change Questionnaire 
The SOCSI was administered at each observation point (baseline, week 1- 4 and 
follow-up session). The final version obtained through the cognitive pretesting 
study outlined above was used.  
6.4.2.3.3 Motivation Scale (MOT)  
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The motivation scale is a twelve-item questionnaire that represents dimensions 
occurring in the natural language to describe motivation to change.(531) The 
three-factor structure reflects dimensions of patient motivation to change: 
importance, ability, and commitment. Internal consistency of the total scale was 
good (Cronbach’s alpha=.86). The authors noted redundancy amongst the 12 
items and identified three items that best reflected each factor, however the 
internal consistency of the 3-item version was low, ranging from 0.39 to 0.69 
across different sites. The 12-item total scale was sensitive to change after 
motivational interviewing style treatment for substance misuse. One limitation 
of the scale noted by the original authors was the ceiling effect, with 43% of the 
sample choosing the highest score 10 on all 12 items.  
 
6.4.2.3.4 Potential Predictors of Adherence 
Additional baseline measures were assessed to examine their relationship with 
adherence. This included a measure of sleepiness as assessed by the Epworth 
Sleepiness Scale [ESS(5)] a measure of fatigue using the Flinders Fatigue Scale 
[FSS(532)] and the illness perception questionnaire-revised [IPQ-R(533)] The ESS 
is a measure of the likelihood of an individual falling asleep in 8 situations with a 
total score ranging from 0-24; a score of ≥ 11 is indicative of excessive daytime 
sleepiness. Test-retest reliability of this scale is good across a 5-month period 
(r=0.85) and internal consistency is excellent (Cronbach’s alpha=0.88).(534). 
Consisting only of 7 items the FFS is a brief measure to document the individuals 
daytime fatigue in different situations. Scores range from 0-32 with higher 
scores indicating greater fatigue experienced. The original paper reported 
excellent internal consistency (Cronbach’s alpha=.91) and non-significant 
correlations between the ESS and FSS support the differentiation between the 
constructs fatigue and sleepiness. The IPQ-R measures how individuals make 
sense of their condition and the treatment on the basis of 7 dimensions Timeline 
acute/chronic, Timeline cyclical, Consequences, Personal control, Treatment 
control, Illness Coherence, Emotional representations (expanded from 
Leventhal’s original five /illness perceptions.(473) The original authors reported 
good internal consistencies for each subscales ranged from (0.7-0.89) and 
adequate test-retest reliability across a 3-week (r=.5-.7) and 6 month period 
(r=.5-.8).  
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6.4.2.3.5 Adherence Measures 
As outlined in the introduction, several subjective methods have been developed 
to measure adherence to components of CBT-I. These vary from 
spousal/therapist rated or self-report questionnaires to adherence scores 
obtained from the sleep diaries. Only one study to date has described the 
objective measurement of adherence using actigraphy.(228) The present study 
reports on the use of 3 types of adherence measurement: self-report, diary and 
actigraphy.  
6.4.2.3.5.1 Self-report adherence questionnaire 
Well-validated self-report questionnaires to assess CBT-I adherence are sparse. 
One study(208) adapted the five-item Medical Outcomes Study Specific 
Adherence Scale(212) to assess adherence to sleep restriction and stimulus 
control. Three of the five items assessed individuals’ adherence to the 
treatment plan (e.g. I was unable to do what was necessary...”) however two of 
the items assessed ‘ease’ and ‘difficulty’ in adhering to the doctors 
recommendations, aspects that are not truly reflective of adherence: one could 
find something hard, but still do it. This might explain the moderate Cronbach’s 
alpha of .78 reported by the original authors. For the purpose of the present 
study, a self-report (bed restriction specific) adherence questionnaire was 
developed assessing adherence at a general level, as well as adherence to 
threshold and rising time on both weekends and weekdays. Thus 5 measures 
were obtained from this questionnaire: total adherence (sum of all items); and 
average adherence scores for the two threshold, two rise, two weekend and two 
weekday items. See Appendix 15 for the questionnaire.   
6.4.2.3.5.2 Sleep Diary 
A number of studies have made use of the sleep diary data, with some using the 
absolute values to create scores of minute deviation and/or consistency in rising 
time/threshold time(208, 213, 214); and other creating composite scores that 
depict a more conservative estimation of non-adherence.(231) A combination of 
these measurements was used in this study to depict the most appropriate 
assessment of non-adherence:  
1. Composite Score of minute deviation 
2. Rising Time Deviation Variance 
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3. Threshold Time Deviation Variance  
See Table 14 for a detailed description of each measurement.  
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Table 14: Description of Adherence Measurements 
Composite Score (CS) for 
threshold and rising times 
Previous measurements: The composite score was adapted from existing measures reported in the literature. Out of Riedel and Lichstein’s strategies for assessing 
adherence to bed restriction, one measure described absolute deviation in minutes from the agreed time in bed. Bouchard and colleagues computed a composite score based 
on 7 adherence behaviours. Two of these adherent behaviours concerned the bed restriction component of CBT-I. Points from the total composite score were subtracted, if 
the individual went to bed more than 15 minutes before the threshold time and got up more than 30 minutes after the rising time.  
Problem with these techniques: The absolute deviation in Riedel and Lichstein was not related to outcome. The composite score reported in Bouchard included assessments 
of components that might have not needed implementation with improvements in sleep (e.g. removing oneself from bed when awake for more than 30 minutes) and this 
could potentially have biased the score. These limitations were considered when deciding on how to calculate optimally the composite score in this study.  
Calculation of the composite score: The CS was computed from the absolute deviation from the rising and threshold time. Absolute deviation was considered as any time 
before the threshold and any time after the rising time.  Bed and get-up times that fell within the agreed window were scored as zero, so the absolute value represented 
true non-adherence. The score for each rising and threshold deviation time ranged from 1-3, a minute variation of 1-15 indicated an CS of 1, between 16-30 was given a 
score of 2 and anything above 30 minutes was given an CS of 3. Thus for each week an individual could obtain a score between 14-42, with higher scores indicating poorer 
adherence (larger minute deviation). Weekly and total 4-week treatment scores were obtained.  
Rising Time Deviation Variance  Previous measurements: Riedel and Lichstein not only computed the absolute deviation, but also the consistency of time in bed/rising time. A moderate association 
between this measure and outcome indicated that consistency in the bed times was also important, if not more than absolute deviation from the bed restriction window.  
Problem with these techniques: Firstly, the association between consistency and outcome has not been replicated by others(214). Secondly, this should not be considered a 
true measure of adherence, as individuals undergoing bed restriction are instructed to go do bed on or after the threshold time. A true measure of adherence would need to 
take this into account.  
Calculation of the deviation variance score: Instead of calculating a measure of time in bed consistency, it was decided to compute a measure of variance in non-
adherence. So, rather than examining whether participants were consistent in their bed/get up times, it was examined whether they were consistent in their non-adherence. 
From the absolute deviation (only times before threshold and after agreed rising time) standard deviations were created. For example, someone who got up 30, 60 and 120 
minutes after their rising time, had a rising time deviation variance of 46 minutes. Higher values indicated greater variance and thus poorer adherence. Weekly and total 4-
week treatment scores were obtained. 
Threshold Time Deviation 
Variance 
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6.4.2.3.5.3 Actigraphy 
Actigraphy wristwatches (Actiwatch, Cambridge Neurotechnology Ltd., 
Cambridge, UK) worn on the non-dominant wrist were used to measure 
participant’s “objective” adherence to their threshold and get up time. 
Individuals were asked to wear the actiwatch for the duration of the 4-week 
intervention and were asked to depress the event-marker button on the face of 
the watch to indicate each bed and get-up time. Actigraphy watches are 
equipped with a piezoelectric accelerometer and memory card to enable the 
recording and storing of physical movement data. Thus, compared to 
electroencephalogram (EEG), actigraphy does not measure sleep per se, but 
inferences are drawn from the lack of movement about the individuals’ 
sleep/wake pattern. Nevertheless, a large evidence-base is accumulating to 
provide validity of actigraphy when compared to polysomnographic 
recording.(535) Information about the intensity and duration of the activity is 
stored epoch by epoch. Rather than sleep/wake patterns, the outcome measure 
of interest in this study was time in bed, which enabled the measurement of the 
extent to which individuals adhered to their agreed bed window. A time stamp 
for threshold (time to bed) time and rising time was established by electronic 
analysis of movement. Actiwatch data were imported into Philips Respironics Inc 
Co. software and time stamps were identified by the software’s default settings 
for establishing rest periods (time before sleep and wake onset, demarking time 
in bed). Additionally, the depression of the event marker on the face of the 
watch provided information about individuals’ bed and get-up times. The 
actiwatches were set to an epoch length of 1 minute, to obtain information over 
the 4-week intervention period. This technique has previously been reported in 
the use of objective adherence to a sleep restriction therapy in good 
sleepers.(228) The computation of the composite scores and rising and threshold 
time deviation variance for the marker and movement information was identical 
to that of the sleep diary. 
Sleep Diary and Actiwatch adherence measures were only available for 
the 4 weeks treatment phase, as these measures relied on knowledge of weekly-
agreed bed window, which was not available at follow-up.  
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6.4.2.4 Data Preparation: Missing and Excluded data for sleep diaries and 
actigraphy  
In both the sleep diary and actigraphy methods, data were excluded when less 
than half of the data points were present. When this criterion was used for the 
weekly calculations (i.e. <4 of the 7 entries), 9 weeks of the total 972 weeks (4 
treatment weeks per 27 people * 3 adherence measurements * 3 adherence 
methods), equating to 0.009 % of excluded weekly entries. Four-week averages 
created over the 28 days, only one individuals actigraphy threshold variance 
data were excluded (i.e. less than 14 entries). This data were excluded casewise 
in subsequent analysis. According to the Philips Respironics report,(536) the 
automatically determined rest periods require corroboration by visual 
examination of the data. An arbitrarily defined cut off of 2hrs was used to 
determine outliers (when the software determined rest period was more than 
2hrs before or after the agreed threshold and rising time respectively). In this 
case the marker entry was imputed. This occurred for 84 entries (0.08%). If no 
marker existed the entry was deleted. (40 get up times and 52 bed times= 0.04 
and 0.05% respectively) There were no weekly data points excluded for the 
movement data.  
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6.4.2.5 Statistics Analyses 
The core focus of this study is the psychometric evaluation of the SOCSI and its 
association with adherence. Because this is explored in the context of a sleep 
restriction trial, preliminary “assumptions” needed to be met. Firstly the 
treatment intervention was expected to confer improvements in sleep and mood 
related outcome measures. Secondly, with limited consensus on optimal 
measures of adherence, the individual adherence variables and their relationship 
to outcome were examined. The four outcome measures assumed to be related 
to increased adherence were defined a priori as sleep diary obtained sleep 
efficiency (SE), wake after sleep onset (WASO), sleep onset latency (SOL) and 
insomnia severity index (ISI). This enabled further evaluation of the adherence 
variables that most strongly related to outcome. The results section is separated 
into three components: 1) treatment oucome and adherence measures 
(preliminary “assumptions”) 2) psychometric evaluation of the SOCSI and 3) 
content analysis of the open-box response formats.  The subsequent paragraphs 
outline the analytic approach for each of the three components. Continuous 
variables are presented as mean (SD) and p values of <0.05 are considered 
statistically significant. Non-significant trends (p<0.1) are reported; statistical 
results with p-values > 0.1 are not further specified unless deemed theoretically 
interesting, in which case they are further outlined in the appendix.  
6.4.2.5.1 Treatment outcome and Adherence Measures 
Repeated measures ANOVA was computed to examine treatment related effects 
across post treatment and follow-up; Bonferroni correct post-hoc comparisons 
were conducted to follow-up significant main effects. The same statistical test 
was adopted to examine differences between the adherence methods (sleep 
diary, actigraphy marker, actigraphy movement) for the composite score.  
Although some of these variables were non-normally distributed, the ANOVA has 
been shown to be robust measure of non-parametric data in sample sizes of 
more than 25.(537) Normality was assessed with the Shapiro-Wilk test (p>.05) 
and visual inspection of histograms.(538) Pearson’s correlations (Spearman’s 
where data were not normally distributed) were used to examine the 
relationships between adherence*outcome and baseline variables [sleepiness, 
fatigue and illness representations] *adherence. Analysis related to the 
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reliability and validity of the SOCSI is outlined below.  
 
6.4.2.5.2 Psychometric Evaluation of the SOCSI:  
6.4.2.5.2.1 Validity 
Criterion Related Validity was established by examining the relationship 
between stage of change and concurrent adherence and motivation assuming 
that those in higher stages would present with better adherence and increased 
motivation (concurrent validity). The relationship between stage of change at 
baseline and adherence over the 4 weeks treatment phase will provide evidence 
to support the predictive validity of the SOCSI. Because of the small sample size 
and limited spread of frequency counts across the stages, the contemplation and 
preparation stage were merged. Adherence and motivation scores were 
contrasted between the action and pre-action stages using independent samples 
t-test, or Mann-Whitney test where data were non-normally distributed. 
6.4.2.5.2.2 Test-retest reliability 
Although usually a 2-8 week window between measurements is recommended for 
test-retest reliability statistics(539), this is inherently problematic when 
examining stage of change as the model implies dynamic changes across time-
points and some studies have even indicated change as short as three days.(540) 
It is thus usually uncommon for scales measuring stage of change to assess test-
retest reliability. Although some have attempted this over a 2-week period(541, 
542), this methodology is inconsistent with the model. Changes across this time 
period could reflect true stage transitions, rather than an unreliable measure.  
Others have used a much shorter time frame, for example Donovan et al(543) 
assessed stage of change in one session, with other questionnaires intervened 
between the two time points. This methodology might also be unsound, because 
responses to these questionnaires could lead to changes in individuals’ readiness 
to change. Therefore, this study used a shorter time period akin to Donovan et 
al.’s approach, however intervened with a short 10-minute arithmetic task, to 
prevent individuals from rehearsal/rumination of their responses to the SOCSI. 
Test-retest was measured at week 1 only. Details of the arithmetic distractor 
task can be found in Appendix 16. Intraclass Correlation Coefficient between 
time point 1 and timepoint 2 for both the stage of change and self-efficacy item 
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was calculated to determine test-retest reliability.  
6.4.2.5.2.3 Content Analysis of the SOCSI’s open-response questions 
Three questions in the SOCSI were open-response format, generating 
participant’s perceptions on:  
• The advantages of sticking to the action plan 
• The disadvantages of sticking to the action plan  
• Things that help sticking to the action plan.  
 
These questions overlapped with the decisional balance (pros and cons for 
change) and processes of change as outlined in the transtheoretical model. 
Participant generated responses were analysed using content analysis(544). Each 
thematic unit, that is each object that is considered conceptually and logically 
different from other objects, was coded and grouped into semantically 
meaningful categories. Generally, only one-unit responses were generated for 
each question, however a number of participant responses produced multiple 
separate units within the response. Because the question was phrased to 
generate multiple responses e.g. ‘what are the advantages’, each unit was 
identified and counted as an individual unit with equal weightings to one-unit 
responses. Relative frequency counts ((category/all categories generated)*100) 
for each thematic category were subsequently produced for each observation 
point (baseline, week 1-4 and FU) as well as for all time points collectively. The 
analysis of the data generated for the process of change were guided by the 
theoretical underpinnings of the transtheoretical model (10 cognitive and 
behavioural processes of change outlined in Appendix 8). A second reviewer, 
independent to the study reviewed the identification of the themes.  
6.4.3 Results 
6.4.3.1 Patient Characteristics   
Thirty individuals were recruited into the study. At 4 weeks post treatment, 
there were 28 completers and 2 drop outs. Reasons for drop outs were 
overwhelming side effects (n=1) and participation in the study was untimely 
(n=1). Of the 28, one person was exlcuded because of nocturnal actigraphy 
movement output that was visiually indistinguishable from the diurnal output. 
This individual was referred to a neurologist for further investigation. At the 3 
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month follow-up stage, a further 2 participants were lost to follow-up (1= 
uncontacatable; 1=overwhelming negative side effects of treatment). Their data 
was imputed by the last observation carried forward (LOCF). Although 
alternative methods such as using mixed-effects models are prefered over this 
option(545), the present study was not a randomised control trrial, and the LOCF 
method for only 2 cases was not determined as biasing the results. Table 15 
presents the patient demographics of the 27 participants who completed the 
treatment phase. The sample’s mean age was 48 years, ranging from 19-65 
years. The 22 females and 5 males were well-educated, with an average 
education of 15 years. The majority of the sample were either single (n=8) or 
married (n=8), whilst others had a live-in-partners, were divorced, separated, 
withowed or whose partner lived seperately (n=11).  Fourty percent of the 
sample lived alone, whilst 55% lived with a spouce, children, other family 
number or a room mate. Whilst the majority of the sample indicated they were 
either white-british or white-scottish (70%), one individual selected asian-
pakistani and seven individuals did not provide information about their ethnicity. 
The patient characteristics of the 30 recruited are presented in Appendix 17 
 
Table 15: Patient Characteristics 
N 27 
N 27 
Age (mean yrs) 48 (range 19-65) 
Gender, female (%) 22 (81%) 
Education (mean yrs) 15 (range 11-20) 
Insomnia subtype (n) 
Onset 
Maintenance  
Mixed  
Early morning awakening  
 
9 
8 
8 
2 
Insomnia duration (mean yrs) 18 (SD 17, 5 with childhood onset) 
6.4.3.2 Treatment Outcomes for Sleep and Mood Variables 
The sleep restriction intervention produced improvements in both sleep and 
mood variables, see results of the repeated measures ANOVAs in Table 16. Post-
hoc Bonferroni corrected comparisons indicated significant improvements from 
baseline at post treatment and follow-up in insomnia severity (ISI), sleep quality 
(PSQI), dysfunctional beliefs and attitudes about sleep (DBAS) as well as anxiety 
(HADS-A) and depression symptoms (HADS-D). At both post-treatment and 
follow-up it took individuals significantly less time to fall asleep (SOL), and they 
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were awake less during the night (WASO) compared to baseline. In addition, 
early morning awakenings were significantly reduced at both timepoints 
compared to baseline. These improvements were associated with an increase in 
sleep efficiency (SE) and sleep quality (SQ) ratings at post-treatment and follow-
up and total sleep time at follow up only. The effect sizes (Cohen’s d(160)) for 
post-treatment and follow-up improvements were large for the four variables 
considered as outcome measures defined a priori: SE (posttreatment=1.7; 
follow-up=1.3), WASO (.9;.7), SOL (1.0;.7) and ISI (1.2;1.3).  The baseline HADS-
A score was in the mild region(546) despite the exclusion of individuals with 
anxiety disorders.   
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Table 16: Pre-treatment Sleep and Mood Characteristics with Post-treatment and Follow-up Changes 
 Baseline 
mean (SD) 
95% CI 
[lower;higher] 
Post-treatment 
mean (SD) 
95% CI 
[lower;higher] 
Follow-up 
mean (SD) 
95% CI 
[lower; 
higher] 
F DF Sig. Partial 
Eta2 
ISI 19.2 (4.6)  17.4-21 12 (7.6) *** 9-15 11 (8.0) *** 7.9-14.2 24.8 1.6; 40.6 <.001 a 0.5 
PSQI Global 13.2 (2.8) 12.1-14.3 8.4 (3.8) *** 6.9-10 7.7 (4.7) *** 5.9-9.6 31.4 1.2; 33.1 <.001 a 0.5 
DBAS-16 (/16) 6.2 (1.7) 5.5-6.8 5.1 (1.9) *** 4.3-5.8 4.2 (2.2) ***++ 3.4-5.1 31.4 1.5; 40.2 <.001 a 0.5 
HADS-Anxiety 
(/21) 
9 (4.5) 7.2-10.8 6.1 (4.9) *** 4.1-8.0 6.5 (5.3) ** 4.4-8.6 13.7 1.6; 42.5 <.001 a 0.3 
HADS-
Depression 
(/21) 
6.1 (3-8) 4.7-7.4 4.1 (1-8) ** 2.8-5.6 4.0 (1-6) ** 2.5-5.4 10.5 2; 52 <.001 0.3 
Sleep Diary         
TST (min) 281 (98)  242.5-320.1 304 (68)  277.5-331.4 342 (90) **+ 306.2-378.1 9.3 1.6; 41 <.01 a 0.3 
SOL (min) 82.6 (81) 50.3-114.9 24.7 (30.5) ** 12.7-36.8 37.3 (57.6) ** 14.5-60.1 15 1.5; 39.6 <.001 a 0.4 
WASO (min) 59.7 (54.4) 38.1-81.2 19.1 (29.9) ** 7.2-30.8 27.3 (33.1) * 14.2-40.4 10.8 1.2; 32.8 <.01 a 0.3 
EMA (min) 64 (51) 43.6-84.6 15 (16) *** 9.5-22.1 19 (21) *** 11.3-28.6 24.9 1.1; 30.5 <.001 a 0.5 
SE (%) 55.7 (18.8) 48.2-63.1 83.5 (13.8) *** 78.0-88.9 79.9 (18.8) *** 72.8-86.9 42.1 1.6; 41.4 <.001 a 0.6 
Sleep Quality 
(/4) 
1.3 (0.8)  1.0-1.6 2.4 (0.2)  *** 2.1-2.8 2.4 (0.9) *** 2.1-2.8 32.9 1.6; 40 <.001 a 0.6 
* significantly different from baseline at p<.05; ** significantly different from baseline at p<.01; ***significantly different from baseline at p<.001 
+ significantly different from post treatment at p<.05; ++ significantly different from post treatment at p<.01 
a Greenhouse-Geisser corrections 
ISI= Insomnia Severity Index; PSQI= Pittsburgh Sleep Quality Index, DBAS= Dysfunctional Beliefs and Attitudes about Sleep; HADS= Hospital Anxiety and Depression Scale, TST=Total Sleep Time, 
SOL= Sleep Onset Latency, WASO= Wake after sleep onset; EMA= Early morning awakening, SE= Sleep efficiency 
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6.4.3.3 Adherence 
With an effective intervention established, the next paragraphs are concerned 
with the exploration of the adherence variables, beginning with descriptive 
information for the self-report questionnaire and the three methods (sleep 
diary, actigraphy marker, actigraphy movement). Thereafter, information is 
presented on possible differences across methods (sleep diary, marker, 
movement) for the composite score measurement. This section finishes with an 
analysis of the relationship between adherence and outcome.  
6.4.3.3.1 Self-report Questionnaire 
The measurement of adherence obtained from the questionnaire indicated that 
the majority of individuals reported following the bed restriction program 
“most” or “all of the time”. With a possible range of 5-30 and higher scores 
indicating better adherence, total 4-week scores (sum of all items averaged over 
the 4-weeks) ranged between 11.5 and 30, with a median score of 26.3. Total 
average weekday, weekend, threshold and rising scores, over the 4-weeks, were 
also skewed; from a possible score of 6 (averaged responses across 2 items) 
median values were 5.4, 5.3, 5.3 and 5.1 respectively. Interestingly, there was a 
significant difference in self-reported weekday and weekend adherence rates; 
unsurprisingly, participants indicated they adhered to their bed/rise times more 
often on weekdays than weekends [Z = -2.6, p<.05]. There was no difference on 
self-reported adherence to threshold versus rising time (p=.69). Individuals were 
also asked to rate the extent to which they followed the recommendation during 
the follow-up period; similarly to the 4-week treatment ratings, individuals 
reported following the program, both in terms of overall adherence, as well as 
weekday, weekend, threshold and rising time items the “most of the time”. 
Again, adherence on weekdays was significantly higher than on weekends [Z = -
2.9, p<.01], but adherence to threshold and rising time were not significantly 
different (p=.21).   
 
6.4.3.3.2 Sleep Diary 
Based on the information provided in the participants sleep diaries, the median 
deviation of 7.6 minutes from the rising time [IQR= 2.2-24.5] was significantly 
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higher that the median deviation from the threshold time of 3.3 minutes [IQR= 
3.4-9.6] from the threshold time, Z = -3.0, p < .01. The calculated adherence 
variables (composite score, rise and threshold deviation variance) that are 
obtained by the above values are presented in Table 17. 
6.4.3.3.3 Actigraphy 
6.4.3.3.3.1 Marker 
At a descriptive level, information obtained from the marker revealed a median 
deviation of 13.5 minutes from the get up time [IQR= 6.3-26] and this was 
significantly higher that the deviation of 3.3 minutes from the threshold time 
[IQR= 0.6-17.3], Z = -3.3, p < .01. Adherence variables obtained from these 
absolute values are visually depicted in Table 17. 
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Table 17: Descriptive Statistics for Adherence measurements across methods 
Adherence 
Variable  
Sleep Diary* 
 
Actigraphy * 
 Marker Movement 
Mean  SD Median [IQR] Mean SD Median [IQR] Mean SD Median [IQR] 
Composite Score  17.7 5.0 17 [14.5-20.3] 19.1 4.6 18 [15-23] 21.7 5.1 22.5 [16.6-25.8] 
Rise deviation 
variance 
24.2 25.4 15.3 [4.6-37.6] 22.4 21.5 17 [7-28] 26.6 19.9 27 [10.8-37.12] 
Threshold 
deviation 
variance 
14.8 19.2 9.7 [2.8-19.8] 14.4 20.2 1 [5.4-27] 25.4 17.0 27.7 [12.6-34.6] 
*Higher scores indicate worse adherence
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6.4.3.3.3.2 Movement 
Analysis of the movement data also provided information about the extent to 
which individuals adhered to their agreed bed window. The median of the 
absolute deviation score of the average 28 days for the rising and threshold time 
was 21.5 [IQR= 4.4-38.1] and 13.6 [IQR= 3.6-30.4] minutes respectively. There 
was no difference between these times (p=.2). The mean and median values for 
each adherence variable are presented in Table 17. 
6.4.3.4 Relationship between Adherence methods 
A repeated-measures ANOVA comparing the three methods  [sleep diary, marker, 
movement] across the composite score, revealed a significant main effect of 
method [F(1.6;41.6)= 27.7, p<.001; partial eta2=.5, Greenhouse Geisser 
corrected] Post-hoc Bonferroni-corrected contrast showed significant differences 
between all pairwise comparisons. The composite score from both the 
movement and the marker data was significantly higher than the composite 
score obtained from the sleep diary. The movement composite score was also 
significantly higher from the same measurement obtained from the markers [all 
p < .01].  
 
6.4.3.5 Adherence and Outcome 
Treatment Outcome was classified in the follwing ways: 
1. Sleep efficiency, WASO and SOL change score obtained from the diary.  
2. ISI change score  
The correlations between outcome variables and all adherence measures 
are outlined in Appendix 18. When adherence was assessed using the self-report 
questionnaire across the 4-weeks, there was no relationship between 
participants’ ratings of implementation of the program and any outcome 
measures. Similarly, neither sleep diary nor actigraphy movement adherence 
variables were related to ISI change, or changes of sleep efficiency, sleep onset 
latency or wake after sleep onset. Moderate significant correlations were found 
between the composite scores obtained from the actigraphy markers and sleep 
efficiency change scores at posttreatment (rho=-.49; p=0.009) and follow-up 
(rho=-.40; p=.04). With higher scores on the adherence measures indicating 
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poorer adherence, these negative correlations indicate that greater adherence is 
associated with improvements in sleep efficiency, see Figure 13. 
There were trends for a significant relationship between follow-up sleep 
efficiency and the following adherence measures: 
  
• Sleep diary threshold deviation variance (rho=-.35; p=.066) 
• Marker rise deviation variance (rho=-.38; p=.053) 
It is important however, to interpret these results in light of the multiple 
comparisons conducted.
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Figure 13: Relationship between composite score and post-treatment sleep 
efficiency change 
 
In order to reduce the number of comparisons in subsequent analyses, the 
one adherence variable that was significantly correlated with outcome was 
selected for further testing:  
1. Marker Composite Score 
6.4.3.6 SOCSI Validity and Reliability 
With both treatment effects and adherence measures established, this section 
focuses on the reliability and validity of the SOCSI. The first part of this section 
reports data on the stage of change component of the SOCSI, including 
frequency counts and stage transitions across the intervention weeks. The next 
part provides information on concurrent and predictive validity of the stage of 
change component. The self-efficacy component is subsequently examined in 
relation to both adherence and the stage of change component providing support 
for its validity. The section concludes with test-retest reliability analysis. 
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6.4.3.6.1 Stage of Change Across Treatment 
Frequency counts for the Stage of Change across the baseline-post treatment 
and follow-up are plotted in Table 18. The majority of the sample (≈75%) scored 
in the action stage during weeks 1-4, there was considerably more variation at 
follow-up, perhaps indicating that some individuals relapse during the 2- month 
period between the last treatment session and follow-up. Thus, stage transitions 
across these timepoints were examined in addition to the stage allocations.  
 
Table 18: Frequency Count for Stage at each treatment timepoint 
 Baseline 
(n) 
WEEK 1 (n) WEEK 2 (n) WEEK 3 (n) WEEK 4 (n) Follow-Up (n) 
Pre-
Contemplation 
0 0 0 0 0 0 
Contemplation  1 0 1 3 2 5 
Preparation  26 7 5 4 3 7 
Action  - 20 21 20 22 3 
Maintenance  - 0 0 0 0 12 
TOTAL:  27 27 27 27 27 27 
 
6.4.3.6.2 Stage Transitions 
Because stage of change was measured at each time point, it was possible to 
identify 5 types of stage transitions tracked across the 4-week intervention and 
follow-up period, these transitions are adapted from other descriptions.(547) At 
4-weeks post-treatment, the majority (74%) had transitioned through the stages 
in a positive linear fashion- ‘up through the stages’- the remaining individuals 
displayed a negative/non-linear transition. At follow-up, eight individuals had 
relapsed into a lower stage, moving from the positive linear category, to an 
inverted v-shaped pattern. Figure 14 is a visual representation of the five 
patterns along with percentages of the sample scoring in the respective 
categories at post-treatment (top pie chart) and follow-up (lower pie chart). 
Interestingly, those who transitioned in a linear fashion through till follow-up 
(from preparation to action stages) had better adherence (lower marker 
composite score) across the 4- week intervention phase than those progressing in 
a non-linear fashion, i.e. relapsing at some point, or not progressing; U=49, z=-
2.0, p<0.05. There were no significant differences in adherence rates between 
stage transition patterns through till post-treatment. 
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Figure 14: Stage Transitions 
Stage Transitions (left boxes) across 4-weeks (top pie chart) and through till follow-up (lower pie chart) 
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6.4.3.6.3 Criterion-related Validity 
To assess the validity of the stage of change construct in this sample, the 
relationship between stage allocation and a criterion was established. Adherence 
(the composite score from the marker) was identified as both a criterion for 
concurrent and predictive validity, and patient motivation was assessed at each 
time point to povide further evidence for concurrent validity. Baseline scores for 
stage of change were not included in this analysis because of a lack of 
variablility (see Table 18). The criterion variable was compared across those who 
scored in the preparation and action stage at week 1. For the remaining 
observation points (week 2-4 and follow-up), the contemplation and preparation 
stages were combined because of small frequencies counts in each stage. 
6.4.3.6.3.1 Concurrent Validity 
6.4.3.6.3.1.1 SOC and Adherence at each week 
The relationship between stage of change and concurrent adherence was 
assessed for each observation point. Mann-Whitney tests revealed significant 
differences in adherence between stages at all weeks, as seen in Table 19. 
Table 19: Differences in Marker Composite Scores between stages across the each 
observation time point 
Stage of Change Week 1 Week 2 Week 3 Week 4 
 Median [IQR] Median [IQR] Median [IQR] Median [IQR] 
Contemplation/
Preparation 
26 [20-30] 21 [18.8-27] 25 [18-28] 21 [19-30] 
Action 15 [14-18]** 16.5[14.3-19.8]* 17 [15- 19]* 16 [14.8-22.3]* 
Significantly different from adherence rates in contemplation/preparation stage at  
*p<.05; **p<.01  
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6.4.3.6.3.1.2 SOC and Motivation  
When comparing stage of change with concurrently measured motivation, only 
the first week revealed significant differences, with those in the action stage 
scoring higher on the motivation scale [median=9.5; IQR=9.3-9.9], than those in 
the preparation stage [median=9; IQR=8.8-9.3], U=122, z=2.9, p<.01. There was 
a non-significant trend for week 3. Those in action stage [median=10.0; IQR=9.7-
10.0] had a higher motivation than those in contemplation/ preparation stages 
[median=8.8; IQR=8.4-10.0], U=100, z=1.7, p=0.08. All other comparisons (week 
2, 4; follow-up) were non-significant (p>0.05) see Appendix 19 for median 
values. 
 
6.4.3.6.3.2 Predictive Validity 
It was hypothesised that stage of change (SOC) measured at baseline would be 
related to adherence over the 4-week treatment period. With no variation in 
SOC at baseline-the majority (96%) of the sample in the preparation stage- week 
1 SOC was used to predict adherence over the 4-week treatment period.  
When measured at week 1, stage of change was related to 4-week 
adherence (marker composite score). Individuals who aligned themselves to the 
action stage were significantly more adherent across the 4-week treatment 
phase than those in the preparation stage. The composite score obtained from 
the marker was lower (better adherence) in the former group [median, 16.5; 
IQR= 15-19], compared to those in the preparation stage [median= 24; IQR=22-
26], U= 20, z=-2.78., p<.01. Figure 15 shows a visual representation of this 
difference.  
 
Chapter 6 The Stage of Change Scale for Insomnia  240 
 
 
Figure 15: Difference in Adherence at week 4 between preparation and action stage (week 1) 
 
6.4.3.6.4 Self-Efficacy 
Individual’s rating of their confidence in being able to follow the sleep 
restriction routine (self-efficacy), when measured before treatment was 
initiated (baseline), was moderately correlated with the composite score 
obtained from the marker, (rho= -.41, p<.05). When was measured one week 
into the intervention, the strengths of the associations increased slightly. Self-
efficacy ratings at week 1 were significantly related to adherence (rho =-.46, 
p<.05).  
The transtheoretical model predicts that individuals, who score in 
theoretically superior stages, will present with higher ratings of confidence in 
engaging in behaviour change [concurrent validity of the self-efficacy measure]. 
In this sample, there was a significant difference in self-efficacy ratings in those 
scoring in the action [median=4, IQR= 3.3-4] and preparation stage [median=3, 
IQR=3-3], when these were measured at week 1, U=112, z=2.7, p<0.01. Similarly 
significant were these comparisons at week 3 (p<0.01) and at follow-up (p<0.01). 
All other weeks were non significant (p>0.05).  
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6.4.3.6.5 Test-retest Reliability 
Stage of change allocation and self-efficacy ratings were compared before and 
after the mental arithmetic test at week 1. The Intraclass correlation coefficient 
(ICC) for stage of change was 1, with all individuals scoring in the same stage. 
There was also a strong overlap for self-efficacy ratings; 26 of the 27 individuals 
reported identical self-efficacy ratings at both time points. One individual 
scored higher at time point 2; the ICC for self-efficacy was high accordingly 
(ICC=.95). 
6.4.3.7 Content Analysis:  
A total of 481 responses were provided from all 27 participants across the 6 
observation time points. Of these, 10 responses (0.02%) were excluded from 
analysis. Seven responses to the disadvantages question were excluded because 
they were considered vague (‘short term pain’). Three responses to the 
processes of change question were not analysed because they did not qualify as 
a process of change (‘can sleep consistently‘). Of the remaining 471 analysable 
individual responses 107 responses were considered multiple units (e.g. ‘short 
term fatigue, disruption to family life’) and each unit was counted equal as 
described in the methods section.  
6.4.3.7.1 Decisional Balance 
6.4.3.7.1.1 Pros for adhering to the sleep restriction routine 
The three most frequently generated advantages for adhering to the sleep 
restriction programme over all observation time points were: 
1. Improvements in sleep quality/quantity (47.6%) 
2. Improvements in energy/motivation (13.5%) 
3. Improved outlook (7.4%) 
Table 20 depicts the themes and relative frequency counts for data 
generated across all time points. The three most frequently reported themes are 
in bold.  
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Table 20: Themes and relative frequency counts: Pros for change 
Theme Example Quote Relative 
Frequency 
Count (%) 
Improved sleep 
quality/quantity  
Better quality of sleep and more sleep 
47.6 
Improved 
Energy/motivation 
More rested , more energy to exercise and do 
things 13.5 
Improved Outlook  Ability to make plans for holiday /social events 7.4 
Curing insomnia  The treatment is working, so could lead to a cure 6.1 
Improved Emotional 
regulation  
Better mood 
5.2 
Better sleep pattern  Help get me into a good sleep routine 4.8 
Improved Performance 
at work/school/daily 
activities 
Able to arrange meetings 
3.5 
Improved Cognition Better memory, concentration 3.1 
Less Concern about 
sleep  
Being more relaxed about sleep  
 2.6 
Improved Health/well 
being 
Improved health 
2.6 
Improved Sleepiness More awake 1.7 
Treatment effectiveness 
The evidence shows that this method is 70-80% 
effective 0.4 
Improved Social 
functioning  
Better social life  
0.4 
More time  Better use of time 0.4 
Improved Appearance Have no bags under my eyes now   0.4 
 
The theme ‘improved sleep quality/quantity’ was most frequently cited 
as a pro at all time observation points. There was also stability in the frequency 
counts of the theme ‘improved energy/motivation’, with this the second most 
frequent pro at all time points, except for baseline (surpassed by ‘improved 
outlook’). There was considerably more variability in the third most frequently 
cited advantage across the weeks: the following themes ‘curing insomnia’, 
‘better sleep pattern’, ‘health/wellbeing’ and ‘emotional regulation’ were rated 
the third highest advantages across different weeks. 
6.4.3.7.1.2 Cons for adhering to the sleep restriction routine  
Interestingly, of the total number of responses given across all observation 
points, 34.3% depicted no real disadvantage to implementation of the treatment 
regime. Following that, the disadvantages that were mentioned included 
‘reduced energy/motivation’ (23.8%), ‘increased sleepiness’ (9.4%) and 
‘disruption to routine and social activities’ (7.2%). Table 21 displays the themes 
along with representative quotes and respective frequency counts. 
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Table 21: Themes and Frequency Counts: Cons for change 
Theme Example Quote Relative Frequency 
Count (%) 
No disadvantages No real disadvantages 34.3 
Reduced Energy/motivation  Tiredness during the working 
week 23.8 
Increased Sleepiness Short term problems with 
sleepiness 9.4 
Disruption to routine and 
social activities 
Restriction of normal evening 
activity 7.2 
Impaired performance at 
work/school/daily activities 
Reduced ability to work 
5.5 
Disruption to family/household Keeping partner awake 
 3.9 
Migraines Headaches continuing 3.3 
Concern over loss of 
sleep/sleep opportunity  
Getting less sleep than I would 
like 2.8 
Impaired emotional regulation  Continuing to feel worthless + 
irritable 2.2 
Fear of no change  No change to insomnia 2.2 
Health/wellbeing Not feeling so good  1.7 
Need to find activities  Finding things to do 0.6 
Lowered self-confidence Questioning my staying power 
(motivation) 0.6 
Social functioning  Falling asleep at sociable hours 0.6 
Boredom  Boredom in the evening 0.6 
Requires discipline Requires discipline 0.6 
Cognition  Brain not functioning as well 0.6 
Burden Remembering to keep to 
restricted times 0.6 
 
Similar to the advantages, the two most frequently counted themes were 
stable across the observation points; except at baseline, where reduced 
energy/motivation was more often reported than no disadvantages. The third 
most frequently identified theme was variable across the time points: ‘increased 
sleepiness’, ‘disruption to routine and social activities’ and ‘impaired 
performance at work/school/daily activities’ represented approximately 10% of 
the responses made across different observation points. 
6.4.3.7.2 Processes of Change  
When asked to describe strategies that helped them implement the sleep 
restriction program, self-liberation strategies (43.3%) were most frequently 
quoted by individuals across all observation time points.  This was followed by 
counter conditioning strategies (26.3%) and consciousness raising (16.0%), see 
Table 22. 
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Table 22: Themes and Frequency Counts: Processes of change 
Theme Example Quote Relative 
Frequency Count 
(%) 
Self-liberation  Be more determined to improve 43.3 
Counter conditioning  Find interesting things to keep me occupied 26.3 
Consciousness raising  Think how bad I was before and what I can 
achieve 16.0 
Helping relationships  Get support from sleep centre and friends 
who believe in bed restriction therapy 9.3 
Emotional arousal  Think positively about overcoming my sleep 
problem 2.1 
Self-re evaluation  Be confident to myself [sic] 1.5 
Stimulus control  Try to limit things happening that bother me  1.5 
Cognitive processes  
15.4 
Behavioural processes 84.6 
 
As described in Appendix 8, self-liberation strategies involve a process of 
making firm commitments for change, take responsibility and strengthen belief 
in own capabilities for change.  Counter conditioning, an additional behavioural 
process, includes pursuing situations that facilitate behaviour change. In this 
sample, this process consisted largely of ways to find activities helping them to 
stay up until their threshold time. The cognitive strategy consciousness raising 
was a process that was also frequently raised, this process includes making use 
of informational resources- in this case to remember how bad the sleep was 
prior to treatment implementation and what improvements can be made- to 
raise awareness of the need to engage in the new behavioural pattern. Other 
behavioural strategies included helping relationships, i.e. getting support from 
significant others; and stimulus control- removing unwanted stimuli that would 
impede adherence to the sleep restriction program. Other cognitive processes 
included emotional arousal and self-re-evaluation, which reflected emotional 
thoughts about the intervention itself and in terms of personal values, 
respectively. At baseline counter conditioning was the most frequently reported 
strategy, closely followed by self-liberation. There was a crossover at week 1 
that remained through till follow-up. Third highest frequency counts were 
exposed for consciousness raising across all weeks except for baseline and week 
two, where this strategy was surpassed and tied with helping relationships, 
respectively. Overall, behavioural strategies (84.6%) were more often quoted 
than cognitive processes (15.4%) and a similar ratio was present for all weeks.   
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6.4.3.8 Other predictors of Adherence  
Exploratory correlation analysis was conducted to examine potential baseline 
predictors of adherence, in addition to the main results reported above. Of the 
possible baseline predictors of adherence, only the IPQ subscale ‘illness 
coherence’ was related to outcome.  Interestingly, a Spearman’s correlation 
revealed worse adherence (higher composite scores from the marker data) in 
those who had a greater personal understanding of their sleep problem rho=.50; 
p<0.05. There was a trend for the IPQ-R subscale emotional representation 
rho=.34; p=0.08. All other correlations (all other IPQ-R subscales, ESS and FSS) 
and were not significantly related to adherence (p>0.05), see Appendix 20.    
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6.5 Discussion 
Adherence to medical treatments is less than optimal and the interest in 
improving adherence is steadily growing. Interventions with a theoretical 
underpinning have been considered more successful that their a-theoretical 
counterparts. One model specifically, the transtheoretical model of behaviour 
change, has gained considerable attention in the health psychology field, and its 
potential for understanding adherence to treatments for sleep disorders is 
emerging in recent investigations. The limitations of these studies translate into 
the need to:  
• develop and cognitively pre-test a questionnaire to measure appropriately 
the components of the TTM model for the use in sleep research  
• Determine the concurrent and predictive validity of the scale when 
applied to an insomnia population completing a bed restriction program 
• examine additional subjective and objective measures of adherence to 
bed restriction therapy. 
 
In order to achieve these goals, two studies were conducted.  
6.5.1 Study 1 
Study 1 describes the development and preliminary validation of the Stage of 
Change Questionnaire. The SOCSI was developed to meet the following criteria: 
assess all components of the transtheoretical model, to be a brief scale that can 
be used as both a research and clinical tool to assess and potentially modify 
stage of change and offer the opportunity, as a generic scale, to be adapted to 
other health domains. In order to accomplish these criteria, the questionnaire 
assessed stage of change and self-efficacy; and in addition recorded patient-
generated pros and cons and processes of change. The latter feature, patient-
generated responses from an open-box format, allows for the generation of 
qualitative data that can a) be used for further scale development to produce a 
reliable research tool that measures decisional balance and process of change 
but also used in its current format as a valid clinical tool that records patient-
specific pros/cons and strategies for behaviour change. This process of content 
analysing patinet-generated reponses for providing potential items for the 
decisional balance has been utilised successfully in the marijuana use 
literature.(548) Using this open-response format for components of the 
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transtheoretical model, as a clinical tool, has not been previously reported. 
However, motivational interviewing, a technique that runs hand in hand with the 
transtheoretical model(359), describes the importance of patient-generated 
change talk in order to increase individuals’ readiness to change and engage in 
treatment.(432) Lastly, the open response box for patients to record their 
‘action plan’ discussed with their therapist, permits the possible adaptation of 
the SOCSI to other sleep disorders /health domains.  
After the development of the SCOSI, the comprehensibility of the 
questionnaire was tested in a representative sample of the potential end users: 
individuals undergoing a CBT-I program. The cognitive pretesting highlighted 
issues with the questionnaire that need to be addressed before further reliability 
and validity assessment could be made. These change include minor issues with 
layout, confusing wording, and the use of jargon. More substantial changes were 
made to describe better the term behavior change of interest, i.e. ‘the action 
plan’; distinguish better between the stage of change items preparation and 
contemplation, and use terms, such as ‘advantages and disadvantages’ and 
‘strategies to help stick to the action plan’ that were easily understood for 
describing the decisional balance and processes of change components. Overall 
these changes to the SCOSI made it more comprehensible, were in line with the 
theoretical underpinnings of the TTM and were in concordance with the goals of 
producing a research and clinical tool to monitor and potentially enhance 
individuals’ readiness to change. This latter point was particularly emphasised 
by three individuals remarking that completing the SCOSI led to a cognitive shift 
in their attitude towards the treatment. Because the majority of individuals in 
the cognitive pretesting sample preferred the algorithm version of the SOCSI, 
this was used in study 2 for further evaluation.  
6.5.2 Study 2  
Further validaty and reliability testing of the SOCSI occured in the context of a 
sleep restriction trial. Once prior assumptions had been met [1) the intervention 
produced significant effects and 2) this occurred as a function of adherence] the 
SOCSI showed to be a reliable and valid scale to measure elements of the 
Transtheoretical Model and their relationship to adherence.  
In relation to the first assumption, significant treatment improvements 
were witnessed with the sleep restriction intervention. These outcomes are 
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similar to a trial with a similar study design;(139) although the baseline values in 
the present study are slightly lower for TST, WASO and sleep efficiency and 
higher for SOL, the effect sizes for improvements in the outcome measures SE, 
SOL, WASO and ISI at the follow-up were similar to those reported in Kyle et 
al.’s study.(139) The second assumption was also met. The composite score 
obtained from the actigraphy marker data was related to improvements in sleep 
efficiency at both post-treatment and follow-up. There were also non-significant 
trends for the variance in deviation from 1) the threshold obtained from the 
sleep diary 2) the rise time obtained from the marker. These correlations were 
moderate, but this is perhaps not suprising, considering the comparison of an 
objective (actigraphy adherence) and subjective (outcome) measure.  The 
consistency/variance measures of non-adherence were not related to outcome in 
this chapter, although there were non-significant trends. The only associated 
measurements with outcome in Riedel and Lichstein’s study [R&L], were 
adherence measures ‘time in bed consistency’ and ‘rise time consistency’.(213) 
Intersetingly though, this was not replicated by others(208, 214). The adherence 
measures in this chapter were different from these previous studies, by 
considering any times within the agreed window (after threshold and before 
rising times) as adherent, which might explain differences in the results 
presented above. Whether consistency of bed/get up times [R&L] or variance in 
non-adherence [present study], is a stronger predictor of outcome needs to be 
evaluated further. There were also no relationships between self-reported 
adherence and outcome in this chapter. This contrasts with the Vincent et al. 
study(208), where self-reported adherence was significantly related to 
improvements in TST, WASO and insomnia severity. These correlations, similar to 
the ones reported in the present study, were however only moderate. Vincent et 
al.’s study presented bed restriction within a CBT-I package; any additional 
sleep-related benefits from other components could have had an effect on the 
the relationship between adherence and outcome and might explain these 
differences observed. 
The main aim of the present study was to evaluate the validity and 
reliability of the SOCSI. To assess criterion-related validity of the SOCSI, the 
relationship between stage of change and concurrent adherence and motivation 
(concurrent validity) and future adherence (predictive validity) was examined. 
This approach to assessing validity of stage of change measures has previously 
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been reported in studies examining adherence(523, 549) and other helath 
behaviours(550-553). Results inidcated that adherence rates were poorer in 
individuals scoring in the contemplation/preaparation stage than in the 
action/maintenance stage. The motivation scale provided a further criterion the 
SOCSI was validated against. However, the only significant relationships was 
found during week 1, where scores on the motivation scale were higher in those 
who were in the action compared to individuals in the preparation stage. The 
failure in finding differences during the subsequent weeks, and only trends in 
week 3, might be a result of a ceiling effect, in the motivation scale, see 
Appendix 19; a finding that was also reported in the original paper.(531) Taken 
together though, this indicates evidence for the concurrent validity of this 
component; the inability to compare across all five stages, however reduces the 
confidence with which this claim can be made.  
The relationship between stage of change at early phases of the 
treatment and later adherence provided information about predictive validity. 
Limited variability of stage of change at baseline prevented this time point from 
being used; however, at week 1, those individuals who scored in the action stage 
had better adherence across the 4-weeks intervention period, than those in the 
pre-action stage. This finding is consistent with the transtheoretical model and 
suggests that measurement of stage of change is helpful for identifying those 
who are more likely to adhere to the bed restriction intervention. To date this is 
the first investigation of stage of change in respect to adherence to bed 
restriction. Only two studies in the insomnia literature have investigated 
components of the transtheoretical model. Belleville and colleagues reported 
that none of the TTM components at baseline were related to subsequent 
hypnotic tapering, yet when self-efficacy when measured at a later stage, this 
variable was related to hypnotic use.(511) Perhaps more comparable to the 
SOCSI study design was an investigation of the TTM model for predicting 
adherence to an internet-based CBT-I.(223). In this study, individuals who were 
more contemplative had better self-reported adherence to sleep hygiene rules. 
No relationship was found between readiness to change and sleep restriction. 
This might seem contradictory to the results of the present study, however the 
concept readiness to change as assessed in Hebert et al.’s study is a more 
generic concept, which represents people’s motivation to change(513), as 
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opposed to stage of change, which represents the stage individuals are at in the 
change process.  
As integral aspects of the transthoeretical model, stage transitions and 
self-efficacy were examined in addition to stage of change. Although the 
majority of individuals transitioned through the treatment in a linear fashion, 30 
% of the sample relapsed from the action stage at post treatment to the 
preparation stage at follow-up. This potentially identifies a critical period during 
which individuals might need further support, possibly with booster session, to 
ensure continued adherence to the bed restriction routine during this follow-up 
period. Of course ‘falling’ back into the preparation stage does not necessarily 
indicate a relapse; individuals might have improved to the extent they do not 
feel the need to continue with the routine.  
Self-efficacy measured at baseline was related to adherence and this 
relationship increased when self-efficacy was measured at week 1. The 
increased strength in relationship between self-efficacy and stage of change 
throughout the weeks of treatment mirrors previous results reported in this 
area.(231, 286, 511) The relationship between self-efficacy and stage of change 
is an integral part of the TTM; this is somewhat supported with the results in the 
present study reporting higher self-efficacy rates in the action compared to the 
pre-action stages at week 1, 3 and follow-up. This also provides further 
information about concurrent validity of the stage of change component. Why 
there were no differences in the other weeks is however suprising.  
In summary, these results indicated good construct validity of the SOCSI 
and contributes to the evidence supporting the use of TTM construct stage of 
change and self-efficacy as useful in understanding behaviour change in this 
population. 
Test-retest of the stage of change and self-efficacy components revealed 
very high correlation coefficient. This suggests the SOCSI is highly reliable in 
measuring stage of change and self-efficacy. However as noted above, test-
retest reliability is not paramount in assessing scales measuring components of 
the transtheoretical model. The choice of such a short timeframe is 
controversial, however this was deemed most appropriate, considering the 
theoretical underpinnings of the model. The magnitude of overlap between the 
two timepoints reported here is slightly higher than a study examining test-
retest in a similarly short time span. Donovan’s et al. show pearson correlations 
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of around .78 .72 and .59 in individuals who wanted to reduce smoking, reduce 
alcohol intake and increase exercise respectively. The use of the pearson’s 
correlations were validated here with high frequency counts in all stages. The 
considerably larger sample sizes (n=404 of their interviewed sample wanted to 
reduce smoking, n=57 reduce alcohol intake and n=704 inrease exercise) and 
different population of interest, might account for these differences in 
magnitude of relationship to that reported in the present study.  
Because no validated scales currently exist for decisional balance and 
processes of change for adherence to CBT-I, open response boxes were used to 
generate individual’s own responses. Content analysis of these entries indicated 
considerable stability across the pros, cons and processes generated each week. 
There were changes in the highest frequency generated themes from baseline to 
week 1 and this might be an artefact of comparing responses before and after 
treatment initation. Important advantages for change seem to be improvement 
in nightime symptoms (better sleep quality, quantity and pattern), daytime 
symptoms (energy/motivation, , emotional regulation, cognition, performance 
etc.), as well as more global changes (outlook, curing insomnia, appearance, 
having more time etc.). Overall the sample most often reported no real 
disadvantages for adherence. This finding is potentially linked to the other 
results reported in this sample: overall good adherence to the bed restriction 
therapy and the majority of individuals scoring in the action stage, with limited 
spread across other stages. So, although it was not possible to create a  
decisional balance and examine its relationship with the stages of change, this 
finding provides partial support for the TTM, which claims that individuals 
moving towards the action stage will find the pros outweigh the cons for change. 
Disadvantages that were noted included impariments in daytime functioning ( 
energy/motivation, sleepiness, performance), changes to personal/family life 
(disruptions to social activities, family life) and a general diffiuclty in adhering 
to the bed restriction (boredom, requiring discipline). This finding corroborates 
previous reports that adherence to bed restriction is not as straight forward as 
assumed, and may incur unwanted effects that may impact on continued 
implementation of the routine.(139). Overall, participants generated more 
behavioural (e.g. self-liberation, counter conditioning) than cognitive processes 
(e.g. consciousness raising, emotional arousal). The TTM proposes this kind of 
pattern is representative of transition through later stages (action through to 
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maintenance). Because a large percentage of individuals resided in the action 
stage throughout the treatment, these results might offer preliminary support 
for the processes of change in this population. Although only cautious 
conclusions can be drawn from these generated themes, this information does 
provide important material that can be used in the further development of 
decisional balance and processes of change items. 
A secondary aim of study 2 was to evaluate further subjective and 
objective adherence measures. Four different methods were used for this: self-
report questionnaire, sleep diary, and actigraphy marker and actigraphy 
movement data. Results from the questionnaire highlighted that individual’s 
self-reported high rates of adherence; with a possible total score of 30, more 
than half of the sample scored over 26. These pattern of extreme skewness is 
similarly reported in other studies. Vincent and colleages(208) sample indicated, 
also on a scale from 5-30, a mean self-reported adherence of 21.4 (SD= 4.4). In a 
randomised control trial comparing CBT-I with zopiclone or placebo, Sivertsen et 
al.(210) reported individuals in the CBT-I arm had an average self-reported 
adherence of 4.8 [SD, 0.1] based on a 5-point scale. With these highly skewed 
rates is it perhaps unsuprising that relationships between self-reported 
adherence and outcome were not reported in the SOCSI study. 
In addition to self-report, the SOCSI study made use of sleep diary and 
actigraphy (marker and movement) as measures of adherence. The absolute 
deviations obtained from the sleep diaries in study 2 are somewhat comparable 
to previous studies using sleep diaries. The individuals in the present study, 
according to their diary entry, went to bed on average 7 minutes before their 
threshold time and got up 19 minutes after their rising time across the 4-weeks 
intervention period [of note, the results section reported the median values, as 
these variables were not normally distributed]. Riedel and Lichtstein (R&L) 
report that individuals spent on average 27.89 minutes more in bed than agreed. 
Other studies have used or adapted R&L’s measurements of adherence.(162, 
208, 214) Vincent et al. 2003 calculate time in bed and wake (rather than rise) 
time variance, however fail to report any absolute values of minute deviation 
and in their 2008 study they only report wake up time variance. In a study 
combining CBT-I with mindfulness for individuals with psychophysiological 
insomnia, Ong et al. 2008, report the deviation of time in bed from agreed time 
was 21.95 minutes (SD=38.32 minutes). Additionally, individuals rose 30.46 
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minutes (SD=36.42 minutes) later than their agreed rising time. It seems that the 
degree of non-adherence (in terms of absolute deviation) to the bed restriction 
in this study is within the same range as reported by R&L and Ong’s studies, 
although it is important to note that in the SOCSI study, time points before the 
threshold time and after get up time were set to a value of zero, thus values 
reported here might be slightly higher than if calculated in the way R&L and 
others have done. Thus, comparisons here are to be interpreted with caution.  
The three measures used to evaluate adherence are very different to the 
ones used in previous studies. The composite score was a more conservative 
measure of absolute deviation from threshold and rising time with each of the 
first three 15 minute gradiantes being reduced to a simple scale of 1-3. The 
remaining two measurements reflected the variance in non-adherence, by 
calculating the variance of absolute deviation from both the threshold and rising 
time. To date, no one has computed a composite score in this way and the two 
consistency measurements are different from R&L’s reported consistency, 
whereby the variance in actual time in bed/get up time is calculated. To 
cacluate their measures, R&L included timepoints after the threshold time and 
before the rising time. This of course is valid when examining consistency of 
time in bed/get up time per se, and the importance of consistency in bedtimes 
is not disputed; however with the objective of measuing adherence to a bed 
restriction program, where individuals are instructed to go to bed at or after a 
specific time (as done in the present study), including these times becomes less 
appropriate. In the present study, by setting threshold and get up times within 
the agreed window to zero, results showed that time deviation variance was 24 
minutes, and threshold deviation variance was 15 minutes. Based on these 
differences, comparisons with R&L’s consistency measures is not possible. A 
further difference to R&L’s study is the intervention: sleep compression. Rise 
time consistency, was thus computed from the difference in consistency at 
baseline to consistency at post treatment. Whereas the present study allowed 
for consistency calculations throughout the treatment process. Thus, difference 
in treatment protocols also make comparisons difficult.  Ong et al.’s study is 
perhaps more comparable to the SOCSI study design, however they do not report 
a measure of consistency.  
In addition to sleep diaries, the present study also made use of actigraphy 
to obtain a measure of adherence and this method presents an interesting 
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comparison to the previously mentioned sleep diary. When comparing the three 
adherence methods (sleep diary, marker and movement data) for the composite 
score measurement, there were significant difference at all levels. It is difficult 
to determine which of these methods is the most objective, however the results 
of the ANOVA indicated that individuals are most adherent, when measured with 
the sleep diary, followed by the marker and lastly actigraphy movement. This 
partly supports findings from Carney and colleagues, who reported that a group 
of good sleepers, who were asked to restrict their time in bed across 2 nights 
and were unaware that the actiwatch would record their adherence, had 
significant discrepancy between their actigraphy bed time and agreed bed time, 
no discrepancies were reported in the sleep diary adherence measures. Although 
not reported, this might be synonomous with a significant difference in 
adherence across these two measures, similar to the comparisons in the present 
study. The group who was made aware that the actiwatch recorded adherence 
followed the routine better, both in actiwatch and sleep diary recordings. 
Participants in the present study were not told the actigraph would measure 
their adherence, however a small number of individuals did remark that the 
device would be able to determine whether they were “lying or not”. 
 Despite these considerations, all methods (sleep diary and actigraphy) 
reveal that individuals are very adherent to the bed and rising time (within 
about 30 minutes), and are better able at following the threshold time compared 
to the rising time recommendations, as well as on weekdays compared to 
weekends (self-report). Whether 30 minutes is an adequate cut-off for optimal 
adherence to bed restriction treatment seems possible, however needs to be 
further investigated. 
Baseline variables (sleepiness, fatigue, dysfunctional beliefs and illness 
representations) were examined as possible predictors of subsequent adherence 
in exploratory analysis. Contrary to expectations, only one variable was 
predictive of adherence, sleep problem coherence. Interestingly the relationship 
was possitive, indicating greater personal understanding of the sleep problem at 
baseline was predictive of non-adherence to the bed restriction therapy. This 
contradicts assumtions of the original self-regulatory model, which would 
propose less coherence of the problem to be associated with poorer adherence. 
One potential explanation could be that individuals struggling to make sense of 
their sleep problem were more motivated to engage in the treatment. However, 
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as with the results above, the correlations are only moderate, and because of 
multiple comparisons made, these have to be interpreted with caution.  
In summary, the results of study 1 and 2 have contributed to 
accomplishing the aims outlined for this chapter: 
• Develop and cognitively pre-test a questionnaire to measure appropriately 
the components of the TTM for the use in sleep research (STUDY 1) 
• Determine the concurrent and predictive validity and reliability of the 
scale when applied to an insomnia population completing a sleep 
restriction program (STUDY 2)  
• Develop further subjective and objective measures of adherence to CBT-I 
(STUDY 2)  
It is important to consider these results in light of the limitations of the studies.  
6.5.3 Limitations and future directions:  
The first limitation concerns the sample in study 2. Partly as a result of small 
sample sizes and highly motived research participants, there were not enough 
people in each stage of change, forcing the merge of the contemplation and 
preparation stage. Merging contemplation and preparation into one stage and 
contrasting adherence rates to those in the action stage is akin to predicting 
furture from past behaviour (the qualitative difference between action and 
preparation/contemplation is by definition the presense of behaviour change, 
i.e., adherence). With the merge, the quality of stage differences is lost and 
therefore the complete use of the transtheoretical model cannot be determined. 
Future studies determining the validity and reliability of the SOCSI will need to 
use larger sample sizes and investigate stage of change in a clinical, rather than 
a highly motivated research sample, to ensure a large distribution across all 
individual stages. Individuals with co-morbid psychological or medical problems 
and/or taking medication for their insomnia might be less ready for change and 
thus more likely to reside in the contemplation or pre-contemplation stage.   
Secondly, with the lack of valid decisional balance and processes of change 
measures for CBT-I adherence, open box response format was used. Thus the 
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reliability and (criterion-related) validity of these two measures could not be 
investigated. This study was only able to draw conclusions on the type of pros 
and cons conisdered important in this sample, and could not make inferences on 
how the balance between these two might relate to adherence. Although results 
of study 1 provided evidence for the face validity of these measures, there is a 
need to construct items using the results from the content analysis and develop 
scales for the decisional balance and processes of change that can undergo 
further validity and reliability testing.  
Study 1 indicated good face validity of the SOCSI. Three individuals 
remarked (unprompted) on the ability of the SOCSI to make them aware of their 
motivation towards behaviour change. However, this might be problematic for 
the interpretation of study 2, where individuals could have been aware of the 
assessed construct of the SOCSI and responded according to demand 
characteristics. The potential of individuals becoming aware of the rationale for 
using the actiwatches to monitor adherence might have increased this effect 
even further.(see 228). Additionally, the mere completion of the SOCSI might 
have had an influence on adherence itself (both positive and negative). 
Generating patient-specific information on the pros/cons and processes of 
behaviour change might have made people more aware of their beliefs and 
attitudes towards treatment.  
Using an actiwatch as a measure of objective adherence certainly furthers 
our understanding of adherence to a bed restriction program. Although the 
Respironics software determined rest periods have been validated against sleep 
diaries(554), the automatic scoring is corroborated with visual examination of 
the data, which may introduce an element of subjectivity and error. 
Furthermore, the participants in this study were undergoing sleep restriction 
therapy and potentially spending time resting prior to their threshold time (e.g. 
on the couch watching T.V.). This extended amount of inactivity (or lowered 
activity) compared to an active good sleeper retiring to bed at 10, might have 
led to an overestimation in the minute deviation for the threshold time in the 
movement compared to the sleep diary and marker data; the results of the 
ANOVA might support this possibility. Thus, the further development of ways of 
obtaining an objective account of adherence to the behavioural components of 
CBT-I is warranted. Potentially, the ananlysis of in-lab studies with concurrently 
measured actigraphy, sleep diary entries and video recording might shed light on 
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this issue. This will hopefully lead to a clearer understanding of what actually 
constitutes adherence to bed restriction therapy: is it sticking to the 
threshold/rise time to the minute? How much variation would be considered 
acceptable or even in fact normal error? These questions are currently left 
unanswered. Perhaps even more crucial, what is the individual’s own definition 
of adherence and does influence the response to the SOCSI items? Certainly in 
the cognitive pre-testing study no clear differences in the definition of the term 
‘sticking to the action plan’ emerged across participants. However, the clear 
identification of the behaviour of interest is vital in order to distinguish pre-
action from action stages(503)  The term ‘consistently’ was added to the 
questionnaire to standardise the potential definition of adherence as much as 
possible.  
Hence, further clarification of optimal adherence to bed restriction 
therapy would be fruitful. This could also be accomplished by exploring various 
‘doses’ of adherence to establish the relationship between adherence and 
outcome. The randomisation of participants to a bed window extended by 0, 15, 
30, 60, 90 etc. min to artificially mimic varying degrees of non-adherence could 
provide information for establishing a consensus of optimal adherence, mirroring 
the efforts in the CPAP literature.(see 57) 
The use of the transtheoretical model in understanding and predicting 
adherence to bed restriction is outlined above, however there are important 
alleged limitations of the model itself, that warrant consideration. The 
transtheoretical model was initially conceptualised to understand smoking 
cessation. This behaviour is relatively simple and inferences about self-reported 
stages of change are easily made. However, bed restriction is a complex 
treatment, involving the implementation of several behavioural changes:  going 
to bed at or after the threshold time, getting out of bed at rising time, no 
napping. Thus the application of this model to more complex behaviours might 
be problematic at a conceptual level.  A recent commentary described this as a 
potential explanation for the limited evidence for TTM guided stage-based 
interventions in improving activity levels.(555) Another alleged criticism of the 
model is the stage allocation process itself. Many have argued that the stages 
describe arbitrary cut-offs (e.g. 6 months is often used as the cut-off between 
action and maintenance). However the authors state this process is akin to the 
use of cut-offs in the medical field, e.g. to quantify the severity of a disease; 
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and that the value of the TTM is the inclusion of these discrete variables along 
side continuous ones, i.e. self-efficacy, decisional balance and process of 
change.(556) Increased use of the SOCSI and research into adherence to bed 
restriction therapy is needed, to ensure the cut-offs for stage allocation used in 
the SOCSI are valid.  
A further criticism of the TTM is that stages are descriptive, not 
predictive, and that stage progression is not reflective of actual behaviour 
change.(557) The authors of the TTM respond to this criticism with studies 
indicating good predictive validity of the stages and limitations of studies that 
do not.(556) This present study certainly provides some evidence that the stage 
of change is predictive of behaviour change: i.e. adherence to bed restriction.  
Lastly, some have argued that staging implies individuals make ‘coherent 
and stable plans’ and possible response options do not inclusively reflect their 
thought processes.(see 557). This might be true at the moment-by-moment 
level, where other processes, e.g., in this population, experienced levels of 
sleepiness, potentially influence their decisions. However at the global level, the 
cognitive pre-testing of the SOCSI was one way of establishing whether the 
thought processes of these individuals matched their response patterns, which, 
arguably to the subjectivity of the interviewer, was accomplished.  
With the hope of addressing at least some of these issues with future 
studies, there is potential for the SOCSI to be implemented into routine clinical 
care of individuals with insomnia. The early identification of patients in the pre-
contemplation or contemplation stage, who are less likely to adhere to the 
behavioural components of CBT-I and might benefit from increased cognitive 
restructuring before implementing the behavioural strategies, seems fruitful. In 
contrast, those in the action stage could be introduced to behavioural 
components immediately, being offered cognitive strategies later if needed. 
Thus stage matching based on the TTM model in the insomnia population 
warrants investigation, see also chapter 4. Some have argued that these types of 
stage-matched interventions in improving health related behaviour are not 
considerably successful(558); however the original authors state that studies 
providing evidence against stage-matching often fail to consider all components 
of the TTM model.(556) Previous efforts to tailor CBT-I treatment to individuals 
with different subtypes of insomnia have not been effective,(474, 475) however 
the nature of insomnia as a psychobiological disorder, which is optimally treated 
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with cognitive and behavioural techniques, certainly lends itself to tailoring the 
CBT-I treatment to stage allocation. An alternative to this matched approach 
might be integrating aspects of motivational interviewing(432) into the CBT-I 
program. This technique is currently described as ‘a directive, client-centred 
counselling style for eliciting behaviour change by helping clients to explore and 
resolve ambivalence.’(433, p.326) If individuals are experiencing ambivalence 
when asked to adhere to the behavioural and cognitive components of CBT-I, 
motivational interviewing might help resolve this ambivalence before the 
individual engages in the behaviour change. This technique has recently shown 
to be successful in improving CPAP adherence.(354, 355, 358).  
Lastly, it might be useful to match pharmacological versus behavioural 
techniques to stage allocation. Those in the pre-contemplation/contemplation 
stage might benefit first from short-term improvements with pharmacological 
options before being introduced with a more cognitive-behavioural option, once 
progressed through to a preparation/action stage. This would certainly add to 
the recent efforts to improve the effectiveness of insomnia treatment by 
combining these pharmacological and cognitive behavioural techniques.(166, 
167)  
6.5.4 Concluding remarks 
This chapter presents the development and psychometric evaluation of the Stage 
of Change Scale Specific for Insomnia. Results suggest that the SOCSI is valid and 
comprehensible to individuals. The brevity and easy of administering the SOCSI 
supports its potential for being an integral part of the therapeutic process in 
daily clinical practice. Further psychometric testing of the SOCSI indicated that 
documenting stage of change and self-efficacy at early periods during therapy 
can provide useful information about who will adhere to a bed restriction 
program. The chapter also highlighted the use actigraphy in assessing adherence 
to this type of behavioural treatment for insomnia. Future studies need to assess 
stage of change in larger samples including clinical populations (e.g. with 
comorbid medical and psychological disorders and/or concurrently taking 
hypnotics), and investigate adherence to bed restriction, to permit the full 
evaluation of the transtheoretical model and its applicability in this population.   
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Chapter 7- Overarching discussion 
7.1 Summary of the work conducted in relation to thesis 
aims  
The introductory chapter to this thesis presented the literature on adherence to 
treatments for the two most prevalent disorders of sleep and wakefulness: CPAP 
for obstructive sleep apnoea and CBT-I for insomnia. Despite rigorous evaluations 
of the efficacy of these treatments, no single predictor has been consistently 
linked to CPAP adherence. The literature on CBT-I is very much under 
researched, with limited information on optimal rates/cut-offs for adherence or 
the relationship between adherence and outcome. Thus both areas are currently 
at the cusp of an agenda change. The insomnia literature requires a consensus 
on how to measure and conceptualise adherence to components of CBT-I. This 
progress will hopefully mirror the pathway the CPAP literature has taken. The 
further advanced CPAP literature, on the other hand, might benefit from 
paralleling recent efforts in other domains of health and adherence research. As 
outlined in chapter 1 and 2, the CPAP literature has largely become 
dichotomised. A holistic approach, integrating biomedical, psychological and 
social variables into a biopsychosocial model of CPAP adherence is needed. As 
such, three core targets for CPAP research were derived from the conclusions of 
the narrative review in chapter 2.  Firstly there is a need for an extensive 
investigation of the largely under researched psychological and social variables 
that might influence CPAP adherence (Aim 1). Secondly, biomedical and 
psychosocial factors need to be considered as interacting variables influencing 
CPAP use; not only in a multifactorial, but also holistic fashion (Aim 2).  Lastly, 
to translate this biopsychosocial approach into routine clinical practice, brief 
scales with good validity (not least face validity) measuring psychological and 
social variables need to be developed and rigorously tested, adding to already 
established biomedical measures (Aim 3). These conclusions were primarily 
drawn with CPAP adherence in mind, where the divergence between biomedical 
and psychosocial approaches was most evident. However, these conclusions can 
be equally extended to the CBT-I literature, or even to any area of adherence 
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research; ensuring adequate adherence is a health care task and after all, this, 
according to Engel, is managed best within a biopsychosocial framework.  
To contribute towards these aims, four studies were completed within the 
remit of this thesis. Table 23 summarises the main outcomes of each of the four 
studies included in this thesis.  
Table 23: Summary of main outcomes by study 
Experimental 
Chapters 
Aim of study Methodology used Summary of results Thesis 
aim 
targeted 
 Chapter 3- A 
longitudinal 
qualitative analysis 
of the experience 
of using Continuous 
Positive Airway 
Pressure 
Investigate the 
experience of CPAP 
adherence to 
understand further 
psychosocial variables 
predictive of machine 
use 
Longitudinal 
approach, 
interviewing OSA 
patients before CPAP 
initiation, 1 week and 
3 months after 
machine purchase 
using semi-structured 
interviews 
CPAP embodies a treatment 
some individuals are 
resistant to use. Many 
resolve the conflict between 
feeling abnormal and 
longing for normalcy, begin 
to integrate CPAP into their 
life, making use of internal 
and external resources and 
motivators.  
1 
Chapter 4: A 
thematic analysis of 
patient experience 
of cognitive 
behaviour therapy 
for insomnia (CBT-I) 
Understand how 
individuals 
experience the 
implementation of 
CBT-I components 
using a qualitative 
approach  
Semi-structured 
interviews with 
individuals with 
insomnia who had 
recently completed a 
CBT-I program for 
their sleep problem  
Establishing the meaning of 
CBT-I at the global level is 
fundamental. Individuals 
then begin to focus on the 
components, evaluating 
each component against 
certain criteria. CBT-I 
remains a challenging 
treatment with associated 
obstacles that need to be 
overcome. 
1 
Chapter 5: The 
effect of 
continuous positive 
airway pressure 
usage on sleepiness 
in obstructive sleep 
apnoea: real 
effects or 
expectation of 
benefit? 
To examine the 
extent to which 
physiological and 
psychological effects 
account for the 
relationship between 
CPAP adherence and 
outcome 
Patient-level meta 
analysis of three 
randomised placebo 
controlled cross-over 
trials identifying the 
effects of CPAP on 
daytime sleepiness 
Above physiological effects, 
some of the outcomes 
witnessed from using real 
CPAP are a result of 
psychological effects, 
potentially influenced by an 
expectation of benefit 
2 
Chapter 6: The 
Stage of Change 
Scale for Insomnia 
(SOCSI) - A new 
scale to monitor 
stage of change 
during sleep 
restriction therapy 
for insomnia 
Develop and validate 
a scale to assess 
components of the 
transtheoretical 
model (stage of 
change, self-efficacy, 
decisional balance 
and strategies for 
change) 
Cognitive pretesting 
for the development 
of the scale (study 1) 
and validity and 
reliability testing in 
the context of a sleep 
restriction trial (study 
2) 
Good face, concurrent and 
predictive validity was 
established for the SOCSI. 
The scale provides an 
optimal measure for 
assessing stage of change to 
understand adherence to 
sleep restriction therapy 
3 
 
The first two experimental chapters (3 & 4) used a qualitative 
methodology to allow for a detailed and thorough investigation of individual’s 
thought processes whilst implementing treatment recommendations for their 
sleep problem. This method provides a window into the patients’ attitudes and 
beliefs and enables the identification of psychosocial variables that need to be 
considered in interaction with biomedical variables (Aim 1).  
As summarised in Table 23, the results of chapter 3 confirmed that CPAP 
is perceived as an intrusive therapy and revealed how individuals battle with the 
conflict between the perceived need for treatment and the simple unwillingness 
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to use the machine. Longing for normalcy highlighted the dichotomy between 
feeling abnormal with the machine and the desire to regain normal functioning 
during the day. These resolved in some, however remained present for others 
despite the attempts to integrate CPAP into their life, making use of motivators 
and resources.  Reflecting on these results in light of the aims of the thesis 
several points can be mentioned.  
Both self-endorsed and externally inflicted stigma contributed to the 
unwillingness to accept and adhere to treatment. Feeling old, sick or lazy were 
common attributes of this stigma. Although emerging in some of the qualitative 
studies, this has not been quantitatively explored and its contribution to 
adherence within the biopsychosocial model needs to be assessed. For example 
men might be more inclined to endorse the feelings of stigma compared to 
women. The acceptance of the sleep disorder and adherence to treatment might 
be equated with taking on a sick role and this may stand in opposition to the 
authoritative/protective role some men might still take on within the family. 
Age might also be differentially associated with stigma. As outlined in chapter 1, 
some studies have indicated younger age to be associated with poorer 
adherence. The perception of needing “oxygen therapy” to help one to sleep 
and to breathe is equated with feeling old, and this may result in resistance in 
younger individuals. Lastly, this psychological variable might interact with social 
factors, such marital status. The contrast between taking care of one’s family 
and taking on a sick role, is less relevant for single (male) individuals. Turning 
the attention to other health domains and adherence research, a well-validated 
scale outside the CPAP literature is the Illness Perception Questionnaire-Revised 
(IPQ-R)(533) and its subscale emotional representation, which assesses the 
extent to which negative emotional connotations are attached to the illness; an 
example item of this subscale is ”I get depressed when I think about my sleep 
problem”. This scale might tap into the construct of stigma, however does not 
depict an exact representation of it. Nevertheless, the IPQ might prove useful in 
understanding the emotional representations these individuals might endorse.  
A further aspect emerging from the results of chapter 3 that has been 
largely neglected in the CPAP adherence field is the impact of social factors. As 
outlined in chapter 1 and the discussion of chapter 3, variables such as spousal 
support and improvement in partner’s sleep quality have been associated with 
CPAP adherence. However, the results of this qualitative investigation highlight 
Chapter 7  Overarching Discussion 263 
 
the need to expand our understanding of how both the illness and treatment 
impact on the patient’s surrounding. The individuals in this sample expressed 
concerns about how the integration of CPAP would affect their bed-partner, but 
at the same time were encouraged to adhere to treatment as a result of spousal 
support and the potential improvements in their partner’s sleep and their 
relationship. These results emphasise the importance of involving the partner 
into the clinical setting, as has successfully been done in interventions to 
improve CPAP use(e.g., 351). The consideration of the patient’s social network 
also coincides with the merits of the biopsychosocial model- seeing the patient 
from a holistic perspective. Consequently, not only must further exploration of 
social variables occur, but also effort should be made to understand how these 
factors relate to variables within the biomedical and psychological domain. For 
example, extensive partner support might be useful in dealing with adverse 
effects or support might be beneficial in those with high, but not those with low 
disease severity, as has previously been shown.(338) Thus chapter 3 highlights 
additional psychological and social variables that could be considered in relation 
to CPAP adherence, and lays a path for the investigation of possible interactions, 
built on the recent efforts described in chapter 2.  
As a result of the dearth of information on CBT-I adherence and limited 
qualitative exploration in this area, the aim of chapter 4 was to offer an in-
depth account of the individual’s experience, in order to expand our, as of yet, 
limited knowledge on adherence to CBT-I. Similar to chapter 3, the results of 
this qualitative investigation pointed towards the importance of considering 
social aspects. This was prominent in the subthemes “evaluation of self against 
others” and “negative/unwanted consequences”. These issues pertain to two 
important issues that need to be mentioned here. Firstly, the delivery of CBT-I 
in a group format, and secondly, the role of family/bed partner in the cognitive 
behavioural treatment of insomnia. Two studies have established a group format 
to be as equally effective as individual CBT-I delivery in head-to-head 
evaluations,(477, 478) however neither reported on potential differential effects 
on adherence. From the results in chapter 4, it is evident that the group format 
had an effect on the individuals’ behaviour. The investigation of the intricate 
relationship between group dynamics and adherence to CBT-I in quantitative 
studies is warranted.  
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The influence of the bed partner has largely been neglected in the 
understanding of the onset, maintenance and treatment of insomnia, as outlined 
in a very recent literature review.(559) Chapter 4 results indicated how 
individuals are concerned that the implementation of some behavioural 
components will impact on the bed partner and household in general. In this 
recent review, Rogojanski and colleagues outline the potential beneficial effect 
of integrating the bed partner into the treatment environment, mainly to 
encourage support with adherence, but also to educate the partner about 
behaviour that may be maintaining the problem, including those of the partner. 
The potential impact behavioural components may have on the partner’s sleep 
are unfortunately not addressed in this review, despite the negative 
consequences this could have on augmented support. The quantitative 
exploration of this relationship may be fruitful; as well as addressing the 
partner’s sleep, or at least the patients concern’s about negative consequences, 
within the clinical setting. In summary, the results of chapter 4 highlight the 
need to provide fundamental information about factors within the social domain 
of a BPS model contributing to adherence to CBT-I.  Chapter 4 also highlights the 
dynamic nature of adherence to CBT-I, within the context of two themes: 
“ongoing evaluation of components” and the subtheme “is the timing right”, 
indicating that the psychological construct readiness to change might be 
valuable in understanding treatment adherence (as further evaluated in chapter 
6).  In respect to biomedical factors, side effects associated with 
implementation of behavioural components were identified in this qualitative 
investigation. This has previously been established in a trial on sleep 
restriction,(139) however has not been identified in a study of multi-component 
treatment. The further quantification of how side effects may play a role in 
patient adherence is warranted, as are possible interactions with psychological 
and social variables. For example, increased daytime sleepiness and reduced 
functioning as an unwanted side effect of sleep restriction might fuel the 
dysfunctional belief of requiring 8 hours of sleep in order to ensure adequate 
next day functioning. In summary, chapter 4 highlights potential psychological, 
social and biomedical variables that yet have to be explored within the 
framework of a BPS model.  
The two qualitative chapters were explicitly designed to expose possible 
psychological and social factors that predict adherence to CPAP and CBT-I. 
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Chapter 2 emphasised the importance of considering adherence not only as a 
multi-dimensional, but also as a biopsychosocial phenomenon (Aim2). As outlined 
in Table 23, Chapter 5 aimed to elucidate the differential physical and 
psychological effects on the relationship between CPAP use and symptomatic 
improvement. The patient-level meta-analysis of three randomised placebo-
controlled crossover trials indicated that increased use of real CPAP conferred 
improvements in daytime sleepiness, but interestingly, so did increased use of 
placebo CPAP. As described in chapter 1, the relationship between adherence 
and outcome might be bidirectional, with increased adherence leading to better 
symptomatic improvements [the direction exclusively concentrated on in 
chapter 5], but improvements might also encourage increased machine use. 
Regardless of this point, the results suggest this (bi-directional) relationship is a 
result of both physiological and psychological effects [significant interaction 
effect]. Thus studies reviewed in chapter 1 exposing symptomatic improvement 
as a strong predictor of CPAP use, might stem from the actual physiological 
improvements in sleepiness, but also from a psychological expectation of 
benefit. The results also reveal that daytime sleepiness should not be purely 
considered a biomedical variable, but malleable to psychological effects or 
rather an expectation of benefit [placebo effect per se]. Thus the evidence for 
adopting a biopsychosocial approach to CPAP adherence emerges from two 
aspects of chapter 5 results: the significant interaction effect and placebo effect 
per se.   
As outlined in chapter 2, the translation of a biopsychosocial approach of 
adherence into routine clinical practice requires the development and validation 
of questionnaires facilitating the identification of psychological and social 
variables (Aim 3). The final study in chapter 6 outlined this process for a scale 
assessing components of the transtheoretical model. Particular care was given to 
a number of issues to ensure this could be translated easily into clinical care. 
First of all, the scale had to be brief, ensure face validity and potentially 
transferrable to other sleep problems or health domains. To ensure brevity, 
there was a conscious decision against the use of multi-dimensional continuous 
measures of readiness to change, such as the 32-item version of the URICA.(512) 
Although the merit of this scale is the continuous measurement of readiness to 
change, however the brevity of an algorithm based scale with few items was 
deemed more appropriate for accomplishing the thesis aims.  
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Secondly, the scale had to warrant face validity and this was 
accomplished with the cognitive pretesting of the SOCSI (study 1). Future studies 
might want to test the face validity of the scale as rated by treating 
practitioners, however this was beyond the scope of the thesis. Although the 
SOSCI was developed and then successfully validated within the context of an 
insomnia population (study 2), certain steps were taken to ensure it could easily 
be adapted for the use in other sleep populations, or even other health domains. 
This included the consideration of open-box response formats, and the use of the 
term “action plan”. This effort extends the aims of a BPS model of CPAP 
adherence to a holistic model of adherence in general. This though perhaps 
stems from the main strength of this thesis: the consideration of two sleep 
disorders, see below. 
Before considering the strengths and limitations of the thesis in the next 
paragraph, it is worth briefly discussing the secondary aim of chapter 6: to 
provide information about measurement of adherence to SRT. With most 
individuals within 30 minutes of their threshold and rising time, and only small 
to moderate correlations with outcome, it is difficult to establish meaningful 
cut-offs for optimal adherence. Intuitively, 30 minutes seems a logical, and this 
is a figure used for cut-offs of insomnia symptoms (SOL, WASO).  As described in 
the discussion of chapter 6., future dose-response studies might elucidate 
further on this matter.  
7.2 Strengths/Limitations of the Thesis and Future 
Directions  
Because the specific strengths and limitations of each study have been 
presented in the individual discussions of each chapter, only overreaching 
strengths and limitations of the thesis will be considered here, with remarks to 
possible translation into future studies/directions in this field.  
The main strength of this thesis is the consideration of both OSA and 
insomnia. This has hopefully allowed for a more holistic approach to the 
phenomenon of adherence in general, by not becoming immersed in aspects that 
are only unique to one disorder. However, the two disorders have been 
considered as two separate conditions within this thesis. Yet, as highlighted in 
chapter 1, there is considerable overlap between these disorders. The 
introduction of CPAP might further exacerbate any underlying insomnia, or 
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contribute to a new incidence of insomnia and this might negatively impact on 
adherence to CPAP. Likewise, the use of CPAP might complicate adherence to 
components of CBT-I. Getting up in the middle of the night according to the 
quarter of an hour rule might seem even less appealing in full CPAP attire. 
Future studies need to take an integrative approach, not only to adherence, but 
also at the level of sleep disorders. Less “siloing” and dichotomising between 
physiologists and psychologists is vital, if the field of sleep medicine is to 
progress.(343, 365, 560) Related to this limitation is the aspect of conducting 
four very disparate experimental studies. This has both strengths and limitations 
in itself. There is a benefit at the level of the learning outcomes of the thesis, 
becoming skilled in various methodologies, including qualitative, patient-level 
meta-analysis and scale development, see Table 23. However simultaneously, 
this has made the translation of the experimental findings of each chapter into 
studies that follow on from and complement previous results slightly less likely.  
The results of all experimental chapters provide support for the adoption of a 
BPS approach; however conducting four disparate experimental studies also 
precludes the systematic evaluation of a BPS approach to either sleep disorder. 
Future studies should focus on the systematic exploration of possible 
interactions across all BPS domains, as outlined throughout this thesis. 
In a concluding remark, this thesis has not exploited the uniqueness of 
sleep itself in understanding the phenomenon of adherence. Sleep is supposed to 
be restful, peaceful, and the introduction of something as intrusive as CPAP or 
sleep restriction and stimulus control is naturally going to meet with 
resistance.(see 561) Furthermore, the consequences of sleep 
deprivation/disturbances on mood in the long-term can lead to higher rates of 
depression and that is known to affect adherence to medication;(234) this might 
be a unique consideration for disorders of sleep.(562) Crucially, non-adherence 
to treatments for sleep disorders such as insomnia and OSA occur largely at a 
time where rational decision-making is impaired: at night. This aspect was 
briefly touched upon in chapter 3, however there is sufficient scope in future 
studies to understand how sleep might be present itself as a unique 
consideration for adherence. Furthermore, this has particular implications for 
interventions that incorporate non-rational aspects of human behaviour, such as 
habit-forming principles.(e.g., 437)  
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In reflection on this body of work, an exclusive focus on only one of these 
sleep disorders might have enabled a more comprehensive exploration of 
possible predictor variables, leading to a development of an interventions to 
improve adherence. The latter aspect has not been explored experimentally 
within this thesis. However, the definite advantages of the simultaneous 
consideration of both OSA and insomnia will hopefully allow for an interesting 
translation into further research, possible interventions, and clinical practice 
beyond this thesis. 
7.3 Concluding remarks 
In summary this thesis aimed to advance our understanding of contributing 
factors to the variance in adherence to treatments for OSA and insomnia. With 
the literature in both domains just at the cusp of agenda change, this thesis 
aimed to provide novel information about potential psychological and social 
variables, the interaction of variables from different domains of the 
biopsychosocial model of adherence and to develop tools to facilitate the 
assessment of these variables. Various avenues for future research to pursue 
have been suggested. Importantly, these need to consider adherence as a 
biopsychosocial phenomenon and begin to understand the unique consideration 
of the sleep state; after all,   
 
"Sleep&that&knits&up&the&ravelled&sleeve&of&care&&
The&death&of&each&day's&life,&sore&labour's&bath&&
Balm&of&hurt&minds,&great&nature's&second&course,&&
Chief&nourisher&in&life's&feast."&&
??&William&Shakespeare&
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Appendix 1: Research Diagnostic criteria for Primary Insomnia Taken from Edinger et al.(92)
 
Appendices  270 
 
Appendix 2- Consent form for Qualitative Studies1 
  
                                         
1Consent forms for insomnia and OSA populations were identical. Layout differed according to research setting (e.g. 
Glasgow University and NHS headings were replaced with Royal Prince Alfred Hospital and Woolcock Institute logos, 
see appendix xxx).  
Study Number:  
Participant Identification Number for this study: 
 
 
Consent Form 
 
Title of the Project: Adherence in the Treatments of Disorders of Sleep and 
Wakefulness 
Name of Researchers: Megan Crawford and Professor Colin Espie 
 
 
 
1. I confirm that I have read and understand the information sheet and 
received my own copy dated the 12th of February 2009 for the above 
study. 
 
2. I have had the opportunity to consider the information provided, ask 
questions and have had these answered satisfactorily. 
 
3. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving reason, without my medical care or 
legal rights being affected. 
 
4. I understand that the data collected during this study may be looked at by 
responsible individuals from the research team or from regulatory 
authorities where it is relevant to them taking part in research. I give 
permission for these individuals to have access to my records. 
 
5. I understand that the study will be tape recorded and audio data will be 
destroyed after transcription. 
 
6. I give permission to contact my GP and/or sleep specialist for information 
regarding this particular study. 
 
7. I consent to the results, which may be in form of direct quotes 
(anonymised form), of this study being published in relevant journals 
 
8. I would be interested in being contacted in the furture from the University 
of Glasogow Sleep Centre regarding future studies. 
 
9. I agree to take part in the above study. 
 
 
 
  
Name of Participant   Date    Signature 
 
 
Megan Crawford   20th of April 2009   
  
Researcher    Date    Signature 
 
Version 2: 12/02/2009 
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Appendix 3- Participant Information Sheet for 
Qualitative Study- OSA 
 
 
 
 
 
 
 
 
Adherence in the Treatments of Disorders of Sleep and Wakefulness 
 
Participant Information Sheet for Obstructive Sleep Apnoea 
 
Purpose of the Study 
 
Obstructive Sleep Apnea (OSA) is a common sleep disorder which has 
major negative health implications and is a serious risk factor for cardiovascular 
disease.  Continuous Positive Airway Pressure (CPAP) is the most effective and 
widely used treatment choice as it reduces the number of nocturnal respiratory 
events or the number of times you stop breathing during sleep, improves the 
quality of sleep and reduced daytime sleepiness.  However many individuals do 
not take up their CPAP treatment for a number of reasons. 
Previous testing (an overnight sleep study) has shown that you have sleep apnea and due to 
the severity of your disease CPAP was recommended as the first choice of treatment 
following screening and discussion with your sleep physician.  
 
You are invited to participate in a research study aiming to understand the experience 
implementing the recommendations given by your practitioners about using CPAP. 
Understanding the factors that enable participants to start and maintain treatment 
recommendations is important in helping us further improve treatment interventions.  
 
 
Voluntary Participation and Withdrawal from the Study 
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You have a right not to participate in the study and you can withdraw at any time.  A 
decision not to participate or to withdraw from the study will not affect your current or 
future treatment or your relationship with the University of Sydney or Royal Prince Alfred 
Hospital or any of the participating hospitals or institutions co-operating in this study or 
any person treating you. 
 
Description of Study and Risks 
 
If you decide to participate in this study, you will be invited to come to 
the Woolcock Institute of Medical Research, where firstly you will be asked to 
sign the Participant Consent Form.  Thereafter you will, as part of routine 
treatment, undergo a CPAP titration study, which is similar to your overnight 
diagnostic sleep study. This time however you will be using a CPAP machine to 
determine what water pressure is required to stop your ‘stopping breathing’ 
episodes. Treatment as Usual (TAU) also consists of a standard education 
presentation of 12 slides, which describe normal sleep; sleep staging; what is 
obstructive sleep apnoea and how CPAP works (this education session is given 
before your titration study). In addition to this routine treatment procedure you 
will be asked to take pat in one-on-one interviews with the research co-
ordinator at 3 different time points. The first interview will be on the same day 
you come in for your CPAP titration (so you will need to come in a few hours 
before your titration study to meet for the interview). You will be then, as for 
all clinic patients, asked to purchase and pick up your own CPAP machine, mask 
and tubing after you have received a script from the sleep unit staff stating the 
information you will need. After you pick up your mask, you will be asked to 
contact the research investigator, and you will then be invited to come for 2 
additional interviews, the second interview will be held 1 week and the third 
interview 3 months after you pick up your mask.  
 
The interviews will last approximately 1 hour and will be one-on-one 
semi-structured interviews. It will resemble mostly an informal conversation; 
however some questions regarding your experience with your OSA and CPAP 
treatment will be prepared. The interview will be tape-recorded and the data 
will be deleted after transcription. The results of this study will be published in 
a relevant journal so that the general public is also aware of these findings. 
These reports/publications may include quotes from the participants, however 
all information regarding your/their identity will not be revealed in these. Also, 
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anything you say will not affect your subsequent treatment delivery. After each 
interview you will also be asked to fill in some questionnaires (described below). 
All the information that is collected, during the course of the study, will remain 
strictly confidential. This means that all information will be kept secured in 
locked filling cabinets and only the researcher will be able to access these, you 
will be given a unique code that will ensure confidentiality and anonymity of all 
your data. The researchers would like to have access to your medical record to 
obtain information relevant to this study. 
 
Description of Questionnaires2  
 
• Epworth Sleepiness Scale (ESS) presents 8 everyday situations and you are 
asked to rate your chance of dozing in these circumstances. 
• Hospital Anxiety and Depression Scale (HADS) is a validated 14-point scale 
that asks you to rate your mood and feelings in relation to a number of different 
statements. 
• Pittsburgh Sleep Quality Index (PSQI) is a validated 11 point questionnaire 
widely used in sleep research which assesses sleep quality, insomnia 
symptoms, medication use and other sleep disorders. 
• The Illness Perception Questionnaire (IPQ-R) asks you about your perceptions about your 
illness in terms of consequences, time-line, cure/control, coherence and emotional 
representation.  
• Transtheoretical Model Scale (TM) is a validated questionnaire and assesses variables 
involved in changing behaviour.   
• The Daytime Functioning Scale is a 12 item scale that ask you to rate the importance of 
various effects of your sleep problem on your daytime functioning . 
• The Glasgow Sleep Impact Inventory (GSII) is a rating scale of the impact your sleep problem 
has on your life.  
• The University of Rhode Island Change Assessment Scale-Insomnia (URICA) is a scale 
adapted from the validated URICA used to assess individuals’ readiness to change.  
• Functional Outcomes Sleep Questionnaire (FOSQ) is a quality of life scale developed 
specifically to assess lifestyle difficulties associated with any sleep disorders you may or may 
not experience. 
• The Social Cognitive Theory scale (SCT) is a validated questionnaire with items asking about 
the outcome expectancies you have, ratings of your self-efficacy and the social support you 
have.  
 
While we intend that this research study furthers medical knowledge and 
may improve treatment of OSA in the future, it may not be of direct benefit to 
you. 
 
 
Confidentiality and Disclosures of Information 
                                         
2 These questionnaires were part of secondary analysis are not included in this thesis.  
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Any information that is obtained in connection with this study and can be 
identified with you will remain confidential and will be disclosed only with your 
permission or except as required by law.  If you give us your permission by 
signing the Participant Consent Form, we plan to publish the results in medical 
or scientific journals and we may also reanalyse the data at some later stage.  In 
any publication, information will be provided in such a way that you cannot be 
identified. 
 
If you have any questions, please feel free to ask us.  If you have any additional questions 
concerning the availability of medical care, or if you think you have experienced a research 
related illness, injury or emergency, please immediately contact the Principal Investigator, 
Professor Ron Grunstein, on (02) 9114 0007, the co-investigator  Dr Delwyn Bartlett, on 
(02) 9114 0460, or the research coordinator/officer for this project, Megan Crawford (02) 
9114 0456. 
 
Ethics Approval 
 
This study has been approved by the Ethics Review Committee (RPAH) of the Sydney 
South West Area Health Service.  Any person with concerns or complaints about the 
conduct of a research study can contact the Secretary on (02) 9515 6766 and quote 
protocol number xxx. 
 
This information sheet is for you to keep.  
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Appendix 4- Interview schedule for Qualitative 
Studies 
 
Preamble to Semi-Structured Interview 
Knowing about people’s experiences of a sleep problem and their treatments 
can be very useful in helping us to improve treatment experience. Often 
research uses questionnaires and designs experiments to find out how individuals 
react to treatments and how and why they try to follow treatment 
recommendations. Another research tool is to ask the individual to report of 
their experience of the sleep problem and the treatments. This provides unique 
information that questionnaires and experiments do not always do. Therefore I 
would like to ask you a few questions about your sleep problem, how you 
experience(d) treatment, and how you tried to follow the advice given by your 
doctor/therapist. I will start with some general questions and then follow with 
some more specific ones. All the information you give will remain anonymous 
and you are free to withdraw from the study/stop the interview at any time. The 
interview will be audio-taped, but you may disagree with this, if you wish for it 
not to be recorded. 
 
The Disorder and Treatment 
 
1. Can you describe the history of your sleep problem, from when it started 
to the beginning of treatment? 
 
2. How did you feel about having sleep apnoea/insomnia? 
PROMPT: What did it mean to you? 
PROMPT: What kind of implications did it have for you? 
 
3. What did you feel at first when this treatment was suggested? 
PROMPT: What were your thoughts/knowledge about the 
treatment before it was suggested? 
PROMPT: What did you expect from the treatment? 
   
4. What did you feel when you first tried it out? 
PROMPT: physically, emotionally, mentally. 
 
5. What is using CPAP/CBT like for you now? 
PROMPT: physically, emotionally, mentally. 
PROMPT: How are things different for you now? 
 
Appendices  276 
 
6. How does CPAP/CBT affect your every day life? 
PROMPT: Is it positive/helpful or more a burden? 
 
7. How do you feel about your sleep problem now? 
PROMPT: What does it mean to you? 
PROMPT: What kind of implications does it have for you? 
 
         
 
Implementing Treatment 
 
8. Can you describe a typical night when using your CPAP machine/CBT? 
PROMPT: What do you think influenced your behaviour? 
 
9. Can you describe a typical night when you did not use your machine/CBT? 
PROMPT: What do you think influenced your behaviour? 
 
10. Different people behave differently when asked to follow a set routine? 
Do you have any thoughts on that? 
PROMPT: Can you give an example of your own experience? 
PROMPT: Is this similar to your experience with CPAP/CBT? 
 
11. If you could choose one thing to change that would help you follow a set 
routine to the requirements, what would that be? 
PROMPT: Can you give any further examples? 
 
12. What do you think your medical practitioner emphasises as important in 
following treatment recommendations? 
 
13. Is there anything you would like to add to the information given so far? 
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Appendix 5: Poster preseted at the American 
Professional Sleep Societies Conference, 
Minneapolis, 2011 
 
Background
Methods
Measures and Subjects
 Thirty-four individuals with OSA were conveniently sampled 
from a large randomised controlled cross-over study 
(n=108) evaluating the effectiveness of MAD versus CPAP.
 Treatment Acceptability for both MAD and CPAP, Health 
Value (all variables split into high vs. low based on median) 
and general self efficacy were measured. We examined the 
effects of these variables on adherence to both treatments. 
Results
Funding: Australian and UK MRC 
Are Treatment Acceptability and Health Value Associated with Adherence to 
Treatments for Obstructive Sleep Apnea
Megan R. Crawford1,2,3 Greenwood, A.2 Bartlett D.J.2,3 Espie, C.A.1,3 Grunstein, R.R.2,3 Cistulli, P.A.2,3
1 University of Glasgow Sleep Centre, Scotland, UK, 2 Woolcock Institute of Medical Research, University of Sydney, Australia 
3 NHMRC Centre for Integrated Research and Understanding of Sleep (CIRUS)
Acknowledgements
 Mandibular advancement devices (MAD) offer an 
alternative to Continuous Positive Airway Pressure (CPAP)  
for Obstructive Sleep Apnea (OSA).
 Some evidence is available regarding the disease 
phenotype (e.g. AHI, upper airway physiology) that might 
predict which individuals respond best to either treatment. 
 It is unclear which psychological variables might predict 
adherence. 
 Treatment effectiveness might be a predictor of adherence 
to treatment, but self-efficacy could mediate this relationship, 
especially for CPAP- a cumbersome, demanding treatment. 
Aims
 To establish a psychological profile that might predict 
adherence to treatments for OSA. 
Effects of Acceptability and Health Value on CPAP adherence 
Conclusions
 This study reveals that acceptability of CPAP might have an effect on treatment use, yet contrary to our 
hypothesis, this relationship was not mediated by the belief in one’s own capabilities. 
 Individuals who value their health are increased CPAP users. 
 Interestingly, these relationships are not reflected in MAD use, potentially, because this treatment is seen 
as more convenient than CPAP, and thus psychological variables have less of an impact on adherence. 
Statistical analysis
 Differences in Treatment Acceptability (each subscales: 
acceptability, convenience, severity of side effects, 
effectiveness)  was examined for CPAP and MAD using a 
student t-test or the equivalent non-parametric test. 
 Analysis of Co-Variance (ANCOVA) was computed to 
establish the effect of treatment acceptability and health value
on adherence to CPAP and MAD, controlling for self-efficacy.
Table 1:  Characteristics of the sampled 34 patients
10 (SD2)Prescribed CPAP pressure (cmH20)
4 (11%) femaleGender (female) 
152 (SD 67)Maximal Protrusion with MAD (%)
22 (SD 11)Baseline Apnea Hypopnea Index
8 (SD 4)Baseline Epworth Sleepiness Scale
47 (range25-66)Age (Years)
34Number of Participants
Differences in treatment acceptability between CPAP and MAD
 Post-Acclimatisation Period
 There was no difference between the acceptability subscales, except for Convenience. MAD (mean=2.5, 
SD=0.9) was considered more convenient than CPAP (mean=1.9 SD=0.9), t(32)= -2.6; p<0.01, (Figure 1).  
These effects were retained post treatment (Figure 2). 
Figure 1: POST ACCLIMITISATION
Differences between Treatment Acceptability Subscales 
for MAD and CPAP
Figure 2: POST TREATMENT
Differences between Treatment Acceptability Subscales 
for MAD and CPAP 
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 There was a trend for an effect of treatment acceptability on adherence levels in the CPAP phase;
 Mean adherence for the high scoring acceptability group (mean = 4.6, SD = 2.5) was higher than for the low 
scoring acceptability group (m=3.4, SD=2.0), t (30) =-1.7, p=0.08, representing a medium effect, d=0.6 (Figure 3).
 This effect remained after controlling for self-efficacy. 
 Health value had a large effect (d=0.8) on adherence in the CPAP phase; higher mean adherence was evident in 
those that viewed their health as important (m=4.8, SD=2.1) as compared to those who viewed it as less important 
(m=2.9, SD=2.5), t (31) =-2.4, p<0.05 (Figure 3).
 Interestingly the relationship between adherence and psychological variables was not observed in the MAD 
phase. 
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Figure 3: Effects of Treatment Acceptability and Health Value on adherence to CPAP. Bars represent mean value of adherence with 
standard error bars. 
Contact: m.crawford.1@research.gla.ac.uk
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Appendix 6- Participant Information Sheet for 
Qualitative Study- Insomnia 
 
 
 
 
 
Version 2: 12/02/2009 
 
Participant Information Sheet- Insomnia 
 
Title: Adherence in the Treatments of Disorders of Sleep and Wakefulness 
 
You are being invited to take part in a research study. Before you decide 
whether or not to take part, it is important for you to understand why the 
research is being done and what it will involve. Please take time to read the 
following information carefully and discuss it with other if you wish. Ask us if 
there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part.  
 
The Study 
It is a research study being conducted at the University of Glasgow Sleep Centre 
. This study is designed to understand the experience of having a sleep problem, 
what treatments for your sleep disturbances are like and your experience in 
trying to follow the recommendations of your doctor. In order to understand this 
kind of information, researchers carry out interviews to ask people about their 
experiences. This is also the nature of this study; therefore, you will be invited 
to the University of Glasgow Sleep Centre for an interview, where the researcher 
will ask about your experiences with your sleep problem and the treatment. This 
will hopefully give us more information of how to improve treatments and how 
to help people trying to follow treatment advice. 
 
Do I have to take part? 
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Taking part in the research is entirely voluntary. This means that it is up to you 
to decide whether or not you would like to take part. If you do not wish to take 
part it will not affect the case or your rights in any way. If you decide to take 
part in the study, you can keep this information sheet and return the consent 
form and your responses to the questionnaires enclosed. If you do decide to take 
part, you can change your mind and withdraw from the study at any time, even 
after the study has finished. 
 
What does taking part involve?  
If you decide to take part, you will be invited to come to the University of 
Glasgow Sleep Centre at the Southern General for an interview. You will meet 
with the researcher who is interested in finding out about your experiences with 
your sleep problem and the treatments. A few questions will be prepared that 
the interviewer will ask, but generally the interview will be more like an 
informal conversation. The interview will last approximately one hour. 
Afterwards you have the opportunity to answer a few questionnaires, which will 
take a few minutes of your time and we will also ask you for some feedback on 
the interview that might improve future interviews. 
 
Would my results be kept confidential? What will happen to the results of the 
study? 
All the information that is collected, during the course of the study, will remain 
strictly confidential. This means that all information will be kept secured in 
locked filling cabinets and only the researcher will be able to access these, you 
will be given a unique code that will ensure confidentiality and anonymity of all 
your data. The interview will be tape-recorded and the data will be deleted 
after transcription. The results of this study will be published in a relevant 
journal so that the general public is also aware of these findings. These 
reports/publications may include quotes from the participants, however all 
information regarding your/their identity will not be revealed in these. Also, 
anything you say will not affect your subsequent treatment delivery. 
 
 
What are the potential benefits of taking part? 
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 Taking part will hopefully help us broaden our knowledge of how patients 
experience their sleep problem and treatments. This in turn will provide us with 
information of how to improve treatments and how best to support the patients 
during the course of treatment.  
 
 
If I decide to take part what happens next? 
Apart from this Participant Information Sheet you will also find a consent form, 
which you will need to return and send back to the Sleep Centre in the self-
addressed envelope. Enclosed is also a leaflet with Frequently Asked Questions 
to help you with any problems that may arise. 
 
Thank you for reading this information. If there is anything you are not clear 
about or if you have any questions regarding this study you can e-mail the 
researcher at 
 
m.crawford.1@research.gla.ac.uk or call: 
 
University of Glasgow Sleep Centre Recruitment Number: 07503730769 
 
If you would like some independent advice from someone who is not involved in 
the study, please contact Dr Maria Gardani +44 (0)141 232 7700 or 
M.Gardani@clinmed.gla.ac.uk  
 
 !
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Appendix 7: Supplementary Figure: Dose-
response curves for CPAP use and ESS 
improvement
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Appendix 8- Description of the Transtheoretical 
Model 
 
Stage of Change 
 
In the early versions of their model Prochaska and DiClemente described how 
smokers pass through distinct stages when considering and implementing 
change(504, 563). In further refinements of their model through experimental 
studies, they identified 5 stages of change: pre-contemplation, contemplation, 
preparation, action and motivation.(564-567)  
Each stage represents an amalgamation of the indvidual’s current 
behavioural state and intention to change. In precontemplation stage, the 
unhealthy behaviour (e.g. smoking) is the status quo and the individual has no 
intention of changing, at least not in the near future (usually 6 months). At the 
next stage, the individual reaches a point of ambivalence; the importance for 
the new behavioural pattern starts to emerge and the individual begins to 
contemplate behaviour change. It is a period of extreme instability and often 
individuals become stuck in this stage for a lengthy period of time.(504) At the 
point at which the benefits for the new behaviour outweigh the costs, the 
individual begins to make concrete plans for change within the near future. 
Irregular implementation of behaviour in the past year is often described as 
characteristic of this preparation stage(503). The consistent behavioural 
implementation occurs in the action stage, and once the new behaviour becomes 
the status quo for a period of time (often described as 6 months), the 
maintenance stage is reached. These temporal distinctions are somewhat 
arbitrary, but necessary to place individuals into distinct categories.(556)  
 Although the theoretical progression through these stages reflects a 
linear increase in readiness to change, the natural progression through these 
stages is described as cyclical, often portrayed as the revolving door principle 
(after moving through to later stages, relapsing back to earlier stages prior to 
continued progression).(504, 564) Interestingly, their experimental work 
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suggests that individuals learn from their experience with only 15% of smokers 
relapsing to the earliest stage of pre-contemplation(503), see also Figure 16. 
 
 
Figure 16: A spiral model of the stages of change.  
Source: Prochaska et al. 1992(564) 
 
Process of Change 
 
The model further specifies distinct processes that initiate the transition to 
theoretically superior stages.(502) Modelled again on existing theories, they 
describe 10 internal and external strategies that can be implemented to 
facilitate stage transition. These are classified as overt (behaviour) or covert 
(cognitive) and it is claimed that the covert processes are involved in the 
transition through the earlier stages to initiate contemplation of change, 
whereas overt processes are involved in facilitating maintenance of change.(547) 
See Table 24. 
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Table 24: Processes of Change 
 Process Description 
Covert 
(Cognitive) 
Consciousness raising Making use of informational resources 
to raise awareness of the new 
behavioural pattern 
Self-reevaluation Evaluation of the new behavioural 
pattern against personal values 
Environmental reevaluation Evaluation of the impact on 
environmental context (e.g. family) 
Emotional arousal/dramatic 
relief 
Considering the emotional impact of 
the potential behavioural change 
Social liberation Becoming aware of the social norms 
surrounding the old and new 
behavioural pattern 
Overt 
(Behavioural) 
Self-liberation Making firm commitments for change, 
take responsibility and strengthen 
belief in own capabilities for change 
Conditioning/counter 
conditioning 
Pursue situations that facilitate 
behaviour change 
Stimulus 
generalisation/control 
Removal of stimuli that elicit old 
behavioural patterns  
Reinforcement management Seeking rewards for successful 
behavioural implementation  
Helping relationships Utilise social support to facilitate the 
implementation of the new behaviour 
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Markers of change: Decisional Balance and Self-efficacy/Temptation 
 
With the precision of their model, Prochaska and colleagues included markers of 
change: the decisional balance and self-efficacy/temptation. The decisional 
balance was modified from Janis and Mann’s decision making theory(568) and 
describes change as a process of weighing up potential benefits against costs of 
the new behavioural pattern. Visually plotting the importance pros and cons for 
behaviour change across the stages in Figure 17 highlights how the costs of the 
new behaviour outweigh the benefits in the preparation stage, an equal balance 
in the contemplation stage; and finally a cross-over occurs, when the pros for 
change outweigh the cons for change in the remaining stages. (569) 
 
Lastly, the TTM also gives prominence to self-efficacy; a concept 
originally framed by Albert Bandura, which has found its way into numerous 
theoretical models and describes the individual’s self-reflected efficacy 
expectations. That is, the belief in one’s capabilities to achieve set goals, 
especially when confronted with certain barriers(339, 570). The TTM states that 
with progression through the stages, the impact of self-efficacy increases in a 
linear fashion.(496) A large evidence base supports the significance of this 
concept in predicting maintenance of change.(571, 572). This is not to say that 
self-efficacy is not also imperative in the earlier stages -a deflated belief in 
one’s abilities might inhibit contemplation and initiation of change(573) - 
however there is a complex interaction between self-efficacy, stage of change 
and processes of change.(496) Self-efficacy is a marker of increased use of 
cognitive change processes in the earlier stages. However, in the action and 
maintenance stages, increased self-efficacy is associated with less use (or need 
to use) of behavioural change processes;(573) hence, self-efficacy can be 
described as both a marker, mediator and moderator of change dependant on 
stage.(574)  
Temptation is described as the counterpart to self-efficacy and is found to 
correlate negatively with self-efficacy, however is not its exact mirror image: 
the temptation to engage in the old behavioural pattern can be high, despite the 
individuals increased confidence to resist that temptation.(496)  
Figure 17 is a visual representation of the processes and markers of 
change and how these relate to the individual stages.  
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Figure 17: TTM overview 
Relationships between processes and markers of change. With progression through the 
stages, pros outweigh the cons for change (the influence of the pros on change diminishes 
once behaviour is implemented and maintained. The TTM model states that the importance 
of self-efficacy increases with stage progression, whereas temptation is reduced. Cognitive 
processes induce change in earlier stages, wheras behavioural processes are most 
important in transition between the latter stages. Adapted from Velicer et al. 1998.(575) 
Measuring stage of change 
 
In experimental studies individuals have been assigned to stages using algorithms 
or measures with stage-specific subscales. Staging algorithms present the 
individuals with a series of questions and responses classify individuals into one 
stage only. An alternative is to present a statement for each stage and 
individuals are asked to indicate which they agree with most. These statements 
are often modelled on published stage descriptions in smokers(566, 567) see 
Table 25.   
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Table 25:  Description of stages used in staging algorithms  
Pre-contemplation ‘I don’t currently have a problem, and I am not willing to change 
within the next 6 months’ 
Contemplation ‘I have a problem, I am thinking of changing within the next 6 
months’ 
Preparation ‘I am planning to change within the next 30 days’  
Action ‘I have implemented the new behaviour within the last 6 months’ 
Maintenance ‘I have implemented the new behaviour for more than 6 months’  
  
This method is particularly useful, because these algorithms are short and 
easily integrated into both cumbersome research protocols and clinical settings. 
There is emerging evidence for the use of this approach in domains other than 
smoking cessation, for example drug use(576) or medication adherence.(523, 
549)  
Three main multidimensional measures have been used, whereby stage 
allocation is determined either by highest scoring subscale or cluster analysis. 
The University of Rhode Island Change Assessment(URICA, 512) the Readiness to 
Change Questionnaire(RCQ, 577) and the Stages of Change Readiness and 
Treatment Eagerness Scale,(SOCRATES, 578) are measures that have been 
frequently used in research administering TTM dimensions. The advantage of 
these scales over the algorithms is the possibility of generating both a 
continuous and categorical outcome variable. However, the key criticism of the 
use of these measures is the lack of overlap with the 5 stages of the 
transtheoretical model, with few replicating the cluster profile described in the 
model.(579)  
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Appendix 9: Interview Schedule- Excerpt 
BOLD text indicates instructions for the interviewer 
Italicised text indicates instructions to be read to the participant 
Underlined text indicates the material being tested. 
 
Cognitive Interview: 
 
Date ___/ ___/ ____ Interview # ______ Interviewer Initials ___ ___ ___ 
Enter start time of interview __ __ : __ __ 
 
Read these instructions in their entirety or paraphrase them but 
include elements 1 to 7 
Thanks for coming in. Let me tell you a little more about what we’ll be 
doing today. 
 
1. We’re testing a new questionnaire with the help of people such as 
yourself.  
2. I’ll ask you questions and you answer them, just like a regular survey.  
3. However, our goal here is to get a better idea of how the questions are 
working. So I’d like you to think aloud as you answer the questions- just 
tell me everything you are thinking about as you go about answering 
them.  
4. At times I’ll also stop and ask you more questions about the terms or 
phrases in the questions and what you think a questions is asking about. 
I’ll also take notes.  
5. Please keep in mind that I really want to hear all of your opinions and 
reactions. Don’t hesitate to speak up whenever something seems unclear, 
is hard to answer, or doesn’t seem to apply to you.  
6. Finally we’ll do this for an hour unless I run out of things to ask you 
before then.  
7. Do you have any questions before we start? 
 
Practice task 
I’d like to begin with a practice questionnaire so you get a feel for 
what is required in the real interview. First of all, I would like you to 
answer the questions on this sheet. After you have answered them, please 
mark your comments on the questionnaire with a pen.  Mark down any 
difficult words or any phrases which are unclear. Please keep in mind that I 
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want to hear all of your opinions, so don’t hesitate to make as many 
comments as you want.   
Give the questionnaire to the participant and let them fill it out on 
their own. 
Practice question 1: How many windows are there in the house or 
apartment where you live?  
Practice question 2: How difficult was it for you to get here to do the 
interview today: very difficult, somewhat difficult, a little difficult, or not at 
all difficult? 
 
Now go through question and answer each individually.  
Okay now I will ask you a series of questions about the questionnaire 
you just filled out. Remember to try to think aloud as you answer.  
So starting with question 1, What is this question asking you? 
 [Probe as necessary]: I see you answered [answer]. How did you come 
up with that answer? 
 
Moving on to question 2,  What is this question about? 
Looking at the answer options, what do the terms “somewhat 
difficult” and “a little difficult mean” to you? Are they different? 
 [Probe as necessary]: Tell me about your answer, why did you say 
[answer]? 
 
Make a note of any difficulties the patient has with this task 
Have they grasped thinking aloud? 
Are they reticent about making critical comments? 
Any Other issues? 
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Appendix 10: Conditioned Probes 
The following conditioned probes were used in the cognitive pretesting if 
necessary: 
 
Conditioned Probing:  
Condition Conditional Probe 
1. Subject cannot answer or 
does not know the answer 
“What was going through your mind as you 
tried to answer the question?” 
2. Subject answers after a 
period of silence. 
“You took a little while to answer that 
question. What were you thinking about?” 
3.  Subject answers with 
uncertainty using explicit cues such 
as “um,” “ah” chaning an answer, 
etc. 
“You seem to be somewhat uncertain. If so, 
can you tell me why?” “What cause you to 
change your answer?” 
4.  Answer is contingent on 
certain conditions being me, e.g. 
“I’d say about 25 times if you don’t 
need a super precise answer.” 
“You seem a little unsure. If so, can you tell 
me why?” 
5. Erroneous answer; verbal 
report implies misconception or 
inappropriate response process. 
Clarify respondent’s understanding of the 
particular team or the process used. For 
example, if the respondent appeared to 
misunderstand the word “manage”, probe 
the term (“so you don’t manage any staff”) 
6. Subject requests 
information instead of providing an 
answer. 
“If I weren’t available or able to answer, 
what would you decide it means?” “Are 
there different things you think it might 
mean? What sorts of things?” 
Taken from(Conrad & Blair (2001, cited in 525) 
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Appendix 11: SOCSI Final Version 
 
© The SOCSI is copyrighted. It may not be used, altered, sold (paper or electronic), translated or adapted for another 
medium without the permission of  M. Crawford, University of Glasgow Sleep Centre, Southern General Hospital, 
Glasgow, UK; megan.r.crawford@gmail.com  
 
 
SOCSI-TREATMENT VERSION 2 
 
ID:      Date: Session 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
People often find it difficult to stick to action plans consistently, even after they have 
agreed their therapy goals. This sheet is a step-by-step way of recording what your 
goals are at the moment; and how you feel about sticking to the action plan between 
now and your next treatment session.  Please complete the 6 steps below. 
 
STEP 1. What action plan (e.g. relaxation, sleep schedule) did you discuss with your therapist, 
in order to help with your sleep problem? 
    
 
 
 
PLEASE TURN THE PAGE 
STEP 2. Please follow through the next set of questions. 
 
 
Q.1. Do you currently consistently stick to the action plan? 
a. Yes (Go to Q2) 
b. No (Go to Q3) 
 
 
Q.2. Have you been consistently sticking to the action plan… 
 
i. within the last 4 weeks 
ii. and for longer than 4 weeks  
 
 
 
Q.3. Are you thinking about consistently sticking to the action plan?  
a. Yes, I will start doing so from now on  
b. Yes, I am considering doing so in the future 
c. No, I am not considering doing so in the future  
 
A 
M 
Office Use  
Prep 
C 
PreC 
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© The SOCSI is copyrighted. It may not be used, altered, sold (paper or electronic), translated or adapted for another 
medium without the permission of  M. Crawford, University of Glasgow Sleep Centre, Southern General Hospital, 
Glasgow, UK; megan.r.crawford@gmail.com  
 
 
 
STEP 3. How confident are you about sticking to the action plan? 
    
  
Not at all confident Slightly confident Moderately confident Very confident Totally confident 
0 1 2 3 4 
 
 
STEP 4. What do you see as the advantages of sticking to the action plan?  
    
 
 
 
STEP 5. What do you see as the disadvantages of sticking to the action plan?  
    
 
 
 
STEP 6. What can you do to help you stick to the action plan?  
    
 
 
 
Thank you very much for completing this survey! 
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Appendix 12: Initial Screening Form 
PLEASE MAKE SURE THAT ALL OF THE FORM IS FILLED IN CLEARLY INCLUDING 
WHO TOOK THE CALL AND THE DATE AND TIME.  NOTES SHOULD BE KEPT ON 
SEPARATE PIECE OF PAPER. 
 
Source 
 
How did you find out about the 
University of Glasgow Sleep Centre? 
 
 
 
 
Why have you contacted us?  
 
Method of initial contact (mobile, 
email, office phone)? 
 
 
 
Personal  
 
Full Name: 
 
Date of Birth: Age: 
Telephone: 
 
Address: 
Alternative Telephone: 
 
When is a good time to call? 
 
 
 
What GP practice do you attend, and 
who is the GP you normally see? 
 
 
 
Sleep  
 
Do you have difficulty sleeping at the moment? (Y/N) 
 
 
Are you generally satisfied with the amount of sleep you 
get (Y/N) 
 
Have you always been a poor sleeper? (Y/N) 
 
 
How long have you had a sleep problem?(yr)  
Do you have difficulty falling asleep? (Y/N) 
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How many nights per week do you have difficulty falling 
asleep? (out of 7) 
 
 
 
How long does it normally take you to fall asleep?(min) 
 
 
 
Do you experience sleep disturbance because of waking up 
during the night?(Y/N) 
 
How many nights per week do you have a difficulty with 
waking up during the night?(out of 7) 
 
How long are you normally awake during the night, in total? 
(min) 
 
 
What time do you normally go to bed? (time) 
 
 
 
What time do you normally get up?(time) 
 
 
How long do you normally sleep?(hr/min)  
Do you have any other difficulties with your sleep (e.g. restless legs, 
breathing problems, sleep walking)? 
Do you work shifts, night shifts? 
 
 
 
Roughly, how many units of alcohol do you drink per week? 
(Remember: One standard (175ml) glass of wine = 2 unit 
                                   One pint of standard lager = 2.3  
units   
                                   Spirit & Mixer   = 1 unit) 
 
 
 
Does your sleep disturbance affect how you feel and 
function during the day (e.g. fatigue, sleepiness, 
concentration, memory, mood, motivation, irritable, 
work/social functioning etc.).  If yes, specify most salient.  
 
 
 
 
Health 
 
Do you keep in good health physically? (Y/N) 
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What physical health problems do you have (if applicable)? 
 
 
What medicines do you take for your physical health? (if applicable) 
 
 
Do you keep in good health mentally? (Y/N) 
 
 
What mental health  problems do you have (if applicable)? 
 
 
What medicines do you take for your mental health? (if applicable) 
 
 
 
Do you give your consent for us to contact your GP if necessary regarding 
your health? 
 !
Suggested Algorithm to Screen for Sleep Disorder Other Than Insomnia. !
Ask the lead question, and then proceed with supplementary only if answer 
is ‘yes’. 
 
1. Narcolepsy 
a. Do you sometimes fall asleep in the daytime completely without 
warning? (YES/NO) 
 
b. Is it literally impossible to resist ‘sleep attacks’ during the day? 
c. Do you have collapses or extreme muscle weakness triggered by extreme 
emotion? 
d. Do you have visual hallucinations, either just as you fall asleep or when 
you wake in the morning? 
e. Are you paralysed and unable to move when you wake up from your 
sleep? 
[Possible narcolepsy: 1a¼‘‘TRUE’’ AND (1b OR 1c OR 1d OR 1e¼‘‘TRUE’’)] 
 
2. Sleep breathing disorder 
a. Are you a very heavy snorer? (YES/NO) 
 
b. Does your partner say that you sometimes stop breathing? 
c. Do you often wake up gasping for a breath? 
d. Are you often excessively sleepy during the day or fall asleep without 
wanting to? 
[Possible sleep breathing disorder: 2a¼‘‘TRUE’’ AND (2b OR 2c OR 
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2d¼‘‘TRUE’’)] 
 
3. PLMS/ RLS 
a. Do your legs often twitch or jerk or can’t keep still in bed?(YES/NO) 
 
b. Is it very difficult to get to sleep because of repeated muscle jerks? 
c. Do you frequently wake from sleep with sudden jerky movements or with 
a compulsion to move your legs? 
d. Do you simply have to get out of bed and pace around to get rid of these 
feelings? 
[Possible PLMS/ RLS: 3a¼‘‘TRUE’’ AND (3b OR 3c OR 3d¼‘‘TRUE’’)] 
 
 
 
4. Circadian Rhythm Sleep Disorder 
a. Do you tend to sleep well but just at the ‘‘wrong times’’? (YES/NO) 
 
b. Can you sleep well enough, but only if you stay up very late? 
c. Are you in a very sound sleep at normal waking time and could sleep on 
for hours more? 
d. Can you sleep well enough, but only if you go to bed very early? 
e. Do you wake very early, bright and alert and no longer sleepy? 
[Possible CRSD: 4a¼‘‘TRUE’’ AND EITHER (4b AND 4c¼‘‘TRUE’’) OR (4d AND 
4e¼‘‘TRUE’’)] 
5. Parasomnia 
a. Do you have unusual behaviours, like sleepwalking,  associated with 
your sleep that trouble you or that are dangerous?(YES/NO) 
 
b. Do you sleepwalk frequently and run the risk of injuring yourself or 
others? 
c. Do you have frequent night terrors when you are extremely distressed 
but not properly awake? 
d. Do you act out your dreams and risk injuring yourself or others? 
e. Do you have terrible recurring nightmares? 
[Possible parasomnia: 5a¼‘‘TRUE’’ AND EITHER (5b OR 5c OR 5d OR 
5e¼‘‘TRUE’’ 
 
If YES to b. or c. 
Ask : Do you currently experience these?(YES/NO) 
      : How often in the past 6 months? 
 
 !
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Appendix 13: Sleep/Bed Restriction Protocol 
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Introduction 
This information manual aims to help describe, in detail, bed restriction therapy, 
particularly the theory behind how it works, how to implement it practically, and any 
frequently asked questions you may have surrounding its use. If, after reading this 
information, you would still like to know more about Bed Restriction Therapy for 
insomnia please ask one of the researchers at the University of Glasgow Sleep Centre.  
Regulation of sleep 
Sleep is an automatic process and therefore out of our own direct, voluntary control.  
Whether awake or asleep we are at the mercy of two biological processes:  
(1) Sleep Homeostasis, commonly known as ‘Sleep Pressure’ 
(2) The Circadian Rhythm, otherwise known as the ‘Body Clock’ 
These two processes work in harmony to promote good consolidated sleep at night, 
and it is the goal of Bed Restriction Therapy to help restore the functioning of these two 
processes to enable undisturbed, good quality sleep to occur.  
Below we describe how sleep pressure and our body clock work across a normal 
24-hour day. By understanding how these processes we are able to find out what 
alterations may occur in insomnia, and crucially how these can be restored and improved 
with bed restriction therapy.  
Sleep Pressure 
Sleep pressure can be thought of as the brains pressure and need for sleep, which becomes 
greater with the increasing amount of time that we are awake. In this way, the pressure to 
sleep is directly related to the amount of time that we have been awake. For example, when 
we wake-up in the morning after a good night’s sleep, we will have a very low sleep 
pressure or ‘need to sleep’. As we continue throughout the day, sleep pressure will begin to 
accumulate (a bit like an hourglass egg-timer). Look at the diagram below which illustrates 
this increasing sleep pressure over the waking day. At the end of a full day, at bedtime, we 
will have a great amount of pressure to sleep. By going to bed and having another good 
night’s sleep, then sleep pressure will be reset for the start of the next day.   
Diagram of Sleep Homeostasis (Sleep Pressure) 
The diagram below shows sleep pressure over the course of a day. The dashed line (---) 
shows that by staying awake later than your normal bedtime, you will continue to 
accumulate sleep pressure. 
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Circadian Rhythm (Body Clock) 
The Circadian Rhythm (Body clock) is an internally generated biological rhythm that 
allows a number of processes to rise and fall over the twenty four hour period. Commonly, 
its effects are mostly realised with jet lag when one travels through many different time 
zones rapidly. This is when the circadian rhythm is out of synchrony with the new 
environment and can take a number of days to go back to normal.  
In a good sleeper, who is in-synch with the environment, the circadian rhythm will 
naturally rise in the early morning, promoting wakefulness and alertness - this is 
sometimes known as the alerting force. As the day continues, the circadian rhythm will 
promote wakefulness until it reaches a peak at about midday (see the diagram below 
showing this rise and fall in alertness). After this time, the circadian rhythm will start to 
dip. This initial fall is known as the ‘post lunch dip’ (you may be familiar with greater 
feelings of sleepiness after lunch) and as a time for a siesta in other cultures. As we 
continue through the day, the circadian rhythm continues to fall and does not promote as 
much arousal as before. With the onset of bedtime and sleep, the circadian rhythm drops to 
the lowest level and helps to maintain sleep. In this way, sleep pressure is very high, while 
the alerting effect of our body clock is low, creating the optimal opportunity to sleep.  
After this low point, the circadian rhythm will then rise again in anticipation for the 
next day. The body clock is difficult to manipulate and may be disrupted in a number of 
poor sleep conditions.  
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Diagram of Circadian Rhythm (Body Clock) 
The diagram below shows how our body clock controls our alertness over the course of the 
day.  
 
How will this information help me sleep? 
It is possible that in individuals with insomnia both sleep pressure and the body clock are 
not functioning optimally, and bed restriction aims to ‘jump-start’ these two processes to 
help promote consolidated and good quality sleep. Bed restriction involves: 
(1). Reducing the amount of time that you spend in bed. This will lead to a build-up 
of sleep pressure to encourage falling asleep straight away and prevent middle-of-the-night 
awakenings. 
(2). Standardising the time you go to bed at and get up at each day. This will help 
create a strong circadian rhythm, with natural peaks and troughs of alertness similar to a 
good sleeper.   
Implementing Bed Restriction Therapy 
Bed Restriction Therapy begins with a one week sleep diary. This is filled out every 
morning for seven days, recording on the morning of the first night and is to be repeated 
everyday throughout this first week. This will give an indication of the amount of time you 
spent awake in bed and how much sleep you actually obtain on an average night – this is 
often hard to know because your sleep can vary from night to night. Understanding how 
much time you spend in bed and how much time you spend asleep will help form the 
foundations of Bed Restriction Therapy.  
Working out your average sleep time 
The first step in Bed Restriction Therapy is to work out your average sleep time from the 
sleep diary. This is found in part 9 of your sleep diary. By using your sleep diary record 
from the past seven nights it will be possible to calculate your average sleep time for those 
nights.  
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For Example: 
    Day     Amount Slept         (Minutes)    
  Monday   6 hours 30 min            (390) 
  Tuesday   3 hours 30 min  (210)  
  Wednesday   5 hours 15 min   (315) 
  Thursday   6 hours 15 min   (375) 
  Friday   4 hours           (240) 
  Saturday   6 hours                        (360) 
  Sunday   5 hours 30 min          (330) 
   
Therefore in this example, by adding up the total amount of time slept on average 
each night and by dividing that by the number of nights you have data for (in this case 
seven) we are able to calculate your average sleep time.  
Total amount slept  = 37 hours          or             (2220 minutes) 
             ÷ 
    Number of days (7) 
 
Average Sleep Time  = 5 hours 17 minutes or (317 minutes)  
                               = 5 hours 15 minutes, to the nearest 15 
minutes 
This example suggests that this person has slept approximately on average five 
hours and 15 minutes. However, in order to try and get to sleep this person has been 
spending an awful lot of time in bed in order to obtain this amount of sleep. A more 
efficient strategy used within Bed Restriction Therapy is to try to match your time in bed to 
the time that you spend asleep on average. As a result, we shall now attempt to get your 
sleep into a regular and efficient pattern. This will seek to utilise the two processes that 
regulate sleep - the previously mentioned circadian rhythm and the accumulation of sleep 
pressure. 
 
Getting your sleep into a regular pattern 
The first modification to your sleep within Bed Restriction Therapy is to set a morning 
rising time, a time to get out of bed. It is best to calculate a time to rise from bed in the 
morning as this is something that we can control. In this example, it was decided that due 
to work reasons the set morning rising time would be at 6 am. We call this the Set Rising 
Time or Anchor Time as this should be the time that you rise from bed everyday of the 
week (even weekends!).   
With this new set Rising Time, we then work backwards around the clock with the 
amount of time that you on average slept for the preceding week (previously worked out to 
be five hours and 15 minutes from the sleep diary). This enables us to decide on your 
‘Threshold Time’. 
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The Threshold time is the time after which you can now retire to your bedroom and 
to bed. In this example, with a Set rising time of 6am and an average sleep time of 5 hours 
and 15 minutes the Threshold Time is 00:45am; after this you can go to bed. 
You can adjust your preferred threshold and rising times e.g. threshold 01:45, then 
rising time would be 7am. Or threshold 11:45, then rising time would be 5am. This period 
between going to bed and rising from bed is called the ‘sleep window’.  
However, it is vitally important to keep a minimum of 5 hours of time spent in bed.  
For example, if your average total sleep time is equal to 4 hours and 30 minutes 
then the minimum of 5 hours of time spent in bed must be applied. With this example the 
set rising time would be 7:00 am and the threshold time would be 7:00am – 5hours and 
therefore equal 2:00am. 
Sleep Efficiency 
One of the main goals of bed restriction therapy is to make your sleep more efficient. What 
we mean by this is that, when you go to bed, you fall asleep quickly and have very little 
wake time during the night. Sleep efficiency therefore refers to the amount of time that you 
spend asleep as a percentage of the time that you spend in bed. The example below shows 
how this can be calculated. 
Go to bed:          11:00pm 
Get to sleep:      12:30am 
Wake up:            6:30am 
Time asleep:    6 hours (or 360 minutes) 
Time in bed:    7.5 hours (or 450 minutes) 
Sleep efficiency = time asleep ÷ time in bed (x 100)  
                        = 6 ÷ 7.5 x 100 = 80%                             
We will use the Sleep Efficiency ratio to help find out changes in your sleep 
pattern. A ‘good sleep efficiency’ is around 90% however this can be variable even in a 
good sleeper. Sleep efficiency scores less than this suggest a poor sleep. 
You can work out your average sleep efficiency for the previous week by using 
your sleep diary. This will give you an indication of how much time you are sleeping when 
you are in your bed. Here are the steps to work this out: 
Appendices  303 
 
Sleep Diary 
Below is an example of a sleep diary with the parts in red which are used to 
calculate the time spent asleep on average (number 9) and the average total time in bed 
(numbers 2 & 4). 
Aim: To sleep for at least 90% of the time you spend in bed 
Step 1: Work out your current average sleep 
Step 2: Decide on a morning rising time 
Step 3: Work out your threshold time 
Step 4: Calculate current sleep efficiency  
Sleep efficiency is also a useful tool to use when you leave the treatment 
intervention as it allows you to re-take control of your sleep-wake schedules and 
implement it when you require it.  
 
Making these changes 
You may find that the mornings will provide you with new opportunities to do exercise or 
catch up with things that you have long put off. It is also beneficial to get as much light as 
!   
MEASURING THE PATTERN OF YOUR SLEEP 
! DAY 
1 
! DAY
2 
! DAY 
3 
! DAY 
4 
! DAY 
5 
! DAY 
6 
! DAY 
7 
  
!
1. Did you nap at any point yesterday? If yes, 
how long for (minutes)? 
  
!   !   !   !   !   !   !   !
  
2. At what time did you rise from bed this 
morning?  
    
!   !   !   !   !   !   !   !
  
3. What time did you wake up at this morning? 
  
!   !   !   !   !   !   !   !
  
4. At what time did you go to bed last night? 
  
!   !   !   !   !   !   !   !
  
5. What time did you switch off the light at 
intending to go to bed?                           
!   !   !   !   !   !   !   !
  
6. How long did it take you to fall asleep  
    (minutes)? 
!   !   !   !   !   !   !   !
  
7. How many times did you wake up during 
    the night? 
!   !   !   !   !   !   !   !
  
8. How long were you awake during the  
    night (in total)? 
!   !   !   !   !   !   !   !
  
9. About how long did you sleep altogether 
    (hours/mins)? 
!   !   !   !   !   !   !   !
  
10. How much alcohol did you take last  
    night? 
!   !   !   !   !   !   !   !
  
11. Did you take sleeping pills to help you sleep 
last night? If so, how many? 
!   !   !   !   !   !   !   !
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possible in the morning to help synchronise your internal Circadian rhythm to the morning 
rising time.  
Bed Restriction Therapy also stops negative associations about the bedroom 
environment - as it strengthens the idea that the bedroom should only be used for sleeping 
or intimacy. With this therapy you should no longer worry about trying to get to sleep in 
the bedroom. Instead you will relish going to bed and it will now become a place for you to 
finally fall asleep. 
 
Questions and Answers 
When will I start to get more sleep? 
• Once you are sleeping 90% (sleep efficiency) of your time in bed. After this we 
will be able to Increase your time in bed by 15 minutes. 
• You will then be asked to stay with this new pattern for at least another week. 
• We will review your progress and make changes each week for the next 4 weeks. 
What do I do with this extra evening time? 
• Continue with normal daily tasks, whatever you want to do. 
• But do not fall asleep before ‘threshold time’ 
• Safety: do not take risks. 
Can I nap during the day? 
• Napping may reduce the effectiveness of bed restriction therapy. 
• Only take a short nap (15-20 minutes) if you are struggling to stay awake during 
the day. 
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Appendix 14: Sleep Diary3
                                         
3 The PM page and first line of the AM page were added to the baseline version (which only contained questions 1-11; and 
sleep quality questions on the AM page). This sleep diary was given to individuals once SRT started (week 1). The 
added questions will be analysed with a time-series analysis, but because this was secondary analysis, have not been 
included in this thesis. 
   
SLEEP DIARY 
Name______________________________________     Day 1:_______ Session 4____________________________ 
 
The sleep diary is designed to provide a record of your sleep pattern as well as how you feel on awakening.  Please complete 
one column of the AM PAGE each morning, soon after you wake up and the PM PAGE every evening before you go to bed.  
Take a few minutes to do this, trying to be as accurate as you can.  It is your best estimate that we are looking for, but try not to 
get into the habit of clockwatching at night.  
 
 
 
 
 
 
 
 
 
I. Write down here what you have agreed with your therapist to change for this week 
 
 
 
 
 
 
1 How ready are you to do this tonight? 
    0             1            2            3            4 
      not at all                   moderately                     very 
       
 
2. How important is it for you to do this tonight? 
    0             1            2            3            4 
      not at all                   moderately                     very  
       
 
3. How confident are you to do this tonight? 
    0             1            2            3            4 
         not at all                   moderately                  very  
       
 
 
 
 
 
MEASURING YOUR TREATMENT PATTERN 
DAY 
1 
DAY
2 
DAY 
3 
DAY 
4 
DAY 
5 
DAY 
6 
DAY 
7 
 
 
PM PAGE: Tonight’s sleep  
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 !
   
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MEASURING THE QUALITY OF YOUR SLEEP 
 
1 How rested / restored do you feel this morning? 
    0             1            2            3            4 
      not at all                   moderately                     very 
       
 
2. How alert do you feel this morning? 
    0             1            2            3            4 
      not at all                   moderately                     very  
       
 
3. How would you rate the overall quality of your 
sleep last night? 
    0             1            2            3            4 
         poor                                                      very good 
       
 
 
 
MEASURING THE PATTERN OF YOUR 
SLEEP 
DAY 
1 
DAY
2 
DAY 
3 
DAY 
4 
DAY 
5 
DAY 
6 
DAY 
7 
 
Write down here what you have agreed with your 
therapist to change for this week 
 
 
How well/often did you do this last night? 
    0             1            2            3            4 
         Not very well                                     very well 
       
1. Did you nap at any point yesterday? If yes, how 
long for (minutes)? 
 
       
 
2. At what time did you rise from bed this morning?  
    
       
 
3. What time did you finally wake up at this 
morning? 
 
       
 
4. At what time did you go to bed last night? 
 
       
 
5. What time did you switch off the light at intending 
to go to sleep?                           
       
 
6. How long did it take you to fall asleep  
    (minutes)? 
       
 
7. How many times did you wake up during 
    the night? 
       
 
8. How long were you awake during the  
    Night because of these awakenings (in total 
minutes)? 
       
 
9. About how long did you sleep altogether 
    (hours/mins)? 
       
 
10. How much alcohol did you take last  
    night? 
       
 
11. Did you take sleeping pills to help you sleep last 
night? If so, how many? 
       
AM PAGE: Last night’s sleep  
Please choose a behaviour that has been recommended to you by your therapist for 
this week and write it down in the grey shaded boxes below 
 
Appendices  308 
 
Appendix 15: Bed Restriction Specific Adherence Scale 
 
Appendix 10-Adherence Scale 
NAME:______________________________________        Date: ______Session 1________________________ 
 
Bed Restriction therapy 
 
 
How often was each of the following statements true for you during the past week?  Please Circle the most accurate response. 
 
 
                                                                                 None of           A little                Some of           A good bit               Most of                All of  
                                                                                 the time         of the time          the time           of the time               the time             the time 
 
 
 
I followed the bed restriction programme…            1                        2                           3                          4                           5                          6  
 
 
 
I went to bed at my calculated  
‘threshold time’ on..: 
                           (a) weekdays                                     1                       2                           3                          4                           5                          6 
 
                          
                           (b) weekends                                     1                       2                           3                          4                           5                          6      
 
 
I got up at my calculated                                              
‘rising time’ on...: 
                          (a) weekdays                                      1                       2                           3                          4                           5                          6   
                      
  
                          (b) weekends                                      1                       2                           3                          4                           5                          6 
 
__________________________________________________________________________________________________________________ 
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Appendix 16: Mental Arithmetic Task 
Appendix 17  Digit Span Task Description 
 
Digit Span:  
In this task I will read you a number sequence, starting with 2 digit. I will ask you to 
recite them in correct order.  
 
The number sequence increases after each correct response by one digit. This is 
continued until the individual makes two consecutive mistakes. This task can also be 
done in reverse: the individuals recite the given sequence in reverse.  
 
 
4 7 
1 6 2 
4 7 8 8 
8 6 1 2 6 
3 2 1 9 6 4 
9 4 2 4 5 3 5 
9 1 1 3 6 6 8 6 
3 8 9 9 2 4 9 6 8 
9 2 8 7 7 3 2 6 5 5 
9 4 3 4 3 5 6 8 3 3 2 
1 6 6 7 2 8 1 9 6 5 7 5 
 
 
Number Task:  
I am going to ask you to countdown from the number 300 in steps of 3. 
 
300 450 1736 
297 443 1728 
294 436 1720 
291 429 1712 
288 422 1704 
285 415 1696 
282 408 1688 
279 401 1680 
276 394 1672 
273 387 1664 
270 380 1656 
267 373 1648 
264 366 1640 
261 359 1632 
258 352 1624 
255 345 1616 
252 338 1608 
249 331 1600 
246 324 1592 
243 317 1584 
240 310 1576 
237 303 1568 
234 296 1560 
231 289 1552 
228 282 1544 
225 275 1536 
222 268 1528 
219 261 1520 
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Appendix 17: Patient Characteristics of Sample 
Recruited 
 
N 30 
Age (mean yrs) 48 (range 19-65) 
Gender (female) 23 (77%) 
Education (mean yrs) 15 (range 11-20) 
Insomnia subtype (n) 
Onset 
Maintenance  
Mixed  
Early morning awakening  
 
9 
8 
8 
2 
Insomnia duration (mean yrs) 20 (SD 19; 7 with childhood 
onset) 
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Appendix 18: Correlation between Adherence and Outcome 
Table 26: Spearman Rho correlations between Adherence Variables and Outcome post-treatment and follow-up 
 ISI Change Diary Sleep Efficiency Change Sleep Diary SOL Sleep Diary WASO 
 Posttreatment Follow-up Posttreatment Follow-up Posttreatmen
t 
Follow-up Posttreatmen
t 
Follow-up 
Questionnaire         
Total score -.25 -.12 .19 .05 -.20 -.23 .00 .15 
Weekdays -.32 -.23 .19 .15 -.03 -.10 -.03 .07 
Weekends -.19 -.05 .19 .15 -.29 -.30 .00 .17 
Rising time -.27 -.16 .18 .14 -.05 -.10 -.01 .14 
Threshold -.16 -.04 .19 .05 -.32 -.30 .06 .21 
Sleep Diary         
Composite .20 .20 -.23 -.30 -.05 .09 .25 .23 
Rise Deviation Variance .15 .29 -.25 -.35 -.09 .02 .22 .13 
Threshold Deviation 
Variance 
.33 .07 -.17 -.35 + -.16 .05 .28 .27 
Actigraphy-Marker         
Composite (MarkCOMP) .24 .23 -.49* -.40* .10 .19 .18 .19 
Rise Deviation Variance .28 .35 -.33 -.38 + -.14 -.05 .19 .16 
Threshold Deviation 
Variance 
.23 .02 -.32 -.32 .05 .12 .15 .18 
Actigraphy-Movement         
Composite .26a .08 a -.21 a  -.18 a .06 .12 .11 .05 
Rise Deviation Variance .26 a .15 a -.21 a -.14 a -.08 -.04 .12 .11 
Threshold Deviation 
Variance 
.18 a -.05 a -.25 a -.09 a .21 .27 -.07 -.01 
*Significant correlation, p<0.05; + Trend at p≤0.07 a Pearson’s r for normally distributed data
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Appendix 19- Mann-Whitney test: non-signifcant 
results comparing motivation scores across 
stages of change 
 
Table 27: Mann-Whitney test comparing motivation scores across stages of change 
 Median  C/Pr 
[IQR] 
Median Ac/M p-value 
Motivation Week 2 9.8 [9.1-10] 9.9 [9.6-10] 0.78 
Motivation Week 4 9.0 [8.3-10] 9.9 [9.3-10] 0.38 
Motivation FU 9.3 [9.0-9.7] 9.7 [9.4-10] 0.13 
C=comtemplation; Pr=Preparation; Ac= Action; M=Maintenance; IQR= Interquartile range 
Appendix 20- Spearman Correlations between 
baseline variables and adherence 
Table 28: Spearman Correlations between baseline variables and adherence 
Baseline(
Questionnaire(
Spearman’s rho P-value 
Baseline(IPQ0R(
timeline(subscale4 
0.09 0.65 
Baseline(IPQ0R(
timeline(cyclical 
0.04 0.85 
Baseline(IPQ0R(IPQ(
Consequences 
0.12 0.54 
Baseline(IPQ0R(
Personal(Control 
-0.1 0.60 
Baseline(IPQ0R(
Treatment(Control 
0.08 0.68 
Baseline(ESS( 0.03 0.89 
Baseline(FSS( 0.13 0.51 
                                         
4 The identity and causal items are not included here. Identity was not measured to a) 
reduce the item numbers and b) because it did not seem appropriate for a disorder with 
such different symptoms (sleep onset vs. sleep maintenance). There is not a total 
score for causal attributions, thus although measured, this was not analysed here. 
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